---
document_datetime: 2023-09-21 20:21:37
document_pages: 126
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-ii-0039-epar-assessment-report-variation_en.pdf
document_name: tecentriq-h-c-004143-ii-0039-epar-assessment-report-variation_en.pdf
version: success
processing_time: 322.6787391
conversion_datetime: 2025-12-19 10:44:19.113408
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
17 September 2020 EMA/584169/2020

Committee for Medicinal Products for Human Use (CHMP)

## CHMP extension of indication variation assessment report

Invented name: Tecentriq

International non-proprietary name: atezolizumab

Procedure No. EMEA/H/C/004143/II/0039

Marketing authorisation holder (MAH) Roche Registration GmbH

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................6                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................7                       |
| 2.1. Introduction.........................................................................................................7 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................7           |
| 2.1.2. About the product..............................................................................................8     |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ........9                                                                                               |
| 2.1.4. General comments on compliance with                                                                                  | GCP........................................................10                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................10          |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................10                                             |
| 2.2.2. Discussion and conclusion on non-clinical aspects................................................10                  |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................10    |
| 2.3.1. Introduction....................................................................................................10   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................11      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................16         |                                                                                                         |
| 2.3.4. Discussion on clinical pharmacology...................................................................20             |                                                                                                         |
| 2.3.5. Conclusions on clinical pharmacology.................................................................21              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................21    |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................21                     |
| 2.4.2. Main study......................................................................................................21   |                                                                                                         |
| 2.4.3. Discussion on clinical efficacy............................................................................69        |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................70          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................71  |
| 2.5.1. Discussion on clinical safety ............................................................................           | 109                                                                                                     |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 110                                                                                                     |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 110 |
| 2.6. Risk management plan......................................................................................             | 110                                                                                                     |
| 2.7. Update of the Product information ......................................................................               | 121                                                                                                     |
| 2.7.1. User consultation...........................................................................................         | 121                                                                                                     |
| 3. Benefit-Risk Balance............................................................................121                      |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ......................................................................................... 121           |
| 3.1.1. Disease or condition.......................................................................................          | 121                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 122                                                                                                     |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 122             |
| 3.2. Favourable effects ............................................................................................        | 122                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 122                                                                                                     |
| 3.4. Unfavourable effects.........................................................................................          | 123                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 123                                                             |
| 3.6. Effects Table....................................................................................................      | 123                                                                                                     |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 124                                                                                                     |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 124                                                                                                     |
| 3.7.2. Balance of benefits and risks...........................................................................             | 124                                                                                                     |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance ......................................... 124

3.8. Conclusions .....................................................................................................  124

4. Recommendations ...............................................................................  125

5. EPAR changes  ......................................................................................  125

CHMP extension of indication variation assessment report

<div style=\"page-break-after: always\"></div>

## List of abbreviations

Abbreviation

Definition

1L

first-line

2L

second-line

AASLD

American Association for the Study of Liver Diseases

ADA

anti-drug antibody (same as anti-therapeutic antibody [ATA])

ADR

adverse drug reaction

AE

adverse event

AESI

adverse event of special interest

AFP

α -fetoprotein

Atezo + Bev

atezolizumab in combination with bevacizumab

BCLC

Barcelona Clinic Liver Cancer

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

Cmax

maximum serum or plasma concentration

Cmin

minimum serum or plasma concentration

CR

complete response

CSR

clinical study report

DCR

disease control rate

DOR

duration of response

ECOG PS

Eastern Cooperative Oncology Group performance status

EHS

extrahepatic spread

EMA

European Medicines Agency

EORTC QLQ-C30

European Organisation for the Research and Treatment of Cancer

Quality

-

of

-

Life Questionnaire Core 30

EORTC QLQ-HCC18

European Organisation for the Research and Treatment of Cancer

HCC Disease-Specific Quality - of - Life Questionnaire

EU

European Union

FDA

Food and Drug Administration

GHS

global health status

HBV

Hepatitis B virus

HCC

hepatocellular carcinoma

HCV

Hepatitis C virus

HR

hazard ratio

IgG1

immunoglobulin G1

IRF

independent review facility

IRR

infusion-related reaction

ITT

intent-to-treat

IV

intravenous

MedDRA

Medical Dictionary for Regulatory Activities

mRECIST

modified RECIST

MVI

macrovascular invasion

NSCLC

non - small cell lung cancer

ORR

objective response rate

OS

overall survival

PD

progressive disease

PD-1

programmed death - 1

PD-L1

programmed death - ligand 1

PFS

progression-free survival

PK

pharmacokinetic

PopPK

population pharmacokinetics

PRO

patient-reported outcome

PT

preferred term

Q3W

every three weeks

RECIST

Response Evaluation Criteria in Solid Tumors

RTOR

Real-Time Oncology Review

SAE

serious adverse event

sBLA

supplemental Biologics License Application

SCE

Summary of Clinical Efficacy

SCP

Summary of Clinical Pharmacology

SCS

Summary of Clinical Safety

SmPC

Summary of Product Characteristics

<div style=\"page-break-after: always\"></div>

US United States USPI United States Prescribing Information VEGF vascular endothelial growth factor

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 23 January 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include, in combination with bevacizumab, the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, based on the results of the pivotal study YO40245 (IMbrave150) as well as data from Arms A and F of the supportive Phase Ib study GO30140.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the Tecentriq 1200 mg concentrate for solution for infusion SmPC are updated. The Package Leaflet is updated in accordance.

An updated RMP version 13.0 was provided as part of the application.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0207/2019 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP was completed.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Jan Mueller-Berghaus

<div style=\"page-break-after: always\"></div>

| Timetable                                                 | Actual dates      |
|-----------------------------------------------------------|-------------------|
| Submission date                                           | 23 January 2020   |
| Start of procedure:                                       | 29 February 2020  |
| CHMP Rapporteur Assessment Report                         | 24 April 2020     |
| CHMP Co-Rapporteur Assessment Report                      | 23 April 2020     |
| PRAC Rapporteur Assessment Report                         | 28 April 2020     |
| PRAC members comments                                     | 06 May 2020       |
| Updated PRAC Rapporteur Assessment Report                 | 07 May 2020       |
| PRAC Outcome                                              | 14 May 2020       |
| CHMP members comments                                     | 18 May 2020       |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report      | 20 May 2020       |
| Request for Supplementary Information                     | 28 May 2020       |
| Rapporteur's preliminary assessment report circulated on: | 18 August 2020    |
| PRAC Rapporteur's Assessment Report                       | 26 August 2020    |
| PRAC outcome                                              | 04 September 2020 |
| Updated CHMP Rapporteur(s) Assessment Report              | 10 September 2020 |
| CHMP opinion:                                             | 17 September 2020 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It occurs in patients with chronic liver inflammation due to HBV, HCV, excessive alcohol intake or other toxins such as aflatoxin. Furthermore, haemochromatosis, alpha 1-antitrypsin deficiency, metabolic syndrome and NASH increase the risk of HCC.

## State the claimed therapeutic indication

Tecentriq in combination with bevacizumab for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

<div style=\"page-break-after: always\"></div>

## Epidemiology

Hepatocellular carcinoma (HCC) is the sixth most common cancer type in the world, and the fourth most deadly cancer (Globocan 2018). There are over 700,000 new cases diagnosed each year worldwide with large geographic variation in both risk factors and incidence (El-Serag 2011, Ferlay et al. 2010). HCC is the fifth most common cancer in Europe and has been predicted to be responsible for 77,400 deaths in Europe in 2018.

Hepatocellular carcinoma (HCC) is a highly lethal disease with a mortality to incidence rate ratio of 0.98 and 0.95 in males and females, respectively (Kamangar et al. 2006). Up to 80% of patients first presenting with HCC have advanced, unresectable or metastatic disease because of the late appearance of symptoms.

## Biologic features

The majority ( &gt; 80%) of cases occur in Sub-Saharan Africa and Eastern Asia, and China alone accounts for 55% of cases worldwide. Hepatitis B virus (HBV) infection is the main risk factor for HCC in Asia ( &gt; 70%), while in Western countries and Japan, the main risk factor is Hepatitis C virus (HCV) infection (50% to 70%) and excessive alcohol intake (20%), along with other causes of cirrhosis (10%) (Llovet et al. 2003).

## Clinical presentation, diagnosis and stage/prognosis

It is a medically complex and difficult to treat disease as the majority of HCC patients have underlying cirrhosis requiring management of both the malignancy and underlying liver disease. HCC patients with locally advanced or metastatic disease have a poor prognosis, with rapid progression and short OS.

## Management

Sorafenib remains as the global standard of care for treatment of patients with unresectable HCC based on two multicenter, randomized, double -blind, placebo-controlled Phase III trials: the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in Western regions and a trial conducted in the AsiaPacific region (Asia-Pacific Trial) (Llovet et al. 2008, Cheng et al. 2009). Both studies demonstrated a survival benefit of sorafenib vs. placebo. Sorafenib is often poorly tolerated, and dose reductions or drug discontinuations due to AEs are common (Llovet et al. 2008).

Recently, treatment with lenvatinib, a multi-targeted receptor tyrosine kinase inhibitor, was shown to be non-inferior to sorafenib in terms of the primary efficacy endpoint of OS (lenvatinib vs. sorafenib hazard ratio HR 95% confidence interval [CI]: 0.79, 1.06; non-inferiority margin = 1.08) (REFLECT, Kudo et al. 2018).

## 2.1.2. About the product

Tecentriq  (atezolizumab)  is  an  Fc-engineered  humanised  immunoglobulin  G1  (IgG1)  monoclonal antibody  that  binds  to  programmed  death-ligand  1  (PD -L1)  and  inhibits  its  interactions  with programmed death-1 (PD-1) and B7.1 receptors, both of which can provide inhibitory signals to T cells. Avastin (bevacizumab) is a recombinant humanised monoclonal IgG1 antibody that binds to and inhibits

<div style=\"page-break-after: always\"></div>

the biologic activity of human vascular endothelial growth factor (VEGF) in both in vitro and in vivo assay systems.

Combining anti-PD-L1 and anti-VEGF therapies has shown synergy and positive outcomes in Phase I to III studies, particularly in settings where high VEGF levels are known to play an important role in tumor growth (Chen and Hurwitz 2018). HCC is a highly vascularised tumor in which several proangiogenic factors play a role in its pathogenesis. In HCC, increased VEGF correlates with vascular density, tumor invasiveness and metastasis, and poor prognosis (Frenette 2012; Boige et al. 2012). In addition, VEGFA signaling is known to activate angiogenesis-independent, inductive angiocrine signals from sinusoidal endothelium that stimulate hepatocyte-mediated liver regeneration (LeCouter et al. 2003; Ding et al. 2010).

In addition to its role in angiogenesis and liver regeneration, the VEGF-A pathway also plays a crucial role  in  exerting  and  maintaining  an  immunosuppressive  tumor  microenvironment  through  several mechanisms.  For instance, VEGF-A has been shown to induce Fas ligand (FasL) expression on endothelial cells,  which  have  the  ability  to  kill  effector  CD8+  T  cells,  but  not  T-reg  cells  (Motz  et  al.  2014). Administration of anti-VEGF-A attenuated tumor endothelial FasL expression and produced a significant increase in the influx of tumor-rejecting CD8+ over FoxP3+ T cells, which was FasL-dependent, and led to CD8-dependent tumor growth suppression (Motz et al. 2014). Furthermore, bevacizumab can restore and/or maintain the antigen presentation capacity of dendritic cells, leading to enhanced T-cell infiltration in tumors (Oelkrug et al 2014; Wallin et al. 2016).  In addition to increased trafficking of T cells into tumors (Manning et al. 2007), several publications have illustrated that anti-VEGF therapies can also reduce frequency of myeloid-derived suppressor cells, decrease production of suppressive cytokines, and lower expression of inhibitory checkpoints on CD8+ T cells in tumors (Roland et al. 2009; Voron et al. 2015). Therefore, the immunomodulatory effect of bevacizumab is expected to increase CD8-positive T-cell  recruitment  and  relieve  intratumoral  immunosuppression,  thereby  boosting  the  effects  of atezolizumab.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The clinical development of atezolizumab in unresectable HCC comprises one pivotal Phase III study (IMbrave150), and three supportive Phase I studies (GO30140, PCD4989g, and YO29233). In addition, a  Phase  III  study  (WO41535  [IMbrave050])  of  Atezo  +  Bev  versus  active  surveillance  as  adjuvant therapy in HCC patients at high risk of recurrence after surgical resection or ablation is currently ongoing.

The Sponsor sought Scientific Advice feedback on the proposed Phase III study design (IMbrave150) from the Committee for Medicinal Products for Human Use (CHMP) and received a written advice in November 2017.

Overall, the CHMP supported the proposed Phase III study design with Atezo + Bev in unresectable HCC; the  CHMP  agreed  with  the  proposed  study  population,  the  study  design  including  the  comparator (sorafenib) and stratification factors, the statistical analysis plan and the planned safety database.

The CHMP did not fully support the open-label design of the study as they considered double-blind design feasible. However, the CHMP noted that with OS as the primary endpoint, this may not be a critical concern.  The CHMP did not agree with having ORR by investigator as co-primary endpoint with the

<div style=\"page-break-after: always\"></div>

concern being that it could lead to a potential premature end of the study not allowing to capture final OS. The Sponsor consequently changed the co-primary endpoint of ORR by investigator to PFS by IRF per RECIST v1.1. In addition, the CHMP did not encourage the inclusion of an interim analysis for OS. However, in case the Sponsor decided to include an interim analysis, it was noted that randomization should be retained to ensure final OS data could be captured and trial integrity maintained.

The applicant held separate meetings with the Rapporteur (Danish Medicines Agency) and Co-Rapporteur (Paul-Ehrlich-Institute) in December 2018 to discuss the acceptability of a proposed filing strategy and content based on the Phase Ib Study GO30140, to provide updated efficacy and safety data from Arm A of Study GO30140 and to provide an update on the ongoing HCC clinical development plan.  In general, both Agencies did not recommend the filing based on single arm Phase Ib data due to the exploratory nature of such studies and the limitations associated with non-randomized comparisons.

## 2.1.4. General comments on compliance with GCP

The study was conducted in compliance with GCP.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Atezolizumab is an IgG1 monoclonal antibody produced by recombinant DNA technology, a protein with a molecular mass of ~150 kDa. As an unaltered protein, being extensively degraded in the patient's body by regular proteolytic mechanisms before excretion, atezolizumab is unlikely to result in a significant environmental exposure. Atezolizumab is expected to biodegrade in the environment and does not pose a significant risk to the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), atezolizumab is exempt from the submission of Environmental Risk Assessment studies as the product and excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion and conclusion on non-clinical aspects

No new non-clinical data has been provided for this extension. No further data is required.

## 2.3. Clinical aspects

## 2.3.1. Introduction

The clinical pharmacology evaluations of atezolizumab and bevacizumab (herein referred to as Atezo + Bev) are based on pharmacokinetic and immunogenicity data obtained from four clinical studies where atezolizumab was administered as a single agent or in combination with bevacizumab to HCC patients. All atezolizumab and bevacizumab doses were administered as an IV infusion.

<div style=\"page-break-after: always\"></div>

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 1: Summary of atezolizumab studies conducted in monotherapy and combination settings in patients with HCC

| Atezolizumab Monotherapy Study   | Phase   | Indication                                                                                                                                                                                 | N Enrolled/ PK evaluable (Total 595/579)   | Design/Dose/Primary Clinical Endpoint                                                                                                |
|----------------------------------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| PCD4989g (GO27831)               |         | Multiple solid and hematologic tumors (data provided only for subset of patients with 1L and 2L+ HCC)                                                                                      | 15/15                                      | Monotherapy/ 1200 mg q3w/ PK and safety                                                                                              |
| YO29233                          |         | Multiple solid tumors (data provided only for subset of patients with 1L and 2L+ HCC)                                                                                                      | 21/21                                      | Monotherapy in Chinese Pts/ 1200 mg q3w/ PK and safety                                                                               |
| GO30140                          | Ib      | Multiple solid tumors (data provided only for subset of patients with advanced or metastatic and/or unresectable HCC who have received no prior systemic therapy enrolled in Arms A and F) | 223/219                                    | ArmA: Single arm study/ Atezo 1200 mg q3w& Bev15mg/kgq3w/ORR Arm F:2-arm/Atezo 1200mgq3w& Bev 15 mg/kg q3w vs. Atezo 1200 mg q3w/PFS |
| IMbrave150 (YO40245)             | III     | Patients with locally advanced or metastatic and/or unresectable HCC who have received no prior systemic therapy                                                                           | 336/324                                    | 2-arm/Atezo (1200 mg q3w) +Bev (15 mg/kg q3w) vs. Sorafenib (400 mg PO BID)/OS and PFS                                               |

HCC=hepatocellular carcinoma; Bev=bevacizumab 15 mg/kg q3w; PK=pharmacokinetic; q3w=every 3 weeks; ORR=overall response rate; OS=overall survival PFS=progression free survival.

Source:CSR PCD4989g (Report No.1064914),CSRYO29233(Report No.1092638),CSR GO30140 (Report No.1091227),CSR IMbrave150 (Report No.1092943).

Study GO30140(14June 2019);Study IMbrave150(YO40245)(29August 2019)

## 2.3.2. Pharmacokinetics

## Population PK in Study IMbrave150

Pharmacokinetic  data  were  collected  in  the  Phase  III  Study  YO40245  (hereafter  referred  to  as 'IMbrave150'), which was an open-label, randomized study to investigate the efficacy and safety of

<div style=\"page-break-after: always\"></div>

atezolizumab in combination with bevacizumab compared with sorafenib for patients with previously untreated locally advanced or metastatic HCC.

Table 2: Number of PK samples and patients included or excluded in the atezolizumab analysis

|                       | Number ofpatientsin thedataset   | Number ofpatientsin thedataset   | Number ofpatientsin thedataset   | Number ofPKsamplesinthedataset   | Number ofPKsamplesinthedataset   | Number ofPKsamplesinthedataset   | Number ofPKsamplesinthedataset   |
|-----------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Study / Arm           | Total                            | No Eval PK                       | Eval                             | Total                            | Excl                             | Eval                             | BLQ                              |
| IMbrave150/ Atezo+Bev | 325a                             | 2                                | 323 (99%)                        | 1518b                            | 30 (2%)                          | 1189 (78%)                       | 299 (20%)                        |

PK=patients without any evaluablePKsample;BLQ=number of BLQ concentrations,notused for the analysis.

a Number of patients in “poppk\\_pooled\\_20191031\\_hcc.csv\" file.

b sum of Exclusion+evaluable+ BLQ.

Atezo+BevArm=Atezolizumab+Bevacizumab

PopPK analysis was performed using NONMEM, Version 7.4 and perl-speaks-NONMEM, Version 4.8.1 was used to evaluate/validate the popPK model using predictive checks. Data, exploration and visualisation of the data as well as descriptive statistics were performed using R V3.3.3 in addition to CRAN packages.

The Phase I popPK model PK parameter estimates were fixed to final estimates to perform a Bayesian post-hoc  estimation  based  on  IMbrave150  data  and  estimate  patient-level  random  effect  and  PK parameters. The goodness-of fit plots suggest that the model was able to describe the PK profiles well and no trend was observed in goodness-of fit plots at the individual level. The pcVPC suggested that the median, 95th, and 5th percentiles of observed Cmax and Cmin were generally well within the prediction intervals of the Phase I popPK model, see Figure 1.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Pl=prediction interval; popPK=population pharmacokinetics; VPC=visual predictive check. Source: IMbrave150 PopPK Report No. 1099305, Figure 2

Figure 1: Prediction-corrected VPC of peaks and troughs of atezolizumab (all patients, semi-log scale) (study IMbrave150)

The effects  of  baseline  body  weight,  albumin,  tumour  burden,  ADA,  and  gender,  indicated  that  the relationships estimated in the Phase I popPK model adequately described trends in IMbrave150 study. The  positive  correlation  (p&lt;0.001)  between  albumin  and  CL  suggested  a  less  steep  relationship  in IMbrave150 patients than the one estimated in the Phase I popPK model, and the positive correlation (p&lt;0.001) between body weight and V2 appears to be a possible relationship specific for HCC. Age, race, number of metastatic sites, ECOG performance status, CRCL, eGFR, and platelet count did not appear to affect atezolizumab pharmacokinetics using IMbrave150 data. No covariate effect was related to liver function, i.e. ALT, AST, bilirubin, and LDH. No consistent trend in random effects was observed between hepatic  impairment  categories  although  there  was  an  increasing  trend  in  Eta.  CL  of  patients  with moderate hepatic impairment was lower than that of patients with either normal liver function or mild hepatic impairment. The number of patients with severe hepatic impairment (N = 2) was too small for comparison. There was no association between aetiology, macrovascular invasion, extrahepatic spread, alcohol use, or alpha-fetoprot ein level (&lt;400 ng/mL or ≥400 ng/mL) and atezolizumab PK.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Notallobserveddata aredisplayed;x-axisistruncated to50weeks.

Figure 2: 90% prediction interval of the PK profile using the Phase I PopPK model with IMbrave150 observed concentrations

The Phase I popPK model was used to derive the individual PK estimates for HCC patients, based on atezolizumab observed concentration-time profiles in IMbrave150.

Table 3: Summary statistics (geometric mean [Geometric Mean CV%]) of atezolizumab exposure metrics at Cycle 1 predicted using popPK model

| Study (N)/Arm (N)               | Cmax (μg/mL)   | Cmin (μg/mL)   | AUC (μg.day/mL)   | t1/2beta (day)*   |
|---------------------------------|----------------|----------------|-------------------|-------------------|
| IMbrave150,Atezo+BevArm (N=323) | 380 [20.1]     | 70.8 [40.8]    | 2851 [22.6]       | 22.1 [7.13]       |

N=Number of patients; Cmax=Cmaxat Cycle 1; Cmin=Cmin at Cycle 1; AUC=AUC(o-21) at Cycle 1;

thisparameter,harmonicmeanandstandarddeviationarereported.

Atezo+BevArm=Atezolizumab+Bevacizumab

Table 4: Summary statistics (geometric mean [Geometric Mean CV%]) of atezolizumab exposure metrics at steady-state predicted using popPK model

| Study (N)/Arm (N)               | Cmax,ss (μg/mL)   | Cmin,ss (μg/mL)   | AUC, ,ss (μg.day/mL)   | Post-hoc accumulationratio   |
|---------------------------------|-------------------|-------------------|------------------------|------------------------------|
| IMbrave150,Atezo+Bev Arm(N=323) | 554 [27.0]        | 163 [61.9]        | 5505[40.4]             | 1.93 [19.6]                  |

CV%=coefficient ofvariation;N=number ofpatients;Cmax,ss=Cmaxat steady-state;Cmin,ss=Cmin at steady- state;AUC,ss=AUCatsteady-state.

AccumulationratioisderivedastheratiobetweenAuCandAUCss;

Atezo+BevArm:Atezolizumab+Bevacizumab

## Absorption

Atezolizumab is administered as an IV infusion. There have been no clinical studies performed with other routes of administration.

## Distribution

PopPK analysis indicate that V1 is 3.28 L and Vss is 6.91 L in the typical patient.

<div style=\"page-break-after: always\"></div>

## Elimination

PopPK analysis indicate that the typical CL of atezolizumab is 0.200 L/day and the typical terminal t1/2 is 27 days.

## Dose proportionality and time dependencies

The previously developed popPK model estimated geometric mean accumulation ratio for Cmin, Cmax, and AUC was 2.75, 1.46, and 1.91-fold, respectively, following multiple dose administration of atezolizumab q3w days. The observed extent of accumulation is in close agreement with that predicted based on the popPK reported t1/2 of 27 days dosed q3w. Atezolizumab PK was linear over a dose range of 1 to 20 mg/kg of atezolizumab, including the fixed 1200 mg dose of atezolizumab.

Based on simulations, 90% of steady-state is attained after the following median (range) number of cycles: 3 cycles (1-6), 2 cycles (1-4), and 3 cycles (1-5) for Cmin, Cmax, and AUC, respectively.

The summary of the individual exposure metrics (IMbrave150) at cycle 1 and at steady-state based on the Phase 1 popPK Model is presented in the Tables below. The geometric mean accumulation ratio based on AUC was 2-fold. Cmin and Cmax accumulated 2.3- and 1.5-fold (geometric means), respectively.

Table 5: Summary Statistics (Geometric Mean [Geometric Mean CV%]) of Atezolizumab Exposure Metrics at Cycle 1 Predicted Using PopPK Model (Study IMbrave150)

| Study, Arm (N)                  | Cmax (μg/mL)   | Cmin (μg/mL)   | AUC (μg.day/mL)   | t112beta (day)*   |
|---------------------------------|----------------|----------------|-------------------|-------------------|
| IMbrave150,Atezo+BevArm (N=323) | 380 [20.1]     | 70.8 [40.8]    | 2851 [22.6]       | 22.1 [7.13]       |

N=Number of patients; Cmax=Cmax at Cycle 1; Cmin=Cmin at Cycle 1; AUC=AUC(0-21) at Cycle 1; CV%=coefficientofvariation

*t1/2 beta is the terminal half-life based on post-hoc parameter estimates. For this parameter, harmonicmeanandstandarddeviation arereported.

Atezo+ Bev Arm=Atezolizumab+Bevacizumab.

Table 6: Summary Statistics (Geometric Mean [Geometric Mean CV%]) of Atezolizumab Exposure Metrics at Steady-State Predicted Using PopPK Model (Study IMbrave150)

| Study, Arm (N)                  | Cmax,ss (μg/mL)   | Cmin,ss (μg/mL)   | AUC,ss (μg.day/mL)   | Post-hoc accumulation ratio   |
|---------------------------------|-------------------|-------------------|----------------------|-------------------------------|
| IMbrave150,Atez0+BevArm (N=323) | 554 [27.0]        | 163 [61.9]        | 5505 [40.4]          | 1.93 [19.6]                   |

CV%=coefficient of variation; N=number of patients; Cmax,ss=Cmax at steady-state; Cmin.ss=Cmin at steady-state; AUC,ss=AUC at steady-state.

Accumulation ratio is derived as the ratio between AUC and AUCss;

Atezo+BevArm:Atezolizumab+Bevacizumab

## Special populations

## Atezolizumab concentrations after 1200 mg q3w across studies

Exposures of Atezo + Bev in IMbrave150 were consistent with those observed in prior studies in HCC patients which followed the same 1200 mg q3w regimen of atezolizumab, indicating that the addition of bevacizumab therapy did not affect the PK of atezolizumab.

<div style=\"page-break-after: always\"></div>

Table 7: Mean (SD) Serum Atezolizumab PK Concentrations (µg/mL) by Study and Treatment Group Following Multiple IV Doses of Atezolizumab 1200 mg Given Every 3 Weeks

|                    |                           | NSCLC       | mUC         | HCC         | HCC         | HCC                   | HCC                    | HCC                | HCC             |
|--------------------|---------------------------|-------------|-------------|-------------|-------------|-----------------------|------------------------|--------------------|-----------------|
|                    |                           | OAK         | IMvigor211  | PCD4989g    | YO29233     | GO30140               | GO30140                | GO30140            | IMbrave150      |
| Nominal Time (day) | DoseRegimen PKDescription | ATZ (N=561) | ATZ (N=423) | ATZ (N=14)  | ATZ (N=21)  | Am A: ATZ+BEV (N=104) | Arm F1: ATZ+BEV (N=59) | Arm F2: ATZ (N=56) | ATZ+BEV (N=324) |
| 0.02               | CmaxDose 1                | 400 (127)   | 366 (125)   | 410 (140)   | 490 (140)   | 374 (84.0)            | 385 (NE)               | NA                 | 398 (131)       |
| 21                 | Cmin Dose 1 (q3w)         | 83.2 (31.0) | 73.9 (29.1) | 82.1 (43.4) | 90.5 (19.1) | 74.4 (28.6)           | 81.6 (28.5)            | 93.6 (31.7)        | 79.6 (50.3)     |
| 42                 | CminDose2(q3w)            | 130 (55.8)  | 111 (46.5)  | 135 (83.4)  | 144 (45.3)  | 111 (41.8)            | 127 (43.6)             | 133 (49.9)         | 102 (55.8)      |
| 42.04              | Cmax Dose 3(q3w)          | NA          | NA          | 447 (182)   | NA          | 489 (113)             | NA                     | NA                 | NA              |
| 63                 | CminDose3(q3w)            | 158 (66.4)  | 139 (56.9)  | 155 (73.9)  | 160 (44.7)  | 133 (56.9)            | 150 (47.4)             | 157 (54.0)         | 131 (64.4)      |
| 84                 | Cmin dose 7 (q3w)         | NA          | NA          | 142 (32.5)  | NA          | NA                    | NA                     | NA                 | NA              |

ATZ=atezolizumab;BEV=bevacizumab;Cmn=minimumserumconcentration;Cmax=maximumserumconcentration;N=numberused tocalculatestatistics; NA=notavailable;NE=notevaluable,only1value;SD=standarddeviation.

## 2.3.3. Pharmacodynamics

## Dose rationale

Both GO30140 (Arms A and F1) and IMbrave150 (Atezo + Bev) evaluated atezolizumab administered at a fixed dose of 1200 mg by IV infusion q3w in combination with 15 mg/kg of bevacizumab by IV q3w in patients with metastatic and/or unresectable HCC (see supportive studies).

Atezolizumab administered at a fixed dose of 1200 mg q3w (1200 mg on Day 1 of each 21-day cycle), is an approved dosage for atezolizumab. Anti-tumor activity has been observed across doses ranging from 1 mg/kg to 20 mg/kg q3w. In the Phase I Study GO27831 (PCD4989g, Report No. 1064914) the maximum tolerated dose of atezolizumab was not reached and no dose-limiting toxicities were observed at any dose. The fixed dose of 1200 mg q3w (equivalent to an average body weight based dose of 15 mg/kg q3w) was selected on the basis of both nonclinical studies (Deng et al. 2016) and available clinical PK, efficacy, and safety data.

Bevacizumab administered at a fixed dose of 15 mg/kg q3w on Day 1 of each 21-day cycle is an approved dosage for bevacizumab (see Avastin approved label). The 15 mg/kg q3w dose of bevacizumab aligns with the atezolizumab dosing schedule (1200 mg q3w), and is also the dosage used in the GO30140 (Arms A and F1) and IMbrave150 studies (Atezo+Bev) in combination with atezolizumab. This dose was generally well-tolerated, the incidence and severity of bevacizumab AESIs with combination of Atezo+ Bev in the overall population of Arm A (N = 104) and Arm F1 (N = 60) of study GO30140, as well as in the IMbrave150 study was consistent with that reported in the bevacizumab label indicating that the addition of atezolizumab to bevacizumab does not exacerbate the incidence or severity of bevacizumab AESIs.

## Mechanism of action

Atezolizumab targets human programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) and tumor cells (TCs), and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80, B7-1). Both of these interactions are reported to provide inhibitory signals to T cells.

Bevacizumab targets vascular endothelial growth factor (VEGF). VEGF is a pleiotropic inflammatory factor that is normally associated with wound repair. VEGF and angiogenesis is an essential factor in the oncogenic process, and plays a role in pathogenesis. VEGF is associated with vascular density, tumor invasiveness and metastasis, and poor prognosis (Frenette 2012; Boige et al. 2012).

<div style=\"page-break-after: always\"></div>

## Primary and secondary pharmacology

## Immunogenicity

- Study IMbrave150

Blood samples were collected to characterize atezolizumab PK and ADA incidence following atezolizumab treatment. Serum samples for PK and ADA analysis were obtained at multiple timepoints before, during, and after treatment with atezolizumab (Table 9).

Table 8: IMbrave150: Atezolizumab ADA and PK Sampling Schedule

| Pre-DoseatCycleCx,Day1   | Pre-DoseatCycleCx,Day1   | Pre-DoseatCycleCx,Day1   | Pre-DoseatCycleCx,Day1   | Pre-DoseatCycleCx,Day1   | Pre-DoseatCycleCx,Day1   | Pre-DoseatCycleCx,Day1   | Tx DiscVisit           |
|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------------------|
| C1a                      | C2                       | C3                       | C4                       | c8                       | C12                      | C16                      | (≤30daysafterlastdose) |
| X                        | X                        | X                        | X                        | X                        | X                        | X                        | X                      |

ADA=anti-drug antibody;Atezo=atezolizumab;Bev=bevacizumab; C=Cycle;CSR=Clinical Study Report;Disc=discontinuation;PK=pharmacokinetic;Tx=treatment.

SamplesforatezolizumabPKanalysiswerecollectedpre-doseand30±10minutes post-infusion C1D1. ADA sample was collected only pre-dose in C1 (i.e., not post-infusion C1).

Note:Each cycle in this studyhas a durationof 21days.SamplesapplytoAtezo+Bevarm only.

Source:IMbrave150PrimaryCSR(ReportNo.1092943).

## Atezolizumab Immunogenicity Rates

The incidence of treatment-emergent atezolizumab ADAs in the Atezo+Bev arm is within the range of treatment-emergent ADA-positive incidence rates observed across atezolizumab studies.

Table 9: IMbrave150: Baseline Prevalence and Post-Baseline Incidence of ADAs to Atezolizumab

|                                                                    | Atezo+Bev N=329   |
|--------------------------------------------------------------------|-------------------|
| Baseline evaluablepatients                                         | N=311             |
| No. of patients positive for ADA                                   | 7 (2.3%)          |
| No. of patients negative for ADA                                   | 304               |
| Post-baselineevaluablepatients                                     | N=315             |
| No. of patients positive for ADA (treatment-emergent ADA-positive) | 88 (27.9%)        |
| Treatment-induced ADA                                              | 88                |
| Treatment-enhanced ADA                                             | 0                 |
| No. of patients negative for ADA                                   | 227 (72.1%)       |
| Treatment-unaffected ADA                                           | 7                 |

ADA=anti-drug antibody; Atezo+Bev=atezolizumab+bevacizumab; CSR=Clinical Study Report. Note: See Section 1.1 for further details on definitions of treatment-induced and treatment-enhanced ADA. Data cutoff: 29 August 2019.

## Atezolizumab pharmacokinetics by ADA status

Atezolizumab concentrations up to Cycle 16 Day 1 by ADA status are summarized in Table 11 for all PK-evaluable atezolizumab-treated patients. The arithmetic mean Cmax values at Cycle 1 were 408 and 372 μg/mL for ADA -negative and ADA-positive patients, respectively, a difference of 8.82% (Table 11). The corresponding Cmin values at Cycle 1, Day 21 (i.e., Predose Cycle 2), were 89.3 and 54.4 μg/mL, respectively, a difference of 39.1%. The vast majority of patients had Cmin above the targ et exposure of 6 μg/mL, regardless of ADA status.

<div style=\"page-break-after: always\"></div>

Table 10: Summary Statistics for Atezolizumab Cmax and Cmin by Treatment-Emergent ADA Status Following Atezolizumab 1200 mg IV Given Every 3 Weeks (Study IMbrave150)

| Visit/ Timepoint           | Nominal Time (Days)   | N              | AM (μg/mL)     | AM SD (μg/mL)   | AM (CV %)      | GM (μg/mL)     | GM (% CV)      | Median (μg/mL)   | Min (μg/mL)    | Max (μg/mL)    |
|----------------------------|-----------------------|----------------|----------------|-----------------|----------------|----------------|----------------|------------------|----------------|----------------|
| Negative (227)             | Negative (227)        | Negative (227) | Negative (227) | Negative (227)  | Negative (227) | Negative (227) | Negative (227) | Negative (227)   | Negative (227) | Negative (227) |
| Cycle 1 Cmax/C1D1          | 0.06                  | 210            | 408            | 133             | 32.7           | 388            | 32.7           | 395              | 111            | 1260           |
| Cycle 1 Cmin/Predose C2D1  | 21                    | 212            | 89.3           | 54.5            | 61.0           | 77.5           | 74.0           | 81.6             | 0.0890         | 596            |
| Cycle 2 Cmin/Predose C3D1  | 42                    | 26             | 125            | 51.3            | 41.2           | 114            | 47.2           | 118              | 37.8           | 263            |
| Cycle 3 Cmin/Predose C4D1  | 63                    | 192            | 138            | 58.4            | 42.2           | 125            | 49.9           | 133              | 19.8           | 386            |
| Cycle 7 Cmin/Predose C8D1  | 147                   | 67             | 153            | 61.2            | 40.1           | 141            | 40.8           | 138              | 60.9           | 319            |
| Cycle11Cmin/PredoseC12D1   | 231                   | 55             | 194            | 76.6            | 39.4           | 181            | 40.7           | 179              | 73.5           | 437            |
| Cycle15Cmin/PredoseC16D1   | 315                   | 30             | 196            | 75.4            | 38.4           | 182            | 42.3           | 183              | 81.5           | 345            |
| Positive (88)              | Positive (88)         | Positive (88)  | Positive (88)  | Positive (88)   | Positive (88)  | Positive (88)  | Positive (88)  | Positive (88)    | Positive (88)  | Positive (88)  |
| Cycle 1 Cmax/C1D1          | 0.06                  | 84             | 372            | 119             | 32.0           | 356            | 30.9           | 354              | 130            | 915            |
| Cycle 1 Cmn/Predose C2D1   | 21                    | 82             | 54.4           | 23.1            | 42.5           | 42.3           | 178.1          | 51.7             | 0.0300         | 109            |
| Cycle 2 Cmn/Predose C3D1   | 42                    | 13             | 58.2           | 34.9            | 59.9           | 34.0           | 493.1          | 59.3             | 0.120          | 125            |
| Cycle 3Cmin/Predose C4D1   | 63                    | 71             | 111            | 75.3            | 68.2           | 82.6           | 138.2          | 104              | 0.518          | 540            |
| Cycle 7 Cmn/Predose C8D1   | 147                   | 34             | 125            | 51.2            | 40.9           | 114            | 47.3           | 120              | 31.1           | 256            |
| Cycle11Cmn/PredoseC12D1    | 231                   | 19             | 124            | 55.2            | 44.6           | 110            | 56.5           | 148              | 44.1           | 215            |
| Cycle 15 Cmn/Predose C16D1 | 315                   | 7              | 145            | 68.1            | 47.1           | 125            | 72.6           | 159              | 36.4           | 232            |

ADA=Anti-Drug Antibodies; Cmax=maximum concentrations of atezolizumab in serum; Cmin=minimum (trough) concentrations of atezolizumab in serum; CV=coefficientofvariation.

SixRecordsfrom5patientswereexcludedduetodosediscrepancy,2Recordsfrom2patientswereexcludedduetoanomalouscollectiondate/time,3Records from3patientswereexcludedduetoanomalousPKconcentration

CxD21 (Cmin) is the same as C(x+1)D1 Predose.

There were 14 patients with missing ADA status. Total number of patients=227+88+14=329.

Source:IMbrave150CSR(ReportNo.1092943).Table57

A mean serum atezolizumab concentration-time plot (log scale) following multiple doses of atezolizumab 1200 mg q3w by ADA positivity is shown in Figure 4.

<!-- image -->

Data source: IMbrave150(Report No. 1092943) CSR Figure 13

Figure 3: Box Plot of Atezolizumab Concentrations vs. Time by Treatment- Emergent ADA Status Following Multiple IV Doses of Atezolizumab (Study IMbrave150)

<div style=\"page-break-after: always\"></div>

Table 11: Summary statistics (mean [SD]) and t-test on atezolizumab clearance and exposure metrics by ADA status

| Variable (unit)              | ADA Negative N=227   | ADAPositive N=88   |   p-value | MeanDifference (95%CI)   |
|------------------------------|----------------------|--------------------|-----------|--------------------------|
| Clearance (L/d)              | 0.208 (0.0862)       | 0.308 (0.121)      |  9.19e-11 | -0.1(-0.128,-0.0724)     |
| Cmax, Cycle 1 (μg/mL)        | 395 (83.2)           | 368 (70.1)         |  0.00494  | 26.4 (8.1,44.8)          |
| Cmin, Cycle 1 (μg/mL)        | 81.3 (23.8)          | 60.3 (19.6)        |  1.22e-13 | 21 (15.8,26.2)           |
| AUCo-21, Cycle 1 (μg.day/mL) | 3060 (646)           | 2550 (496)         |  1.79e-12 | 512 (377,645)            |

Cmin = Individual model-predicted minimum atezolizumab concentration at Cycle 1, Cmax=lndividual modelpredicted maximum atezolizumabconcentration at Cycle1;AUCo-21=Areaunder thecurvefrom0 to21 days at Cycle 1 ;CV = coefficient of variation, SD=standard deviation; Cl=confidence interval, The 95% CI fordifference/ratioandt-test.

Thetwo-sidedp-valueisfromtwo-samplet-test.

N:number of patients ineachADAstatusgroup in thepopPK population.

There was significant difference (p&lt;0.001) between atezolizumab clearance in ADA positive patients and ADA negative patients. A substantial difference was also observed for other exposure metrics (i.e., Cmin and AUC0-21) with lower exposure in ADA positive patients compared to ADA negative patients, less pronounced for Cmax.

<!-- image -->

Note:OnlythePKvisitswithatleast20 samplesaredisplayedontheplot.

3PRED-concentrationsbelow1μg/mL arenotdisplayedon thisplot

Figure 4: Prediction-corrected VPC of peaks and troughs of atezolizumab by ADA status (semi-log scale) (study IMbrave150)

## Incidence of ADAs across studies (GO30140, IMbrave150 and pooled analysis)

The pre-treatment ADA prevalence and post-treatment ADA incidence for atezolizumab is shown in Table 12 for IMbrave150 and GO30140. The ADA prevalence at baseline was 2.3% for atezolizumabtreated patients with a baseline ADA sample in IMbrave150, and 0%, 3.4%, and 3.4%, respectively for Arms A, F1, and F2 of GO30140.

<div style=\"page-break-after: always\"></div>

Post-treatment, the atezolizumab ADA incidence rates were 27.9% in IMbrave150, and 23.8%, 37.9% and 29.8% in Arms A, F1, and F2, respectively, of GO30140 as shown in Table 12. These are within the range of treatment-emergent ADA incidence rates observed across atezolizumab studies. For Arm F2 of GO30140, ADA samples obtained post crossover were not used for ADA status derivation.

When pooled across the two studies evaluating atezolizumab plus bevacizumab treatment in HCC there were 134 of 474 ADA-evaluable patients who developed treatment-emergent ADAs to atezolizumab (incidence rate of 28.3%).

Table 12: Baseline Prevalence and Post-Baseline Incidence of ADAs to Atezolizumab

|                                  | IMbrave150                         | GO30140                 | GO30140                 | GO30140                         | Both Studies               |
|----------------------------------|------------------------------------|-------------------------|-------------------------|---------------------------------|----------------------------|
|                                  | Atezo+Bev Treated Patients (N=329) | Arm A Atezo+Bev (N=104) | Arm F1 Atezo+Bev (N=60) | Arm F2 Atezo Monotherapy (N=58) | Combined Atezo+Bev (N=493) |
| Baselineevaluablepatients        | 311                                | 104                     | 58                      | 58                              | 473                        |
| No. of patients positive for ADA | 7 (2.3%)                           | 0                       | 2 (3.4%)                | 2 (3.4%)                        | 9 (1.90%)                  |
| No. of patients negative for ADA | 304                                | 104                     | 56                      | 56                              | 464                        |
| Post-baselineevaluablepatients   | 315                                | 101                     | 58                      | 57                              | 474                        |
| No. of patients positive for ADA | 88 (27.9%)                         | 24 (23.8%)              | 22 (37.9%)              | 17 (29.8%)                      | 134 (28.3%)                |
| Treatment-induced ADA a          | 88                                 | 24                      | 21                      | 17                              | 133                        |
| Treatment-enhanced ADA b         | 0                                  | 0                       | 1                       | 0                               | 1                          |
| No. of patients negative for ADA | 227                                | 77                      | 36                      | 40                              | 340                        |
| Treatment-unaffected ADA         | 7                                  | 0                       | 1                       | 2                               | 8                          |

ADA=anti-drugantibodies,canalsobereferredtoasATAoranti-therapeuticantibodies

Note:SeeShankar et al. 2014 for further details on the definition of treatment-induced and treatment-enhanced ADA.

a Treatment-induced ADAs=Patients who had a baseline-negative ADA result or were missing data who developed anti-drug antibodies at any time after initial drug administration.

b Treatment-enhanced ADA=Patients who had a baseline-positive ADA result in whom the assay result was enhanced (greater than baseline titer by ≥0.60 titer units) at any time after initial drug administration.

c Treatment-unaffected ADAs=Patients who had a baseline-positive ADA result in whom the assay result was not enhanced (not greater than s

Source=Table52ofGO30140CSR(Report No.1091227),andTable54of IMbrave150(YO40245)CSR(Report No.1092943)

## 2.3.4. Discussion on clinical pharmacology

Samples received for determination of atezolizumab concentrations in serum from HCC patients were analysed  within  established  sample  storage  stability  using  validated  analytical  methods.  For  the IMbrave150 Phase III study conducted in HCC patients, the in-study validation was acceptable and incurred  sample  reanalysis  was  performed  and  met  the  acceptance  criteria.  All  analyses  including assessment of immunogenicity were conducted with assays assessed in previous procedures.

The IMbrave150 study was an open-label, randomized study to investigate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib for patients with previously untreated locally advanced or metastatic HCC. Pharmacokinetic data collected in IMbrave 150 was used for external validation of the Phase I PopPK model, with determination of individual Bayesian estimates for  the  HCC  patients.  The  phase  I  PopPK  model  could  reasonably  well  describe  the  atezolizumab concentrations of IMbrave150, although some overprediction was observed for Ctrough. VPCs stratified for ADA status showed overprediction at Cycle 1 Ctrough for ADA positives whereas the fit was acceptable for ADA negatives. Overprediction was also observed of Ctroughs for patients with mild hepatic impairment (NCI-ODWG Group B1+B2). The Phase 1 popPK model was used to estimate the exposure metrics after multiple injections of 1200 mg q3w atezolizumab. The predicted exposure of atezolizumab in IMbrave 150 was comparable to the exposure achieved in other studies with atezolizumab 1200 mg q3w dosing, with or without bevacizumab and across indications. Atezolizumab administered at a fixed dose of 1200 mg q3w is already  approved  hence  the  dose  rationale  for  treatment  of  HCC  patients  is  considered acceptable. The incidence of ADAs in the Atezo+Bev arm of IMbrave150 was 27.9% which is within what

<div style=\"page-break-after: always\"></div>

has been observed in other atezolizumab indications. Atezolizumab clearance was significantly lower (p&lt;0.001) in ADA positive patients as compared to ADA negative patients. NAb data for IMbrave150 were submitted and showed that 65 patients out of 313 evaluable patients had neutralising antibodies (88/315 patients were ADA positive).

## 2.3.5. Conclusions on clinical pharmacology

Overall atezolizumab PK is sufficiently described and no apparent differences are detected compared to the previous description of PK following 1200 mg q3w IV administered as monotherapy and in other indications.

The analysis of immunogenicity revealed that atezolizumab exposure and efficacy was lower in ADApositive as compared to ADA-negative patients (see also 2.4.2. Main Study).

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No explicit dose response studies have been provided.

## 2.4.2. Main study

A Phase III, Open-label, Randomized Study of Atezolizumab in Combination with Bevacizumab  Compared  with  Sorafenib  in  Patients  with  Untreated  Locally  Advanced  or Metastatic Hepatocellular Carcinoma.

<!-- image -->

## Randomization Stratification Factors

- Geographic Region (Asia excluding Japan vs rest of the worid)
- Macrovascular invasion and/or extrahepatic spread (presence or absence)
- +Baseline α feto-protein (&lt;400 ng/mL vs ≥400 ng/mL)
- Baseline ECOG performance status (0 or 1)

Figure 5: Study design for IMbrave150

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

## Inclusion Criteria

## General Inclusion Criteria

Patients had to meet all of the following criteria to be eligible for study entry:

- At least one measurable (per RECIST v1.1) untreated lesion
- ECOG Performance Status of 0 or 1 within 7 days prior to randomization
- Adequate hematologic and end organ function

## Disease-Specific Inclusion Criteria

Patients had to meet all of the following criteria for study entry:

- Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (see details in Protocol) in cirrhotic patients

Patients without cirrhosis required histological confirmation of diagnosis.

- Disease that was not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
- No prior systemic therapy (including systemic investigational agents) for HCC Previous use of herbal therapies/traditional Chinese medicines with anti-cancer activity included in the label was allowed, provided that these medications were discontinued prior to randomization.
- Patients who received prior local therapy (e.g., radiofrequency ablation, percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused ultrasound, transarterial chemoembolization, transarterial embolization, etc.) were eligible provided the target lesion(s) had not been previously treated with local therapy or the target lesion(s) within the field of local therapy had subsequently progressed in accordance with RECIST v1.1.
- Child-Pugh class A within 7 days prior to randomization
- Serum bilirubi n ≤3xthe upper limit of normal (ULN)
- Serum albumin ≥28 g/L (2.8 g/dL) without transfusion
- For patients not receiving therapeutic anticoagulation: INR or a PTT ≤2xULN
- Documented virology status of hepatitis, as confirmed by screening HBV and HCV serology test
- For patients with active hepatitis B virus (HBV):

-HBV DNA &lt;500 IU/mL obtained within 28 days prior to initiation of study treatment, and anti-HBV treatment (per local standard of care; e.g., entecavir) for a minimum of 14 days prior to study entry and willingness to continue treatment for the length of the study

## Exclusion Criteria

## General Exclusion Criteria

Patients who met any of the following criteria were excluded from study entry:

<div style=\"page-break-after: always\"></div>

- History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate &gt;90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Moderate or severe ascites
- History of hepatic encephalopathy
- Co-infection of HBV and HCV

Patients with a history of HCV infection who were negative for HCV RNA by PCR were considered noninfected with HCV.

- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding

Patients had to undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) had to be assessed and treated per local standard of care prior to enrollment. Patients who had undergone an EGD within 6 months prior to initiation of study treatment did not need to repeat the procedure.

- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment

## Exclusion Criteria Related to Medications

Patients who met any of the following criteria were excluded from study entry:

- Prior allogeneic stem cell or solid organ transplantation
- History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
- Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulation
- Treatment with strong CYP3A4 inducers within 14 days prior to initiation of study treatment, including rifampin (and its analogues) or St. John's wort
- Treatment with any agent that may interfere with the immunostimulatory nature of atezolizumab.

## Exclusion Criteria Related to Bevacizumab

All patients had to meet several bevacizumab-specific criteria based on the known safety profile of this drug. These criteria excluded patients with evidence of or a possibility for bleeding issues, uncontrolled hypertension, and/or gastrointestinal perforations.

<div style=\"page-break-after: always\"></div>

## Treatments

Table 13: Study treatment regimens

<!-- image -->

| Arm                | Cycle Length   | Dose,Route,andRegimen (drugs listed in order of administration)   | InfusionRate                                                                                                                          |
|--------------------|----------------|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Sorafenib          | 21 days        | Sorafenib 400 mg BID, by mouth, continuously                      | Not applicable                                                                                                                        |
| Atezo+Beva 21 days |                | Atezolizumab1200 mg IV on Day 1                                   | Over 60 (± 15) minutes (for the first infusion); 30 (±10) minutes for subsequent infusions if tolerated                               |
| Atezo+Beva 21 days |                | Bevacizumab 15 mg/kg IV on Day 1                                  | Over 90 (± 15) minutes (for the first infusion); shortening to 60 (± 10) then 30 (± 10) minutes for subsequent infusions if tolerated |

For patients randomized to the Atezo+Bev arm,on Day 1 of each cycle, atezolizumab was administered first, followed by bevacizumab, with a minimum of 5 minutes between dosing. BID =twice per day.

## Objectives

## Primary Efficacy Objective

The primary efficacy objective of IMbrave150 is to evaluate the efficacy of the combination of atezolizumab and bevacizumab compared to sorafenib monotherapy administered to patients with locally advanced or metastatic HCC who have received no prior systemic treatment, as measured by:

- Overall Survival (OS), defined as the time from randomization to death from any cause
- Progression-free Survival (PFS), defined as the time from randomization to the first occurrence of disease progression as determined by an Independent Review Facility (IRF) according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death from any cause (whichever occurred first)

## Secondary Efficacy Objectives

The secondary efficacy objectives of IMbrave150 are as follows:

<div style=\"page-break-after: always\"></div>

AFP = α-fetoprotein; EORTC=European Organisation for Research and Treatment of Cancer; HCC mRECIST=modified RECIST for HCC; IRF=independent review facility; PFS=progression-free survival; PRO=patient-reported outcome; QLQ-C30=quality-of-life questionnaire for cancer; RECiST v1.1 =Response Evaluation Criteria in Solid Tumors, Version 1.1

<!-- image -->

| SecondaryEfficacyObjectives                                                                                                                                                                                        | Corresponding Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To evaluate the efficacy of atezolizumab+bevacizumab comparedwithsorafenib                                                                                                                                         | Objective response rate (ORR), defined as a complete or partial response, as determined by an IRF according to RECIST v1.1 by an IRF according to HCC mRECIST by the Investigator according to RECiST v1.1 Duration of Response (DoR), defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) as determined by an IRF according toRECISTv1.1 by an IRF according to HCC mRECIST by the Investigator according to RECIST v1.1 PFSas determined by an IRF according to HCC mRECIST by the Investigator according to RECIST v1.1 Time to progression (TTP), defined as the time from randomizationtothefirstoccurrenceofdisease progression, as determined: by an IRF according to RECIST v1.1 by an IRF according to HCC mRECIST by the Investigator according to RECIST v1.1 |
| specified biomarkers with the efficacy of atezolizumab + bevacizumab compared with sorafenib                                                                                                                       | To evaluate the association of pre-·PFS as determined by the Investigator and by an IRF according to RECIST v1.1 and overall survival (OS) by baseline serum AFP level (< 400 ng/mL vs.≥ 400 ng/mL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| To evaluate patient-reported outcomes (PROs)of disease/treatment-related symptoms, global health status/quality of life (GHS/QoL), and functionexperienced by patientsonatezolizumab+ bevacizumab versus sorafenib | Time to Deterioration (TTD), defined as the time from randomization tofirst deterioration(decrease frombaseline of ≥ 10 points), maintained for two consecutive assessmentsoroneassessment followedbydeathfrom any cause within 3 weeks in the following EORTC QLQ- C30 subscales: - Physical functioning (PF) -Role functioning (RF) - Global health status/quality of life (GHS/QoL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

## Safety objectives

The safety objectives of IMbrave150 are to evaluate the safety and tolerability of atezolizumab administered in combination with bevacizumab compared with sorafenib monotherapy in patients with HCC as measured by the following endpoints:

- Incidence and severity of adverse events, with severity determined according to NCI CTCAE v4.0 (National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0)
- Vital signs
- Clinical laboratory test results

## Pharmacokinetic objectives

The pharmacokinetic (PK) objectives of IMbrave150 are to characterize the PK profile of atezolizumab when given in combination with bevacizumab. The pharmacokinetics of bevacizumab was not investigated in this study.

<div style=\"page-break-after: always\"></div>

## Immunogenicity objectives

The immunogenicity objectives of IMbrave150 are to evaluate the immune response to atezolizumab as measured by the presence of anti-drug antibodies (ADAs) to atezolizumab during the study relative to the presence of ADAs at baseline.

## Exploratory objectives

The exploratory objectives of IMbrave150 defined in the protocol and reported in this CSR are as follows:

- To evaluate the efficacy of atezolizumab administered in combination with bevacizumab compared to sorafenib monotherapy as measured by PFS, TTP, ORR, and DOR, as determined by the Investigator according to immune-modified RECIST
- To evaluate patient-reported outcomes (PROs) of disease/treatment-related symptoms (including abdominal pain and itching), global health status/quality of life, and function experienced by patients on atezolizumab+bevacizumab versus sorafenib, as measured by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and European Organization for the Research and Treatment of Hepatocellular Carcinoma Questionnaire 18 (EORTC QLQ-HCC18)
- To evaluate potential effects of ADAs to atezolizumab on efficacy or safety, and on the pharmacokinetics of atezolizumab+bevacizumab
- To identify tissue or blood-based biomarkers that are associated with response to atezolizumab+bevacizumab versus sorafenib, or can increase the understanding of HCC disease evolution under atezolizumab+bevacizumab treatment

## Outcomes/endpoints

Co-primary endpoint: OS and PFS by IRF

<div style=\"page-break-after: always\"></div>

Table 14: Statistical analysis of primary, secondary and exploratory efficacy endpoints

<!-- image -->

## Secondary endpoints:

- ORR: defined as a complete or partial response, as determined
- o by an IRF according to RECIST v1.1
- o by an IRF according to HCC mRECIST
- o by the Investigator according to RECIST v1.1
- DOR: defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) as determined
- o by an IRF according to RECIST v1.1
- o by an IRF according to HCC mRECIST
- o by the Investigator according to RECIST v1.1
- PFS as determined
- o by an IRF according to HCC mRECIST

<div style=\"page-break-after: always\"></div>

- o by the Investigator according to RECIST v1.1
- Time to Deterioration (TTD), defined as the time from randomization to first deterioration (decrease from baseline of ≥ 10 points), maintained for two consecutive assessments or one assessment followed by death from any cause within 3 weeks in the following EORTC QLQC30 subscales:
- o Physical functioning (PF)
- o Role functioning (RF)
- o Global health status/quality of life (GHS/QoL)

## Sample size

A total of approximately 480 patients was planned to be randomized in the global enrolment phase of this study, using a 2:1 randomization ratio to allocate patients to either the atezolizumab + bevacizumab arm (Arm A) or the sorafenib arm (Arm B).

The sample size of the study was determined based on the number of deaths required to demonstrate efficacy in terms of OS. To detect an improvement in OS using a log-rank test at a two-sided significance level of 0.048, approximately 312 deaths were considered to be required to achieve 80% overall power assuming a target HR of 0.71 (median OS improvement vs. control is 4.9 months).

## Randomisation

IMbrave150 was a randomized study. After written informed consent had been obtained, all screening procedures and assessments had been completed, and eligibility had been established for a patient, the study site obtained the patient's identification number and treatment assignment from the interactive voice or web-based response system (IxRS). Patients were randomized to one of two treatment arms, Atezo+Bev or sorafenib, according to a 2:1 randomization ratio using a permuted-block randomization method.

Randomization was stratified according to the following stratification factors:

- Geographic region (Asia excluding Japan vs. rest of world)
- Macrovascular invasion and/or extrahepatic spread (presence vs. absence)
- Baseline AFP (&lt;400 vs. ≥ 400 ng/mL)
- ECOG Performance Status (0 vs 1)

## Blinding (masking)

The study was an open-label study.

## Statistical methods

## Co -primary Endpoint: Overall Survival

To  detect  an  improvement  in  OS  using  a  log-rank  test  at  a  two-sided  significance  level  of  0.048., approximately  312  deaths  were  required  at  the  final  OS  analysis  to  achieve  an  overall  80%  power assuming a target hazard ratio (HR) of 0.71 (median OS improvement vs. control of 4.9 months). The minimum detectable difference (MDD) of OS is an HR of 0.783 (median OS improvement vs. control of 3.3 months). This analysis is expected to occur approximately 33 months after first-patient in (FPI). The

<div style=\"page-break-after: always\"></div>

estimates of the number of events required to demonstrate efficacy in the ITT population with regard to OS were based on the following assumptions:

- Patients were to be randomized to the Atezo+Bev and Sorafenib arms in a 2:1 ratio
- OS followed a one-piece exponential distribution
- The median OS in the control arm was to be 12 months
- The stopping boundaries of two interim analyses and the final analysis of OS were to use the O'Brien-Fleming boundaries approximated using the Lan-DeMets method
- The dropout rate was to be 5% for the Atezo+Bev arm and 10% for the Sorafenib arm over 12 months for OS
- The recruitment of approximately 480 patients was to take place over approximately 10 months

## Co-Primary Endpoint: Progression-Free Survival by IRF Assessment per RECIST v1.1

To detect an improvement in Progression-Free Survival per RECIST v1.1 by Independent Review Facility (IRF-PFS) using a log-rank test at a two-sided significance level of 0.002, approximately 308 events were required for the primary PFS analysis to achieve approximately 97% power with a target HR of 0.55 (median PFS improvement vs. control of 3.3 months). The MDD was a PFS HR of 0.688 (median PFS improvement vs. control of 1.8 months). The clinical cutoff date for this primary PFS analysis was expected to occur approximately 16 months after the first patient was enrolled in the study.

The estimates of the number of events required to demonstrate efficacy in the ITT population with regard to PFS were based on the following assumptions:

- Patients were to be randomized to the Atezo+Bev and Sorafenib arms in a 2:1 ratio
- PFS followed a one-piece exponential distribution
- The median PFS in the control arm was to be 4 months
- The dropout rate was to be 5% for the Atezo+Bev arm and 10% for the Sorafenib arm over 12 months for PFS
- The recruitment of approximately 480 patients was to take place over approximately 10 months

## Overall Type I Error Control

The overall type I error rate for this study was controlled at a two-sided significance level of 0.05 by a graphical approach, i.e., alpha splitting and recycling. The overall two-sided significance level of 0.05 was split into a two-sided significance level of 0.048 for the testing of OS and a two-sided significance level of 0.002 for the testing of PFS initially. If OS was statistically significant, the allocated two-sided significance  level  of  0.048  could  be  recycled  to  PFS  such  that  PFS  could  be  tested  at  a  two-sided significance level of 0.05 instead of 0.002. If the analysis of PFS was statistically significant, then the two-sided significance level of 0.002 (or 0.05 if OS was statistically significant) was to be recycled to key secondary endpoints (IRF-assessed ORR according to RECIST v1.1 and HCC mRECIST) to be formally tested in a hierarchical fashion. If PFS and both key secondary endpoints were statistically significant at a two-sided significance level of 0.002, then OS could be tested at a two-sided significance level of 0.05 instead  of  0.048.  An  overview  of  the  type  I  error  rate  control  strategy  for  the  co-primary  and  key secondary efficacy endpoints is shown in Figure 6.

<div style=\"page-break-after: always\"></div>

Figure 6: Overview of the type I error control for co-primary and key secondary endpoints

<!-- image -->

## Multiplicity Control for Key Secondary Endpoints

If the co-primary endpoint of IRF-PFS according to RECIST v1.1 was statistically significant, then ORRIRF (confirmation required) according to RECIST v1.1 and ORR-IRF (confirmation required) according to HCC mRECIST were to be hierarchically tested. Specifically, ORR-IRF per RECIST v1.1 was to be tested first and if it was statistically significant, ORR-IRF per HCC mRECIST was then to be tested. If ORR-IRF per  RECIST v1.1  was not statistically  significant,  ORR-IRF  per  HCC  mRECIST  was  not  to  be  tested. Implementation of this ordered statistical testing procedure will strongly control the type I error at 5% (two-sided) among all key hypotheses. The key secondary endpoints (ORR-IRF per RECIST v1.1 and ORR-IRF per HCC mRECIST) were to be tested at a two-sided alpha of 0.002 if the co-primary endpoint PFS-IRF per RECIST v1.1 has reached statistical significance at a two-sided alpha of 0.002, but OS has not reached statistical significance at the first interim analysis that was to be conducted at the time of the primary PFS analysis. On the other hand, if both co-primary endpoints of PFS and OS have reached statistical significance at the specified two-sided alpha level at the time of the primary PFS analysis, key secondary endpoints were to be tested at a two-sided alpha of 0.05.

## Analysis Timing

There were no interim analyses planned for the co-primary endpoint of IRF=PFS in this study. The primary analysis of IRF-PFS per RECIST v1.1 was to be conducted when approximately 308 PFS events had occurred in the ITT population. The clinical cutoff date for this primary PFS analysis was expected to occur approximately 16 months after the first patient was enrolled in the study.

Two interim analyses were planned to be conducted for OS. The first interim analysis was to be performed at the time of the primary PFS analysis. It was anticipated that at that time, approximately 172 deaths would have been observed. The respective MDD OS hazard ratio was 0.633 (median OS improvement vs.  control  of  6.9  months).  The  second  OS  interim  analysis  is  planned  to  be  conducted  when approximately 243 deaths have been accumulated, estimated to occur approximately 24 months after the first patient was enrolled in the study. The respective MDD OS hazard ratio is 0.728 (median OS improvement vs. control of 4.6 months).

The respective MDD OS hazard ratio for the final OS analysis is 0.783 (median OS improvement vs. control of 3.3 months).

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

In total, 725 patients were screened for entry into this study and 224 patients failed screening based on information collected on the IxRS. The most common specified reasons for screen failure included:

- inadequate hematologic and end-organ function (n=49)
- non-Child-Pugh Class A (n=29)
- withdrawal of consent (n=17)
- other (n=13; no additional information provided)
- active HBV with ≥ 500 IU/mL HBV DNA and/or no anti-HBV treatment as required (n=12)
- presence of untreated or incompletely treated oesophageal and/or gastric varices with bleeding or high-risk for bleeding (n=11), and
- presence of serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture (n=11).

As of the clinical cutoff date of 29 August 2019, 14.5% and 34.5% of patients in the Sorafenib arm and 43.5% and 24.4% of patients in the Atezo+Bev arm were continuing any study treatment or in survival follow-up, respectively.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Asoftheclinicalcutoffdate,fortheSorafenibarm,ofthe9patientswhodidnotreceive treatment, 7 patients withdrew from the study and 2 patients are ongoing in survival follow-up and for the Atezo+Bev arm, all 7 patients who did not receive any treatment withdrew from the study. For both treatment arms, patients withdrawn from study treatment as well as patients who did not receive study treatment contribute to the numbers displayed for the categories \"Ongoing survival follow-up\" and \"Withdrawn from study\". Atezo+Bev=atezolizumabplusbevacizumab

Figure 7: Disposition of patients - Imbrave150

<div style=\"page-break-after: always\"></div>

Table 15: Reasons for Discontinuation from Study Treatment (Safety-Evaluable Population)

|                                           | Sorafenib (N=156)   | Sorafenib (N=156)   | Atezo+Bev (N=329)   | Atezo+Bev (N=329)   | Atezo+Bev (N=329)   | Atezo+Bev (N=329)   |
|-------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|                                           | Sorafenib           |                     | Atezolizumab        | Atezolizumab        | Bevacizumab         | Bevacizumab         |
| Received At Least One Study Treatment Yes |                     | 156 (100%)          |                     | 329 ( 100%)         |                     | 329 ( 100%)         |
| Treatment Status Ongoing                  |                     | 24 (15.4%)          |                     | 146 (44.4%)         |                     | 137 (41.6%)         |
| Withdrawn from treatment                  |                     | 132 (84.6%)         |                     | 183 (55.6%)         |                     | 192 (58.4%)         |
| Withdrawn From Treatment Reason DEATH     | 7                   | (4.5%)              |                     | 15 ( 4.6%)          |                     | 16 ( 4.9%)          |
| ADVERSE EVENT                             | 16                  | (10.3%)             | 29                  | (8.8%)              | 49                  | (14.9%)             |
| SYMPTOMATIC DETERIORATION                 | 4                   | ( 2.6%)             | 10                  | ( 3.0%)             | 9                   | (2.7%)              |
| PROGRESSIVEDISEASE                        | 93                  | (59.6%)             | 111                 | (33.7%)             |                     | 100 (30.4%)         |
| PHYSICIAN DECISION                        | 4                   | ( 2.6%)             | 3                   | (0.9%)              | 4                   | (1.2%)              |
| WITHDRAWAL BY SUBJECT                     | 7                   | (4.5%)              | 15                  | (4.6%)              | 14                  | (4.3%)              |
| OTHER                                     | 1                   | ( 0.6%)             | 0                   |                     | 0                   |                     |

Table 16: Patient Disposition from Study (ITT Population)

|                       | Sorafenib (N=165)   | Sorafenib (N=165)   | Atezo+Bev (N=336)   | Atezo+Bev (N=336)   | All Patients (N=501)   | All Patients (N=501)   |
|-----------------------|---------------------|---------------------|---------------------|---------------------|------------------------|------------------------|
| Received Treatment    |                     | 156 (94.5%)         | 329                 | (97.9%)             |                        | 485 (96.8%)            |
| On study              | 81                  | (49.1%)             | 228                 | (67.9%)             | 309                    | (61.7%)                |
| On Treatment          | 24                  | (14.5%)             | 146                 | (43.5%)             | 170                    | (33.9%)                |
| In Follow-Up          | 57                  | (34.5%)             |                     | 82 (24.4%)          |                        | 139 (27.7%)            |
| Discontinued study    | 84                  | (50.9%)             | 108                 | (32.1%)             | 192                    | (38.3%)                |
| Death                 | 65                  | (39.4%)             | 95                  | (28.3%)             | 160                    | (31.9%)                |
| Progressive disease   | 0                   |                     | 1                   | ( 0.3%)             | 1                      | ( 0.2%)                |
| Withdrawal by subject | 19                  | (11.5%)             |                     | 12 ( 3.6%)          |                        | 31 ( 6.2%)             |

\"On Treatment\" indicates that the patient is still receiving at least one of the study treatments.

## Recruitment

First patient enrolled: 15 March 2018, Last patient enrolled: 30 January 2019, Data cut-off: 29 August 2019

111 sites in 17 countries/regions. The number of patients enrolled and randomized per country/region, followed by the number of centers (in parentheses): China mainland 78 (15), United States 74 (19), Japan 61 (13), Republic of Korea 47 (6), France 42 (10), Taiwan 41 (5), Hong Kong 18 (2), Russian Federation 24 (2), Poland 23 (5), Italy 17 (6), Singapore 17 (2), Germany 16 (7), United Kingdom 13 (4), Spain 11 (5), Australia 9 (4), Canada 5 (4), Czech Republic 5 (2).

## Conduct of the study

## Changes in Conduct of Study

The first version of the protocol was issued on 18 October 2017 and was amended three times. The key changes to the protocol along with the rationale are summarised in Table 6.

<div style=\"page-break-after: always\"></div>

Table 17: Summary of protocol amendments

<!-- image -->

| Protocol Amendment (Date)   | Key Changes and Rationale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Version 1 (18 0ct 2017)     | Original protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Version 2(14 March2018)     | First version under which patients were treated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Version 3 (15 Sep 2018)     | The co-primary endpointsforthestudywere changed from Investigator-assessedORRandOStoIRF-assessedPFSand OS, given that ORR for atezolizumab + bevacizumab was being extensivelyinvestigated inthePhaseIbstudyGO30140 The eligibility criteria were updated to refine the patient population, with the intent to ensure the safety of the patients, considering the toxicity profile of the study drugs The window for assessing EcOG performance status, Child-Pugh Class A, and adequate hematologic and end-organ function lab tests was shortened from 14 days to 7 days prior to randomization toensurefitpatientswereenrolledandtoexcludepatientswho could have progressively deteriorating liver function and overall health status Immune-related nephritis was added as an important identified risk for atezolizumab along with management guidelines |
| Version 4 (20 Feb 2019)     | statistical analysis and to align with the SAP to include a second Other changes in the statistical analysis plan included: Themethod usedforcontrolof theoverall typeIerrorratewas 5% (two-sided) The secondary endpoint for PROs of TTD was amended to align with the co-primary endpoints of PFS and OS PFSwasadded astheprimaryendpointof theChina                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

ADA=anti-drug antibody; HCC =hepatocellular carcinoma; INV=Investigator; IRF=independent review facility; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; PRO=patient-reported outcome; PK = pharmacokinetic; TTD = time to deterioration.

## Changes in Planned Analyses

## Protocol deviations

As of the clinical cutoff date of 29 August 2019, 33.7% of all randomized patients had at least one major protocol deviation. The overall frequency and type of major protocol deviations were generally similar across the treatment arms.

<div style=\"page-break-after: always\"></div>

Table 18: Major protocol deviations (ITT population)

| Protocol Deviation Category Protocol Deviation Description                                    | Sorafenib (N=165)   | Atezo+Bev (N=336)   | A11 Patients (N=501)   |
|-----------------------------------------------------------------------------------------------|---------------------|---------------------|------------------------|
| Totalnumber ofpatientwith atleast one deviation                                               | 49(29.78)           | 120 (35.78)         | 169 (33.78)            |
| Overall total number of deviations                                                            | 70                  | 224                 | 294                    |
| EXCLUSION CRITERIA                                                                            |                     |                     |                        |
| Total number of patient with at least one deviation                                           | (0.68)              | 5 1.58)             | 6 (1.28) 6             |
| Totalnumber of events Active or history of autoimmune disease or immune deficiency            | 1 (0.68)            | 5 0                 | 1 (0.2%)               |
| Currentorrecentuseofaspirinor trmt with dipyramidole, ticlopidine, clopidogrel, cilostazol    | 0                   | 1 (0.38)            | 1 (0.2%)               |
| Known fibrolamellar HCC, sarcomatoid HCc, or mixed cholangiocarcinoma and HCC                 | 0                   | 1 (0.3%)            | 1 (0.28)               |
| Major surgical procedure, open biopsy, significant                                            | 0                   | 1 (0.3%)            | 1 (0.28)               |
| Treatment withtherapeutic oral or IVantibiotics within 2 weeks prior to initiation of IP      | 0                   | 1 (0.3%)            | 1 (0.28)               |
| chronic daily trmt w/a non steroidal anti- inflammatory drug                                  | 0                   | 1 (0.3%)            | 1 (0.2%)               |
| INCLUSION CRITERIA                                                                            |                     |                     |                        |
| Totalnumber ofpatientwith at least one deviation                                              | 6 (3.6%)            | 1.28)               | 10 (2.0%)              |
| Total number of events Adequate hematologic and end-organ function as defined in the protocol | 6 3 (1.88)          | 4 3 (0.98)          | 10 6 (1.28)            |
| At least one measurable (per RECISTvl.l)untreated lesion                                      | 1 (0.68)            | 0                   | 1 (0.28)               |
| Child-Pugh class A HBVDNA<500IU/mlw/in28daysandantiHBVtrmt                                    | 0 (0.6%)            | 1 (0.38) 0          | 0.28） 0.28）            |
| forminimum of 14d andwiiling to_continue trmt no prior systemic treatment for HCC             | (0.68)              | 0                   | 1 (0.2%)               |
| MEDICATION                                                                                    |                     |                     |                        |
| Total number of patient with at least one deviation                                           | 9 (5.58)            | 28 (8.38)           | 37 (7.48) 44           |
| Total number of events Received prohibited concomitant medication                             | 9 2 1.28)           | 35 0                | 2 0.48)                |
| Sig deviation from dose except AE management                                                  | 23 1.28)            | 2 0.68)             | 4 0.8%)                |
| Sig deviation from scheduled drug admin visit                                                 | 1.8%)               | 12 3.68)            | 15 3.08)               |
| Sig deviation from study med acministration                                                   | 1 0.68)             | 13 3.98)            | 14 2.88)               |
| Use of protocol-prohibited therapy (Section 4.4.3)                                            | 0.68)               | 1 0.38)             | 2 0.48)                |
| PROCEDURAL                                                                                    |                     |                     |                        |
| Total number of patient with at least one deviation                                           | 42 (25.58)          | 105 (31.38) 180     | 147 (29.38) 234        |
| Totalnumber of events Change in imaging modality impacting the primary                        | 54 (0.68)           | 0                   | (0.28)                 |
| encipoint Deviation from reporting timelines SAEs                                             | 5 (3.0%)            | 10 3.08)            | 15 3.08)               |
| Error with stratification                                                                     | 0                   | 0.38)               | 1 0.28)                |
| Error with randomization                                                                      | 6 (5.58)            | 39 (11.6%)          | 48 9.68)               |
| ICF not sigmed by patient or study personnel Missing consent to updated ICF                   | 0 2 1.28)           | 21 (89:0 3.38)      | 2 0.48) 13 2.68)       |
| Missing or out of window assessment impact study                                              | 13 7.98)            | 33 9.8%)            | 46 (9.28)              |
| integrity, _safety No signed ICF for optional RBR                                             | 0                   | 1 0.38)             | 1 0.28)                |
| Omission of labs prior to drug acministration                                                 | 5 3.08)             | 24 18)              | 29 5.88)               |
| Omission of tumorassessment                                                                   | 14 (8.58)           | 31 9.28)            | 45 (9.0%)              |

The percentage of patients with protocol deviations for each of the 5 categories of protocol deviations highlighted by CHMP is presented in the table below.

Table 19: Selected Categories of Protocol Deviations, Intent-to-Treat Population

| Protocol Deviation Category a                                      | Sorafenib (N = 165)   | Atezo + Bev (N = 336)   |
|--------------------------------------------------------------------|-----------------------|-------------------------|
| Deviation from scheduled drug administration visit                 | 3 (1.8%)              | 12 (3.6%)               |
| Deviation from study medication administrations                    | 1 (0.6%)              | 13 (3.9%)               |
| Error with stratification                                          | 9 (5.5%)              | 39 (11.6%)              |
| Missing or out of window assessment impact study integrity, safety | 13 (7.9%)             | 33 (9.8%)               |
| Omission of lab tests prior to drug administration                 | 5 (3.0%)              | 24 (7.1%)               |

a A patient will be only counted once if received more than one deviation of the same type.

Many of the deviations that occurred in these categories in the Atezo + Bev arm were missed thyroid panels, missed urinalysis tests, or missed components of other lab panels.

Table 20: Stratification Factor Errors

| Stratification Factor Error                       | Atezo + Bev (Arm A)   | Sorafenib (Arm B)   |
|---------------------------------------------------|-----------------------|---------------------|
| Geographic Region                                 | 0                     | 0                   |
| Macrovascular invasion and/or extrahepatic spread | 31*                   | 8                   |
| Baseline AFP                                      | 3                     | 1                   |
| ECOG Status                                       | 6*                    | 0                   |
| Total                                             | 40 errors             | 9 errors            |

AFP = Alpha Feto-Protein; ECOG = Eastern Cooperative Oncology Group.

<div style=\"page-break-after: always\"></div>

* = one patient, randomized to Arm A, had 2 stratification errors; 1) macrovascular invasion and/or extrahepatic spread and 2) ECOG status

## Baseline data

Table 21: Demographic and baseline disease characteristics

|                                              | Sorafenib (N=165)                            | Atezo+Bev (N=336)       | A11 Patients (N=501)      |
|----------------------------------------------|----------------------------------------------|-------------------------|---------------------------|
| Age (yr)                                     |                                              |                         |                           |
| n Median                                     | 165 66.0                                     | 336 64.0                | 501 65.0                  |
| Age group (yr)                               |                                              |                         |                           |
| n                                            | 165                                          | 336 18 (5.48)           | 501 25 (5.0%) 224 (44.7%) |
|                                              | (4.28) 67 (40.6%) 91 (55.2%)                 | 157 (46.78)             |                           |
| 18-40                                        |                                              |                         |                           |
| 41-64 >=65                                   |                                              | 161 (47.9%)             | 252 (50.38)               |
| Sex                                          |                                              |                         |                           |
| n                                            | 165                                          | 336                     | 501                       |
| Male                                         | 137 (83.0%)                                  | 277 (82.48)             | 414 (82.6%)               |
| Race                                         |                                              |                         |                           |
| n                                            | 165                                          | 336                     | 501                       |
| Asian                                        | 96 (58.28)                                   | 188 (56.08)             | 284 (56.78)               |
| White                                        | 52 (31.5%)                                   | 123 (36.6%)             | 175 (34.98)               |
| Geographic Region (eCRF)                     |                                              |                         |                           |
| n.                                           | 165                                          | 336                     | 501                       |
| Asia (excluding Japan)                       | 68 (41.28)                                   | 133 (39.6%)             | 201 (40.1%)               |
| Rest of World                                | 97(58.8%)                                    | 203 (60.48)             | 300 (59.98)               |
| ECoG Performance Status at Screening _(eCRF) | ECoG Performance Status at Screening _(eCRF) |                         |                           |
| no                                           | 165                                          | 336                     | 501                       |
| 1                                            | 103 (62.48) 62 (37.6%)                       | 209 (62.28) 127 (37.8%) | 312 (62.38) 189 (37.7%)   |
| PD-Ll Category 1                             |                                              |                         |                           |
| n                                            | 58                                           | 124                     | 182                       |
| TC and IC < 18                               | 25 (43.1%)                                   | 45 (36.38)              | 70 (38.58)                |
| TC or IC >= 18                               | 33 (56.98)                                   | 79 (63.78)              | 112 (61.58)               |
| PD-Ll Category 2                             |                                              |                         |                           |
| n                                            | 58                                           | 124                     | 182                       |
| TC and IC< 58                                | (70.78)                                      | 78 (62.98)              | 119 (65.4号)               |
| TC or IC >= 58                               | 1 (29.38)                                    | 46 (37.18)              | 63 (34.68)                |
| PD-Ll Category 3                             |                                              |                         |                           |
| n                                            | 58                                           | 124                     | 182                       |
| TC and IC < 108                              | 53(91.48)                                    | 112 (90.38)             | 165 (90.78)               |
| TC or IC >= 10                               | 5 (8.68)                                     | 12 (9.78)               | 17 (9.38)                 |

the viralcause was prioritized over non-viral causes to define the primary etiology of the patient.

the calculations of Time from Initial Diagmosis.

[2]Apatient may have more than one cause of disease.

<div style=\"page-break-after: always\"></div>

Table 22: Hepatocellular carcinoma history and disease characteristics (ITT population)

|                                                             | Sorafenib (N=165)                                           | Atezo+Bev (N=336)                                           | A11 Patients (N=501)          |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------|
| BCLCStage at Study Entry                                    |                                                             |                                                             |                               |
| n                                                           | 165                                                         | 336                                                         | 501                           |
| STAGE A1                                                    | 3 (1.8%)                                                    | (1.58)                                                      | 8 (1.68)                      |
| STAGE A4                                                    | 3(1.8%)                                                     | 3 (0.98)                                                    | 6 (1.2%)                      |
| STAGE B                                                     | 26 (15.8%)                                                  | 52 (15.58)                                                  | 78 (15.68)                    |
| STAGE C                                                     | 133(80.68)                                                  | 276 (82.1%)                                                 | 409 (81.68)                   |
| Etiology of HCC                                             |                                                             |                                                             |                               |
| n                                                           | 165                                                         | 336                                                         | 501                           |
| Hepatitis B                                                 | 76 (46.18)                                                  | 164 (48.8%)                                                 | 240 (47.98)                   |
| Hepatitis C                                                 | 36 (21.88)                                                  | 72 (21.48)                                                  | 108 (21.68)                   |
| Non-viral                                                   | 53 (32.1%)                                                  | 100 (29.8%)                                                 | 153 (30.58)                   |
| Extrahepatic Spread (EHS) Present at Study Entry (eCRF)     | Extrahepatic Spread (EHS) Present at Study Entry (eCRF)     |                                                             |                               |
| n                                                           | 165                                                         | 336                                                         | 501                           |
| Yes                                                         | 93(56.48)                                                   | 212 (63.18)                                                 | 305 (60.98)                   |
| Macro-Vascular Invasion (MVI) Present at Study Entry (eCRF) | Macro-Vascular Invasion (MVI) Present at Study Entry (eCRF) | Macro-Vascular Invasion (MVI) Present at Study Entry (eCRF) |                               |
| n                                                           | 165                                                         | 336                                                         | 501                           |
| Yes                                                         | 71 (43.08)                                                  | 129 (38.48)                                                 | 200 (39.9%)                   |
| EHS and/or MVI Present at Study Entry_ (eCRF)               | EHS and/or MVI Present at Study Entry_ (eCRF)               | EHS and/or MVI Present at Study Entry_ (eCRF)               |                               |
| n Yes                                                       | 165 120 (72.7%)                                             | 336 258 (76.88)                                             | 501 378 (75.48)               |
| Child Pugh Category                                         | Child Pugh Category                                         |                                                             |                               |
| n A5                                                        | 165                                                         | 334                                                         | 499                           |
|                                                             | 121 (73.3%)                                                 | 239 (71.6%)                                                 | 360 (72.18)                   |
| A6 B7                                                       | 44 (26.78) 0                                                | 94 (28.18) 1(0.3%)                                          | 138 (27.7%) 1 (0.28)          |
| Baseline Sum of Target Lesion Diameter ANI ted (u)          | Baseline Sum of Target Lesion Diameter ANI ted (u)          | Baseline Sum of Target Lesion Diameter ANI ted (u)          |                               |
| n                                                           | 164                                                         | 336                                                         | 500                           |
| Mean (SD)                                                   | 92.32 (63.53)                                               | 84.51 (58.82)                                               | 87.08 (60.45)                 |
| Median                                                      | 83.20                                                       | 71.80                                                       | 74.00                         |
| Min - Max                                                   | 10.0-312.0                                                  | 10.0 - 321.0                                                | 10.0-321.0                    |
| AFP Category at Screening (eCRF)                            | AFP Category at Screening (eCRF)                            |                                                             |                               |
| n                                                           | 165                                                         | 336                                                         | 501                           |
| <400_ng/mL >=400 ng/mL                                      | 104 (63.0%) 61 (37.0%)                                      | 210 (62.58) 126 (37.5%)                                     | 314 (62.7%) 187 (37.38)       |
| Varices at time of Enrollment                               | Varices at time of Enrollment                               | Varices at time of Enrollment                               | Varices at time of Enrollment |
| n Yes                                                       | 165 43 (26.18)                                              | 336 88 (26.28)                                              | 501 131 (26.18)               |
|                                                             | 85                                                          | 161                                                         | 246                           |
| Type of Prior Local Therapy                                 | Type of Prior Local Therapy                                 | Type of Prior Local Therapy                                 | Type of Prior Local Therapy   |
| n                                                           |                                                             |                                                             | 71 (14.2%)                    |
| Radiofrequency Ablation (RFA)                               | 24 (14.58)                                                  | 47 (14.0%)                                                  | 200 (39.98)                   |
| Transarterial Chemoembolization (TACE)                      | 70 (42.48)                                                  | 130 (38.7%)                                                 |                               |
| Prior Cancer Radiotherapy                                   | Prior Cancer Radiotherapy                                   | Prior Cancer Radiotherapy                                   | Prior Cancer Radiotherapy     |
| n Yes                                                       | 165 17 (10.3%)                                              | 336 34 (10.18)                                              | 501 51 (10.28)                |

the

[l]Partial Diagnosis date is imputed with lst day of the month if the day ismissing in viral cause was prioritized over non-viral causes to define the primary etiology of the patient.

the calculations of Time from Initial Diagmosis.

[2]Apatient may have more than one cause of disease.

120CT2019 4:48

Table 23: Prior local hepatocellular carcinoma treatment history (ITT population)

|                                                                | Sorafenib (N=165)   | Atezo+Bev (N=336)   | Atezo+Bev (N=336)   |
|----------------------------------------------------------------|---------------------|---------------------|---------------------|
| Totalnumber of patientswith at least one treatment             | 85 (51.5%)          |                     | 161 (47.98)         |
| Totalnumber of treatments                                      | 296                 |                     | 548                 |
| Therapy Intent                                                 |                     |                     |                     |
| ADJUVANT                                                       | 10 (6.18)           |                     | 14( 4.28)           |
| CURATIVE                                                       | 44 (26.7%)          |                     | 86 (25.6%)          |
| NEO-ADJUVANT                                                   | 4                   |                     | (1.8%)              |
| PALLIATIVE                                                     | （2.48） 36 (21.88)   |                     | 61 (18.28)          |
| Other                                                          | 3 (1.88)            |                     | 11 ( 3.3%)          |
| Name of Therapy                                                |                     |                     |                     |
| PercutaneousEthanol Injection (PEI)                            | 3 (1.8%)            |                     | 12(3.68)            |
| Radiofrequency_Ablation (RFA)                                  | 24 (14.58)          | 47                  | (14.08)             |
| Transarterial Embolization (TAE)                               | 8 (4.8%)            | 12                  | (3.68)              |
| Transarterial Chemoembolization (TACE)                         | 70 (42.48)          | 130                 | (38.78)             |
| Drug Eluting Beads -Transarterial Chemoembolization (DEB-TACE) | 1 0.68)             | 3                   | 0.9%)               |
| Transcatheter Arterial Infusion (TAI)                          | 2 1.28)             | 3                   | 0.98)               |
| Transarterial Radioembolization (TARE)                         | 4 2.4%)             | 8                   | 2.48)               |
| Other                                                          | 4.28)               |                     | 6 1.88)             |

Multiple cases within a specific therapy intent or name of therapy for apatient were counted once in the frequency for the therapy intent or name of therapy.

<div style=\"page-break-after: always\"></div>

Table 24: Prior hepatocellular carcinoma radiation therapy (ITT population)

<!-- image -->

| Therapy Setting Site                                 | Sorafenib (N=165)   | Atezo+Bev (N=336)   |
|------------------------------------------------------|---------------------|---------------------|
| Totalnumber ofpatientswith at least onetreatment     | 17 (10.3%)          | 34 (10.18)          |
| Totalnumber of treatments                            | 22                  | 36                  |
| PALLIATIVE                                           |                     |                     |
| Totalnumber ofpatientswith at least one treatment    | 8 (4.8%)            | 24 (7.1%)           |
| Total_numberoftreatments                             | 12                  | 25                  |
| ABDOMINAL CAVITY                                     | 0                   | 0.38)               |
| BONE                                                 | 2 1.28)             | 13 0.98)            |
| BRAIN                                                | 1 0.68)             | 0                   |
| LIVER                                                | 2.48)               | 17 5.18)            |
| LYMPH NODE                                           | 0                   | 1 0.3%)             |
| PELVIS                                               |                     | 1 0.38)             |
| STOMACH                                              | 0.68)               | 0                   |
| OTHER                                                | 0.6%)               | (0.38)              |
| OTHER                                                |                     |                     |
| Total number ofpatients with at least one treatment  | 4 (2.48)            | 3 (0.9%)            |
| Total number of treatments                           | 4                   | 3                   |
| LIVER                                                | 4 （ 2.4%)           | ② 0.6%)             |
| MEDIASTINUM                                          | 0                   | 0.38)               |
| METASTATIC                                           |                     |                     |
| Total number ofpatientswith at least one treatment   | 3 1.8%)             | 3 (0.98)            |
| Total number of treatments                           | 4                   | 3                   |
| BONE                                                 | 0                   | 1 0.38)             |
| LIVER                                                | 2 1.28)             | 1 (0.38)            |
| LUNG                                                 | 0.6%)               | 0                   |
| OTHER                                                | 0                   | 1 (0.3%)            |
| ADJUVANT                                             |                     |                     |
| Total number of patients with at least one treatment | 2 (1.2%)            | 3 (0.9%)            |
| Total number of treatments                           | 2                   | 3                   |
| LIVER                                                | 0.6%)               | 3 (0.9%)            |
| PROSTATE GLAND                                       | 0.6%)               | 0                   |
| NEO-ADJUVANT                                         |                     |                     |
| Total number of patientswithatleast onetreatment     | 0                   | 2 (0.6%)            |
| Total number of treatments                           | 0                   | 2                   |
| LIVER                                                | 0                   | 2 (0.6%)            |

frequency for the therapy setting.

## Concomitant Treatments for HCC

During the study period, radiation therapy was given to a small number of patients for palliative reasons only: 1 patient in the Sorafenib arm and 5 patients in the Atezo+Bev arm. Radiation therapy to bone was the predominant radiotherapy site reported (5 patients), 1 patient received radiation therapy to liver and 1 patient to lung. During the study period, 3 patients in each treatment arm received cancer-related surgery.

<div style=\"page-break-after: always\"></div>

Table 25: On-study Hepatocellular Carcinoma-Related Surgery

| On-study Surgery On-study Surgery Location           | Sorafenib (N=165)   | Atezo+Bev (N=336)   |
|------------------------------------------------------|---------------------|---------------------|
| Totalnuumber of patients with at leastone treatment  | 3 (1.8%)            | 3 (0.9%)            |
| Total number of treatments                           | 6                   | 4                   |
| PALLIATIVE                                           |                     |                     |
| Total number of patients with at least one treatment | 3 (1.8%)            | 1 (0.3%)            |
| Total number of treatments                           | 6                   | 1                   |
| BONE                                                 | 0                   | 1 (0.3%)            |
| ESOPHAGUS                                            | 1 (0.6%)            | 0:0                 |
| LIVER                                                | 1 (0.6%)            |                     |
| OTHER                                                | 1 (0.6%)            | 0                   |
| CURATIVE                                             |                     |                     |
| Total number of patients with at least one treatment | 0                   | 1 (0.3%)            |
| Total number of treatments                           | 0                   | 1                   |
| LIVER                                                | 0                   | 1 (0.3%)            |
| DIAGNOSTIC                                           |                     |                     |
| Total number of patients with at least one treatment | 0                   | 1 (0.3%)            |
| Totalnumberof treatments                             | 0                   | 2                   |
| LIVER                                                | 0                   | 1 (0.3%)            |

surgery.

## Numbers analysed

Table 26: Analysis populations (all patients)

|                                          |   Sorafenib |   Atezo+Bev |
|------------------------------------------|-------------|-------------|
| All Randlomized Intent-to-Treat Patients |         165 |         336 |
| AllSafetyEvaluable Patients              |         156 |         329 |
| AllPRO EvaluablePatients                 |         145 |         309 |
| AllADAEvaluablePatients                  |           0 |         315 |
| AllPK EvaluablePatients                  |           0 |         324 |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Co-primary endpoint - OS and PFS

Table 27: Overview of efficacy: co-primary and key secondary efficacy endpoints (ITT population)

|                                    | Sorafenib N =165     | Atezo+Bev N=336      |
|------------------------------------|----------------------|----------------------|
| Co-Primary Endpoints               | Co-Primary Endpoints | Co-Primary Endpoints |
| Overall Survival                   |                      |                      |
| No. (%) of patients with event     | 65 (39.4%)           | 96 (28.6%)           |
| Median, months                     | 13.24                | NE                   |
| 95% CI                             | (10.41, NE)          | NE                   |
| Stratified hazard ratio (95% Cl) a | 0.58 (0.42, 0.79)    | 0.58 (0.42, 0.79)    |
| p-value (log-rank)                 | 0.0006               | 0.0006               |
| 6-month OS (%)                     | 72.2%                | 84.8%                |
| IRF-AssessedPFSperRECISTv1.1       |                      |                      |
| No. (%) of patients with event     | 109 (66.1%)          | 197 (58.6%)          |
| Median, months                     | 4.27                 | 6.83                 |
| 95% CI                             | (3.98, 5.55)         | (5.75, 8.28)         |
| Stratified hazard ratio (95% Cl) a | 0.59 (0.47, 0.76)    | 0.59 (0.47, 0.76)    |
| p-value (log-rank)                 | <0.0001              | <0.0001              |
| 6-month PFS (%)                    | 37.2%                | 54.5%                |

<!-- image -->

Hazardraticand p-value arefromstratifiedanalysis Straltification factors include geographic region (Asia excluding Japan vs. rest of world). macrovascular invasion and/or extrahepatic spread (presence vs. absence) and AFP (&lt;400 vs. &gt;=400 ng/mL) at screening per IxRS.

Figure 8: Kaplan-Meier plot of overall survival (ITT population) - cut-off date: 29 August 2019

<div style=\"page-break-after: always\"></div>

<!-- image -->

Hazardratioandp-valuearefromstratifiedanalysis. Stratification factors include geographicregion(Asia excluding Japan vs.rest of world).macrovascular invasion and/orextrahepatic spread (presencevs.absence)and AFP(&lt;400 vs.&gt;=400 ng/mL)at screening per IxRS.

Figure 9: Kaplan-Meier plot of progression-free survival based on IRF-assessment per RECIST v1.1 (ITT population) - cut-off date: 29 August 2019

The MAH has computed adjusted p-values for all efficacy endpoints that were formally tested (co-primary endpoints: OS and IRF-assessed PFS per RECIST version 1.1; key secondary endpoints: IRF-assessed ORR per RECIST v1.1 and per HCC modified RECIST) using the method described in Bretz et al. 2009. These adjusted p-values adjust for multiplicity of the co-primary and key secondary efficacy endpoints, in the context of the group-sequential design of OS (as described in the protocol), and therefore are to be compared with the overall two-sided alpha of 0.05.  Table 31 lists the unadjusted observed p-values as reported in the IMbrave150 CSR (versus the respective multiplicity adjusted alpha boundaries) and the respective adjusted p-values (versus alpha boundary of 0.05, two-sided) for the co-primary and key secondary efficacy endpoints that were formally tested in IMbrave150.  All p-values, confidence intervals, alpha boundaries in Table 31 are two sided.  The statistical testing conclusions remain the same after the adjustment.

Table 28: Adjusted and Unadjusted P-values for Co-Primary and Key Secondary Efficacy Endpoints in IMbrave150

| Endpoint               | Unadjusted Observed P-value vs multiplicity adjusted Alpha Boundary   | Adjusted P-value vs Alpha Boundary of 0.05   | Comments            |
|------------------------|-----------------------------------------------------------------------|----------------------------------------------|---------------------|
| OS                     | 0.0006 vs 0.0033                                                      | 0.0006 vs 0.05                               | Boundary is crossed |
| PFS (IRF-RECIST v1.1)  | < 0.0001 vs 0.02                                                      | 0.0005 vs 0.05                               | Boundary is crossed |
| ORR (IRF- RECIST v1.1) | < 0.0001 vs 0.02                                                      | 0.0006 vs 0.05                               | Boundary is crossed |
| ORR (IRF- HCC mRECIST) | < 0.0001 vs 0.02                                                      | 0.0006 vs 0.05                               | Boundary is crossed |

IRF = Independent Review Facility; mRECIST = modified RECIST; ORR = objective response rate;  OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumors.

Key secondary endpoints

<div style=\"page-break-after: always\"></div>

Table 29: Confirmed objective response rate based on IRF-assessment per RECIST v1.1 (ITT population with measurable disease at baseline)

|                                                                                                                                              | Sorafenib (N=159)       |                                              | Ateso+Bev (N=326)        |
|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|----------------------------------------------|--------------------------|
| Reapgnders 95FCI                                                                                                                             | 19(11.98) (7.35, 18.03) |                                              | 89(27.31) (22.54, 32.48) |
| Stratified Analysis Difference in Orerall Response Rates (95+ C1) p-value (Cochrsn-Mentel-Hhenssel) Odds Ratio for Overall Response (95t (15 |                         | 15.35 (7.90, 22.81) <.0001 2.90 (1.68, 5.01) |                          |
| Complete Response (CR) 951 CI                                                                                                                | D (0.00,2.29)           |                                              | 18 ( 5.54) (3.30,8.59)   |
| Partial Response (PR) 95: CI                                                                                                                 | 19_(11.9) (7.35, 18.03) |                                              | 71(21.8) (17.42, 26.66)  |
| Stable 0isea9e (80) 95+ CI                                                                                                                   | 69(43.41) (35.57,51.48) |                                              | 151(46.3) (40.81, 51.90) |
| Progressive Disesse (PD) 951 C1                                                                                                              | 39(24.5) (18.06,31.97)  |                                              | 64(19.6) (15.46, 24.37)  |
| Not Evaluable (NE) Missing                                                                                                                   | 14(8.8) 18 (11.3)       |                                              | 8 (2.51) 14 4.31         |

<!-- image -->

Table 30: Confirmed objective response rate based on IRF-assessment per HCC mRECIST (ITT population with measurable disease at baseline)

|                                                                                                                                            | Sorafenib (N=158)       |                                            | Ateno+Bev (N=325)        |
|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|--------------------------------------------|--------------------------|
| 96 C                                                                                                                                       | 21(13.3) (8.42,19.60)   |                                            | 108(33.2) (28.13, 38.64) |
| Stratified Analysis Differenge in Overall Response Rates (95+CI) P-value (Cochran-Mantel-iaenssel) Odds Ratio for Overall Responss (95:C1) |                         | 19.94(12.10,27.76) c.0001 3.39 (2.02,5.71) |                          |
| Complete Response (CR) 95+ CI                                                                                                              | 3 (1.9) (0.39, 5.45)    |                                            | 33(10.2) (7.09, 13.96)   |
| Rartial Response (FR) 951 C1                                                                                                               | 18_(11.4) (6.89, 17.41) |                                            | 75(23.1) (18.61, 28.05)  |
| Btsble Disease (80) 10496                                                                                                                  | 66(41.6) (33.99,49.87)  |                                            | 127(39.1) (33.74,44.62)  |
| Brogressive Disease (PD) 95R CI                                                                                                            | 40(25.3) (18.74, 32.84) |                                            | 66(20.3) (16.07, 25.10)  |
| Not Evaluable (NE) Missing                                                                                                                 | 14 [8.9#) 7 (10.81)     |                                            | 10 (3.1) 14 (4.38)       |

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 31: Duration of confirmed response based on IRF-assessment per RECIST v1.1 (confirmed responders population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 32: Duration of confirmed response based on IRF-assessment per HCC mRECIST (confirmed responders population)

|                                                                            | Sorafenib (N=158)   | Ateno+Bav (N=325)   |
|----------------------------------------------------------------------------|---------------------|---------------------|
| Patients included in analysis (H)                                          | 21 ( 1008)          | 108 ( 1008)         |
| Patients with event (H) Earliest contributing event Death                  | 8(38.18)            | 24(22.28)           |
|                                                                            |                     | 8                   |
| Disease Progression                                                        |                     | 16                  |
| Patients without event (H)                                                 | 13(61.98)           | 84(77.88)           |
| Time to Event (Months) Median. 951 C1                                      | 6.28 14.86. NE)     | NE NE               |
| 251 and 75t-i1e Range                                                      | 4.86.ME             | 8.15, NE            |
|                                                                            | 1.4* to 9.1*        |                     |
|                                                                            |                     | 1.3* to 13.4*       |
| Stratified Analysig p-value (log-renk)                                     |                     | 0.0048              |
| Hagard Ratio 951 C1                                                        |                     | 0.30 (0.12,0.73)    |
| Unutratified Analysis p-value (log-renk)                                   |                     | 0.0293              |
| Harard Ratio 951 C1                                                        |                     | 0.42 (0.18, 0.94)   |
| Time Point Analysis 6 Months Patients remnining Et risk Event Free Rate () | 62.50               | 51 82.25            |
| Year Patients remeining atrisk ()                                          | (38.34,86.66) E     | 5 65.29             |
| Euent Free Rate                                                            | NE                  |                     |
| 95+ CI                                                                     |                     | (52.84,77.75)       |

<!-- image -->

## PRO

Table 33: Summary of the PRO secondary efficacy endpoints (ITT population)

<!-- image -->

| Endpoint/Scale                        | Sorafenib N = 165                           | Atezo+Bev N = 336                           |
|---------------------------------------|---------------------------------------------|---------------------------------------------|
|                                       | TTD: Median (95% Cl) Time to Event (Months) | TTD: Median (95% Cl) Time to Event (Months) |
| PhysicalFunctioningper EORTC-QLQ-C30  |                                             |                                             |
| No. (%) of patients with events       | 64 (38.8%)                                  | 114 (33.9%)                                 |
| Median (95% Cl) time to event, months | 4.86 (3.48, 6.24)                           | 13.14 (9.69, NE)                            |
| Stratified hazard ratio(95%Cl)a       | 0.53 (0.39, 0.73)                           | 0.53 (0.39, 0.73)                           |
| RoleFunctioningper EORTC-QLQ-C30      |                                             |                                             |
| No. (%) of patients with events       | 69 (41.8%)                                  | 136 (40.5%)                                 |
| Median (95% Cl) time to event, months | 3.58 (2.20, 5.98)                           | 9.13 (6.51, NE)                             |
| Stratified hazard ratio (95% Cl) a    | 0.62 (0.46, 0.84)                           | 0.62 (0.46, 0.84)                           |
| GHS/QoL per EORTC-QLQ-C30             |                                             |                                             |
| No. (%) of patients with events       | 66 (40.0%)                                  | 132 (39.3%)                                 |
| Median (95% Cl) time to event,months  | 3.58 (3.02, 6.97)                           | 11.24 (5.98, NE)                            |
| Stratified hazard ratio(95%Cl)        | 0.63 (0.46, 0.85)                           | 0.63 (0.46, 0.85)                           |

Cl =confidenceinterval;GHS/QoL=global healthstatus/qualityof life;HCC=hepatocellular carcinoma; N = number; TTD = time to deterioration

α Stratification factors include geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence) and AFP (&lt;400 vs. ≥400 ng/mL) at screening per IxRS

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Sensitivity analysis

The impact of missing scheduled tumour assessments on the co-primary efficacy endpoint of PFS based on IRF-assessment per RECIST v1.1 was assessed. In this analysis, patients who missed two or more consecutive tumor assessments scheduled immediately prior to the date of PD or death in any treatment arm were censored at the last tumor assessment prior to the missed visit.

Table 34: Sensitivity analysis for PFS based on IRF-assessment per RECIST v1.1 censored for missing visits (ITT population)

Cut off date:2019-08-29

|                                                                                                                                                   | Sorafenib (N=165)                            | Atezo+Bev (N=336)                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-------------------------------------------------|
| Patients with event (%) Earliest contributing event Dea th Disease Progression Patients without event (%)                                         | 100 (60.6%) 21 79 65 (39.4%)                 | 190 (56.5%) 28 162 146 (43.5%)                  |
| Time to Event (Months) Median 95% CI 25% and 75%-ile Range                                                                                        | 4.21 (3.94,5.55) 2.07,8.57 0.0* to 14.6*     | 6.87 (5.68, 8.57) 2.92, NE 0.0* t0 14.7*        |
| Stratified Analysis p-value (log-rank) Hazard Ratio 95% CI                                                                                        |                                              | <.0001 0.60 (0.47,0.77)                         |
| Unstratified Analysis p-value (log-rank) Hazard Ratio                                                                                             |                                              | <.0001 0.60 (0.47,0.77)                         |
| 95°CI Time Point Analysis 6 Months Patientsremaining at risk Event Free Rate (%) 95% CI Year Patients remaining at risk Event Free Rate (%) 95%CI | 39 36.29 (27.87,44.72) 2 15.38 (5.77, 24.99) | 163 54.14 (48.63,59.64) 33 35.00 (28.80, 41.19) |

<!-- image -->

The MAH has conducted the two requested sensitivity analyses for the co-primary endpoint of PFS as assessed by IRF per RECIST version 1.1.

Sensitivity Analysis 1 : Patients who missed ≥ 1 consecutive tumor assessments immediately prior to progressive disease (PD) or death are counted as event at the last tumor assessment prior to the missed visit;

Sensitivity Analysis 2 : Patients who missed ≥ 2 consecutive tumor assessments immediately prior to PD or death are counted as event at the last tumor assessment prior to the missed visit.

<div style=\"page-break-after: always\"></div>

Table 35: IRF-assessed PFS per RECIST v1.1, Primary and Sensitivity Analyses

|                                              | Sorafenib N = 165   | Atezo + Bev N = 336   |
|----------------------------------------------|---------------------|-----------------------|
| IRF-PFS Primary Analysis reported in the CSR |                     |                       |
| No. (%) of patients with event               | 109 (66.1%)         | 197 (58.6%)           |
| Median, months                               | 4.3                 | 6.8                   |
| 95% CI                                       | (4.0, 5.6)          | (5.7, 8.3)            |
| Stratified hazard ratio (95% CI)             | 0.59 (0.47, 0.76)   |                       |
| IRF-PFS Sensitivity Analysis 1               |                     |                       |
| No. (%) of patients with event               | 109 (66.1%)         | 197 (58.6%)           |
| Median, months                               | 4.0                 | 6.8                   |
| 95% CI                                       | (2.8, 4.2)          | (5.6, 7.7)            |
| Stratified hazard ratio (95% CI)             | 0.56 (0.44, 0.72)   |                       |
| IRF-PFS Sensitivity Analysis 2               |                     |                       |
| No. (%) of patients with event               | 109 (66.1%)         | 197 (58.6%)           |
| Median, months                               | 4.2                 | 6.8                   |
| 95% CI                                       | (2.8, 4.7)          | (5.6, 7.9)            |
| Stratified hazard ratio (95% CI)             | 0.57 (0.45, 0.72)   |                       |

Atezo = atezolizumab ; Bev = Bevacizumab ; CI = confidence interval; IRF = Independent Review Facility; PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumors.

Stratification factors include geographic region (Asia excluding Japan vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence) and baseline AFP (&lt;400 vs. &gt;=400 ng/mL) per IxRS.

<!-- image -->

Program:rcot/clinical\\_studies/RO5541267/CDT30091/YO40245/data\\_analysis/LoPA/prod/program/g\\_ef\\_km.sas Output:root/clinical\\_studies/R05541267/CDT30091/YO40245/data\\_analysis/LoPA/prod/output/g\\_ef\\_km\\_IT\\_0S\\_29AUG2019\\_40245.pdf 24APR202014:07

Atezo+Bev=atezolizumab+bevacizumab; N=number of patients; NE=not estimable

Figure 10: Kaplan-Meier plot of overall survival, ITT population (sensitivity analysis incorporating stratification factor information based on eCRF) - cut-off date: 29 August 2019

<div style=\"page-break-after: always\"></div>

<!-- image -->

24APR202014:08

Atezo+Bev=atezolizumab+bevacizumab; Cl=confidence interval; N=number of patients

Figure 11: Kaplan-Meier plot of progression-free survival based on IRF-assessment per RECIST v1.1, ITT population (sensitivity analysis incorporating stratification factor information based on eCRF) - cutoff date: 29 August 2019

<div style=\"page-break-after: always\"></div>

## Subgroup analysis

| BaselineRiskFactors                                                          |         | Sorafenib (N=165) Median   | Sorafenib (N=165) Median   | Sorafenib (N=165) Median   | Atezo+Bev (N=336)   | Atezo+Bev (N=336)   | Atezo+Bev (N=336)   | Atezo+Bev (N=336)   | 95%Wald                 |
|------------------------------------------------------------------------------|---------|----------------------------|----------------------------|----------------------------|---------------------|---------------------|---------------------|---------------------|-------------------------|
|                                                                              | Total n | n                          | Events                     | (Months)                   | n                   | Events              | Median (Months)     | Hazard Ratio        | CI                      |
| AllPatients                                                                  | 501     | 165                        | 65                         | 13.2                       | 336                 | 96                  | NE                  | 0.60                | (0.44,0.82)             |
| Age group 1 (yr) 41-64 T8-40 S9=<                                            |         | 79                         |                            | 14.9 NE                    |                     | 69                  | N                   | 0.64                | (0.16.2.57} .37.        |
| Age group2(yr) 65 s9=<                                                       | 242     |                            | 多                          | 11.4                       | 165                 |                     | NE                  | 0.58                | (8.38: 0:81)            |
| Sex Male Female                                                              | 44      |                            | 2                          | 13                         |                     |                     | NE                  | 8.55                | (8:475. 8.87)           |
| Race AmericanIndianorAlaskaNative Asian BlackorAfricanAmerican White Unknown | 142155  | 164212                     | 02256                      |                            | 186189              |                     |                     | 0.40                | 1.32)                   |
| GeographicRegion(eCRF) Asia(excludingJapan) RestofWorld                      | 301     |                            |                            | 13:1                       | 233                 | 32                  | NE                  | 0.53                | [8.:4. .3               |
| ECoGPerformanceStatus(eCRF) 01                                               | 313     | 10℃                        | 34                         |                            | 2                   | 50                  | NE                  | 8.97                | (8:43: 1:88)            |
| PD-L1Category1 Teandies1 %L Unknown                                          |         |                            |                            |                            |                     | 2132                |                     |                     | 8:3: 0.88 (0.42,0.93)   |
| PD-L1Category T& 2 50% <5% Unknown                                           |         |                            | 1#                         |                            | #2                  | 22G                 |                     |                     | 1828: 1283 (0.42,0.93)  |
| PD-L1Category <10% 3 10% Unknown                                             |         |                            | ##                         |                            |                     | 13G                 |                     |                     |                         |
| Tobacco Use History Unknown Never Current Previous                           | 12 228  |                            | #                          |                            |                     |                     |                     |                     | NE                      |
| Alcohol UseHistory Unknown Never Current Previous                            | 1       |                            |                            | 4.9                        |                     |                     |                     | NE                  | NE                      |
| PriorLocal Therapy ON Yes                                                    | 245     | 8                          | 2                          | 11                         | 165                 | 55                  | N                   | 0.53                | (8:38: 0.87)            |
| BCLCStage at StudyEntry                                                      |         |                            |                            | N 14.4                     |                     | 0196                | 2222                | 666<                | NE (0.00 NE) (8:33: 355 |
| Etiology Heais Non-viral                                                     | 24      |                            | 319                        |                            | 18                  | 484                 |                     | 53 0.91             | 1822 8873 (0.52,1.60)   |
| ExtrahepaticSpread atStudyEntry ON Yes                                       | 105     | 弱                          | 2号                         | 18:4                       |                     |                     | N                   | 22:8                | (8:33: 1:33)            |
| MVIatStudyEntry ON s                                                         | 281     | 4                          |                            | 14.9                       | 223                 | 43                  | 125                 | 8:54                | (8:48 1:3               |
| MVIand/orEHSatStudyEntry(eCRF) No Yes                                        |         | 125                        | 5g                         |                            | 258                 | 14                  |                     | 0.55                | (8:38 1:95)             |
| BaselineAFPCategory(eCRF) <400ng/mL >=400ng/mL                               | 314     | #                          | 28                         | 13.9                       |                     |                     | 12.5                | 8.52                | (8:34: 0:833            |

NE=Notestimable.

1/100

HazardratiosrelativetoSorafenibandtheassociatedconfidenceintervalswereestimatedusingunstratifiedCoxregression.

MedianswereestimatedfromKaplan-Meiermethod.

Theverticaldashedlineindicatesthehazardratioforallpatients.

Program:root/clinical\\_studies/RO5541267/CDT30091/YO40245/data\\_analysis/CSRSEP2018/prod/program/g\\_eftte\\_fp.sas Output:rcot/clinical\\_studies/RO5541267/CDT30091/YO40245/data\\_analysis/CSRSEP2018/prcd/outputg\\_ef\\_tte\\_fp\\_TT\\_OS\\_p2\\_29AUG2019\\_40245.pdf12OCT20195:45

Thesizeof thesymbol isproportional tothesizeof thepopulationinthesubgroup.

Figure 12: Subgroup Analyses of overall survival (ITT population)

100

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                               | Total   | Sorafenib (N=165) Median   | Sorafenib (N=165) Median   | Sorafenib (N=165) Median   | Atezo+Bev (N=336) Median   | Atezo+Bev (N=336) Median   | Atezo+Bev (N=336) Median   |       | PeM%S6                   |
|-------------------------------------------------------------------------------|---------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|-------|--------------------------|
| BaselineRiskFactors                                                           | n       | n                          | Events                     | (Months)                   | n                          | Events                     | (Months)                   | Ratio | CI                       |
| AllPatients                                                                   | 501     | 165                        | 109                        | 4.3                        | 336                        | 197                        | 6.8                        | 0.59  | (0.47,0.75)              |
| Age group 1(yr) - S9=<                                                        | 强       |                            | ##                         |                            |                            | 298                        |                            |       | 8320: 32383 (0.45;0.89)  |
| Age group2(yr) 65                                                             |         | 4                          |                            |                            | 2815                       | 188                        |                            | 8.59  | (8:25: 8:81)             |
| Sex Male Female                                                               | 44      | 128                        |                            |                            |                            |                            | 2                          | 8.5   | (8:35: 9.77) 00.40,0.70F |
| Race, AmericanIndianorAlaskaNative BlackorAfricanAmerican Asian Whitc Unknown |         | 4212 96                    | 00450                      |                            | 186139                     |                            |                            |       | 5                        |
| GeographicRegion(eCRF) Rest Wding Japan EcoGPerformanceStatus(eCRF)           | 381     |                            |                            |                            | 2.8133                     | 122                        | 22                         | 8:48  | (8:31:8.87)              |
| 9 PD-L1Category1 Unknown                                                      |         | 31102                      | 4                          | 4：829                      |                            | 184                        | 7.8                        | 8.53  | (8:42.8.78)              |
| PD-L1Category2 美 Unknown                                                      |         |                            |                            |                            |                            |                            |                            |       |                          |
| PD-L1Category3 TEandi 10% Unknown                                             |         |                            | 琴                          |                            |                            |                            |                            |       | 2 2: 123                 |
| Tobacco UseHistory Unknown Never                                              | 18      | 1626                       |                            | N4582                      |                            | 0439                       | N8N4                       |       | (8:43: .83               |
| Previous Alcohol UseHistory Unknown Never                                     |         |                            | #                          | 程                          |                            | 08                         |                            |       |                          |
| Previous PriorLocalTherapy Vos                                                |         | 24强8                       | 58                         | 42                         | 175                        | 189                        | .7                         | 8.58  | (8:3号: 8:972)            |
| BCLCStage atStudyEntry                                                        | 4683    |                            | 10:35                      |                            | wm 2                       | 21                         |                            |       | 8:88: N                  |
| 6A4BU Etiology                                                                |         |                            |                            | N264                       |                            | 1                          | 222                        | 8     | (8:43: 1.3号)             |
| NoRaia HepatitisB ExtrahepaticSpreadatStudyEntry Yes                          | 3073    |                            | 43                         |                            | 18                         | 1.4                        | 7.8                        | 0.54  | 7 83 183 (8:41. 8:93)    |
| MVIatStudyEntry No                                                            | 201     | #4                         | 58                         |                            |                            |                            |                            | 8:95  | (8:57. 8:9%)             |
| Yes MVIand/orEHSatStudyEntry(eCRF)) Yos                                       |         | 12                         | 3                          | 4:2 723                    | 4:8 258                    |                            | 7.9                        | 228   | (8:47: 1:38)             |
| BaselineAFPCategory(eCRF) <400ng/mL                                           | 384104  |                            |                            |                            |                            |                            |                            | 8:48  | (8:34. 0.96)             |
| >=400ng/mL                                                                    |         |                            | 39                         | 4:472                      |                            |                            | #                          |       |                          |

NE=Notestimable.

MedianswereestimatedfromKaplan-Meiermethod.

Theverticaldashedlineindicatesthehazardratioforallpatients.

HazardratiosrelativetoSorafenibandtheassociatedconfidenceintervalswereestimatedusingunstratifiedCoxregression.

Thesizeof thesymbol isproportionaltothesizeof thepopulationinthesubgroup.

Figure 13: Subgroup Analyses of progression-free survival Based on IRF-Assessment per RECIST v1.1

100

<div style=\"page-break-after: always\"></div>

| Baseline Risk Factors                                                      |         | Sorafenib (N=159)   | Sorafenib (N=159)   | Sorafenib (N=159)   | Sorafenib (N=159)   | Atezo+Bev (N=326)   | Atezo+Bev (N=326)   | Atezo+Bev (N=326)   | Atezo+Bev (N=326)       | Atezo+Bev (N=326)   | Atezo+Bev (N=326)   |
|----------------------------------------------------------------------------|---------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|-------------------------|---------------------|---------------------|
|                                                                            | Total n | n                   | Responder           |                     | n                   | Responder           |                     | odds o              | 95% CI                  | Sorafenib better    | Atezo+Bev better    |
| AllPatients                                                                | 485     | 159                 | 19                  | 11.9                | 326                 | 89                  | 27.3                | 2.77                | (1.62, 4.74)            |                     |                     |
| Age group 1 (yr) >=65                                                      | 34      |                     | 072                 | 105                 | 1                   | 4#                  |                     |                     |                         |                     |                     |
| Age group 2 (yr)                                                           | 241     | 38                  | 12                  | 18:3                | 133                 | 48                  | 2号:8                | 3:23                | (1:58 8:323             |                     |                     |
| Sex Male Female                                                            | 484     | 133                 | SL                  | 1径:1                | 2号9                 | 74                  | 26.3                | 2.86                | (0.153 14:88)           |                     |                     |
| Race, AmericanIndianorAlaskaNative Leisi ackorAfricanAmerican hite Unknown | 126180  | 18492               | 09082               |                     | 18698               | 8001                |                     |                     | (2.04,9.2F (8:02: 4:18) |                     |                     |
| Geographic Region (eCRF)                                                   | 287     | 88                  | 15                  | 18:1                | 139                 | 48                  | 33:4                | 7.58                | (28.8323:613            |                     |                     |
| ECOGPerformanceStatus(eCRF)                                                | 288     |                     | 14                  | 15.8                | 323                 | 28                  | 32:4                | 4.41                | (f.32912:33)            |                     |                     |
| TobaccoUseHistory Unknown Never Curent Previous                            |         | 1594                | 0469                |                     | 1534                | 0344                |                     |                     |                         |                     |                     |
| AlcoholUse History Never Unknown Previous Curent                           | 14738   | 548                 | 649                 | 1                   | im                  | 0540                |                     |                     |                         |                     |                     |
| Prior Local Therapy Nes                                                    |         | 88                  | 12                  |                     | 134                 | 4                   | 25:2                | 1.36                | (1.8974 13:82)          |                     |                     |
| BCLCStaqeat StudyEntry A4                                                  | 7659    | 3358                | 01                  | N38                 | 4398                | 2179                |                     | >999.99 188         | (0.00.NE)               |                     |                     |
| Etiology HoRaia epatitisB                                                  |         | 243                 | 775                 | 2                   |                     | 493                 |                     |                     |                         |                     |                     |
| ExtrahepaticSpreadatStudyEntry Yes                                         | 189     | 88                  |                     |                     | 209                 |                     | 29.;                | 4.35                | (1.9 13:33)             |                     |                     |
| MVIat Study Entry Yes No                                                   | 283     |                     | 14                  | 15.号                | 226                 | 32                  | 2号:                 | 2:22                | (1.516,14:2)            |                     |                     |
| MVIand/orEHSatStudyEntry(eCRF) Yes                                         | 368     | 14号                 | 18                  | 8%                  |                     |                     | 28:6                | 4.84                | (2.245 18:45)           |                     |                     |
| >=400 ng/mL                                                                | 286     |                     | 19                  | 19.1                | 22%                 | 28                  | 32:2                | 3.82                | (0.:9 3:9)              |                     |                     |

Responders refer to all patients with &lt;CR/PR&gt;. A window of 28 days is used for the confirmation of CR/PR.

Odds ratios relative to Sorafenib and the associated Wald confidence intervals were estimated using unstratified logistic regression.

The vertical dashed line indicates the odds ratio for all patients.

The size of the symbol is proportional to the size of the population in the subqroup.

Figure 14: Subgroup Analyses of Confirmed ORR Based on IRF-Assessment per RECIST v1.1 - excerpt

|                          |         | Sorafenib (N=165)   | Sorafenib (N=165)     | Atezo+Bev (N=336)   | Atezo+Bev (N=336)   | Atezo+Bev (N=336)     |    |              |                  |                  |                  |
|--------------------------|---------|---------------------|-----------------------|---------------------|---------------------|-----------------------|----|--------------|------------------|------------------|------------------|
| BaselineRiskFactors      | Total n | n                   | Median Events(Months) |                     | n                   | Median Events(Months) |    | Hazard Ratio | 95%Wald CI       | Atezo+Bev better | Sorafenib better |
| AllPatients              | 501     | 165                 | 65                    | 13.2                | 336                 | 96                    | NE |              | 0.60 (0.44,0.82) |                  |                  |
| AJCCTNMStageatStudyEntry |         |                     |                       |                     |                     |                       |    |              |                  |                  |                  |
| STAGEIA                  | 1       |                     |                       |                     | 1                   | 0                     | NE | NE           | NE               |                  |                  |
| STAGEIB                  | 10      | 4                   |                       | NE                  | 6                   | 1                     | NE | >999.99      | (0.00,NE)        |                  |                  |
| STAGEII                  | 66      | 24                  |                       | NE                  | 42                  | 4                     | NE |              | 0.51 (0.13,2.03) |                  |                  |
| STAGE IIA                | 56      | 18                  |                       | 14.9                | 38                  | 9                     | NE |              | 0.95 (0.31,2.93) |                  |                  |
| STAGEIIIB                | 60      | 24                  |                       | 11.4                | 36                  | 13                    | NE |              | 0.81 (0.36,1.86) |                  |                  |
| STAGEIVA                 | 56      | 16                  |                       | NE                  | 40                  | 13                    | NE |              | 0.83 (0.30,2.35) |                  |                  |
| STAGEIVB                 | 252     | 79                  | 41                    | 8.1                 | 173                 | 56                    | NE |              | 0.48 (0.32,0.72) |                  |                  |

NE=Notestimable

MedianswereestimatedfromKaplan-Meiermethod.

HazardratiosrelativetoSorafenibandtheassociatedconfidenceintervalswereestimatedusingunstratifiedCoxregression.

Thesize of thesymbol isproportional to thesizeof thepopulationinthesubgroup.

Theverticaldashedlineindicatesthehazardratioforallpatients.

Figure 15: Forest-plot - subgroup analysis of overall survival, ITT population (cut-off date: 29 August 2019)

<div style=\"page-break-after: always\"></div>

Table 36: Overall Survival and Progression-Free Survival Based on IRF-Assessment per RECIST v1.1 in Child-Pugh Score A5 and A6 subgroups, Intent to Treat Population (IMbrave150)

|                         | Child-Pugh A5     | Child-Pugh A5     | Child-Pugh A6     | Child-Pugh A6     | Overall Population   | Overall Population   |
|-------------------------|-------------------|-------------------|-------------------|-------------------|----------------------|----------------------|
|                         | Sorafenib         | Atezo + Bev       | Sorafenib         | Atezo + Bev       | Sorafenib            | Atezo + Bev          |
| OS                      |                   |                   |                   |                   |                      |                      |
| n                       | 121               | 239               | 44                | 94                | 165                  | 336                  |
| Events                  | 39 (32.2%)        | 52 (21.8%)        | 26 (59.1%)        | 42 (44.7%)        | 65 (39.4%)           | 96 (28.6%)           |
| Median (months)         | 13.9              | NE                | 6.7               | 12.8              | 13.2                 | NE                   |
| HR (95% CI)             | 0.57 (0.38, 0.86) | 0.57 (0.38, 0.86) | 0.57 (0.35, 0.92) | 0.57 (0.35, 0.92) | 0.60 (0.44, 0.82)    | 0.60 (0.44, 0.82)    |
| IRF-PFS per RECIST v1.1 |                   |                   |                   |                   |                      |                      |
| n                       | 121               | 239               | 44                | 94                | 165                  | 336                  |
| Events                  | 75 (62.0%)        | 135 (56.5%)       | 34 (77.3%)        | 60 (63.8%)        | 109 (66.1%)          | 197 (58.6%)          |
| Median (months)         | 4.8               | 7.1               | 2.8               | 5.7               | 4.3                  | 6.8                  |
| HR (95% CI)             | 0.61 (0.46, 0.82) | 0.61 (0.46, 0.82) | 0.52 (0.34, 0.80) | 0.52 (0.34, 0.80) | 0.59 (0.47, 0.75)    | 0.59 (0.47, 0.75)    |

CI = confidence interval; HR = hazard ratio; IRF = Independent Review Facility; NE = Not Evaluable; PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumors; OS = overall survival.

The results presented are from unstratified analyses.

Table 37: Overall Survival and Progression-Free Survival Based on IRF-Assessment per RECIST v1.1 in Subgroups by Age ( &lt; 75 vs. ≥ 75), Intent to Treat Population (IMbrave150)

|                         | < 75 Age Group    | < 75 Age Group    | ≥ 75 Age Group    | ≥ 75 Age Group    | Overall Population   | Overall Population   |
|-------------------------|-------------------|-------------------|-------------------|-------------------|----------------------|----------------------|
|                         | Sorafenib         | Atezo + Bev       | Sorafenib         | Atezo + Bev       | Sorafenib            | Atezo + Bev          |
| OS                      |                   |                   |                   |                   |                      |                      |
| n                       | 137               | 281               | 28                | 55                | 165                  | 336                  |
| Events                  | 55 (40.1%)        | 82 (29.2%)        | 10 (35.7%)        | 14 (25.5%)        | 65 (39.4%)           | 96 (28.6%)           |
| Median (months)         | 13.2              | NE                | NE                | NE                | 13.2                 | NE                   |
| HR (95% CI)             | 0.61 (0.43, 0.86) | 0.61 (0.43, 0.86) | 0.54 (0.24, 1.21) | 0.54 (0.24, 1.21) | 0.60 (0.44, 0.82)    | 0.60 (0.44, 0.82)    |
| IRF-PFS per RECIST v1.1 |                   |                   |                   |                   |                      |                      |
| n                       | 137               | 281               | 28                | 55                | 165                  | 336                  |
| Events                  | 92 (67.2%)        | 168 (59.8%)       | 17 (60.7%)        | 29 (52.7%)        | 109 (66.1%)          | 197 (58.6%)          |
| Median (months)         | 4.3               | 6.8               | 4.3               | 7.7               | 4.3                  | 6.8                  |
| HR (95% CI)             | 0.59 (0.45, 0.76) | 0.59 (0.45, 0.76) | 0.60 (0.33, 1.10) | 0.60 (0.33, 1.10) | 0.59 (0.47, 0.75)    | 0.59 (0.47, 0.75)    |

Atezo = atezolizumab; Bev = bevacizumab; CI = confidence interval; HR = hazard ratio; IRF = Independent Review Facility; PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumors; OS = overall survival; The results presented are from unstratified analyses.

<div style=\"page-break-after: always\"></div>

Table 38: Overview of efficacy (ITT population): Co-primary and key secondary efficacy endpoints in the China subpopulation and the global population

|                                                           | China Subpopulation   | China Subpopulation   | Global Population   | Global Population   |
|-----------------------------------------------------------|-----------------------|-----------------------|---------------------|---------------------|
| Endpoint                                                  | Sorafenib N=61        | Atezo+Bev N=133       | Sorafenib N=165     | Atezo+Bev N=336     |
| Co-PrimaryEndpoints                                       | Co-PrimaryEndpoints   | Co-PrimaryEndpoints   | Co-PrimaryEndpoints | Co-PrimaryEndpoints |
| OverallSurvival                                           |                       |                       |                     |                     |
| No. (%) of patients with events                           | 25 (41.0%)            | 26 (19.5%)            | 65 (39.4%)          | 96 (28.6%)          |
| Median, months                                            | 11.4                  | NE                    | 13.2                | NE                  |
| Stratifiedhazard ratio(95%Cl)a                            | 0.44 (0.25, 0.76)     | 0.44 (0.25, 0.76)     | 0.58 (0.42, 0.79)   | 0.58 (0.42, 0.79)   |
| IRF-AssessedProgression-FreeSurvival perRECISTv1.1        |                       |                       |                     |                     |
| No. (%) of patients with events                           | 38 (62.3%)            | 75 (56.4%)            | 109 (66.1%)         | 197 (58.6%)         |
| Median, months                                            | 3.2                   | 5.7                   | 4.3                 | 6.8                 |
| Stratified hazard ratio (95% Cl) a                        | 0.60 (0.40, 0.90)     | 0.60 (0.40, 0.90)     | 0.59 (0.47, 0.76)   | 0.59 (0.47, 0.76)   |
|                                                           | KeySecondaryEndpoints | KeySecondaryEndpoints |                     |                     |
| IRF-Assessed Confirmed ObjectiveResponseRateperRECISTv1.1 |                       |                       |                     |                     |
| No. of evaluable patients                                 | 60                    | 130                   | 159                 | 326                 |
| ORR, N (%)                                                | 4 (6.7%)              | 32 (24.6%)            | 19 (11.9%)          | 89 (27.3%)          |
| Difference in Confirmed ORR, % (95% CI)                   | 17.9% (7.0, 28.9)     | 17.9% (7.0, 28.9)     | 15.4% (7.9, 22.8)   | 15.4% (7.9, 22.8)   |
| IRF-AssessedConfirmedObjectiveResponseRateperHCCmRECiST   |                       |                       |                     |                     |
| No. of evaluable patients                                 | 59                    | 128                   | 158                 | 325                 |
| ORR, N (%)                                                | 5 (8.5%)              | 38 (29.7%)            | 21 (13.3%)          | 108 (33.2%)         |
| Difference in Confirmed ORR, % (95% Cl)                   | 21.2% (9.3, 33.1)     | 21.2% (9.3, 33.1)     | 19.9% (12.1, 27.8)  | 19.9% (12.1, 27.8)  |

Atezo=atezolizumab; Bev= bevacizumab; Cl= confidence interval; HCC= hepatocellular carcinoma; IRF= Independent Research Facility; mRECIST=modified RECIST; NE=not estimable; No. =number; ORR=objective response rate; RECIST =Response Evaluation Criteria in Solid Tumors

a Stratification factors include geographic region (Asia excluding Japan vs. Rest of World - Global population only), macrovascular invasion and/or extrahepatic spread (presence vs. absence) and AFP (&lt;400 vs.≥400 ng/mL) at screening per IxRS

## Clinical outcomes by PD-L1 expression status

Table 39: Overall Survival, IRF-Progression-Free Survival per RECIST v1.1, and IRF-assessed Best Confirmed Overall Response per RECIST v1.1 in Subgroups by PD-L1 Category 1 (TC or IC ≥ 1% vs. TC and IC &lt; 1%), Intent to Treat Population (IMbrave150)

|                         | TC or IC ≥ 1%     | TC or IC ≥ 1%     | TC and IC < 1%    | TC and IC < 1%    | Overall Population   | Overall Population   |
|-------------------------|-------------------|-------------------|-------------------|-------------------|----------------------|----------------------|
|                         | Sorafenib         | Atezo + Bev       | Sorafenib         | Atezo + Bev       | Sorafenib            | Atezo + Bev          |
| OS                      |                   |                   |                   |                   |                      |                      |
| n                       | 36                | 86                | 28                | 49                | 165                  | 336                  |
| Events                  | 16                | 24                | 11                | 13                | 65                   | 96                   |
| Median (months)         | 9.1               | NE                | 13.2              | NE                | 13.2                 | NE                   |
| HR (95% CI) a           | 0.48 (0.25, 0.90) | 0.48 (0.25, 0.90) | 0.70 (0.31, 1.58) | 0.70 (0.31, 1.58) | 0.60 (0.44, 0.82)    | 0.60 (0.44, 0.82)    |
| IRF-PFS per RECIST v1.1 |                   |                   |                   |                   |                      |                      |
| n                       | 36                | 86                | 28                | 49                | 165                  | 336                  |
| Events                  | 21                | 48                | 20                | 31                | 109                  | 197                  |
| Median (months)         | 4.4               | 7.0               | 7.0               | 6.7               | 4.3                  | 6.8                  |
| HR (95% CI) a           | 0.67 (0.40, 1.13) | 0.67 (0.40, 1.13) | 0.89 (0.50, 1.58) | 0.89 (0.50, 1.58) | 0.59 (0.47, 0.75)    | 0.59 (0.47, 0.75)    |
| IRF-ORR per RECIST v1.1 |                   |                   |                   |                   |                      |                      |
| n                       | 35                | 85                | 27                | 49                | 159                  | 326                  |
| Responders (n)          | 6                 | 29                | 4                 | 11                | 19                   | 89                   |
| Response (%)            | 17.1              | 34.1              | 14.8              | 22.4              | 11.9                 | 27.3                 |
| OR (95% CI) b           | 2.50 (0.93, 6.71) | 2.50 (0.93, 6.71) | 1.66 (0.47, 5.84) | 1.66 (0.47, 5.84) | 2.77 (1.62, 4.74)    | 2.77 (1.62, 4.74)    |

HR = hazard ratio; IRF = Independent Review Facility; PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumors; OR = odds ratio; ORR = objective response rate; OS = overall survival; PD-L1 = Programmed death-ligand 1.

a = Hazard ratios relative to Sorafenib and the associated confidence intervals were estimated using unstratified Cox regression.

b = Odds ratios relative to Sorafenib with their associated Wald confidence intervals

See also 'Supportive studies' for clinical outcomes by PD-L1 expression status in Phase Ib Study GO30140.

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Summary of Efficacy for trial YO40245 (IMbrave150)

| Study identifier          | untreated locally advanced or metastatic hepatocellular carcinoma. YO40245 (IMbrave150); EudraCT: 2017-003691-31                                                                                        | untreated locally advanced or metastatic hepatocellular carcinoma. YO40245 (IMbrave150); EudraCT: 2017-003691-31                                                                                        | untreated locally advanced or metastatic hepatocellular carcinoma. YO40245 (IMbrave150); EudraCT: 2017-003691-31                                                                                                                                                                                                                 |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier          | Phase III, open-label, multicenter, global, randomized, two-arm study designed to                                                                                                                       | Phase III, open-label, multicenter, global, randomized, two-arm study designed to                                                                                                                       | Phase III, open-label, multicenter, global, randomized, two-arm study designed to                                                                                                                                                                                                                                                |
| Design                    | evaluate the efficacy and safety of atezolizumab + bevacizumab versus sorafenib in patients with locally advanced or metastatic hepatocellular carcinoma who had not received prior systemic treatment. | evaluate the efficacy and safety of atezolizumab + bevacizumab versus sorafenib in patients with locally advanced or metastatic hepatocellular carcinoma who had not received prior systemic treatment. | evaluate the efficacy and safety of atezolizumab + bevacizumab versus sorafenib in patients with locally advanced or metastatic hepatocellular carcinoma who had not received prior systemic treatment.                                                                                                                          |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                          | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                          | 15 March 2018 (FPI) to 29 August 2019 (CCOD) not applicable not applicable                                                                                                                                                                                                                                                       |
| Hypothesis                | Superiority                                                                                                                                                                                             | Superiority                                                                                                                                                                                             | Superiority                                                                                                                                                                                                                                                                                                                      |
| Treatments groups         | Atezolizumab and Bevacizumab (Atezo + Bev)                                                                                                                                                              | Atezolizumab and Bevacizumab (Atezo + Bev)                                                                                                                                                              | Atezolizumab: Intravenous (IV), 1200 mg on Day 1 of each 21-day cycle (every three weeks) until investigator-assessed unacceptable toxicity or loss of clinical benefit. Bevacizumab: Intravenous (IV), 15 mg/kg on Day 1 of each 21-day cycle. N = 336 randomised patients.                                                     |
| Treatments groups         | Sorafenib                                                                                                                                                                                               | Sorafenib                                                                                                                                                                                               | 400 mg (2x200 mg tablets), PO, BID, starting on Day 1 of Cycle 1. N = 165 randomised patients.                                                                                                                                                                                                                                   |
| Endpoints and definitions | Co-Primary endpoints                                                                                                                                                                                    | OS, PFS by IRF per RECIST 1.1                                                                                                                                                                           | -Overall Survival, defined as time from randomization to death due to any cause. -PFS, defined as time from randomization to the first documented disease progression as determined by an IRF according to RECIST Version 1.1, or death from any cause (whichever occurred first).                                               |
| Endpoints and definitions | Key Secondary endpoints                                                                                                                                                                                 | ORR by IRF, DOR by IRF                                                                                                                                                                                  | -Objective response, defined as a complete or partial response, by IRF per RECIST v1.1 and HCC mRECIST. -Duration of response, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), by IRF per RECIST v1.1 and HCC mRECIST. |
| Database lock             | Clinical cut-off date: 29 August 2019                                                                                                                                                                   | Clinical cut-off date: 29 August 2019                                                                                                                                                                   | Clinical cut-off date: 29 August 2019                                                                                                                                                                                                                                                                                            |

## Results and Analysis

Analysis description

Analysis population and time point

description

Descriptive statistics and estimate

variability

Primary Analysis

Intent to Treat (ITT) Population

CCOD of 29 August 2019

Treatment group

Number of subject

OS

(median (months))

95% CI

PFS by IRF per RECIST

v1.1

(median (months))

95% CI

ORR by IRF

per RECIST v1.1

(n, (%))

Sorafenib

165

13.2

10.4; NE

4.3

4.0; 5.6

No. of evaluable patients:

159

19 (11.9%)

Atezo + Bev

336

NE

NE

6.8

5.7; 8.3

No. of evaluable patients: 326

89 (27.3%)

95% CI

7.4; 18.0

22.5; 32.5

ORR by IRF per HCC mRECIST (n, (%))

No. of evaluable patients: 158

21 (13.3%)

No. of evaluable patients: 325

108 (33.2%)

95% CI

8.4; 19.6

28.1; 38.6

DOR by IRF per RECIST v1.1 (median (months))

- No. of evaluable patients:

19

6.3

No. of evaluable patients: 89

NE

95% CI

4.7; NE

DOR by IRF per HCC mRECIST (median (months))

No. of evaluable patients:

21

6.3

No. of evaluable patients: 108

NE

95% CI

4.9; NE

Effect estimate per comparison

OS

Comparison groups

Atezo + Bev vs. Sorafenib

HR

0.58

95% CI

0.42; 0.79

P-value

0.0006

PFS by IRF per RECIST v1.1 (median (months))

Comparison groups

Atezo + Bev vs. Sorafenib

HR

0.59

95% CI

0.47; 0.76

P-value

&lt;0.0001

<div style=\"page-break-after: always\"></div>

## Analysis performed across trials (pooled analyses and meta-analysis)

## · Immunogenicity of bevacizumab

## Study GO30140

The treatment-emergent ADA incidence rate for bevacizumab in study GO30140 was low, ranging between 2.1%-3.8% for the two atezolizumab plus bevacizumab arms. This is in line with ADA incidence rates for bevacizumab that have been reported in other clinical studies across indications. Study IMbrave150

No sampling for bevacizumab ADAs was conducted in study IMbrave150 due to the low post-treatment incidence of bevacizumab ADAs observed across earlier studies in combination with atezolizumab.

## · Immunogenicity of atezolizumab

The treatment-emergent atezolizumab ADA incidence rate was 27.9% in IMbrave150 and ranged from 23.8% to 37.9% across all HCC studies (studies GO30140, PCD4989g, and YO29233). The median time to onset of ADA in IMbrave150 was 3.14 weeks.

<div style=\"page-break-after: always\"></div>

Table 40: Baseline Prevalence and Post-Baseline Incidence of ADAs to Atezolizumab in Studies IMbrave150, GO30140 and Both Studies combined

|                                  | IMbrave150                         | GO30140                 | GO30140                 | GO30140                         | Both Studies               |
|----------------------------------|------------------------------------|-------------------------|-------------------------|---------------------------------|----------------------------|
|                                  | Atezo+Bev Treated Patients (N=329) | Arm A Atezo+Bev (N=104) | Arm F1 Atezo+Bev (N=60) | Arm F2 Atezo Monotherapy (N=58) | Combined Atezo+Bev (N=493) |
| Baseline evaluable patients      | 311                                | 104                     | 58                      | 58                              | 473                        |
| No. of patients positive for ADA | 7 (2.3%)                           | 0                       | 2 (3.4%)                | 2 (3.4%)                        | 9 (1.90%)                  |
| No.ofpatientsnegativeforADA      | 304                                | 104                     | 56                      | 56                              | 464                        |
| Post-baseline evaluable patients | 315                                | 101                     | 58                      | 57                              | 474                        |
| No. of patients positive for ADA | 88 (27.9%)                         | 24 (23.8%)              | 22 (37.9%)              | 17 (29.8%)                      | 134 (28.3%)                |
| Treatment-induced ADA a          | 88                                 | 24                      | 21                      | 17                              | 133                        |
| Treatment-enhanced ADA b         | 0                                  | 0                       | 1                       | 0                               | 1                          |
| No. of patients negative for ADA | 227                                | 77                      | 36                      | 40                              | 340                        |
| Treatment-unaffected ADA c       | 7                                  | 0                       | 1                       | 2                               | 8                          |

ADA=anti-drugantibodies,canalsobereferredtoasATAoranti-therapeuticantibodies

Note:SeeShankaretal.2014forfurtherdetailsonthedefinitionoftreatment-inducedand treatment-enhancedADA.

a Treatment-induced ADAs=Patients who had a baseline-negative ADA result or were missing data who developed anti-drug antibodies at any time afterinitialdrugadministration.

b Treatment-enhanced ADA=Patients who had a baseline-positive ADA result in whom the assay result was enhanced (greater than baseline titer by≥0.60 titer units) at any time after initial drug administration.

c Treatment-unaffected ADAs=Patients who had a baseline-positive ADA result in whom the assay result was not enhanced (not greater than

Demographic and baseline characteristics by atezolizumab ADA status in IMbrave150 Differences in baseline factors ( ≥ 5% absolute difference in categorical variables or ≥ 10% relative difference in continuous variables) were observed between ADA-positive and -negative subgroups (data not shown).

Subgroup Analyses of Efficacy Endpoints by Atezolizumab ADA Status in IMbrave150

Table 41: IMbrave150: Overview of Efficacy by Treatment-Emergent ADA Status without Landmark

|                                               | Atezo+Bev            | Atezo+Bev            |
|-----------------------------------------------|----------------------|----------------------|
| Parameter                                     | ADA-Negative N=227   | ADA-Positive N=88    |
| Co-Primary Endpoints                          | Co-Primary Endpoints | Co-Primary Endpoints |
| OverallSurvival                               |                      |                      |
| No. (%) of patients with event                | 47 (20.7%)           | 36 (40.9%)           |
| Median, months                                | NE                   | 12.78                |
| 95% CI                                        | NE                   | (10.15, NE)          |
| Progression-FreeSurvival (IRF per RECISTv1.1) |                      |                      |
| No. (%) of patients with event                | 123 (54.2%)          | 60 (68.2%)           |
| Median, months                                | 7.16                 | 5.59                 |
| 95% CI                                        | (6.74, 9.66)         | (4.34, 8.57)         |
| Secondary Endpoints                           | Secondary Endpoints  | Secondary Endpoints  |
| ObjectiveResponseRate (IRF per RECIST v1.1)   |                      |                      |
| No. of evaluable patients                     | 217                  | 88                   |
| Confirmed ORR, N (%)                          | 64 (29.5%)           | 24 (27.3%)           |
| 95% CI                                        | (23.51%, 36.04%)     | (18.32%, 37.81%)     |

ADA=anti-drug antibody; Atezo+Bev=atezolizumab+bevacizumab; Cl=confidence interval;

CSR=Clinical Study Report; IRF=Independent Review Facility; NE=not estimable; ORR=objective response rate; RECIST=Response Evaluation Criteria in Solid Tumors.

Data cutoff: 29 August 2019.

<div style=\"page-break-after: always\"></div>

## Efficacy by landmark ADA status in IMbrave150

A separate immunogenicity report for study IMbrave150 was provided, where additional analyses were presented to account for imbalances in baseline demographics and prognostic factors between ADA subgroups that could confound the estimation of treatment effect compared with control (data not shown).

## Supportive studies

## Phase Ib Study GO30140

Study GO30140 is an ongoing open-label, multi-center, global Phase Ib study with non-randomized and randomized arms evaluating the safety, efficacy, and pharmacokinetics of atezolizumab when administered with bevacizumab and/or other treatments in patients with different solid tumours.

Arm A of Study GO30140 was a non-randomized single-arm cohort designed to evaluate the efficacy and safety of Atezo + Bev in patients with advanced or metastatic and/or unresectable HCC who had not received prior systemic therapy (n=104). The primary efficacy endpoint of Arm A was confirmed ORR by IRF per RECIST v1.1. No statistical testing was applied in Arm A of GO30140.

Arm F of Study GO30140 randomized 119 patients open-label in a 1:1 ratio to the combination treatment of Atezo + Bev (Arm F1) or atezolizumab monotherapy (Arm F2) to characterize the single agent contribution to the combination treatment effect in advanced or metastatic and/or unresectable HCC patients without prior systemic therapy. The primary efficacy endpoint of Arm F was PFS by IRF per RECIST v1.1. Arm F was statistically-powered at a two-sided significance level of 0.2 for the primary efficacy endpoint.

<!-- image -->

## RandomizationStratificationFactorsforArmF

- GeographicRegion(AsiaexcludingJapanvsrestof theworld)
- ·Macrovascular invasion and/orextrahepaticspread（presence or absence)
- Baselineα.feto-protein（&lt;400ng/mLvs≥400ng/mL)

Figure 16: Overview of Study Design for GO30140

## Eligibility criteria

Patients with locally advanced or metastatic and/or unresectable HCC who had received no prior systemic therapy were included. At baseline, patients had documented virology status of hepatitis, at least one measurable untreated lesion (per RECIST v1.1), ECOG PS score of 0 or 1, and adequate hematologic and end-organ function. Both studies excluded patients who had co-infection of hepatitis B virus (HBV) and hepatitis C virus (HCV), or with untreated or incompletely treated oesophageal and/or gastric varices with bleeding or high-risk for bleeding. Patients with vascular invasion of the portal or hepatic veins were eligible for both studies. In Arm F of GO30140, patients with Child-Pugh A were

<div style=\"page-break-after: always\"></div>

eligible; Arm A allowed enrolment of patients with Child-Pugh score up to B7. Eligibility criteria regarding life expectancy were only included in GO30140 Arm F, with patients being eligible for the study only if their life expectancy status was determined by the Investigator as ≥ 3 months.

## Schedule of Tumour Assessments

In study GO30140 tumour assessments were done at baseline, then every 8 ( ± 1) weeks for the first 12 months, and every 12 ( ± 3) weeks thereafter (as opposed to IMbrave150 with more frequent assessments every 6 ( ± 1) weeks for the first 54 weeks and 9 ( ± 1) weeks thereafter).

## Patient disposition

Table 42: Discontinuation from Study (Enrolled Patients) - study GO30140

|                             | Arm A Atezo + Bev (N=104)   | Arm A Atezo + Bev (N=104)   |   Arm F1 Atezo + Bev (N=60) | Arm F1 Atezo + Bev (N=60)   | Arm F2 Atezo (N=59)   | Arm F2-Crossover Atezo + Bev (N=26)   |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------|---------------------------------------|
| Received Treatment          |                             | 104 (100.0%)                |                          60 | (100.0%)                    | 58 (98.3%)            | 26 (100.0%)                           |
| Still On-study On Treatment | 55                          | 52.9%)                      |                          43 | 71.7%)                      | 39 (66.1%)            | 18 (69.2%)                            |
|                             | 26                          | 25.0%)                      |                          25 | 41.7%) 30.0%)               | (49.2%)               | 15 57.7%)                             |
| In Survival Follow-up       | 29                          | 27.9%)                      |                          18 | 29 10                       | (16.9%)               | 3 11.5%)                              |
| Discontinued Study          | 49                          | 47.1%)                      |                          17 | 28.3%) 20                   | (33.9%)               | 8 (30.8%)                             |
| Death                       | 47                          | 45.2%)                      |                          16 | 26.7%) 18                   | (30.5%)               | 8 ( 30.8%)                            |
| Withdrawal By Subject       | 2                           | 1.9%)                       |                           1 | 1.7%)                       | 2 ( 3.4%)             | 0                                     |

combination treatment. Note that for every row, except the 'On Treatment' row, the number of patients in the F2 crossover arm\\_are included in the respective Arm F2 column. The row of \"On Treatment\" for Arm F2 column includes 15 patients on the crossover treatment of Atezo + Bev in addition to 14 patients still on Atezo monotherapy. Data Extraction Date: 31JUL2019; Data Cut Date: 14JUN2019

Table 43: Reasons for Discontinuation from Study Treatment (Safety Evaluable Patients) - study GO30140

|                                                                                                                                                      | Arm A Atezo + Bev (N=104)                             | Arm A Atezo + Bev (N=104)                           | Arm F1 Atezo + Bev (N=60)                   | Arm F1 Atezo + Bev (N=60)                    | Arm F2 Atezo (N=58)              | Arm F2-Crossover Atezo + Bev (N=26)   | Arm F2-Crossover Atezo + Bev (N=26)   |
|------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|---------------------------------------------|----------------------------------------------|----------------------------------|---------------------------------------|---------------------------------------|
|                                                                                                                                                      | AtezolizumabBevacizumab                               |                                                     |                                             | AtezolizumabBevacizumab                      | Atezolizumab                     | AtezolizumabBevacizumab               |                                       |
| Received at least one dose of study treatment Yes                                                                                                    |                                                       | 104(100.0%)104(100.0%)                              | 60(100.0%)                                  |                                              | 60(100.0%)58 (100.0%)            | 26 (100.0%)                           | 26 (100.0%)                           |
| Treatment Status Ongoing Withdrawn from treatment                                                                                                    | 25.0%) 75.0%)                                         | 器(器:8)                                              | (:3) (41.78)                                | 41.7%) 35 58.38)                             | 14 24.1%) 44 75.9%)              | 15 57.7%) 11 42.3%)                   | 15 57.7%) 11 42.3%)                   |
| Reason for Treatment Discontinuation DEATH ADVERSE EVENT SYMPTOMATIC DETERIORATION PROGRESSIVEDISEASE PHYSICIAN DECISION WITHDRAWAL BY SUBJECT OTHER | 3 2.9%) 12 (11.5%) 5 4.8%) 52 (50.0%) 0 5 4.8%) 1.0%) | 3 2.9%) 18 17.3%) 4 3.8%) 50 48.1%) 0 4 3.8%) 1.0%) | 0 33 5.0%) 5.0%) 26 43.3%) 21 3.3%) 1.7%) 0 | 0 5 8.3%) 4 6.7%) 23 38.3%) 2１ 3.3%) 1.7%) 0 | ０１０ 1.78) 40 69.0%) 0:3: 5.2%) 0 | 0 1 3.8%) 0 9 (34.6%) 0 3.8%) 0       | 0 109 3.8%) (34.6%) ＴO 3.8%) 0        |

Data Extraction Date: 31JUL2019; Data Cut Date: 14JUN2019

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 44: Summary of Key Demographic Characteristics for IMbrave150 and GO30140

|                        | IMbrave150        | IMbrave150        | GO30140                 | GO30140                             | GO30140    |
|------------------------|-------------------|-------------------|-------------------------|-------------------------------------|------------|
|                        | Sorafenib (N=165) | Atezo+Bev (N=336) | ArmA(Atezo+Bev) (N=104) | ArmF(Atezo+Bev)ArmFAtezoMono (N=60) | (N=59)     |
| Age≥65 (years), n (%)  | 91 (55.2%)        | 161 (47.9%)       | 37 (35.6%)              | 21 (35.0%)                          | 25 (42.4%) |
| Median                 | 66                | 64                | 62.0                    | 59.5                                | 63.0       |
| Sex: Males, n (%)      | 137 (83.0%)       | 277 (82.4%)       | 84 (80.8%)              | 54 (90.0%)                          | 49 (83.1%) |
| Race, n (%)            |                   |                   |                         |                                     |            |
| White                  | 52 (31.5%)        | 123 (36.6%)       | 20 (19.2%)              | 14 (23.3%)                          | 9 (15.3%)  |
| Asian                  | 96 (58.2%)        | 188 (56.0%)       | 75 (72.1%)              | 45 (75.0%)                          | 47 (79.7%) |
| ECOG PS 1, n (%)       | 62 (37.6%)        | 127 (37.8%)       | 52 (50.0%)              | 33 (55.0%)                          | 34 (57.6%) |
| Region, n (%)          |                   |                   |                         |                                     |            |
| Asia (excluding Japan) | 68 (41.2%)        | 133 (39.6%)       | 59 (56.7%)              | 39 (65.0%)                          | 39 (66.1%) |
| RoW                    | 97 (58.8%)        | 203 (60.4%)       | 45 (43.3%)              | 21 (35.0%)                          | 20 (33.9%) |
| PD-L1 (SP263), n (%)+  | N=58              | N=124             | N=86                    | N=43                                | N=52       |
| TC<1% and IC<1%        | 25 (43.1%)        | 45 (36.3%)        | 25 (29.1%)              | 15 (34.9%)                          | 18 (34.6%) |
| TC≥1% or IC≥1%         | 33 (56.9%)        | 79 (63.7%)        | 61 (70.9%)              | 28 (65.1%)                          | 34 (65.4%) |
| TC≥5%or IC≥5%          | 17 (29.3%)        | 46 (37.1%)        | 37 (43.0%)              | 8 (18.6%)                           | 16 (30.8%) |
| TC≥10%orIC≥10%         | 5 (8.6%)          | 12 (9.7%)         | 30 (34.9%)              | 5 (11.6%)                           | 6 (11.5%)  |

ECOG=Eastern Cooperative Oncology Group; IC=tumor-infiltrating immune cell; RoW=Rest of the World; PD-L1=programmed death-ligand 1, TC=tumor cells

+Pre-treatmenttissuesamplecollectionwasoptionalinIMbrave150

<div style=\"page-break-after: always\"></div>

Table 45: Summary of Key Baseline Disease Characteristics for IMbrave150 and GO30140

|                                      | IMbrave150        | IMbrave150        | GO30140                 | GO30140                 | GO30140                   |
|--------------------------------------|-------------------|-------------------|-------------------------|-------------------------|---------------------------|
|                                      | Sorafenib (N=165) | Atezo+Bev (N=336) | Arm A Atezo+Bev (N=104) | Arm F1 Atezo+Bev (N=60) | Arm F2 Atezo Mono (6S =N) |
| HCC Etiology, n (%)                  |                   |                   |                         |                         |                           |
| HBV-positive                         | 76 (46.1%)        | 164 (48.8%)       | 51 (49.0%)              | 34 (56.7%)              | 32 (54.2%)                |
| HCV-positive                         | 36 (21.8%)        | 72 (21.4%)        | 31 (29.8%)              | 11 (18.3%)              | 10 (16.9%)                |
| Non-viral *                          | 53 (32.1%)        | 100 (29.8%)       | 22 (21.2%)              | 15 (25.0%)              | 17 (28.8%)                |
| Child-Pugh Class, n (%)              |                   |                   |                         |                         |                           |
| A5                                   | 121 (73.3%)       | 239 (71.6%)       | 77 (74.0%)              | 43 (71.7%)              | 42 (71.2%)                |
| A6                                   | 44 (26.7%)        | 94 (28.1%)        | 21 (20.2%)              | 17 (28.3%)              | 17 (28.8%)                |
| B7                                   | 0                 | 1 (0.3%)          | 6 (5.8%)                | 0                       | 0                         |
| Time from initial Diagnosis          |                   |                   |                         |                         |                           |
| Median (months)                      | 5.84              | 6.37              | 7.43                    | 10.17                   | 8.79                      |
| BCLC Stage at Study Entry, n (%)     |                   |                   |                         |                         |                           |
| Stage A1                             | 3 (1.8%)          | 5 (1.5%)          | NA                      | NA                      | NA                        |
| Stage A4                             | 3 (1.8%)          | 3 (0.9%)          | 0                       | 0                       | 2 (3.4%)                  |
| Stage B                              | 26 (15.8%)        | 52 (15.5%)        | 10 (9.6%)               | 6 (10.0%)               | 4 (6.8%)                  |
| Stage C                              | 133 (80.6%)       | 276 (82.1%)       | 94 (90.4%)              | 54 (90.0%)              | 53 (89.8%)                |
| MVI, EHS at study Entry, n (%)       |                   |                   |                         |                         |                           |
| MVI Present                          | 71 (43.0%)        | 129 (38.4%)       | 55 (52.9%)              | 20 (33.3%)              | 25 (42.4%)                |
| EHS Present                          | 93 (56.4%)        | 212 (63.1%)       | 74 (71.2%)              | 40 (66.7%)              | 39 (66.1%)                |
| EHSand/orMVIPresent                  | 120 (72.7%)       | 258 (76.8%)       | 91 (87.5%)              | 47 (78.3%)              | 50 (84.7%)                |
| AFP at Baseline≥400, n(%) ^          | 61 (37.0%)        | 126 (37.5%)       | 37 (35.6%)              | 18 (30.0%)              | 19 (32.2%)                |
| Prior Cancer Radiotherapy, n (%) Yes | 17 (10.3%)        | 34 (10.1%)        | 20 (19.2%)              | 21 (35.0%)              | 15 (25.4%)                |
| Prior HCC Local Therapy, n (%)       |                   |                   |                         |                         |                           |
| TACE                                 | 70 (42.4%)        | 130 (38.7%)       | 56 (53.8%)              | 32 (53.3%)              | 28 (47.5%)                |
| RFA                                  | 24 (14.5%)        | 47 (14.0%)        | 21 (20.2%)              | 10 (16.7%)              | 7 (11.9%)                 |

AFP=Alpha Fetoprotein; BCLC=Barcelona Clinic Liver Cancer; EHS=extrahepatic Spread; HBV=hepatitis B virus; HCC=hepatocellular carcinoma; HCV=hepatitis C virus; MVI=macrovascular invasion; NA=not applicable; RFA=radiofrequency ablation; TACE=transarterial chemoembolization;

* Non-viral HCC etiology includes alcohol, non-Alcoholic Related Liver Damage, and unknown cause.

^ Data obtained from eCRF instead of IxRS

Source:IMbrave150andGO30140CSRs

## Outcomes and estimation

The timing (clinical cutoff date of 14 June 2019) for the analyses presented was driven by the event requirements for the primary PFS analysis in Arm F of GO30140, which were met with 74 PFS events observed across both treatment arms. The primary analysis of Arm A was conducted at the same time as the primary analysis of Arm F.

The primary analysis for Arm A was performed approximately 10.5 months after the last patient was enrolled in Arm A. The median duration of survival follow-up was 12.4 months (range 0.7-34.3) in Arm A.

The primary analysis for Arm F was performed approximately 3 months after the last patient was randomized into Arm F. The median duration of survival follow-up was 6.6 months (range 1.0-11.9) in Arm F1 and 6.7 months (range 0.5-11.4) in Arm F2.

<div style=\"page-break-after: always\"></div>

## · Efficacy in Arm A

Table 46: Overview of the Primary Efficacy and Selected Secondary Efficacy Endpoints in Arm A

| Key Efficacy Endpoints     | Arm A (Atezo + Bev) (N=104)   | Arm A (Atezo + Bev) (N=104)   | Arm A (Atezo + Bev) (N=104)            |
|----------------------------|-------------------------------|-------------------------------|----------------------------------------|
|                            | IRF-assessed per RECIST v1.1  | IRF-assessed per HCC mRECIST  | Investigator- assessed per RECIST v1.1 |
| Objective Response Rate ab | 37 (35.6%)                    | 41 (39.4%)                    | 34 (32.7%)                             |
| 95% CI                     | (26.4, 45.6)                  | (30.0, 49.5)                  | (23.8, 42.6)                           |
| Complete Response (CR)     | 12 (11.5%)                    | 16 (15.4%)                    | 3 (2.9%)                               |
| 95% CI                     | (6.11, 19.29)                 | (9.06, 23.78)                 | (0.60, 8.20)                           |
| Partial Response (PR)      | 25 (24.0%)                    | 25 (24.0%)                    | 31 (29.8%)                             |
| 95% CI                     | (16.20, 33.41)                | (16.20, 33.41)                | (21.23, 39.57)                         |
| Duration of Response b     |                               |                               |                                        |
| Number of responders       | n=37                          | n=41                          | n=34                                   |
| Ongoing response, n (%)    | 28 (75.7%)                    | 28 (68.3%)                    | 24 (70.6%)                             |
| Median (months), (95% CI)  | NE (11.8, NE)                 | NE (11.8, NE)                 | NE (11.7, NE)                          |
| (Range)                    | (1.6* - 31.0*)                | (1.6* - 31.0*)                | (3.5 - 31.0*)                          |
| Progression-FreeSurvival   |                               |                               |                                        |
| Number of events (%)       | 69 (66.3%)                    | 69 (66.3%)                    | 75 (72.1%)                             |
| Median, months (95% CI)    | 7.3 (5.4 - 9.9)               | 7.3 (5.4 - 9.9)               | 7.4 (5.6 - 10.7)                       |
| 6-month PFS Rate (%)       | 54%                           | 55%                           | 56%                                    |
| 12-month PFS Rate (%)      | 35%                           | 35%                           | 38%                                    |
| Overall Survival           |                               |                               |                                        |
| Number of deaths (%)       |                               | 47 (45.2%)                    |                                        |
| Median, months (95% CI)    |                               | 17.1 (13.8, NE)               |                                        |
| 6-month OS Rate (%)        |                               | 82%                           |                                        |
| 12-month OS Rate (%)       |                               | 63%                           |                                        |

Cl = confidence interval; HCC =hepatocellular carcinoma; IRF =independent review facility; mRECIST= modified RECIST; NE =not estimable, OS=overall survival; PFS=progression-free survival; REClST =Response Evaluation Criteria in Solid Tumors.

* censored.

a Primary efficacy endpoint; ORR per IRF-assessed RECIST v1.1.

b Only confirmed responders were included in the analysis.

Clinicalcutoffdateof 14June2019.

<div style=\"page-break-after: always\"></div>

## Subgroup Analyses

<!-- image -->

| Name/Level                           | Patientsn Response (%)   | n   | ORR(95%CI)       | 0%   | AlI   | 100%   |
|--------------------------------------|--------------------------|-----|------------------|------|-------|--------|
| AlI                                  | 104(100.0)               | 37  | 35.6(26.4-45.6)  |      |       |        |
| Age Group                            |                          |     |                  |      |       |        |
| <65                                  | 67 (64.4)                | 25  | 37.3(25.8-50.0)  |      |       |        |
| >=65                                 | 37(35.6)                 | 12  | 32.4(18.0-49.8)  |      |       |        |
| Sex                                  |                          |     |                  |      |       |        |
| Male                                 | 84(80.8)                 | 30  | 35.7(25.6-46.9)  |      |       |        |
| Female                               | 20(19.2)                 | 7   | 35.0(15.4-59.2)  |      |       |        |
| Race                                 |                          |     |                  |      |       |        |
| Asian                                | 75(72.1)                 | 26  | 34.7(24.0-46.5)  |      |       |        |
| BlackorAfricanAmerican               | 7(6.7)                   | 3   | 42.9(9.9-81.6)   |      |       |        |
| White                                | 20(19.2)                 | 8   | 40.0 (19.1-63.9) |      |       |        |
| Geographic Region                    |                          |     |                  |      |       |        |
| AsiaExcludingJapan                   | 59(56.7)                 | 19  | 32.2(20.6-45.6)  |      |       |        |
| ROW                                  | 45(43.3)                 | 18  | 40.0(25.7-55.7)  |      |       |        |
| AFPCategories(ng/mL)                 |                          |     |                  |      |       |        |
| <400                                 | 60(57.7)                 | 23  | 38.3(26.1-51.8)  |      |       |        |
| >=400                                | 37(35.6)                 | 13  | 35.1(20.2-52.5)  |      |       |        |
| Macro-VascularInvasion (MVl) Present |                          |     |                  |      |       |        |
| Yes                                  | 55(52.9)                 | 16  | 29.1(17.6-42.9)  |      |       |        |
| No                                   | 49(47.1)                 | 21  | 42.9 (28.8-57.8) |      |       |        |
| ExtrahepaticSpread(EHS)              |                          |     |                  |      |       |        |
| Yes                                  | 74(71.2)                 | 21  | 28.4(18.5-40.1)  |      |       |        |
| No                                   | 30(28.8)                 | 16  | 53.3(34.3-71.7)  |      |       |        |
| MVI and/orEHSpresent                 |                          |     |                  |      |       |        |
| Yes                                  | 91(87.5)                 | 29  | 31.9(22.5-42.5)  |      |       |        |
| No                                   | 13(12.5)                 | 8   | 61.5(31.6-86.1)  |      |       |        |
|                                      | 51(49.0)                 |     |                  |      |       |        |
| HCCEtiology                          |                          |     |                  |      |       |        |
| HepatitisB                           |                          | 17  | 33.3(20.8-47.9)  |      |       |        |
| HepatitisC                           | 31(29.8)                 | 16  | 51.6(33.1-69.8)  |      |       |        |
| Non-viral                            | 22(21.2)                 | 4   | 18.2(5.2-40.3)   |      |       |        |
| ECoGPerformanceScore                 |                          |     |                  |      |       |        |
| 0                                    | 52(50.0)                 | 23  | 44.2(30.5-58.7)  |      |       |        |
| 1                                    | 52(50.0)                 | 14  | 26.9 (15.6-41.0) |      |       |        |
| BCLCStaging atStudy Entry            |                          |     |                  |      |       |        |
| StageB                               | 10(9.6)                  | 7   | 70.0(34.8-93.3)  |      |       |        |
| StageC                               | 94(90.4)                 | 30  | 31.9(22.7-42.3)  |      |       |        |
| PD-L1(IHCSP263)Status(1%cut-off)     |                          |     |                  |      |       |        |
| TCorIC>=1%                           | 61(58.7)                 | 25  | 41.0(28.6-54.3)  |      |       |        |
| TCandIC<1%                           | 25(24.0)                 | 7   | 28.0(12.1-49.4)  |      |       |        |
| PD-L1(IHCSP263)Status(5%cut-off)     |                          |     |                  |      |       |        |
| TCorIC>=5%                           | 37(35.6)                 | 17  | 45.9(29.5-63.1)  |      |       |        |
| TCandIC<5%                           | 49(47.1)                 | 15  | 30.6(18.3-45.4)  |      |       |        |
| PD-L1(IHCSP263)Status(10%cut-off)    |                          |     |                  |      |       |        |
| TCorIC>=10%                          | 30(28.8)                 | 15  | 50.0(31.3-68.7)  |      |       |        |
| TCandIC<10%                          | 56(53.8)                 | 17  | 30.4(18.8-44.1)  |      |       |        |

ROW:Restof theworld refers totheUsA,Australia,NewZealandandJapan.Non-viral HCCetiologyincludesunknownnon-hepatitisBandC cause.Responsesrefertoeithera(confirmed)CRorPRperRECiSTv1.1.95%ClforrateswereconstructedusingClopperPearsonmethod DataExtractionDate:31JUL2019:DataCutDate:14JUN2019

Figure 17: Subgroup Analyses of Confirmed OR Based on IRF-Assessment per RECIST v1.1 in Arm A

- Updated OS results are based on an updated data cut (CCOD 15 October 2019) which provides approximately 4 months of additional follow-up for patients as compared to the primary analysis. At the updated CCOD, 54 (51.9%) of the 104 efficacy evaluable patients in Arm A had died.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Output: rort/dinica1\\_etadieu/R0SSd126TVCDT30875/GOGD14Didats\\_ana ytis/CSA\\_FdEalyprad/eutput/g\\_e\\_im\\_CS\\_ARIM4\\_EE pdF 031AN20G5 16:24

Figure 18: Kaplan-Meier plot of OS, Arm A, efficacy evaluable patients (updated data, CCOD 15 October 2019)

Table 47: Summary of overall Survival in Arm A, Efficacy Evaluable Patients

|                            | Primary Analysis CCOD (14 June 2019) (reported in GO30140 CSR) Arm A Atezo + Bev (N = 104)   | Updated CCOD (15 October 2019) Arm A Atezo + Bev (N = 104)   |
|----------------------------|----------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Patients with event (%)    | 47 (45.2%)                                                                                   | 54 (51.9%)                                                   |
| Time to event (months)     |                                                                                              |                                                              |
| Median                     | 17.1                                                                                         | 18.5                                                         |
| 95% CI for the median      | (13.8, NE)                                                                                   | (13.8, NE)                                                   |
| Time point analysis        |                                                                                              |                                                              |
| 6months                    |                                                                                              |                                                              |
| Patients remaining at risk | 84                                                                                           | 84                                                           |
| Event free probability     | 0.82                                                                                         | 0.82                                                         |
| 95% CI                     | (0.74, 0.89)                                                                                 | (0.74, 0.89)                                                 |
| 1 year                     |                                                                                              |                                                              |
| Patients remaining at risk | 54                                                                                           | 64                                                           |
| Event free probability     | 0.63                                                                                         | 0.62                                                         |
| 95% CI                     | (0.53, 0.72)                                                                                 | (0.53, 0.72)                                                 |

Atezo = atezolizumab; Bev = bevacizumab; CCOD = clinical cutoff date; CI = confidence interval; NE = not estimable.

<div style=\"page-break-after: always\"></div>

## · Efficacy in Arm F

Table 48: Overview of the Primary Efficacy and Selected Secondary Efficacy Endpoints in Arm F

|                            | IRF-assessed per RECIST v1.1   | IRF-assessed per RECIST v1.1   | IRF-assessed per HCC mRECIST   | IRF-assessed per HCC mRECIST   | Investigator-assessed per RECIST v1.1   | Investigator-assessed per RECIST v1.1   |
|----------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|-----------------------------------------|-----------------------------------------|
| KeyEfficacyEndpoints       | Atezo+ Bev (N=60)              | Atezo (6S=N)                   | Atezo+Bev (N=60)               | Atezo (6S=N)                   | Atezo+Bev (N=60)                        | Atezo (6S=N)                            |
| Progression-FreeSurvival a |                                |                                |                                |                                |                                         |                                         |
| Number of events (%)       | 35 (58.3%)                     | 39 (66.1%)                     | 34 (56.7%)                     | 39 (66.1%)                     | 35 (58.3%)                              | 44 (74.6%)                              |
| Median, months (95% Cl)    | 5.6 (3.6 -7.4)                 | 3.4 (1.9-5.2)                  | 5.6 (3.6 -7.4)                 | 3.4 (1.9 - 5.2)                | 5.7 (3.5 - 9.3)                         | 2.0 (1.9 - 3.7)                         |
| Stratified HR* (80% CI)    | 0.55 (0.40, 0.74)              | 0.55 (0.40, 0.74)              | 0.54 (0.40, 0.74)              | 0.54 (0.40, 0.74)              | 0.44 (0.33, 0.60)                       | 0.44 (0.33, 0.60)                       |
| Log-rank p-value*          | 0.0108                         | 0.0108                         |                                |                                |                                         |                                         |
| Objective Response Rate b  | 12 (20.0%)                     | 10 (16.9%)                     | 16 (26.7%)                     | 10 (16.9%)                     | 8 (13.3%)                               | 5 (8.5%)                                |
| 95%Clfor Response Rates    | (10.8, 32.3)                   | (8.4, 29.0)                    | (16.1, 39.7)                   | (8.4, 29.0)                    | (5.9, 24.6)                             | (2.8, 18.7)                             |
| CR                         | 1 (1.7%)                       | 3 (5.1%)                       | 3 (5.0%)                       | 3 (5.1%)                       | 0                                       | 0                                       |
| PR                         | 11 (18.3)                      | 7 (11.9%)                      | 13 (21.7%)                     | 7 (11.9%)                      | 8 (13.3%)                               | 5 (8.5%)                                |
| Difference in ORR (80% CI) | 3.1% (-7.7, 13.8)              | 3.1% (-7.7, 13.8)              | 9.7% (-1.6, 21.0)              | 9.7% (-1.6, 21.0)              | 4.9% (-4.1, 13.8)                       | 4.9% (-4.1, 13.8)                       |
| SD                         | 28 (46.7%)                     | 19 (32.2%)                     | 25 (41.7%)                     | 19 (32.2%)                     | 33 (55.0%)                              | 20 (33.9%)                              |
| Non-CR/Non-PD              | 0                              | 1 (1.7%)                       | 0                              | 1 (1.7%)                       | 0                                       | 0                                       |
| PD                         | 17 (28.3%)                     | 25 (42.4%)                     | 16 (26.7%)                     | 25 (42.4%)                     | 17 (28.3%)                              | 31 (52.5%)                              |
| Missing/Unevaluable        | 3 (5.0%)                       | 4 (6.8%)                       | 3 (5.0%)                       | 4 (6.8%)                       | 2 (3.3%)                                | 3 (5.1%)                                |
| DiseaseControlRate         | 40 (66.7%)                     | 29 (49.2%)                     | 41 (68.3%)                     | 29 (49.2%)                     | 41 (68.3%)                              | 25 (42.4%)                              |

Cl=confidence interval; CR=complete response; HCC =hepatocellular carcinoma; IRF =independent review facility; mRECIST=modified RECIST;

≥400 ng/mL at baseline obtained from IxRS.

Primary efficacy endpoint; PFS per IRF-assessed RECIST v1.1.

b Only confirmed responders were included in analysis.

Clinical cutoff date of 14June 2019.

<!-- image -->

Time

P-value and hazard ratio are based on stratified analyses with the stratification factors as geographic region (Asia excluding Japan vs. Rest of World) and AFP level (&lt;40o ng/mL vs. &gt;=400 ng/mL) obtained from IxRS

DataExtractionDate:31JUL2019:DataCutDate:14JUN2019

Figure 19: KM plot of IRF-Assessed PFS per RECIST v1.1 in GO30140 (Arm F, ITT Population)

The median duration of response could not be estimated at the time of the clinical data cutoff date. As of that date, all of the 12 responders in the Atezo+Bev arm and 8 of the 10 responders in the Atezo monotherapy arm were ongoing.

Overall survival results were not mature at the time of the primary PFS analysis, 16 patients (26.7%) in the Atezo+Bev arm and 18 patients (30.5%) in the Atezo monotherapy arm had died. This resulted

<div style=\"page-break-after: always\"></div>

in a stratified HR of 0.78 (80% CI: 0.50, 1.21). The 6-month OS rate was 88% for the Atezo+Bev patients and 76% for the patients in the Atezo monotherapy arm.

Intra-study crossover was allowed from Atezolizumab monotherapy to the combination treatment (26 patients crossed over from Atezo monotherapy (Arm F2) to treatment with Atezo + Bev after Investigator-assessed disease progression.

- Updated OS results based on a CCOD of 15 October 2019 provide approximately 4 months of additional follow-up for patients as compared to the primary analysis. At the updated CCOD for Arm F, 25 patients (41.7%) of 60 ITT patients in the Atezo + Bev arm and 25 patients (42.4%) of 59 ITT patients in the Atezo monotherapy arm had died.

<!-- image -->

NE:Not estimable

P-value and hazard ratio are based on stratified analyses with the stratification factors as geographicregion (Asia excluding Japan vs.Rest of World) and AFP level (&lt;4o0 ng/mL

vs.&gt;=400ng/mL)obtainedfromIxRS.

DataExtractionDate:23DEC2019:DataCutDate:15OCT2019

Output:roat/clinical\\_studies/RO5541267/CDT30075/GO30140Vdata\\_analysis/CSR\\_90dSafety/prod/output/g\\_ef\\_km\\_OS\\_ARMF\\_EEpdf 03JAN202016:32

Figure 20: Kaplan-Meier plot of overall survival, Arm F, efficacy evaluable patients (updated data, CCOD 15 October 2019)

Time

<div style=\"page-break-after: always\"></div>

Table 49: Summary of overall survival in arm F1 and arm F2, efficacy evaluable patients

|                                 | Primary Analysis CcOD (14 June 2019) (reported in G030140 CSR)   | Primary Analysis CcOD (14 June 2019) (reported in G030140 CSR)   | Updated CCOD (15 0ctober 2019)   | Updated CCOD (15 0ctober 2019)   |
|---------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------|----------------------------------|
|                                 | Arm F1 Atezo+Bev (N=60)                                          | Arm F2 Atezo (N=59)                                              | Arm F1 Atezo+Bev (N=60)          | Arm F2 Atezo (N=59)              |
| Patients with event (%)         | 16 (26.7%)                                                       | 18 (30.5%)                                                       | 25 (41.7%)                       | 25 (42.4%)                       |
| Death                           | 16                                                               | 18                                                               | 25                               | 25                               |
| Time to event (months)          |                                                                  |                                                                  |                                  |                                  |
| Median                          | NE                                                               | NE                                                               | 13.9                             | 12.4                             |
| 95% Cl for the median           | (8.3, NE)                                                        | (8.2, NE)                                                        | 10.1, NE)                        | (10.1, NE)                       |
| Stratified Analysisa            |                                                                  |                                                                  |                                  |                                  |
| Hazard ratio (80% Cl)           | 0.78 (0.50, 1.21)                                                | 0.78 (0.50, 1.21)                                                | 0.83 (0.57, 1.20)                | 0.83 (0.57, 1.20)                |
| Time point analysis             |                                                                  |                                                                  |                                  |                                  |
| 6months                         |                                                                  |                                                                  |                                  |                                  |
| Patients remaining at risk      | 37                                                               | 33                                                               | 51                               | 43                               |
| Event freeprobability (95%Cl)   | 0.88 (0.79, 0.96)                                                | 0.76 (0.65, 0.88)                                                | 0.85 (0.76, 0.94)                | 0.77 (0.66, 0.88)                |
| 1 year                          |                                                                  |                                                                  |                                  |                                  |
| Patients remaining at risk      | NE                                                               | NE                                                               | 13                               | 14                               |
| Event free probability (95% Cl) | NE                                                               | NE                                                               | 0.56 (0.41, 0.70)                | 0.52 (0.37, 0.67)                |

Atezo=atezolizumab; Bev=bevacizumab; CCOD=clinical cutoff date; Cl =confidence interval; NE=not estimable a Stratified analysis included geographic region (Asia excluding Japan vs. Rest of World) and AFP level (&lt;400 ng/mL vs ≥400 ng/mL) at baseline obtained from IxRS as the stratification factors.

<div style=\"page-break-after: always\"></div>

## Subgroup Analyses

|                                                                               |         | ArmF2 Atezo (6S=N)   | ArmF2 Atezo (6S=N)   | ArmF2 Atezo (6S=N)   | ArmF1 Atezo+Bev (N=60)   | ArmF1 Atezo+Bev (N=60)   | ArmF1 Atezo+Bev (N=60)   |                    | 80%Wald                                   | ArmF2 Atezo+Bev better better   |
|-------------------------------------------------------------------------------|---------|----------------------|----------------------|----------------------|--------------------------|--------------------------|--------------------------|--------------------|-------------------------------------------|---------------------------------|
| BaselineRiskFactors                                                           | Total n | n                    | Events               | Median (Months)      | n                        | Events                   | Median (Months)          | Hazard Ratio       | CI                                        | ArmF1 Atezo                     |
| AllPatients                                                                   | 119     | 59                   | 39                   | 3.4                  | 60                       | 35                       | 5.6                      | 0.60               | (0.44,0.81)                               |                                 |
| Age Group <65 >=65                                                            |         | 3                    |                      | 29                   | 39                       | 24                       | 53                       | 0.60 0.51          | (0.41,0.87) (0.29,0.87)                   | H                               |
| Race BlackorAfricanAmerican Asian NativeHawaiianorotherPacificIslander1 White | 92 3 23 | 47 21 9              | 30 207               | 2.0 4.0              | 45 1 14                  | 26 0 9                   | 6.3                      | <0.01 0.61 NE 0.46 | (0.43,0.87) (0.00.NE) (NE,NE) (0.24,0.92) |                                 |
| Sex Male Female                                                               |         | 48                   | 31                   | 7.3                  | 54                       | 31                       | 3:6                      | 8:33               | (0.41,0.80) (0.32,1.64)                   |                                 |
| GeographicRegion AsiaExcludingJapan ROW                                       | 78      | 328                  |                      | 1.2                  | 29                       |                          | .6                       | 58                 | (0.40,0.84) (0.31,0.92)                   |                                 |
| AFPCategories(ng/mL) <400 >=400                                               | 39      | 34                   | 19                   | 4.0 1.9              | 36 18                    |                          | 6.3 4.0                  | 0.68 0.56          | (0.44.1.04) (0.33,0.92)                   |                                 |
| Macro-VascularInvasion(MVl)Present Yes No                                     | 4       | 34                   | 2                    | 4.2                  | 28                       | 13                       | 4.4 5.6                  | 0.41 0.80          | (8.3: 0:26)                               |                                 |
| ExtrahepaticSpread(EHS) Yes No                                                | 740     | 0E                   | 2                    | 3:1                  | 40                       | 26                       | 8.5                      | 0.75 0.28          | (0.:25 1:23                               |                                 |
| MVIandlorEHSpresent Yes No                                                    | 2       | 50 9                 | 35 4                 | 2.2                  | 43                       | 30 5                     | 4.5 7.4                  | 0.66 0.24          | (0.48,0.91) (0.09,0.65)                   |                                 |
| HCCEtiology HepatitisB HepatitisC Non-viral                                   | 613     | 21017                | 24 11                | 3.4                  | 31 15                    | 20/8                     | 9                        | 0.49 1.06 0.49     | (0.33,0.73) (0.4/,2.40) (0.26,0.92)       | HH                              |
| ECoGPerformanceScore 01                                                       |         |                      | 25                   | 4.3                  | 3                        | 12                       | 7.4 3.4                  | 0.45 0.72          | (0.27,0.75) (0.49,1.06)                   | H                               |
| BCLCStaging atStudyEntry StageB Stage C                                       | 10 107  | 53                   | 36                   | 2#                   | 6                        | 1 34                     | 5                        | <0.01 0.66         | (0.00NE) (0.48,0.90)                      |                                 |
| AllPatients                                                                   | 119     | 59                   | 39                   | 3.4                  | 60                       | 35                       | 5.6                      | 0.60               | (0.44, 0.81)                              |                                 |
| PD-L1(IHCSP263)Status(1%cut-off) TC orIC >= 1% TCandIC<1%                     | 62 33   | 34 18                | 22 11                | 2.1 4.0              | 28 15                    | 15 6                     | 5.6 5.7                  | 0.53 0.68          | (0.34, 0.82) (0.38, 1.22)                 |                                 |
| PD-L1(IHCSP263)Status(5%cut-off) TCorIC >=5% TCandIC<5%                       | 24 71   | 16 36                | 12 21                | 1.9 3.7              | 8 35                     | 5 19                     | 4.1 5.7                  | 0.66 0.60          | (0.33, 1.32) (0.40, 0.91)                 |                                 |
| PD-L1(IHC SP263)Status (10% cut-off) TCorIC>=10% TC andIC<10%                 | 11 84   | 6 46                 | 5 28                 | 2.7 3.4              | 5 38                     | 4 20                     | 3.7 5.7                  | 0.95 0.56          | (0.38,2.36) (0.39,0.82)                   |                                 |

HazardratioswereestimatedbyunstratifiedCoxregression.ArmF2isthereference.NE:Notestimable.

ROW:Restof theworld refersto theUSA,Australia,NewZealand andJapan.Non-viral HCCetiologyincludesunknownnon-hepatitisBand Ccause. DataExtractionDate:31JUL2019;DataCutDate:14JUN2019

Figure 21: Subgroup Analyses of PFS Based on IRF-Assessment per RECIST v1.1 in Arms F

## · Clinical outcomes by PD-L1 expression status

Figure 22: ORR by PD-L1 expression - excerpt from subgroup analyses of confirmed IRF-assessed ORR per RECIST v1.1 in Arm A of GO30140

| Study GO30140   |
|-----------------|

1/100

1/10

<!-- image -->

1

10

10

<div style=\"page-break-after: always\"></div>

## · Comparison of efficacy results between IMbrave150 and G030140

|                                                        | IMbrave150                                             | IMbrave150                                             | GO30140                                                | GO30140                                                | GO30140                                                |
|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                        | Sorafenib (N=165)                                      | Atezo+Bev (N=336)                                      | Arm A Atezo + Bev (N = 104)                            | Arm F1 Atezo + Bev (N = 60)                            | Arm F2 Atezo (6S = N)                                  |
| Duration of Survival Follow-up                         | Duration of Survival Follow-up                         | Duration of Survival Follow-up                         | Duration of Survival Follow-up                         | Duration of Survival Follow-up                         | Duration of Survival Follow-up                         |
| Median, months (Min-Max)                               | 8.1 (0.0 - 16.2)                                       | 8.9 (0.1 - 16.9)                                       | 12.4 (0.7 - 34.3)                                      | 6.6 (1.0 - 11.9)                                       | 6.7 (0.5 - 11.4)                                       |
| Overall Survival                                       | Overall Survival                                       | Overall Survival                                       | Overall Survival                                       | Overall Survival                                       | Overall Survival                                       |
| No. (%) of patients with event                         | 65 (39.4%)                                             | 96 (28.6%)                                             | 47 (45.2%)                                             | 16 (26.7%)                                             | 18 (30.5%)                                             |
| Median, months (95% CI)                                | 13.2 (10.4, NE)                                        | NE (NE, NE)                                            | 17.1 (13.8, NE)                                        | NE (8.3, NE)                                           | NE (8.2, NE)                                           |
| Stratified hazard ratio (Cl),p-value *                 | 0.58 (0.42, 0.79)a, 0.0006                             | 0.58 (0.42, 0.79)a, 0.0006                             |                                                        | 0.78 (0.50, 1.21)b, -                                  | 0.78 (0.50, 1.21)b, -                                  |
| 6-Month OS rate (%) (95% CI)                           | 72% (65, 79)                                           | 85% (81, 89)                                           | 82% (74, 89)                                           | 88% (79, 96)                                           | 76% (65,88)                                            |
| Progression-Free Survival: IRF-Assessed per RECISTv1.1 | Progression-Free Survival: IRF-Assessed per RECISTv1.1 | Progression-Free Survival: IRF-Assessed per RECISTv1.1 | Progression-Free Survival: IRF-Assessed per RECISTv1.1 | Progression-Free Survival: IRF-Assessed per RECISTv1.1 | Progression-Free Survival: IRF-Assessed per RECISTv1.1 |
| No. (%) of patients with event                         | 109 (66.1%)                                            | 197 (58.6%)                                            | 69 (66.3%)                                             | 35 (58.3%)                                             | 39 (66.1%)                                             |
| Median, months (95% CI)                                | 4.3 (4.0, 5.6)                                         | 6.8 (5.8, 8.3)                                         | 7.3 (5.4, 9.9)                                         | 5.6 (3.6, 7.4)                                         | 3.4 (1.9, 5.2)                                         |
| Stratified hazard ratio (Cl), p-value *                | 0.59 (0.47, 0.76)a,<0.0001                             | 0.59 (0.47, 0.76)a,<0.0001                             |                                                        | 0.55 (0.40, 0.74)b, 0.0108                             | 0.55 (0.40, 0.74)b, 0.0108                             |
| 6-Month PFS rate (%)(95% CI)                           | 37% (29, 45)                                           | 55% (49, 60)                                           | 54% (45,64)                                            | 46% (32, 59)                                           | 27% (14, 41)                                           |

| Confirmed ObjectiveResponseRate:IRF-Assessed perRECISTv1.1     | Confirmed ObjectiveResponseRate:IRF-Assessed perRECISTv1.1     | Confirmed ObjectiveResponseRate:IRF-Assessed perRECISTv1.1     | Confirmed ObjectiveResponseRate:IRF-Assessed perRECISTv1.1     | Confirmed ObjectiveResponseRate:IRF-Assessed perRECISTv1.1     | Confirmed ObjectiveResponseRate:IRF-Assessed perRECISTv1.1     |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| No. of evaluable patients                                      | 159                                                            | 326                                                            | 104                                                            | 60                                                             | 59                                                             |
| Confirmed ORR, N (%)a (95% CI)                                 | 19 (11.9%) (7.35, 18.03)                                       | 89 (27.3%) (22.54, 32.48)                                      | 37 (35.6%) (26.43, 45.57)                                      | 12 (20.0%) (10.78, 32.33)                                      | 10 (16.9%) (8.44, 28.97)                                       |
| Difference in ORR, (%), (CI), p-value                          | 15.4%, (7.9, 22.8),<0.0001 b                                   | 15.4%, (7.9, 22.8),<0.0001 b                                   |                                                                | 3.1%, (-7.7, 13.8) , -                                         | 3.1%, (-7.7, 13.8) , -                                         |
| Disease Control Rate:IRF-Assessedper RECISTv1.1                | Disease Control Rate:IRF-Assessedper RECISTv1.1                | Disease Control Rate:IRF-Assessedper RECISTv1.1                | Disease Control Rate:IRF-Assessedper RECISTv1.1                | Disease Control Rate:IRF-Assessedper RECISTv1.1                | Disease Control Rate:IRF-Assessedper RECISTv1.1                |
| DCR (%)                                                        | 55.3%                                                          | 73.6%                                                          | 71.2%                                                          | 66.7%                                                          | 49.2%                                                          |
| Duration of Confirmed Response: IRF-Assessed per RECIST v1.1 * | Duration of Confirmed Response: IRF-Assessed per RECIST v1.1 * | Duration of Confirmed Response: IRF-Assessed per RECIST v1.1 * | Duration of Confirmed Response: IRF-Assessed per RECIST v1.1 * | Duration of Confirmed Response: IRF-Assessed per RECIST v1.1 * | Duration of Confirmed Response: IRF-Assessed per RECIST v1.1 * |
| No. of evaluable patients                                      | 19                                                             | 89                                                             | 37                                                             | 12                                                             | 10                                                             |
| No. (%) of patients with event                                 | 6 (31.6%)                                                      | 12 (13.5%)                                                     | 9 (24.3%)                                                      | 0                                                              | 2 (20.0%)                                                      |
| Patients with ongoing response N (%)                           | 13 (68.4%)                                                     | 77 (86.5%)                                                     | 28 (75.7%)                                                     | 12 (100.0%)                                                    | 8 (80.0%)                                                      |
| Median time to event (months) (95% Cl)                         | 6.3 (4.67, NE)                                                 | NE                                                             | NE (11.8, NE)                                                  | NE                                                             | NE (3.7, NE)                                                   |
| 6-Month event-free rate (%)                                    | 59%                                                            | 88%                                                            | 81%                                                            | 100%                                                           | 75%                                                            |

Cl=confidence interval;DCR=disease control rate;IRF=independentreviewfacility;NE=Notestimable;ORR=objectiveresponserate;RECIST

v1.1=response evaluation criteria in solid tumors version 1.1.

aResponses refer to either a (confirmed)CR or PR per RECIST v1.1.

b Two-sided 95% confidence interval is shown. P-value was based on stratified Cochran-Mantel-Haenszel test.

c Two-sided 80% confidence interval is shown.

Cl =confidence interval; IRF =independent review facility; NE=Not estimable; OS=overall survival; PFS=progression-free survival; RECIST v1.1=response evaluation criteria in solid tumors version 1.1

a Stratification factors included geographic region (Asia excluding Japan vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence)and baseline AFP levels (&lt;400 vs.≥400 ng/mL) per IxRS. Sorafenib is the reference. Two-sided 95% confidence interval is shown.

b Stratification factors included geographic region (Asia excluding Japan vs. rest of world) and baseline AFP levels (&lt;400 vs.≥400 ng/mL) per IxRS. Arm F2 is the reference. Two-sided 80% confidence interval is shown.

*. Based on stratified log-rank test, with stratification factors for IMbrave150 and GO30140 Arm F as outlined in footnotes a and b, respectively.

<div style=\"page-break-after: always\"></div>

## Additional studies

Table 50: Summary of Additional Studies

<!-- image -->

|                                       | AtezoMonotherapy                                                                    | AtezoMonotherapy                                                  | BevMonotherapy               | BevMonotherapy               |
|---------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------------------|------------------------------|
|                                       | PCD4989g (GO27831)                                                                  | YO29233 (China PK)                                                | Boige et al., 2012           | Siegel et al.,2008           |
| StudyPhase                            | la                                                                                  |                                                                   | I                            | I                            |
| Treatment Line                        | 1L+                                                                                 | 1L+                                                               | 1L+                          | 1L+                          |
| Study Design                          | Open-label, multicenter, multi- cohort, single-arm, non- randomized,dose-escalation | Open-label, multicenter, multi-cohort, single-arm, non-randomized | Single center, single- arm   | Single center, single- arm   |
| Population                            | PatientswithHCC                                                                     | PatientswithHCC                                                   | PatientswithHCC              | PatientswithHCC              |
| No.of Patients Evaluable for Efficacy | n=15(1L=5;2L+=10)                                                                   | n=21(1L=7;2L+=14)                                                 | n=43                         | n=46                         |
| Dose,Route,and Regimen                | Atezo:IV,1200 mg Q3W                                                                | Atezo:IV,1200 mg Q3W                                              | Bev: 5 mg/kg or 10 mg/kg Q2W | Bev: 5 mg/kg or 10 mg/kg Q2W |
| DataCutoffDate                        | Last Patient Last Visit: 30September2018                                            | Datacutoffdate: 19November2018                                    | Publicationsreferenced       | Publicationsreferenced       |

1L = First Line treatment; 2L = Second-Line treatment; IV = Intravenous infusion; Q2W =dosed every two weeks; Q3W =dosed every three weeks.

## Atezolizumab Monotherapy

Atezolizumab administered as single-agent for the treatment of HCC has been assessed in PCD4989g and YO29233 multi-cohort Phase I studies.

## · Study PCD4989g

As of the last patient last visit (LPLV) of 30 September 2018, there were 15 patients with HCC treated with atezolizumab in PCD4989g (n=5 1L patients, n=10 2L+ patients). None (95% CI: 0.0, 21.8) of the patients with HCC had a confirmed objective response as assessed by the Investigator per RECIST v1.1, two 1L patients achieved SD. Of note, two out of five 1L patients (40%) were alive by the time of the LPLV based on a median duration of survival follow-up of 23.7 months (range 2.2 to 31) for 1L HCC patients.

## · Study YO29233

In the analysis of Study YO29233 based on a CCOD of 19 November 2018, there were 20 patients from the HCC expansion cohort, and 1 patient from the PK cohort treated with Atezo. All patients were Chinese, and were reported to have HBV as a cause of HCC disease. Among those patients, 7 received atezolizumab as 1L treatment and 14 as 2L+ treatment. 2 1L HCC patients (28.6%) had a confirmed Investigator-assessed PR per RECIST v1.1. One of those responses was ongoing (DOR of 14.0+ months) while the other responder had discontinued treatment due to disease progression (DOR of 6.9 months). No 2L+ HCC patients achieved a confirmed response.

## Bevacizumab Monotherapy

Bevacizumab as a single-agent for the treatment of HCC has been assessed in the Investigatorsponsored trials of Siegel et al. 2008 and Boige et al 2012.

- Phase II Study of Bevacizumab in Unresectable HCC *Siegel et al., J Clin Oncol. 2008; 26(18)

In the study conducted by Siegel et al. 2008, 46 adult patients (15 [33%] 1L, 31 [67%] 2L) with organ-confined HCC, ECOG PS of 0-2, and compensated liver function (Child-Pugh A or B7), received bevacizumab 5 mg/kg or 10 mg/kg Q2W until disease progression or treatment-limiting toxicity. Of note, patients with MVI, EHS, or greater than 50% tumor involvement in the liver were excluded.

The primary objective was to determine whether bevacizumab improved the 6-month progression-free survival (PFS) rate from 40% to 60%.

<div style=\"page-break-after: always\"></div>

Forty-six patents were enrolled between February 2003 and September 2006. The median age was 58 years. Eighty-three percent of patients were male, and 95% had an ECOG PS of 0 or 1. One third of patients had received no prior therapy.

Overall, there were 6 objective responses (13%; 95% CI: 3%, 23%), including one complete response and five partial responses and 65% (95% CI: 51%, 79%) of patients were progression-free at 6 months. Median PFS was 6.9 (95% CI: 6.5, 9.1) months and median OS was 12.4 (95% CI: 9.4, 19.9) months.

## · Phase II Study of Bevacizumab in Advanced HCC * Boige et al., The Oncologist 2012; 17

In the study conducted by Boige et al. 2012, 43 patients (22 (51.2%) 1L, 21 [48.8%] 2L) with histologically confirmed advanced HCC not amenable to curative-intent therapies (e.g., resection, liver transplantation, or percutaneous ablation) received bevacizumab 5 mg/kg or 10 mg/kg Q2W until disease progression or unacceptable toxicity. Patients enrolled from May 2005 to December 2007 had ECOG PS ≤2 and compensated liver function (Child -Pugh A or B7) with no more than one prior systemic therapy. More than half of the patients had extrahepatic metastases, (91%) were classified as BCLC stage C.

The primary objective of the study was to assess disease control rate at 16 weeks (16W-DCR) defined as the proportion of patients with a CR, PR, or SD at 16 weeks after study entry, as measured by the Investigator and reviewed by an independent radiologist according to RECIST v1.0. All tumor measurements were performed by the Investigator. At the end of the study, tumor measurements were reviewed by an independent radiologist who was blinded to the clinical and biological data.

Among the 38 patients evaluable for radiologic response, 6 patients achieved a PR (ITT ORR, 14% [95% CI: 4%, 24%]) and the median DOR was 148 days (4.9 months, range 55-362 days). Eighteen patients had SD, including 12 patients who experienced SD for ≥ 16 weeks. The 16W-DCR was 42% (95% CI: 27%, 57%) in the overall population. The median PFS was 3 months (95% CI: 2, 4 months) and the median OS was 8 months (95% CI: 4, 9 months) after a median duration of follow-up of 27 months. The 6- months PFS and OS rates were 33% (95% CI, 20%-47%) and 63% (95% CI, 48%76%), respectively.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The MAH has provided study IMbrave150, a Phase III, open-label, randomized Study of atezolizumab in combination with bevacizumab compared with sorafenib in Patients with untreated locally advanced or metastatic Hepatocellular Carcinoma. Study GO30140 provided supportive data in 1L HCC patients; Arm F used a randomized design to compare the combination treatment against atezolizumab monotherapy, whereas Arm A evaluated Atezo+Bev as single treatment option.

This pivotal study is overall well-designed and well-conducted. No major concerns have been identified. The study design has previously been discussed with the CHMP and endorsed as such (EMEA/H/SA/2522/16/2017/II). Sorafenib is SoC in this patient population. There is no atezo mono arm in this study in order to determine its contribution; however, based on available data from single arm studies and from the supportive study GO30140, it can be assumed that atezolizumab as monotherapy would not be superior to sorafenib. The use of bevacizumab has also previously been investigated in 1L and 2L HCC, showing limited efficacy (Siegel et al. 2008). However, the combination of atezolizumab and bevacizumab in the supportive study (Arm A) led to clinically encouraging results. These have now been confirmed in study IMbrave150.

<div style=\"page-break-after: always\"></div>

The inclusion and exclusion criteria clearly define a patient population with locally advanced or metastatic and/or unresectable HCC not amenable to curative therapy, with no prior systemic treatments, Child-Pugh Class A, no other malignancies for the last 5 years, other types of liver cancer or co-infection with HBV/HCV. This is clearly reflected in section 5.1 of the SmPC.

## Efficacy data and additional analyses

The study met its co-primary endpoint by showing statistically significant PFS gain, with a median PFS of 6.83 vs 4.27 months in atezo+bev and sorafenib arms respectively. The HR is 0.58, (0.47, 0.76), p&lt;0.0001. These results are deemed clinically meaningful in this patients' population with a dismal prognosis.

The OS data from the 1 st  IA show a statistically significant HR of 0.58 (0.42, 0.79) with a p-value of 0.0006. At the time of the 1 st  IA, the OS data were not mature yet with 161 deaths out of 312 deaths per the pre-specified OS analyses were observed. The MAH will submit updated overall survival (OS) data from the IMbrave150 study post-approval, providing 12 months of additional follow-up and the final OS data (after approximately 312 deaths have occurred (Recommendations)).

The key secondary endpoints showed statistically significant and clinically meaningful differences in favour of atezo+bev. ORR by IRF per RECIST 1.1 showed 27.3% vs 11.9%, ORR by IRF per HCC mRECIST showed 33.2% vs. 13.3%. DOR was also considerably longer in the atezo+bev arm.

The effect of ADA on efficacy and safety has long been a concern. In the unresectable hepatocellular carcinoma study (IMbrave150), 27.9% of patients tested positive for ADAs at one or more post-dose time points. These patients generally had poorer health and disease characteristics at baseline compared to patients who only tested negative for ADA. The MAH has been requested to provide analyses of OS and PFS comparing ADA- and ADA+, adjusting for multiple baseline covariates to assess the effect of ADAs on efficacy; these exploratory analyses on OS showed that patients who were ADA-positive by week 6 (20.1%) appeared to have similar OS compared to sorafenib-treated patients, whereas ADA-negative patients by week 6 had an increased OS benefit compared to sorafenib-treated patients. These OS results were inconclusive due to the low number of events in ADA subgroups. Exploratory analyses on PFS suggested treatment benefit with atezolizumab + bevacizumab over sorafenib regardless of ADA status by week 6. It is not possible to draw any firm conclusion regarding the clinical relevance of the impact of ADA on efficacy given that ADA is a postrandomization variable.

Overall, subgroup analyses showed that results are consistent with the overall OS and PFS estimates.

Available data suggest a small benefit of Atezo+Bev compared to sorafenib in the subgroup of patients with negative PD-L1 expression (applying a cutoff of &lt;1%). Considering, that TC and IC expression of &lt;1% was reported in nearly 40% of patients evaluable for PD-L1 expression (70/182) the lack of comprehensive PD-L1 -expression data is regarded as limitation of IMbrave 150. However, current data seem to indicate a treatment benefit in all-comers.

## 2.4.4. Conclusions on the clinical efficacy

Overall, study IMbrave150 met one of its co-primary endpoints, PFS, showing a statistically significant and clinically relevant difference in favour of atezo+bev, and thus considered a positive study. These results are supported by the 1 st  IA of OS and key secondary endpoints.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

The assessment of safety is based on the pivotal study IMbrave 150.

## Patient exposure

Table 51: Extent of study drug exposure (safety-evaluable population)

<!-- image -->

| Sorafenib (N=156)                                                                                                                                              | Atezo+Bev (N=329)                                                        | Atezo+Bev (N=329)                                               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------|
| Sorafenib                                                                                                                                                      | Atezolizumab                                                             | Bevacizumab                                                     |
| Treatment duration (months)                                                                                                                                    |                                                                          |                                                                 |
| n 156 Mean (SD) 4.1 (3.5) Median 2.8 Min - Max 0 -16                                                                                                           | 329 6.8 (4.1) 7.4 0 - 16                                                 | 329 6.5 (4.0) 6.9 0-16                                          |
| Treatment duration (months) n 156 <3 89 (57.18)                                                                                                                | 329 75 (22.8%)                                                           |                                                                 |
| 3 to <6 22 (14.1%) 6 to 6> 28 (17.98) 6 to <12 12 (7.78) >=12 5 (3.28) 156 83.8(20.1) 96.0 27 - 100                                                            | 48 (14.6%) 100 (30.48) 76 (23.18) 30 (9.18) 329 95.1 (6.9) 98.0 54 - 104 | 329 78 (23.78) 58 (17.6号) 97 (29.58) 69 (21.0号) 27 (8.28)       |
| Dose Intensity (8)                                                                                                                                             |                                                                          |                                                                 |
| n Mean (SD) Median Min - Max                                                                                                                                   |                                                                          | 329 93.3 (9.6) 97.0 44 - 104                                    |
| Number of doses received                                                                                                                                       |                                                                          |                                                                 |
| n 156 Mean (SD) 215.1_ (194.6) Median 149.0 Min - Max 6 - 908 Total cumulative dose (mg) n 156 Mean (SD) 84784.6(76639.8) Median 64100.0 Min - Max 2400-362800 | 329 10.4 (5.8) 11.0 1 - 24 329 12440.3 (6917.4) 13200.0 1200 - 28800     | 329 9.8(5.5) 10.0 1 - 23 329 10485.1 (6467.4) 10543.5 723-30510 |

## Adverse events

## Common AEs

<div style=\"page-break-after: always\"></div>

Table 52: Adverse events with an incidence rate of at least 10% in any treatment arm by system organ class and preferred term (safety-evaluable population)

| MedDRA System Organ Class                                                       | Sorafenib        | Atezo+Bev      |
|---------------------------------------------------------------------------------|------------------|----------------|
| MedDRA Preferred Term                                                           | (N=156)          | (N=329)        |
| Total number of patients with at least one adverse event                        | 154( (98.78)     | 323(98.2%)     |
| Overalltotalnumberof events                                                     | 1299             | 3058           |
| Gastrointestinal disorders                                                      |                  |                |
| Totalnumberofpatientswith at leastoneadiverseevent                              | 118 (75.6%)      | 193 (58.7%)    |
| Total number of events                                                          | 293              | 525            |
| Diarrhoea                                                                       | 77 (49.48)       | 62 (18.8%)     |
| Abdominal pain                                                                  | 27 (17.3%)       | 40 (12.28)     |
| Constipation                                                                    | 22 (14.1%)       | 44 (13.4%)     |
| Nausea                                                                          | 25 (16.0%)       | 40 (12.28)     |
| Vomiting                                                                        | 13 8.3%）         | (10.0%)        |
|                                                                                 |                  | 33             |
| General disorders and administration site conditions                            |                  |                |
| Total number of patients with at least one adverse event                        | 77 (49.48)       | 166 (50.58)    |
| Total number of events                                                          | 105              | 278 67         |
| Fatigue                                                                         | 29 (18.68)       | (20.48)        |
| Pyrexia                                                                         | 15 (9.6%)        | 59 (17.98)     |
| Asthenia                                                                        | 21 (13.5%)       | 22 (6.7%)      |
| Skin and subcutaneous tissue disorders                                          |                  |                |
| Totalnumber ofpatientswith at least oneadverseevent                             | 107 (68.6%)      | 123 (37.48)    |
| Total number of events Pruritus                                                 | 187 号 9.6%)      | 197 64 (19.58) |
| Palmar-plantar erythrodysaesthesia syndrome                                     | (48.1%)          | 3 0.9%)        |
| Rash                                                                            | (17.3%)          | 41 (12.5%) 4   |
|                                                                                 | 27 22            | (1.2%)         |
| Alopecia                                                                        | (14.1%)          |                |
| Investigations                                                                  |                  |                |
| Totalnumberofpatientswithatleastoneadverseevent                                 | 68 (43.6%)       | 159 (48.38)    |
| Total number of events                                                          | 223              | 518 64         |
| Aspartate aminotransferase increased                                            | (16.7%)          | (19.58)        |
| Blood bilirubin increased                                                       | 26 22 (14.18) 14 | 43 (13.18)     |
| Alanine aminotransferase increased                                              | (9.0%)           | 46 (14.0%)     |
| Platelet count decreased                                                        | (11.5%)          | 35 (10.6%)     |
|                                                                                 | 18 15 (9.6%)     | 37 (11.2%)     |
| Weight decreased                                                                |                  |                |
| Metabolism and nutrition disorders                                              |                  |                |
| Totalnumber of patients with at least one adverse event                         | 66 (42.38)       | 129 (39.28)    |
| Total number of events                                                          | 118              | 214            |
| Decreased appetite                                                              | 38 (24.4%)       | 58 (17.6%)     |
| Respiratory, thoracic and mediastinal disorders                                 |                  |                |
| Total number of patients with at least one adverse event                        | 47 (30.1号)       | 130 (39.58)    |
| Total number of events                                                          | 71               | 219 (11.9%)    |
| Cough Epistaxis                                                                 | 15 9.68) 4.58)   | 39 34 (10.38)  |
| Vascular disorders                                                              |                  |                |
| Total number of patients with at least one adverse event                        | 42 (26.98) 52    | 108 (32.8%)    |
| Total number of events Hypertension                                             | 38 (24.48)       | 160 98 (29.88) |
| Renal and urinary disorders                                                     | (12.8%)          |                |
| Total number of patients with at least one adverse event                        | 20               | 86 (26.18)     |
| Totalnumber of events Proteinuria                                               | 24 11 (7.1%)     | 120 66 (20.18) |
| Injury, poisoning and procedural complications                                  | 6                | 46 (14.08)     |
| Total number of patients with at least one adverse event Total number of events | 3.88)            | 61             |
| Infusion related reaction                                                       | 0                | 37 (11.28)     |

Includes AEs with onset date on or after the date of the first dose of study drug up to the data cutoff date.

in the \\_column headings. For frequency counts by preferred term, multiple occurrences of the events\" rows, multiple occurrences of the same AE in an individual are counted separately.

<div style=\"page-break-after: always\"></div>

Table 53: Adverse events with a difference of at least 5% between treatment arms by system organ class (safety-evaluable population)

| MedDRA System Organ Class                                                                                | Sorafenib          | Atezo+Bev     |
|----------------------------------------------------------------------------------------------------------|--------------------|---------------|
| MedDRA Preferred Term                                                                                    | (N=156)            | (N=329)       |
| Total number of patients with at least one adverse event                                                 | 154 (98.7%)        | 323 (98.28)   |
| Overall total number of events                                                                           | 1299               | 3058          |
| Gastrointestinal disorders                                                                               |                    |               |
| Total number of patients with at least one adverse event                                                 | 118 (75.6%) 293    | 193 (58.78)   |
| Total number of events                                                                                   |                    | 525           |
| Diarrhoea                                                                                                | 77 (49.49) (17.3%) | 62 (18.8%)    |
| Abdominal pain                                                                                           | 27                 | 40 (12.2*)    |
| General disorders and administration site conditions                                                     |                    | 166           |
| Total number of patients with at least one adverse event                                                 | 77 (49.4%)         | (50.5%)       |
| Total number of events                                                                                   | 105                | 278           |
| Pyrexia                                                                                                  | 15 (9.6)           | 59 (17.9)     |
| Asthenia                                                                                                 | 21 (13.58)         | 23 6.7%)      |
| Oedema peripheral                                                                                        | 5 (3.2%)           | 8.8%)         |
| Skin and subcutaneous tissue disorders                                                                   | (68.6%)            | 123           |
| Total number of patients with at least one adverse event                                                 | 107                | (37.4%)       |
| Total number of events                                                                                   | 187                | 197           |
| Pruritus                                                                                                 | 15 (9.68)          | 64 (19.5)     |
| Palmar-plantar erythrodysaesthesia symdrome                                                              | 75 (48.1%)         | 3 0.9%)       |
| Alopecia                                                                                                 | 22 (14.1*)         | 4 (1.2:)      |
| Investigations                                                                                           |                    | 159           |
| Total number of patients with at least one adverse event                                                 | 68 (43.6%) 223     | (48.38)       |
| Total number of events                                                                                   |                    | 518           |
| Alanine aminotransferase increased                                                                       | 14 (9.0%)          | 46 (14.0)     |
| Metabolism and nutrition disorders                                                                       | (42.3%)            | 129           |
| Total number of patients with at least one adverse event                                                 | 66 118             | (39.28)       |
| Total number of events                                                                                   |                    | 214           |
| Decreased appetite                                                                                       | 38 (24.48)         | 58 (17.6%)    |
| Respiratory, thoracic and mediastinal disorders Total number of patients with at least one adverse event | (30.1%)            | 130           |
|                                                                                                          | 47                 | (39.5%)       |
| Total number of events                                                                                   | 71                 | 219           |
| Epistaxis                                                                                                | 7 (4.58)           | 34 (10.38)    |
| Vascular disorders                                                                                       | (26.98)            |               |
| Total number of patients with at least one adverse event                                                 | 42                 | 108 (32.8%)   |
| Total number of events                                                                                   | 52                 | 160           |
| Hypertension                                                                                             | 38 (24.4%)         | 98 (29.88)    |
| Musculoskeletal and connective tissue disorders                                                          | (21.8%)            |               |
| Total number of patients with at least one adverse event                                                 | 34                 | 100 (30.4)    |
| Total number of events                                                                                   | 44                 | 150           |
| Musculoskeletal pain                                                                                     | 3 (1.9)            | 24 (7.38)     |
| Renal and urinary disorders                                                                              | (12.8%)            |               |
| Total number of 1 patients with at least one adverse event                                               | 20                 | 86(26.18)     |
| Total number of events                                                                                   | 24                 | 120           |
| Proteinuria                                                                                              | 11 ( 7.1)          | 66 (20.18)    |
| Injury, poisoning and procedural complications                                                           |                    |               |
| Totai number of patients with at least one adverse event                                                 | 6( 3.8%)           | 46 (14.08)    |
| Total number of events Infusion related reaction                                                         | 7 0                | 61 37 (11.28) |
| Endocrine disorders                                                                                      |                    | 39            |
| Total number of patients with at least one adverse event                                                 | (3.2)              | (11.98)       |
| Total number of events                                                                                   | 5 5                | 47            |
| Hypothyroidism                                                                                           | 3 3 (1.9%)         | 29(8.88)      |

Includes AEs with onset date on or after the date of the first dose of study drug up to the data cutoff date. Investigator text for AEs are encoded using MedDRA version 22.0. Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the Same AE in an individual are counted only once. For frequency counts of \"Total number of events\" rows, multiple occurrences of the same AE in an individual are counted separately.

## Treatment-related AEs

<div style=\"page-break-after: always\"></div>

Table 54: Adverse events related to study treatment with an incidence rate of at least 5% in any treatment arm by system organ class and preferred term (safety-evaluable population)

|                                                                         | Sorafenib (N=156)   | Atezo+Bev (N=329)   | Atezo+Bev (N=329)   | Atezo+Bev (N=329)    |
|-------------------------------------------------------------------------|---------------------|---------------------|---------------------|----------------------|
| MedDRA System Organ Class MedDRAPreferred Term                          | Sorafenib           | Atezo               | Bev                 | Any treatment        |
| Totalnumber of patients with at least one adverseevent                  | 147(94.28)          | 252 (76.68)         | 241 (73.38)         | 276 (83.98)          |
| Overall totalnumber of events                                           | 790                 | 1259                | 1136                | 1505                 |
| Skin and subcutaneous tissue disorders                                  |                     |                     |                     |                      |
| Total number ofpatients with at least one adverse event                 | 107 (68.68)         | 82 (24.98)          | 42 (12.88)          | 85 (25.8%)           |
| Total number of events Palmar-plantar erythrodysaesthesia               | 175 75 (48.18)      | 123 （0.38)          | 53 1 (0.38)         | 127 2 (0.6%)         |
| syndrome Pruritus                                                       | 13 （8.3%)           | 43 (13.18)          | 17 （5.2%）           | 43 (13.18)           |
| Rash                                                                    | 26 (16.7%)          | 29 (8'8             | 14 4.38)            | 29 8.8%)             |
| Alopecia                                                                | 21 (13.58)          | 3 (86'0             | 2 0.6%)             | 3 (0.9%)             |
| Gastrointestinal disorders                                              |                     |                     |                     |                      |
| Total number of patients with at least oneadverse event                 | 91(58.38)           | 83 (25.28)          | 81 (24.68)          | 97(29.58)            |
| Total number of events                                                  | 178                 | 153                 | 148                 | 180                  |
| Diarrhoea                                                               | 67 (42.9%)          | 34 (10.38)          | 22 6.7%)            | 34 (10.3%)           |
| Nausea                                                                  | 20 (12.8%)          | 19 5.88)            | 19 5.8%)            | 21 (6.48)            |
| Vomiting                                                                | 8 5.18)             | 13 4.0%)            | 13 4.0%)            | 13 4.0%)             |
| Constipation                                                            | 8 5.18)             | 6 1.8%)             | 8 2.48)             | 8 2.48)              |
| Abdominal pain                                                          | 8 5.18)             | 3 0.98)             | 3 (0.98)            | 3 (0.9%)             |
| Investigations                                                          |                     |                     |                     |                      |
| Totalnumberofpatientswithat least oneadverse event                      | 45 (28.8%)          | 107 (32.58)         | 88(26.78)           | 111 (33.7%)          |
| Totalnumber of events                                                   | 124                 | 341                 | 266                 | 357                  |
| Aspartate aminotransferase increased                                    | 11 (7.18)           | 45 (13.78)          | 29 (8.8%)           | 46 (14.0%)           |
| Platelet count decreased                                                | 15 9.68)            | 23 (7.08)           | 24 (7.38)           | 27 (8.2%)            |
| Alanine aminotransferase increased                                      | 4 2.6%)             | 34 (10.3%)          | 18 5.58) 20 6.1%)   | 34 (10.3%) 27 (8.2%) |
| Blood bilirubin increased Weight decreased                              | 9 5.8%) 8 5.1%)     | 27 8.2%) 12 （ 3.6%) | 12 (3.68)           | 13 (4.0%)            |
| General disorders and administration                                    |                     |                     |                     |                      |
| site conditions Totalnumber of patients with at least one adverse event | 58 (37.28)          | 91 (27.78)          | 80 (24.38)          | 97(29.58)            |
| Totalnumber of events                                                   | 71                  | 121                 | 105                 | 132                  |
| Fatigue                                                                 | 24 (15.48)          | 49 (14.98)          | 40 (12.28)          | 50 (15.28)           |
| Pyrexia                                                                 | 8 5.1%)             | 27 8.28)            | 25 (7.6%)           | 30 (9.1%)            |

<div style=\"page-break-after: always\"></div>

| Asthenia                                                                                                            | 16 (10.38)    | 10 (3.0%)     | （2.4%)        | 11 (3.38)     |
|---------------------------------------------------------------------------------------------------------------------|---------------|---------------|---------------|---------------|
| Vascular disorders                                                                                                  |               |               |               |               |
| Total number of patients withat least oneadverse event                                                              | 32(20.58)     | 21 (6.48)     | 81 (24.6%)    | 84(25.58)     |
| Total number of events                                                                                              | 35            | 31            | 102           | 105           |
| Hypertension                                                                                                        | 31 (19.98)    | 17 (5.28)     | 78 (23.78)    | 78(23.78)     |
| Metabolism and nutrition disorders                                                                                  |               |               |               |               |
| Total number of patients with at least one adverse event                                                            | 45 (28.8%)    | 58 (17.68)    | 50 (15.2%)    | 63 (19.18)    |
| Total number ofevents                                                                                               | 69            | 86            | 74            | 92            |
| Decreased appetite                                                                                                  | 31 (19.98)    | 29(8.88)      | 26 (7.9%)     | (10.0%)       |
| Respiratory, thoracic and mediastinal disorders                                                                     |               |               |               |               |
| Total number of patients with at                                                                                    | 25 (16.0%)    | 42 (12.8%)    | 58 (17.68)    | 65 (19.88)    |
| least one adverse event Totalnumber of events                                                                       | 29 10 6.48)   | 51 15 (4.68)  | 73 (6.1%)     | 85 (6.78)     |
|                                                                                                                     | 3 （ 1.98)     | 4             |               | 22 24 (7.38)  |
| Dysphonia Epistaxis Renal and urinary disorders                                                                     |               | 1.28)         | 20 24 (7.3%)  | 69 (21.0%)    |
| Total number of patients with at least one adverse event Total number of events                                     | 8( 5.18) 8    | 33 (10.08) 49 | 68(20.7%) 95  | 96            |
| Proteinuria                                                                                                         | 7(4.58)       | 27 ( 8.2%)    | 62 (18.8%)    | 62 (18.8%)    |
| Blood and lymphatic system disorders Total number of patients with at least one adverse event Totalnumber of events | 18 (11.5%) 32 | 41 (12.58) 68 | 35 (10.68) 78 | 43( (13.18)   |
| Anaemia                                                                                                             | 8 (5.18)      | 6 (2.78)      | 8 （2.48)      | 92 6 (2.78)   |
| Endocrine disorders                                                                                                 |               |               |               |               |
| Total number of patients withat least one adverse event                                                             | 4 (2.6%)      | 35 (10.6%)    | 15 (4.68)     | 36 (10.98)    |
| Totalnumberof events Hypothyroidism                                                                                 | 2 (1.3%)      | 42 25 (7.6%)  | 17 14 (4.3%)  | 43 26 (7.98)  |
| Injury, poisoning and procedural complications                                                                      |               |               |               |               |
| Total number of patients with at least one adverse event                                                            | 0             | 33 (10.0%)    | 10(3.0%)      | 37 (11.2%)    |
| Total number of events Infusionrelatedreaction                                                                      | 0 0           | 40 32 (9.78)  | 13 10 (3.0%)  | 46 36 (10.98) |

Includes AEs with onset date on or after the date of the first dose of study drug up to the data cutoff date.

Investigator text for AEs are encoded using MedDRA version 22.0.Percentages are based on N inthe\\_column headings.For frequency countsby preferred term,multiple occurrences of\\_the same AE in an individual are counted only once. For frequency counts of \"Total number of events\" rows, multiple occurrences of the same AE in an individual are counted separately.

## Grade ≥3 AEs

<div style=\"page-break-after: always\"></div>

Table 55: Adverse events with highest NCI CTCAE grade categories 3-4 and 5 with a difference of at least 2% between treatment arms by system organ class and preferred term (safety-evaluable population)

|                                                          | Borafenib (N=156)   | Borafenib (N=156)   | Ateno+Bev (N=329)   | Ateno+Bev (N=329)   |
|----------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| MedDRA System Orgen Cla99 MedDRA Preferred Term          | Grade 3-4           | Grade 5             | Grade 3-4           | Grade 5             |
| Total number of patients with at least one adverse event | 86(55.11)           | 6 (5.88)            | 186 (56.51)         | 15(4.61)            |
| Investigationg                                           |                     |                     |                     |                     |
| Total mmber of patients with at least one adverseevent   | 25(16.0)            | 0                   | 61(16.5)            |                     |
| Blood bilirubin incresued                                | 10(6.48)            | 0                   | 8(2.4)              |                     |
| Alanine eminotransferase increased                       | (1.31)              |                     | 12 9.0              | 00                  |
| Platelet count decreased                                 | (1.3+)              |                     | 11 (3.34)           |                     |
| Gastrointestinal disorders                               |                     |                     |                     |                     |
| Total mumber of patients with at least one adverse event | 27 (17.31)          | 1(0.61)             | 48 (14.61)          | 5(1.51)             |
| Diarrhoea                                                | 8(5.1#)             | 0                   | 6 (1.8)             | 0                   |
| Vaseular disorders                                       |                     |                     |                     |                     |
| Total mumber of patients with at least one Adverse event | 21 (13.51)          | 0                   | 53 (16.1#)          | 0                   |
| Hypertension                                             | 19 (12.24)          | 0                   | 50 (15.21)          | 0                   |
| Hetabolism and nutrition disorders                       |                     |                     |                     |                     |
| Total number of patients wich at least one adverse event | 21(13.51)           | 0                   | 30(9.18)            | 0                   |
| Deereased appetite Hypophosphataemia                     | 6 (3.88) 6 (3.81)   | 0 0                 | 4 (1.2) 2 (0.61)    | 0 0                 |
| General disorders and sdhinigtration site conditiong     |                     |                     |                     |                     |
| Total number of patients with at least one               | 12 (7.78)           | 3(1.98)             | 14(4.31)            | 1(0.3)              |
| adverse event Aothenis                                   | 4(2.6)              | 0                   | 1(0.3#)             | 0                   |
| Skin and subcutaneous tissue disonders                   |                     |                     |                     |                     |
| Total number of patients with at least one adverse event | 21 (13.51)          | 0                   | 2(0.6)              | 0                   |
| Palmar-plantar erythrodysaesthesia symdrome Rash         | 13(8.31) 4(2.61)    | ! 0                 |                     |                     |
| Renal and urinary disorders                              |                     |                     |                     |                     |
| Total number of patients with at least one adverse event | 6(3.84)             | 0                   | 14(4.31)            | 0                   |
| Proteinuria                                              | 1 (0.61)            | 0                   | 10(3.0)             | 0                   |
| Injury. poisoning and procedural complieabions           |                     |                     |                     |                     |
| Total mumber of patients with at least one               | 2(1.31)             | 0                   | 13 (4.0)            | 0                   |
| adwerse event Infusion related reaction                  | 0                   | 0                   | 8(2.4)              | 0                   |

Includes AEs with onset date on or after the date of the first dose of study drug up to the data cutoff date. quenaidar 6qumos tty *0'zz uotsian 480pek buten peposue 81e 6at 3og qwe4 1oqebga6anu1 patients. Mnltiple gccurrenges of the seme AE in one individual are counted onne at the highest grade for this preferred tem.

at least one AE with the corresponding highest grade is reported.

Adverse Events of Special Interest

<div style=\"page-break-after: always\"></div>

Table 56: Overview of adverse events of special interest for atezolizumab (safety-evaluable population)

|                                                                       | Sorafenib (N=156)   | Sorafenib (N=156)   | Atezo+Bev (N=329)   | Atezo+Bev (N=329)   |
|-----------------------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Total number of patients with at least one AEsI                       | 128                 | (82.18)             | 226                 | (68.78)             |
| Total number of events                                                |                     | 411                 |                     | 866                 |
| Total number of patients with at least one                            |                     |                     |                     |                     |
| AESI Related to any Study Treatment                                   | 115                 | (73.78)             | 173                 | (52.68)             |
| Grade 3/4 AESI                                                        | 47                  | (30.18)             | 85                  | (25.8%)             |
| Treatment-related Grade 3/4 AESI                                      | 39                  | (25.0%)             | 49                  | (14.9%)             |
| Grade 5 AESI                                                          | 2                   | 1.38)               | 3                   | (6'0                |
| Treatment-related Grade 5 AESI                                        | 1                   | 0.68)               | 2                   | 0.6)                |
| Serious AESI                                                          | 17                  | (10.98)             | 45                  | (13.78)             |
| Treatment-related Serious AESI                                        | 13                  | 8.38)               | 20                  | 6.18)               |
| AESI Leading to Withdrawal from any Study Treatment                   | 9                   | 5.88)               | 20                  | 6.1%)               |
| AESI Leading to Dose Interruption/Modification of any Study Treatment | 56                  | (35.98)             | 66                  | (20.18)             |
| AESI Medical Concepts: patients with at least one                     |                     |                     |                     |                     |
| Identified risks for Atezolizumab                                     |                     |                     |                     |                     |
| Immune-Mediated Hepatitis (Diagnosis and Lab Abnormalities)           | 62                  | (39.7%)             | 142                 | (43.28)             |
| Immune-Mediated Hepatitis (Lab Abnormalities)                         | 54                  | (34.6%)             | 126                 | (38.38)             |
| Immune-Mediated Rash                                                  | 96                  | (61.58)             | 64                  | (19.58)             |
| Immune-Mediated Hepatitis (Diagmosis)                                 | 20                  | (12.8%)             | 43                  | (13.18)             |
| Immune-Mediated Hypothyroidism                                        | 4                   | 2.68)               | 36                  | (10.98)             |
| Infusion-Related Reactions                                            | 00                  |                     | 36                  | (10.98)             |
| Immune-Mediated Hyperthyroidism                                       |                     |                     | 15                  | 4.6%)               |
| Immune-Mediated Pancreatitis                                          | 6                   | (3.88)              | 9                   | 2.78)               |
| Immune-Mediated Diabetes Mellitus                                     | 0                   |                     | 8                   | 2.4%j               |
| Immune-Mediated Colitis                                               | 1                   | 0.68)               | 6                   | 1.8%)               |
| Immune-Mediated Pmeumonitis                                           |                     |                     |                     | 1.28)               |
| Immune-Mediated Nephritis                                             | 口                   |                     | 431                 | 0.98)               |
| Immune-Mediated Adrenal Insufficiency                                 | 0                   |                     |                     | 0.38)               |
| Potentialrisks for Atezolizumab                                       |                     |                     |                     |                     |
| Immune-Mediated Severe Cutaneous Reactions                            | 1                   | (0.68)              | 0                   |                     |
| Immune-Mediated Ocular Inflammatory Toxicity                          | 0                   |                     | 1                   | 0.38)               |
| Autoimmune Hemolytic Anemia                                           | 0                   |                     | 1                   | 0.3%)               |
| Immune-Mediated Vasculitis                                            | 0                   |                     | 1                   | 0.3%)               |
| Systemic Immune Activation                                            | 0                   |                     |                     | 0.38)               |

data cutoff date.

Sponsor-defined Adverse Events of Special Interest that have not occurred in any Hcc patient enrolled in the safety analysis population for this output are not displayed.

Investigator text for AEs are encoded using MedDRA version 22.0. Percentages are based on N in\\_the columm headings. Multiple occurrences of the same AE in one individual are counted only once except for \"Total nimber of AEs\" row in which multiple occurrences of the same AE are counted separately.

<div style=\"page-break-after: always\"></div>

Table 57: Overview of adverse events of special interest for bevacizumab (safety-evaluable population)

|                                                                        | Sorafenib (N=156)   | Atezo+Bev (N=329)   | Atezo+Bev (N=329)   |
|------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Total number of patients with at least one AEsI Total number of events | 76 (48.78) 106      | 190                 | (57.88) 388         |
| Total number of patients with at least one                             |                     |                     |                     |
| AESI Related to any Study Treatment                                    | 52 (33.38)          | 146                 | (44.4%)             |
| Grade3/4 AESI                                                          | 29 (18.6%)          | 76                  | [23.1%]             |
| Treatment-related Grade 3/4 AESI                                       | 21 (13.58)          | 53                  | (16.18)             |
| Grade 5 AESI                                                           | 2 (1.38)            | 6                   | 1.88)               |
| Treatment-related Grade 5 AESI                                         | 3                   | 0.98)               |                     |
| Serious AESI                                                           | 15 9.68)            | 40                  | (12.28)             |
| Treatment-related Serious AESI                                         | 3.8%)               | 21                  | 6.48)               |
| AESI Leading to Withdrawal from any Study Ireatment                    |                     | 36                  | 7.981               |
| AESI Leading to Dose Interruption/Modification of any Study Treatment  | 0.68) 9.68)         |                     | (17.0%)             |
| AESI Medical Concepts: patients with at least one                      | (25.68)             |                     |                     |
| Hypertension                                                           | 40                  | 102                 | (31.08)             |
| Bleeding / Haemorrhage                                                 | 27 (17.38)          | 83                  | (25.28)             |
| Proteinuria                                                            | 13 8.38)            | 70                  | (21.3)              |
| Thromboembolic Event -Venous                                           | 3.28)               | 10                  | 3.0%)               |
| Thromboembolic Event - Arterial                                        |                     | 9                   | 2.78)               |
| Congestive Heart Failure                                               | 522 1.38) 1.38)     | 1                   | 0.38)               |
| Wound Healing Complications                                            | 口                   | 1                   | 0.68)               |
| Fistula/Abscess (Non GI)                                               | 1 0.68)             | 0                   |                     |
| Gastrointestinal Perforation                                           | 0                   |                     | (0.3)               |

<!-- image -->

Diabetes mellitus occurred in 2.0% (10/493) of HCC patients who received atezolizumab in combination with bevacizumab. The median time to onset was 4.4 months (range: 1.2 months - 8.3 months). No events of diabetes mellitus led to atezolizumab withdrawal.

## Adverse drug reactions

The table below reflects the adverse drug reactions related of Tecentriq as identified in the pooled safety dataset for atezolizumab monotherapy (n=3568) and in combination therapy (n=4,371).

| Atezolizumab monotherapy (n=3568)    | Atezolizumab monotherapy (n=3568)    | System Organ Class                   | Atezolizumab in combination therapy (n=4371)   | Atezolizumab in combination therapy (n=4371)   |
|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------------------------|------------------------------------------------|
| Frequency (All Grades)               | Incidence% (All Grades)              |                                      | Frequency (All Grades)                         | Incidence% (All Grades)                        |
| Infections and infestations          | Infections and infestations          | Infections and infestations          | Infections and infestations                    | Infections and infestations                    |
| very common                          | 467 (13.1%)                          | Urinary tract infection a            | -                                              | -                                              |
| -                                    | -                                    | Lung infection b                     | very common                                    | 564 (12.9%)                                    |
| -                                    | -                                    | Sepsis aj                            | common                                         | 91 (2.1%)                                      |
| Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders           | Blood and lymphatic system disorders           |
| -                                    | -                                    | Anaemia                              | very common                                    | 1608 (36.8%)                                   |
| common                               | 131 (3.7%)                           | Thrombocytopenia d                   | very common                                    | 1211 (27.7%)                                   |
| -                                    | -                                    | Neutropenia e                        | very common                                    | 1565 (35.8%)                                   |
| -                                    | -                                    | Leukopenia f                         | very common                                    | 571 (13.1%)                                    |
| -                                    | -                                    | Lymphopenia g                        | common                                         | 145 (3.3%)                                     |
| Immune system disorders              | Immune system disorders              | Immune system disorders              | Immune system disorders                        | Immune system disorders                        |
| common                               | 46 (1.3%)                            | Infusion-related reaction h          | common                                         | 157 (3.6%)                                     |
| Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                            | Endocrine disorders                            |
| common                               | 214 (6.0%)                           | Hypothyroidism i                     | very common                                    | 586 (13.4%)                                    |
| uncommon                             | 47 (1.3%)                            | Hyperthyroidism j                    | common                                         | 193 (4.4%)                                     |
| uncommon                             | 11 (0.3%)                            | Diabetes mellitus k                  | -                                              | -                                              |
| uncommon                             | 12 (0.3%)                            | Adrenal insufficiency l              | -                                              | -                                              |
| rare                                 | 3 (<0.1%)                            | Hypophysitis m                       | -                                              | -                                              |
| Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders             | Metabolism and nutrition disorders             |

<div style=\"page-break-after: always\"></div>

| very common                                                  | 855 (24.0%)                                                  | Decreased appetite                                           | very common                                                  | 1091 (25.0%)                                                 |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| common                                                       | 154 (4.3%)                                                   | Hypokalaemia ae                                              | common                                                       | 296 (6.8%)                                                   |
| common                                                       | 174 (4.9%)                                                   | Hyponatraemia af                                             | common                                                       | 235 (5.4%)                                                   |
| common -                                                     | 120 (3.4%) -                                                 | Hyperglycaemia                                               | -                                                            | -                                                            |
| Hypomagnesaemia n common 403 (9.2%) Nervous system disorders | Hypomagnesaemia n common 403 (9.2%) Nervous system disorders | Hypomagnesaemia n common 403 (9.2%) Nervous system disorders | Hypomagnesaemia n common 403 (9.2%) Nervous system disorders | Hypomagnesaemia n common 403 (9.2%) Nervous system disorders |
| very common                                                  | 388 (10.9%)                                                  | Headache                                                     | very common                                                  | 612 (14.0%)                                                  |
| uncommon                                                     | 5 (0.1%)                                                     | Guillain-Barré syndrome p                                    | -                                                            | -                                                            |
| uncommon                                                     | 14 (0.4%)                                                    | Meningoencephalitis q                                        | -                                                            | -                                                            |
| rare                                                         | 1 (<0.1%)                                                    | Myasthenic syndrome r                                        | -                                                            | -                                                            |
| -                                                            | -                                                            | Peripheral neuropathy o                                      | very common                                                  | 1007 (23.0%)                                                 |
| -                                                            | -                                                            | Syncope                                                      | common                                                       | 68 (1.6%)                                                    |
| -                                                            | -                                                            | Dizziness                                                    | common                                                       | 408 (9.3%)                                                   |
| Eye rare                                                     | 3 (<0.1%)                                                    | Disorders Uveitis                                            | -                                                            | -                                                            |
| rare                                                         | 0                                                            | Cardiac disorders Myocarditis s                              | -                                                            | -                                                            |
| common                                                       | 108 (3.0%)                                                   | Vascular disorders Hypotension                               | -                                                            | -                                                            |
| -                                                            | -                                                            | Hypertension ai                                              | very common                                                  | 611 (14.0%)                                                  |
| Respiratory, thoracic, and mediastinal disorders             | Respiratory, thoracic, and mediastinal disorders             | Respiratory, thoracic, and mediastinal disorders             | Respiratory, thoracic, and mediastinal disorders             | Respiratory, thoracic, and mediastinal disorders             |
| very common                                                  | 707 (19.8%)                                                  | Cough                                                        | very common                                                  | 783 (17.9%)                                                  |
| very common                                                  | 678 (19.0%)                                                  | Dyspnoea                                                     | very common                                                  | 695 (15.9%)                                                  |
| common                                                       | 99 (2.8%)                                                    | Pneumonitis t                                                | -                                                            | -                                                            |
| common                                                       | 75 (2.1%)                                                    | Hypoxia ag                                                   | -                                                            | -                                                            |
| common                                                       | 110 (3.1%)                                                   | Nasal congestion                                             | -                                                            | -                                                            |
| common                                                       | 160 (4.5%)                                                   | Nasopharyngitis                                              | -                                                            | -                                                            |
| -                                                            |                                                              |                                                              |                                                              |                                                              |
| Dysphonia common 236 (5.4%)                                  | Dysphonia common 236 (5.4%)                                  | Dysphonia common 236 (5.4%)                                  | Dysphonia common 236 (5.4%)                                  | Dysphonia common 236 (5.4%)                                  |
| very common                                                  | 799 (22.4%)                                                  | Gastrointestinal disorders Nausea                            | very common                                                  | 1504 (34.4%)                                                 |
| very common                                                  | 504 (14.1%)                                                  | Vomiting                                                     | very common                                                  | 808 (18.5%)                                                  |
| very common                                                  | 710 (19.9%)                                                  | Diarrhoea u                                                  | very common                                                  | 1185 (27.1%)                                                 |
| common                                                       | 299 (8.4%)                                                   | Abdominal pain                                               | -                                                            | -                                                            |
| common                                                       | 43 (1.2%)                                                    | Colitis v                                                    | -                                                            | -                                                            |
| common                                                       | 86 (2.4%)                                                    | Dysphagia                                                    | -                                                            | -                                                            |
| common                                                       | 143 (4.0%)                                                   | Oropharyngeal pain w                                         | -                                                            | -                                                            |
| uncommon                                                     | 27 (0.8%)                                                    | Pancreatitis x                                               | -                                                            | -                                                            |
| -                                                            | -                                                            | Constipation                                                 | very common                                                  | 1123 (25.7%)                                                 |
| -                                                            | -                                                            | Stomatitis                                                   | common                                                       | 351 (8.0%)                                                   |
| - - Dysgeusia                                                |                                                              |                                                              | common                                                       | 269 (6.2%)                                                   |
| Hepatobiliary disorders                                      | Hepatobiliary disorders                                      | Hepatobiliary disorders                                      | Hepatobiliary disorders                                      | Hepatobiliary disorders                                      |
| common                                                       | 200 (5.6%)                                                   | AST increased                                                | common                                                       | 390 (8.9%)                                                   |
| common                                                       | 191 (5.4%)                                                   | ALT increased                                                | common                                                       | 392 (9.0%)                                                   |
| common                                                       | 66 (1.8%)                                                    | Hepatitis y                                                  | -                                                            | -                                                            |
| Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       | Skin and subcutaneous tissue disorders                       |
| very common                                                  | 705 (19.8%)                                                  | Rash z                                                       | very common                                                  | 1189 (27.2%)                                                 |
| very common                                                  | 498 (14.0%)                                                  | Pruritus                                                     | very common                                                  | 573 (13.1%)                                                  |
| common                                                       | 216 (6.1%)                                                   | Dry skin                                                     | -                                                            | -                                                            |
| uncommon                                                     | 18 (0.5%)                                                    | Psoriasis                                                    | uncommon                                                     | 24 (0.5%)                                                    |
| -                                                            | -                                                            | Alopecia ah                                                  | very common                                                  | 1152 (26.4%)                                                 |
| Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              | Musculoskeletal and connective tissue disorders              |
| very common                                                  | 485 (13.6%)                                                  | Arthralgia                                                   | very common                                                  | 729 (16.7%)                                                  |
| very common                                                  | 513 (14.4%)                                                  | Back pain                                                    | very common                                                  | 522 (11.9%)                                                  |
| very common                                                  | 525 (14.7%)                                                  | Musculoskeletal pain aa                                      | very common                                                  | 815 (18.6%)                                                  |
| uncommon                                                     | 15 (0.4%)                                                    | Myositis ab                                                  | -                                                            | -                                                            |
| Renal and urinary disorders                                  | Renal and urinary disorders                                  | Renal and urinary disorders                                  | Renal and urinary disorders                                  | Renal and urinary disorders                                  |
| common                                                       | 210 (5.9%)                                                   | Blood creatinine                                             | common                                                       | 255 (5.8%)                                                   |
| rare                                                         | 8 (0.2%)                                                     | increased c ad                                               | -                                                            | -                                                            |
| -                                                            | -                                                            | Nephritis Proteinuria ac                                     | common                                                       | 359 (8.2%)                                                   |
| General disorders and administration site conditions         | General disorders and administration site conditions         | General disorders and administration site conditions         | General disorders and administration site conditions         | General disorders and administration site conditions         |
| very common                                                  | 717 (20.1%)                                                  | Pyrexia                                                      | very common                                                  | 786 (18.0%)                                                  |
| very common                                                  | 1231 (34.5%)                                                 | Fatigue                                                      | very common                                                  | 1442 (33.0%)                                                 |
| very common                                                  | 497 (13.9%)                                                  | Asthenia                                                     | very common                                                  | 780 (17.8%)                                                  |
| common                                                       | 205 (5.7%)                                                   | Influenza like illness                                       | -                                                            | - -                                                          |
| common -                                                     | 230 (6.4%) -                                                 | Chills Oedema peripheral                                     | - very common                                                | 451 (10.3%)                                                  |

<div style=\"page-break-after: always\"></div>

| Investigations   | Investigations   | Investigations                       | Investigations   | Investigations   |
|------------------|------------------|--------------------------------------|------------------|------------------|
| -                | -                | Blood alkaline phosphatase increased | common           | 200 (4.6%)       |

- a  Includes reports of urinary tract infection, cystitis, pyelonephritis, escherichia urinary tract infection, urinary tract infection bacterial, kidney infection, pyelonephritis acute, urinary tract infection fungal, urinary tract infection pseudomonal.
- b  Includes reports of pneumonia, bronchitis, lung infection, lower respiratory tract infection, infective exacerbation of COPD, infectious pleural effusion, tracheobronchitis, atypical pneumonia, lung abscess, paracancerous pneumonia, pyopneumothorax, pleural infection.
- c  Includes reports of blood creatinine increased, hypercreatininaemia.
- d  Includes reports of thrombocytopenia, platelet count decreased.
- e  Includes reports of neutropenia, neutrophil count decreased, febrile neutropenia, neutropenic sepsis, granulocytopenia.

f  Includes reports of white blood cell count decreased, leukopenia.

- g  Includes reports of lymphopenia, lymphocyte count decreased
- h  Includes reports of  infusion related reaction
- i  Includes reports of autoimmune hypothyroidism, autoimmune thyroiditis, blood thyroid stimulating hormone abnormal, blood thyroid stimulating hormone decreased, blood thyroid stimulating hormone increased, euthyroid sick syndrome, goitre,

hypothyroidism, myxoedema coma, thyroid disorder, thyroid function test abnormal, thyroiditis, thyroxine decreased, thyroxine free decreased, thyroxine free increased, thyroxine increased, tri-iodothyronine decreased, tri-iodothyronine free abnormal, tri-

iodothyronine free decreased, tri-iodothyronine free increased, silent thyroiditis, thyroiditis chronic.

- j  Includes reports of hyperthyroidism, Basedow's disease, endocrine ophthalmopathy, exophthalmos.
- k  Includes reports of diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis, ketoacidosis.
- l  Includes reports of adrenal insufficiency, primary adrenal insufficiency.
- m  Incudes reports of hypophysitis, temperature regulation disorder.
- n  Includes reports of hypomagnesaemia, blood magnesium decreased.
- o  Includes reports of neuropathy peripheral, autoimmune neuropathy, peripheral sensory neuropathy, polyneuropathy, herpes zoster, peripheral motor neuropathy, neuralgic amyotrophy, peripheral sensorimotor neuropathy, toxic neuropathy, axonal neuropathy, lumbosacral plexopathy, neuropathic arthropathy, peripheral nerve infection.
- p  Includes reports of Guillain-Barré syndrome, demyelinating polyneuropathy.
- q  Includes reports of encephalitis, meningitis, photophobia.
- r  Incudes reports of myasthenia gravis.
- s  Reported in studies outside the pooled dataset. The frequency is based on the program wide exposure.
- t  Includes reports of pneumonitis, lung infiltration, bronchiolitis, interstitial lung disease, radiation pneumonitis.
- u  Includes reports of diarrhoea, defaecation urgency, frequent bowel movements, diarrhoea haemorrhagic.
- v  Includes reports of colitis, autoimmune colitis, colitis ischaemic, colitis microscopic, colitis ulcerative.
- w  Includes reports of oropharyngeal pain, oropharyngeal discomfort, throat irritation.
- x  Includes reports of autoimmune pancreatitis, pancreatitis, pancreatitis acute, lipase increased, amylase increased.
- y  Includes reports of ascites, autoimmune hepatitis, hepatocellular injury, hepatitis, hepatitis acute, hepatotoxicity, liver disorder,
- drug-induced liver injury, hepatic failure, hepatic steatosis, hepatic lesion, oesophageal varices haemorrhage, varices oesophageal.
- z  Includes reports of acne, acne pustular, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis bullous, dermatitis exfoliative generalised, drug eruption, eczema, eczema infected, erythema, erythema multiforme, erythema of eyelid, exfoliative rash, folliculitis, furuncle,  palmar-plantar erythrodysaesthesia syndrome, rash , rash erythematous, rash follicular, rash generalised, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, rash vesicular, seborrhoeic dermatitis, skin exfoliation, skin toxicity, skin ulcer, toxic epidermal necrolysis, toxic skin eruption.
- aa  Includes reports of musculoskeletal pain, myalgia, bone pain.
- ab  Includes reports of myositis, rhabdomyolysis, polymyalgia rheumatica, dermatomyositis, muscle abscess, myoglobin urine present.

ac  Includes reports of proteinuria, protein urine present, haemoglobinurea, urine abnormality, nephrotic syndrome, albuminuria.

- ad  Includes report of nephritis, Henoch-Schonlein Purpura nephritis.
- ae  Includes report of hypokalaemia, blood potassium decreased.
- af  Includes report of hyponatraemia, blood sodium decreased.
- ag  Includes report of hypoxia, oxygen saturation decreased.
- ah  Includes report of alopecia, madarosis, alopecia areata, alopecia totalis, hypotrichosis.
- ai  Includes reports of hypertension, blood pressure increased, hypertensive crisis, blood pressure systolic increased, diastolic

hypertension, blood pressure inadequately controlled, retinopathy hypertensive, hypertensive nephropathy, essential hypertension.

- aj  Includes  reports of sepsis, septic shock, urosepsis, neutropenic sepsis, pulmonary sepsis, bacterial sepsis, klebsiella sepsis, abdominal sepsis, candida sepsis, escherichia sepsis, pseudomonal sepsis, staphylococcal sepsis.

## Serious adverse event/deaths/other significant events

## Deaths

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                      | Sorafenib (N=156)               | Atezo+Bev (N=329)               | A11 Patients (N=485)                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|---------------------------------|--------------------------------------|
| All Death                                                                                                                                            |                                 |                                 |                                      |
| n. <= 30 days after last dose >30 days after last dose                                                                                               | 64 14 (9.0%) 50 (32.18)         | 93 11 (3.3号) 82 (24.98)         | 157 25 ( 5.2%) 132 (27.28)           |
| Primary Cause of Death                                                                                                                               |                                 |                                 |                                      |
| n Adverse Event Progressive Disease Other\"                                                                                                           | 64 6 ( 5.8%) 51 (32.7%) 4 2.68) | 93 15 (4.68) 71 (21.6%) 7 2.18) | 157 24 (4.98) 122 (25.2%) 11 (2.38)  |
| Death Due To Cardio PulmonaryArrest n Death Due To GI Bleed Death Due To Heart Attack Death Due To Post Study Reporting Of Death Death Due ToUnkmowm | 0 0.6%) 0.6%) 0.68) 0.68)       | 1 0.38) 0:0 2 0.6%)             | 11 0.28) 0.28) 0.28) 5 1.0%) 3 0.68) |

Table 58: Deaths and causes of death (safety-evaluable population)

<!-- image -->

a =All deaths that were not attributed to disease progression and occurred either after the adverse event reporting period (see details in Section 3.9.5.2) or from public records, were reported as \"other\".

<div style=\"page-break-after: always\"></div>

Table 59: Adverse events leading to death (Safety-evaluable population)

<!-- image -->

| MedDRA System Organ Class MedDRA Preferred Term                                                          | Sorafenib (N=156)                                                                                   | Atezo+Bev (N=329)                                                                                   |
|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Totalnumber ofpatients withat least oneadverseevent                                                      | 9(5.8%)                                                                                             | 15 (4.68)                                                                                           |
| Overalltotalnumber of events                                                                             | 9                                                                                                   | 15                                                                                                  |
| Gastrointestinal disorders                                                                               |                                                                                                     |                                                                                                     |
| Totalnumberof patients withatleast one adverse event                                                     | (0.6%)                                                                                              | 5 (1.58)                                                                                            |
| Total number of events                                                                                   | 1                                                                                                   | 5                                                                                                   |
| Gastrointestinal haemorrhage                                                                             | 0                                                                                                   | 3 (0.98) (0.38)                                                                                     |
| Gastric ulcer perforation Oesophageal varices haemorrhage                                                | 0                                                                                                   | 1 (0.38)                                                                                            |
| Peritoneal haemorrhage                                                                                   | (0.68)                                                                                              | 0                                                                                                   |
| Infections and infestations                                                                              |                                                                                                     |                                                                                                     |
| Total number of patients with at least one adverse event                                                 | 1 (0.68)                                                                                            | (1.28)                                                                                              |
| Totalnumber ofevents                                                                                     | 1                                                                                                   | 4                                                                                                   |
| Pneumonia                                                                                                | 0 0                                                                                                 | 2 (0.6%) 1 (0.38)                                                                                   |
| Empyema Hepatitis E                                                                                      |                                                                                                     |                                                                                                     |
| Sepsis                                                                                                   | 1 (0.6%) 0                                                                                          | 0 1 (0.38)                                                                                          |
| General disorders and administration site conditions                                                     |                                                                                                     |                                                                                                     |
| Totalnumber ofpatients with at least oneadverseevent                                                     | 3 (1.9%)                                                                                            | (0.38)                                                                                              |
| Totalnumber of events                                                                                    | 3                                                                                                   | 1                                                                                                   |
| Deatha                                                                                                   | 2 (1.38)                                                                                            | 0                                                                                                   |
| General physical health deterioration                                                                    | 1 (0.68)                                                                                            |                                                                                                     |
| Multiple organ dysfunction syndrome                                                                      |                                                                                                     | 1 (0.38)                                                                                            |
| Hepatobiliary disorders                                                                                  |                                                                                                     |                                                                                                     |
| Total number of patients with at least one adverse event                                                 | 2 (1.38)                                                                                            | 2 (0.68)                                                                                            |
| Totalnumber of events Hepatic cirrhosis                                                                  | 2 2 (1.38)                                                                                          | 2 0                                                                                                 |
| Hepatic function abnormal                                                                                |                                                                                                     | (0.38)                                                                                              |
| Liver injury                                                                                             | 0                                                                                                   | (0.38)                                                                                              |
| Cardiac disorders                                                                                        |                                                                                                     |                                                                                                     |
| Totalnumber ofpatientswithatleastoneadverseevent                                                         | 2 (1.3%)                                                                                            | 1 (0.38)                                                                                            |
| Total number of events Cardiac arrest                                                                    | 2 1 (0.6%)                                                                                          | 1 (0.3%)                                                                                            |
| Cardiac failure                                                                                          | 1 (0.6%)                                                                                            | 0                                                                                                   |
| Nervous system disorders                                                                                 |                                                                                                     |                                                                                                     |
| Total number of patients with at least one adverse event                                                 | 0                                                                                                   | (0.38)                                                                                              |
| Total number of events                                                                                   | 0                                                                                                   | 1                                                                                                   |
| Subarachnoid haemorrhage                                                                                 | 0                                                                                                   | (0.38)                                                                                              |
| Respiratory, thoracic and mediastinal disorders                                                          |                                                                                                     |                                                                                                     |
| Total number of patients with at least one adverse event                                                 | 0                                                                                                   | 1 (0.38)                                                                                            |
| Totalnumber of events                                                                                    |                                                                                                     |                                                                                                     |
| Respiratory distress                                                                                     | 0                                                                                                   |                                                                                                     |
| IncludesAEswith onsetdateon or after the dateofthefirst dose ofstudy drugup tothe data cutoff date.      | IncludesAEswith onsetdateon or after the dateofthefirst dose ofstudy drugup tothe data cutoff date. | IncludesAEswith onsetdateon or after the dateofthefirst dose ofstudy drugup tothe data cutoff date. |
| Program:r0ot/clinical_studies/R05541267/CDT30091/Y040245/data_analysis/CSRSEP2018/prod/ program/t_ae.sas |                                                                                                     |                                                                                                     |
| Investigator text for AEs are encoded using MedDRA version 22.0.                                         |                                                                                                     | 1 (0.3%)                                                                                            |

a = The investigator reported the event as 'death' when the patient died suddently and no autopsy result was avalilable.

## Treatment-Related Fatal Adverse Events

In the SE population, 1 treatment-related Grade 5 AE occurred in the Sorafenib arm (hepatic cirrhosis) and  6  treatment-related  Grade  5  AEs  occurred  in  the  Atezo+Bev  arm.  In  the  Atezo+Bev  arm,  the treatment-related Grade 5 AEs were pneumonia, subarachnoid hemorrhage, liver injury, hepatic function abnormal, gastric ulcer perforation, and gastrointestinal hemorrhage; and each of them occurred in 1 patient.

Summaries of the treatment-related Grade 5 AEs reported in the both arms are provided below.

## Hepatic cirrhosis

This 47-year-old male patient had hepatic cirrhosis, esophageal varices and splenomegaly. No confirmed signs of disease progression were noted prior to the event of decompensated liver cirrhosis. The last dose of sorafenib was administered on Study Day 132. On the same day, the patient experienced ascites and a general condition of swelling of the legs. Relevant laboratory work-up showed AST 55 U/L, ALT 27 U/L, total

<div style=\"page-break-after: always\"></div>

bilirubin 28.2 mmol/ L, and albumin 29 g/l. He was diagnosed with a Grade 2 decompensated liver cirrhosis.  The  patient  received  diuretic  therapy  and  correction  of  water  and  electrolyte  disorders. Sorafenib was discontinued due to the event of decompensated liver cirrhosis. The patient's condition worsened  and  he  died  due  to  decompensated  liver  cirrhosis  on  Study  Day  223.  The  investigator considered this event as related to sorafenib and also as related to the concurrent condition of hepatic cirrhosis.

## Pneumonia

This 71-year old male patient had no relevant concurrent condition reported and received the most recent dose of atezolizumab and bevacizumab prior to the event on Study Day 225. Prior to event onset, no confirmed disease progression was noticed. The patient developed severe lung infection and was admitted for septic shock on Study Day 231, which subsequently led to multi-organ impairment (kidney, heart, lung). The CT scan showed consolidation in the lungs. The patient died due to pneumonia on Study Day 240. The investigator considered the event as related to both atezolizumab and bevacizumab.

## Subarachnoid hemorrhage

This 88-year-old male patient had a medical history of hypertension that was controlled under treatment. He received the most recent dose of atezolizumab and bevacizumab prior to the event on Study Day 126. The patient developed acute diffuse subarachnoid hemorrhage and was admitted to the intensive care unit on Study Day 147. The patient's blood pressure was 190/78 mm/Hg. CT head showed bilateral acute subarachnoid hemorrhage. Carotid duplex showed less than 50% stenosis of bilateral internal carotid arteries and greater than 50% stenosis of the bilateral external carotid arteries. The patient died due to subarachnoid hemorrhage on Study Day 152. The event was assessed as related to bevacizumab and disease under study but not related to atezolizumab by the investigator.

## Liver injury

This  61-year-old  male  patient  with  hepatic  cirrhosis  and  esophageal  and  gastric  varices  at  baseline received the most recent dose of atezolizumab and bevacizumab prior to the event on Study Day 85. Prior to event onset, no confirmed disease progression was noticed. On Study Day 94, a laboratory workup showed increased levels of total bilirubin of 9.35 mg/dl, ALT of 202 U/L, AST of 367 U/L, ALP of 298 U/L and the patient was diagnosed with Grade 2 liver injury. Liver biopsy result revealed bilirubinostasis and  the  conventional  histological  picture  for  toxic  damage  under  the  mentioned  therapy.  Both atezolizumab and bevacizumab were interrupted due to the event. The event did not improve after treatment with steroids and immunosuppressive agents (mycophenolate mofetil and tacrolimus). The patient died due to liver injury on Study Day 121. The event of liver injury was considered as related to atezolizumab and disease under study but not related to bevacizumab by the investigator.

## Hepatic function abnormal

This  74-year-old  male  patient  with  hepatic  fibrosis  at  baseline  received  the  most  recent  dose  of atezolizumab and bevacizumab prior to event on Study Day 22. The patient discontinued both study treatments on Study Day 43 due to disease progression. On Study Day 73, a laboratory work-up showed increased levels of AST of 806 U/L and ALT of 735 U/L. He developed Grade 4 hepatic function abnormal on Study Day 77, which was assessed as related to atezolizumab, and started treatment with steroids. On Study Day 86, a CT scan revealed hepatic atrophy which suggested that the patient developed liver failure and plasma exchange was started. The event did not improve and the patient died due to hepatic function abnormal on Study Day 90. The autopsy result revealed remarkable liver atrophy. There was also a necrosis of the ascending and transverse colon due to the direct invasion by HCC. The AE of hepatic function abnormal was assessed as related to atezolizumab, disease under study, and concurrent illness but not related to bevacizumab by the investigator.

## Gastric ulcer perforation

<div style=\"page-break-after: always\"></div>

This 76-year-old male patient had concurrent condition of duodenal ulcer and received the most recent dose of atezolizumab and bevacizumab prior to the event on Study Day 43. Prior to event onset no confirmed disease progression was noticed. On Study Day 64, a gastric penetration was identified on computer  tomography  (CT).  The  upper  gastrointestinal  series  revealed  no  leakage  of  the  contrast medium from the stomach. Gastroscopy revealed an ulcer on the stomach's anterior wall. The patient's Hemoglobin was 6.4 g/dl and he received blood transfusion, omeprazole, and paracetamol for the event. The patient developed  a  gastric  perforation  despite  treatment.  Atezolizumab  and  bevacizumab  were  both discontinued due to gastric ulcer perforation. The patient developed peritonitis on Study Day 87. He died on Study Day 190 from deterioration of his nutritional condition due to the gastric ulcer perforation. The event of gastric ulcer perforation was assessed as related to bevacizumab by the investigator.

## Gastrointestinal hemorrhage

This 58-year-old male patient was positive for macro-vascular invasion with portal vein tumor thrombosis in the first-order branches of the portal vein (VP3) and had hepatic cirrhosis at baseline. He received the most recent dose of atezolizumab and bevacizumab prior to the event on Study Day 44. The patient vomited blood at home on Study Day 62 and died at home on the next day. His last tumor assessment indicated stable disease. The Grade 5 AE of gastrointestinal hemorrhage was assessed as related to both atezolizumab and bevacizumab and also related to disease under study by the investigator.

## Serious AEs

Table 60: Serious adverse events with an incidence rate of at least 1% in any treatment arm by system organ class and preferred term (safety-evaluable population)

| MedDRA System Organ Class MedDRA Preferred Term          | Sorafenib (N=156)   | Atezo+Bev (N=329)   |
|----------------------------------------------------------|---------------------|---------------------|
| Total number of patients with at least one adverse event | 48(30.8%)           | 125 (38.0%)         |
| Overalltotalnumberof events                              | 83                  | 221                 |
| Gastrointestinal disorders                               |                     |                     |
| Total number ofpatients withat least one adverse event   | 18 (11.58)          | 49 (14.9%)          |
| Totalnumber of events                                    | 22                  | 58                  |
| Gastrointestinal haemorrhage                             | 3 1.98)             | 8 2.4号)             |
| Oesophageal varices haemorrhage                          | 1 0.6%)             | 8 2.4%)             |
| Ascites                                                  | 1 0.6%)             | 5 1.58)             |
| Abdominal pain                                           | 2 1.38)             | 2 0.6%)             |
| Upper gastrointestinal haemorrhage                       | 2 1.38)             | 2 0.68)             |
| Pancreatitis                                             | 1.38)               | 1 0.38)             |
| Peritoneal haemorrhage                                   | 22 1.38)            | 0                   |
| Infections and infestations                              |                     |                     |
| Total number of patients with at least one adverse event | 3 1.98) 3           | 24 (7.3%)           |
| Totalnumber of events                                    | 0                   | 28                  |
| Sepsis                                                   |                     | 5 (1.58)            |
| Hepatobiliary disorders                                  |                     |                     |
| Total number of patients with at least one adverse event | 6 5.88)             | 16 (4.9%)           |
| Total number of events                                   | 6                   | 19                  |
| Cholangitis                                              | 0.68)               | 4 (1.2%)            |
| Hepatic cirrhosis                                        | 1.38)               | 0                   |
| Hepatic failure                                          | 2 1.38)             | 0                   |
| Respiratory, thoracic and mediastinal disorders          |                     |                     |
| Totalnumberof patientswithat least one adverseevent      | 7 (4.58)            | 15 ( 4.6%)          |
| Total number of events                                   | 9                   | 16                  |
| Dyspnoea                                                 | 2 1.38)             | 3 (0.9%)            |
| Pulmonary embolism                                       | 2 1.38)             | 3 0.9%)             |
| General disorders and administration site conditions     |                     |                     |
| Total number of patients with at least one adverse event | 5 (3.28)            | 10 (3.0%)           |
| Total number of events                                   | 5                   | 10                  |
| Pyrexia                                                  | 1.38)               | 7 ( 2.1号)           |
| Death                                                    | 1.3%)               | 0                   |
| Nervous system disorders                                 |                     |                     |
| Totalnumberofpatientswithatleastoneadverseevent          | 5 (3.28)            | 10 (3.0%)           |
| Totalnumberof_events                                     | 5                   | 10                  |
| Hepatic encephalopathy                                   | 3 (1.9%)            | 2 (0.6%)            |

<div style=\"page-break-after: always\"></div>

```
Metabolism and nutrition disorders
```

```
Total number of patients with at least one adverse event 4 2.68) 10 3.0%) Totalnumber of events 5 11 Hyponatraemia 2 1.38) 0 Investigations Total number of patients with at least one adverse event 4 （ 2.68) 6 (2.78) Total number of events 6 10 Blood bilirubin increased 2 (1.38) 4 (1.28) Blood and lymphatic system disorders Total number of patients with at least one adverse event 4 (2.6%) 6 (1.8%) Total number of events 4 10 Anaemia 2 1.38) 4 1.28) Thrombocytopenia 2 1.38) 2 0.6%) Injury, poisoning and procedural complications Total number of patients with at least one adverse event 2 1.38) 7 (2.1%) Total number of events 2 8 Infusion related reaction 0 五 1.2%) Renal and urinary disorders Total number of patients with at least one adverse event 3 3(1.98) 3 (0.9%) Total number of events 3 3 Acute kidney injury 2 (1.38) 2 (0.6%) Includes AEs with onset date on or after the date of the first dose of study drug up to the data cutoff date. Investigator text for AEs are encoded using MedDRA version 22.0. Percentages are based on N Jo raqumu tenoi. ro saunoo Aouanbery Tog :eouo Atuo peaunoo are tenptatput ue ut af sues events\"rows，multiple occurrences of the same AE inan individualarecounted separately.
```

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Table 61: Clinically relevant laboratory safety test shifts from baseline (NCI CTCAE Grade 0-2 to Grade 3-4) (Safety-evaluable population)

|                                              | Sorafenib (N=156)   | Atezo +Bev (N=329)   | All patients (N=485)   |
|----------------------------------------------|---------------------|----------------------|------------------------|
| Hematology                                   |                     |                      |                        |
| Hemoglobin (High)                            | 0                   | 0                    | 0                      |
| Hemoglobin (Low)                             | 6 ( 3.9%)           | 10 ( 3.1%)           | 16 ( 3.4%)             |
| Lymphocytes Abs (High)                       | 0                   |                      |                        |
| Lymphocytes Abs (Low)                        | 8 ( 9.1%)           | 28 (12.7%)           | 36 (11.7%)             |
| Platelet (Low)                               | 7 ( 4.6%)           | 21 ( 6.5%)           | 28 ( 5.9%)             |
| Neutrophils, Total, Abs (Low)                | 1 ( 1.1%)           | 5 ( 2.3%)            | 6 ( 1.9%)              |
| Total Leukocyte Count (High)                 | 0                   | 0                    | 0                      |
| Total Leukocyte Count (Low)                  | 2 ( 1.3%)           | 11 ( 3.4%)           | 13 ( 2.7%)             |
| Coagulation                                  |                     |                      |                        |
| International Normalized Ratio (High)        | 1 ( 0.7%)           | 1 ( 0.3%)            | 2 ( 0.4%)              |
| Activated Partial Thromboplastin Time (High) | 1 ( 0.7%)           | 0                    | 1 ( 0.2%)              |
| Chemistry                                    |                     |                      |                        |
| Albumin (Low)                                | 1 ( 0.7%)           | 5 ( 1.5%)            | 6 ( 1.3%)              |
| Alkaline Phosphatase (High)                  | 7 ( 4.6%)           | 14 ( 4.3%)           | 21 ( 4.4%)             |
| SGPT/ALT (High)                              | 7 ( 4.6%)           | 24 ( 7.5%)           | 31 ( 6.5%)             |
| SGOT/AST (High)                              | 23 (15.1%)          | 50 (15.6%)           | 73 (15.4%)             |
| Bilirubin (High)                             | 20 (13.2%)          | 25 ( 7.7%)           | 45 ( 9.5%)             |
| Calcium (High)                               | 0                   | 1 ( 0.3%)            | 1 ( 0.2%)              |
| Calcium (Low)                                | 2 ( 1.3%)           | 1 ( 0.3%)            | 3 ( 0.6%)              |
| Creatinine (High)                            | 4 ( 2.6%)           | 3 ( 0.9%)            | 7 ( 1.5%)              |
| Glucose (High)                               | 5 (3.4%)            | 25 ( 7.9%)           | 30 ( 6.5%)             |
| Glucose (Low)                                | 1 ( 0.7%)           | 4 ( 1.2%)            | 5 ( 1.1%)              |
| Magnesium (High)                             | 2 ( 1.3%)           | 2 ( 0.6%)            | 4 ( 0.9%)              |
| Magnesium (Low)                              | 0                   | 0                    | D                      |
| Phosphorus (Low)                             | 23 (15.3%)          | 14 ( 4.4%)           | 37 ( 7.9%)             |
| Potassium (High)                             | 3 ( 2.0%)           | 6 ( 1.9%)            | 9 ( 1.9%)              |
| Potassium (Low)                              | 9 ( 5.9%)           | 4 ( 1.2%)            | 13 ( 2.7%)             |
| Sodium (High)                                | 0                   | 1 ( 0.3%)            | 1 ( 0.2%)              |
| Sodium (Low)                                 | 14 ( 9.2%)          | 40 (12.5%)           | 54 (11.4%)             |

Note: A clinically relevant shift is defined as a shift from Grade 0, 1 or 2 at baseline to Grade 3 or 4 post-baseline.

The proportion of patients who had normal TSH at baseline and treatment-emergent TSH abnormalities (high TSH) was lower in the Sorafenib arm (16.7%) compared to the Atezo+Bev arm (28.0%). The proportion of patients who had normal TSH at baseline and treatment-emergent TSH abnormalities (low TSH) was numerically lower on Sorafenib (2.6%) compared to the Atezo+ Bev arm (8.2%). There were patients with both treatment-emergent TSH high and TSH low laboratory values in the Atezo+Bev arm.

<div style=\"page-break-after: always\"></div>

Table 62: TSH Shift Table of post-baseline changes - safety-evaluable population (cut-off date 29 Aug 2019)

Laboratory Test: Thyroid-Stimulating Hormone (mU/L)

|                     |                                    | Post-Baseline   | Post-Baseline   | Post-Baseline   | Post-Baseline   | Post-Baseline   | Post-Baseline   |
|---------------------|------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Treatment Group     | Baseline Reference Range Indicator |                 | Low             | Normal          | Normal          | Hi gh           | Hi gh           |
| Sorafenib (N=156)   | Low                                | 0               |                 | 0               |                 | 0               |                 |
| Sorafenib (N=156)   | Normal                             | 4               | (2.6%)          | 135             | (86.5%)         | 26              | (16.7$)         |
| Sorafenib (N=156)   | High                               | 1               | (0.6%)          | 6               | 3.8$)           | 18              | (11.5$)         |
| Sorafenib (N=156)   | Missing                            | 0               |                 | 2               | 1.3$)           | 1               | (0.68)          |
| Atezo + Bev (N=329) | Low                                | 9               | (2.78)          | 7               | (2.18)          | 0               |                 |
| Atezo + Bev (N=329) | Normal                             | 27              | (8.2$)          | 284             | (86.38)         | 92              | (28.08)         |
| Atezo + Bev (N=329) | High                               | 4               | (1.2%)          | 13              | 4.0$)           | 31              | (9.48)          |
| Atezo + Bev (N=329) | Missing                            | 0               |                 | 4               | 1.2$)           | 1               | (0.38)          |

<!-- image -->

An overview of safety in the safety-evaluable population with moderate hepatic impairment is provided in the table below.

Table 63: Overall Summary of Adverse Events in patients with moderate hepatic impairment (Safety Evaluable Population)

|                                                                               | Patients with Moderate Hepatic Impairment   | Patients with Moderate Hepatic Impairment   | All Patients Population   | All Patients Population   |
|-------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------|---------------------------|
|                                                                               | Sorafenib N = 18                            | Atezo + Bev N = 28                          | Sorafenib N = 156         | Atezo + Bev N = 329       |
| Total number of patients with at least one AE                                 | 18 (100%)                                   | 27 (96.4%)                                  | 154 (98.7%)               | 323 (98.2%)               |
| Total number of patients with at least one: AE Related to any Study Treatment | 17 (94.4%)                                  | 22 (78.6%)                                  | 147 (94.2%)               | 276 (83.9%)               |
| AE Related to Atezolizumab                                                    | 0                                           | 21 (75.0%)                                  | 0                         | 252 (76.6%)               |
| AE Related to Bevacizumab                                                     | 0                                           | 18 (64.3%)                                  | 0                         | 241 (73.3%)               |
| Grade 3 - 4 AE                                                                | 11 (61.1%)                                  | 16 (57.1%)                                  | 86 (55.1%)                | 186 (56.5%)               |
| Treatment-related Grade 3 - 4 AE                                              | 9 (50.0%)                                   | 9 (32.1%)                                   | 71 (45.5%)                | 117 (35.6%)               |
| Grade 5 AE                                                                    | 1 ( 5.6%)                                   | 2 ( 7.1%)                                   | 9 (5.8%)                  | 15 (4.6%)                 |
| Treatment-related Grade 5 AE                                                  | 0                                           | 0                                           | 1 (0.6%)                  | 6 (1.8%)                  |
| Serious AE                                                                    | 6 (33.3%)                                   | 14 (50.0%)                                  | 48 (30.8%)                | 125 (38.0%)               |
| Related Serious AE                                                            | 4 (22.2%)                                   | 6 (21.4%)                                   | 24 (15.4%)                | 56 (17.0%)                |
| AE Leading to Withdrawal from any Study Treatment                             | 2 (11.1%)                                   | 5 (17.9%)                                   | 16 (10.3%)                | 51 (15.5%)                |
| AE Leading to Withdrawal from Atezolizumab                                    | 0                                           | 3 (10.7%)                                   | 0                         | 28 (8.5%)                 |
| AE Leading to Withdrawal from Bevacizumab                                     | 0                                           | 5 (17.9%)                                   | 0                         | 48 (14.6%)                |
| AE Leading to Withdrawal from Both Atezolizumab and Bevacizumab               | 0                                           | 3 (10.7%)                                   | 0                         | 23 (7.0%)                 |
| AE Leading to Dose Modification/Interruption of any Study Treatment           | 11 (61.1%)                                  | 14 (50.0%)                                  | 95 (60.9%)                | 163 (49.5%)               |
| AE Leading to Dose Interruption of any Study Treatment                        | 10 (55.6%)                                  | 14 (50.0%)                                  | 64 (41.0%)                | 163 (49.5%)               |
| AE Leading to Dose Reduction of Sorafenib                                     | 6 (33.3%)                                   | 0                                           | 58 (37.2%)                | 0                         |

Note: Includes AEs with onset date on or after the date of the first dose of study drug up to the data cutoff date.  Investigator text for AEs are encoded using MedDRA version 22.0.  Percentages are based on N in the column headings.  Multiple occurrences of the same AE in one individual are counted only once except for \"Total number of AEs\" row in which multiple occurrences of the same AE are counted separately.  Grade 3-4 AE and Treatment-Related Grade 3-4 AE refer to highest grade experienced.

<div style=\"page-break-after: always\"></div>

Table 64 : Summary of Adverse Events of Special Interest for Atezolizumab (Safety-Evaluable Population)

|                                                               | Patients with Moderate Hepatic Impairment   | Patients with Moderate Hepatic Impairment   | All Patients Population   | All Patients Population   |
|---------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------|---------------------------|
|                                                               | Sorafenib N = 18                            | Atezo+Bev N = 28                            | Sorafenib N = 156         | Atezo+Bev N = 329         |
| Total number of patients with at least one: Atezolizumab AESI |                                             |                                             |                           |                           |
| Immune-Mediated Hepatitis (Diagnosis and Lab Abnormalities)   | 12 (66.7%)                                  | 22 (78.6%)                                  | 62 (39.7%)                | 142 (43.2%)               |
| Immune-Mediated Hepatitis (Lab Abnormalities)                 | 11 (61.1%)                                  | 18 (64.3%)                                  | 54 (34.6%)                | 126 (38.3%)               |
| Immune-Mediated Hepatitis (Diagnosis)                         | 2 (11.1%)                                   | 9 (32.1%)                                   | 20 (12.8%)                | 43 (13.1%)                |
| Immune-Mediated Rash                                          | 12 (66.7%)                                  | 3 (10.7%)                                   | 96 (61.5%)                | 64 (19.5%)                |
| Immune-Mediated Hypothyroidism                                | 0                                           | 4 (14.3%)                                   | 4 (2.6%)                  | 36 (10.9%)                |
| Infusion-Related Reactions                                    | 0                                           | 6 (21.4%)                                   | 0                         | 36 (10.9%)                |
| Immune-Mediated Hyperthyroidism                               | 0                                           | 1 (3.6%)                                    | 0                         | 15 (4.6%)                 |
| Immune-Mediated Pancreatitis                                  | 0                                           | 3 (10.7%)                                   | 6 (3.8%)                  | 9 (2.7%)                  |
| Immune-Mediated Diabetes Mellitus                             | 0                                           | 2 ( 7.1%)                                   | 0                         | 8 (2.4%)                  |
| Immune-Mediated Colitis                                       | 0                                           | 1 (3.6%)                                    | 1 ( 0.6%)                 | 6 (1.8%)                  |
| Immune-Mediated Pneumonitis                                   | 0                                           | 0                                           | 0                         | 4 (1.2%)                  |
| Immune-Mediated Nephritis                                     | 0                                           | 0                                           | 0                         | 3 (0.9%)                  |
| Autoimmune Hemolytic Anemia                                   | 0                                           | 0                                           | 0                         | 1 (0.3%)                  |
| Immune-Mediated Adrenal Insufficiency                         | 0                                           | 0                                           | 0                         | 1 (0.3%)                  |
| Immune-Mediated Ocular Inflammatory Toxicity                  | 0                                           | 0                                           | 0                         | 1 (0.3%)                  |
| Immune-Mediated Severe Cutaneous                              | 1 ( 5.6%)                                   | 0                                           | 1 (0.6%)                  | 0                         |
| Reactions Immune-Mediated Vasculitis                          | 0                                           | 1 ( 3.6%)                                   | 0                         | 1 (0.3%)                  |
| Systemic Immune Activation                                    | 0                                           | 0                                           | 0                         | 1 (0.3%)                  |
| Bevacizumab AESI                                              |                                             |                                             |                           |                           |
| Hypertension                                                  | 4 (22.2%)                                   | 5 (17.9%)                                   | 40 (25.6%)                | 102 (31.0%)               |
| Bleeding / Haemorrhage                                        | 3 (16.7%)                                   | 7 (25.0%)                                   | 27 (17.3%)                | 83 (25.2%)                |
| Proteinuria                                                   | 0                                           | 7 (25.0%)                                   | 13 (8.3%)                 | 70 (21.3%)                |
| Thromboembolic Event - Venous                                 | 0                                           | 1 ( 3.6%)                                   | 5 (3.2%)                  | 10 (3.0%)                 |
| Thromboembolic Event - Arterial                               | 0                                           | 1 ( 3.6%)                                   | 2 (1.3%)                  | 9 (2.7%)                  |
| Congestive Heart Failure                                      | 1 ( 5.6%)                                   | 0                                           | 2 (1.3%)                  | 1 (0.3%)                  |
| Wound Healing Complications                                   | 0                                           | 0                                           | 0                         | 2 (0.6%)                  |
| Fistula/Abscess (Non GI)                                      | 1 ( 5.6%)                                   | 0                                           | 1 (0.6%)                  | 0                         |
| Gastrointestinal Perforation                                  | 0                                           | 0                                           | 0                         | 1 (0.3%)                  |

AESIs = adverse events of special interest

Note: Includes AEs with onset date on or after the date of the first dose of study drug up to the data cutoff date.

## Hy's Law Analysis

Potential Hy's law cases were defined in the study protocol as ALT or AST increases above 3xfold the baseline with concomitant total bilirubin increases above 2xfold the ULN within 7 days.

Following detailed review, 24 of the 26 potential Hy's law cases (13 in the Sorafenib and 11 in the Atezo+Bev arm) did not qualify as true Hy's law cases due to the following reasons:

- Patients had liver function test abnormalities in the context of investigator-assessed progressive disease (9 cases in the Sorafenib arm and 6 cases in the Atezo+Bev arm)
- The liver function abnormalities could be attributed to alternate etiologies, including cholangitis or disease under study (4 cases in the Sorafenib arm and 5 cases in the Atezo+Bev arm).

The 2 remaining potential Hy's law cases (1 patient in each treatment arm) were classified as true Hy's law cases due to the lack of alternate etiology. The patient in the Sorafenib arm experienced Grade 3 blood bilirubin increased on Study Day 22. Sorafenib was interrupted due to the event and the Grade 3 blood bilirubin increased resolved on Study Day 29. On Study Day 50, the patient experienced elevated liver function tests in the Hy's law range with a corresponding Grade 4 liver function test increased and Grade 3 blood bilirubin increased. Sorafenib was permanently discontinued due to these events and the

<div style=\"page-break-after: always\"></div>

event resolved on Study Day 78. The event was assessed as related to Sorafenib. Due to the lack of alternate etiology and the positive re-challenge, this case met the criteria for Hy's law.

The patient in the Atezo+Bev arm experienced Grade 4 hepatobiliary disease on Study Day 9 prior to elevated liver function tests in the Hy's law range on Study Day 36. The event led to both atezolizumab and bevacizumab discontinuation. The patient received mycophenolate mofetil and methylprednisolone for  the  event.  Hepatobiliary  disease  resolved.  The  event  was  assessed  as  related  to  both  study treatments.

Table 65: Summary for potential Hy's law analysis (safety-evaluable population)

Borafenib

(N=156)

Ateno+Bev

(N=329)

Hy's Law Criteria Met 14 (9.0t)12 (3.6H)

Hy'gLawCriteria re

Fatientswho met afterlatestHLTorAsT&gt;3nbaseline.

A11

Patients

(N-185)

26(5.48)

orted at lesst one TBlLI &gt; 2 x ULN within 7 days

ReferenceRangeof Local Labs are used.

ALT =Alanine Aminotranuferase.Asr =AgpartateAminotransferase,TBitI = Bilirubin

'Teu9N 4Twt1 3eddn : Nn *Nin l9 PaPtnTP 6anoo6 peq1ode1 644 eie fanoo6 peaTteuoN

## Safety in special populations

## Intrinsic factors: age, safety in elderly

Overall, the safety profile of Atezo+Bev was generally comparable across all age groups.

The majority of patients across all age groups reported at least one AE. The distribution of AE categories was comparable between the &lt; 65 years and ≥ 65 years age subgroups).

The smaller sample size for the subgroups of 75-84 years (n = 66) and ≥ 85 years (n = 7) limits meaningful conclusions in these two subgroups.

While there were some numerical differences in certain atezolizumab AESI categories between patients aged &lt; 65 years (n = 277) and ≥ 65 years (n = 216), the overall atezolizumab AESI profiles were also similar between the two groups.

<div style=\"page-break-after: always\"></div>

Table 66: Overview of AE by Age between Atezo+Bev and sorafenib population (&lt;65 vs. ≥65 years)

|                                               | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|-----------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                               | <65 (N=69)              | >=65 (N=87)             | <65 (N=277)             | >=65 (N=216)            |
| Total nuzmber ofpatients with at least one AE | 67 (97.1) 519           | 87（100号） 780            | 266 (96.06) 2661        | 214(99.16) 2038         |
| Total numnber ofpatients with at least one    |                         |                         |                         |                         |
| Treatment-related AE                          | 89 (91.38)              | 84 (69'96)              | 226 (81.6%)             | 182 (84.3)              |
| Atezo-related AE                              | 0                       | 0                       | 202 (72.98)             | 166 (76.98)             |
| Grade3-4AE                                    | 35 (50.7号)              | 51 (58.6)               | 140 (50.5号)             | 123 (56.94)             |
| Treatment-related Grade 3-4 AE                | 26 (37.7%)              | 45 (51.74)              | 87 (31.48)              | 83 (38.4)               |
| Atezo-related Grade 3-4 AE                    |                         | 0                       | 67 (24.26)              | 50 (23.18)              |
| Grade SAE                                     | 4.38)                   | 6 (6.99）                | 10 (3.6号)               | 12 (5.63)               |
| Treatmont-related Grade S AE                  | 0310 1.4%)              | 00                      | 3 1.1$）                 | 6 2.8号）                 |
| Atezo-related Grade S AE                      |                         |                         | 3 (1.18）                | 4 （1.9号)                |
| Serious AE                                    | 16 (23.26)              | 32 (36.86)              | 101 (36.58)             | 85 (39.48)              |
| Treatment-related serious AE                  | 8 (11.6号)               | 16 (18.48)              | 46 (16.69)              | 42 (19.45)              |
| Atezo-related serious AE                      |                         | 0                       | 34 (12.36)              | 31 (14.45)              |
| AE leading to any Study Treatment withdrawal  | 030 4.38)               | 13 (14.94)              | 33 (11.96)              | 42 (19.48)              |
| AE leading to Atezo withdrawal                |                         | 0                       | 19 (6.96)               | 23 (10.69)              |
|                                               | 40 (58.0号)              | 55 (63.28)              | 113 (40.86)             | 109 (50.5)              |
| AE leading to Atezo interruption              | 0                       | 0                       | 08 (28.96)              | 85 （39.48)              |

Atezo-Atezo1izumab Bev-Bevacizumab. Sorafenib HCc: Yo40245（Arm B).Atezo+Bev HCC: Yo40245（Arm A) + Go30140(Arm A+Fl). Investigator text for AEs encoded using MedDRA v22.o.Peroentages are based on N in the colun headings. Multiple occurrences of the same AE in one individual are counted only once except for Total number of events\" rows,multiple occurrences of the same AE in an individual are counted separately.All treatment emergent AEs are included.

c1inicalcut-0ffdates:YO40245:29AUG2019,G030140:14JUN2019.

Table 67: Overview of AE by Age between Atezo+Bev and sorafenib population (≥65 years)

|                                                                      | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|----------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                                      |                         | 65 -74 (N=63)           | 75 -84 (N=23)           | >=85 (N=1)              | 65 -.74 (N=143)         | 75 -84 (N=66)           | >=85 (N=7)              |
| Total number of patients with at least one AE Total number of events | 606                     | 63 (.100%)              | 23 3(100%) 166          | 1 (100%) 8              | 141 (98.6%) 1306        | 66 (_100%) 652          | 7 (100%) 80             |
| Total number of patients with at least one                           |                         |                         |                         |                         |                         |                         |                         |
| Treatment-related AE                                                 | 61                      | (96.8%)                 | 22 (95.7%)              | 1 (100%)                | 119 (83.2%)             | 59 (89.4%)              | 4 (57.1%)               |
| Atezo-related AE                                                     | 0                       |                         | 0                       | 0                       | 108 (75.5%)             | 55 (83.3%)              | 3 (42.9%)               |
| Grade 3-4AE                                                          | 39                      | (61.9%)                 | 11 (47.8%)              | 1 (100%)                | 76 (53.1%)              | 42 (63.6%)              | 5 (71.4%)               |
| Treatment-related Grade 3-4 AE                                       | 33                      | (52.4%)                 | 11 (47.8%)              | 1 (100%)                | 50 (35.0%)              | 31 (47.0%)              | 2 (28.6%)               |
| Atezo-related Grade 3-4 AE                                           | 0                       |                         | 0                       | 0                       | 25 (17.5%)              | 24 (36.4%)              | (14.3%)                 |
| Grade 5 AE                                                           | 4                       | (6.3%)                  | 2 (8.7%)                | 0                       | 7 4.9%)                 | 4 6.1%)                 | (14.3%)                 |
| Treatment-related Grade5 AE                                          | 0                       |                         | 0                       | 0                       | 3 2.1%)                 | 3.0%)                   | (14.3%)                 |
| Atezo-related Grade5AE                                               | 0                       |                         | 0                       | 0                       | 3 2.1%)                 | 21 1.5%)                | 0                       |
| Serious AE                                                           | 23                      | (36.5%)                 | 8 (34.8%)               | 1 (100%)                | 50 (35.0%)              | 31 (47.0%)              | 4 (57.1%)               |
| Treatment-related serious AE                                         | 13                      | (20.6%)                 | 2 (8.7%)                | 1 (100%)                | 22 (15.4%)              | 19 (28.8%)              | 1 (14.3%)               |
| Atezo-related serious AE                                             | 0                       |                         | 0                       | 0                       | 15 (10.5%)              | 16 (24.2%)              | 0                       |
| AE leading to any Study Treatment withdrawal                         | 9                       | (14.3%)                 | 4 (17.4%)               | 0                       | 25 (17.5%)              | 16 (24.2%)              | 1 (14.3%)               |
| AE leading to Atezo withdrawal                                       | 0                       |                         | 0                       | 0                       | 11 (7.7%)               | 11 (16.7%)              | 1 (14.3%)               |
| AE leadingto any Dose modification or Study Treatment interruption   | 39                      | (61.9%)                 | 15 (65.2%)              | 1 (100%)                | 68 (47.6%)              | 37 (56.1%)              | 4 (57.1%)               |
| AE leading to Atezo interruption                                     | 0                       |                         | 0                       | 0                       | 53 (37.1%)              | 28 (42.4%)              | 4 (57.1%)               |

+ GO30140(Arm A+F1). Investigator text for AEs encoded using MedDRA v22.0. Percentages are based on N in the column headings. Multiple occurrences of the a  o  s  o   n   o individual are counted separately. All treatment emergent AEs are included. Clinical cut-off dates:YO40245:29AUG2019,G030140:14JUN2019.

<div style=\"page-break-after: always\"></div>

Table 68: Overview AESI for Atezo by Atezolizumab, by Age Categories (Years)

|                                                                                          | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|------------------------------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                                                          | <65 (N=277)             | >=65 (N=216)            | 65-74 (N=143)           | 75-84 (N=66)            | >=85 (N=7)              |
| Total number of patients with at least one AE of Special Interest Total number of events | 187 (67.58) 439         | 133 (61.68) 314         | 86 (60.18) 205          | 44 (66.78) 103          | 3(42.9%) 6              |
| Totalnumber ofpatientswithatleast one                                                    |                         |                         |                         |                         |                         |
| Treatment-related AE of Special Interest                                                 | 143 (51.6%)             | 97 (44.98)              | 61 （42.7%）              | 34 (51.5%)              | 2 (28.68)               |
| Atezo-related AE of Special Interest                                                     | 138 (49.8%)             | 91 (42.18)              | 57 (39.9%)              | 33 (50.0%)              | 1 (14.3%)               |
| Grade 3-4AE of Special Interest                                                          | 66 (23.88)              | 49 (22.7%)              | 32 (22.48)              | 15 (22.78)              | 2 (28.6%)               |
| Treatment-relatedGrade 3-4 AE of SpecialInterest                                         | 33 (11.9%)              | 31 (14.48)              | 17 (11.9%)              | 13 (19.7%)              | 1 (14.3%)               |
| Atezo-related Grade 3-4 AE of Special Interest                                           | 32 (11.6%)              | 27 (12.5%)              | 14 (8'6                 | 12 (18.28)              | 1 (14.38)               |
| Grade 5AE of Special Interest                                                            | 2 0.78)                 | 4 1.9%)                 | 2 1.48)                 | 2 3.0%)                 | 0                       |
| Treatment-related Grade 5 AE of Special Interest                                         | 2 0.7%)                 | 3 1.4%)                 | 2 1.4%)                 | 1 1.5%)                 | 0                       |
| Atezo-related Grade 5AE of Special Interest                                              | 2 0.7%)                 | 3 1.48)                 | 2 1.48)                 | 1 1.58)                 | 0                       |
| Serious AE of Special Interest                                                           | 29 (10.5%)              | 37 (17.18)              | 23 (16.1%)              | 13 (19.78)              | 1 (14.3%)               |
| Treatment-relatedSerious AE of SpecialInterest                                           | 13 4.7%)                | 21 9.78)                | 11 7.7%)                | 10 (15.28)              | 0                       |
| Atezo-related Serious AE of Special Interest                                             | 12 4.38)                | 18 8.38)                | 6 6.38)                 | 9 (13.6%)               | 0                       |
| AE of Special Interest leading to any Study Treatment withdrawal                         | 12 4.3%)                | 17 7.98)                | 13 9.18)                | 4 6.18)                 | 0                       |
| AE of Special Interest leading to Atezo withdrawal                                       | 10 (3.6%)               | 12 (5.6%)               | 8 5.6%)                 | 4 6.18)                 | 0                       |
| Treatment interruption                                                                   | 42 (15.28)              | 39 (18.1)               | 26 (18.2%)              | 11 (16.7%)              | 2 (28.68)               |
| AE of Special Interest leading to Atezo interruption                                     | 37 (13.48)              | 33 (15.38)              | 24 (16.8%)              | 7 (10.68)               | 2 (28.68)               |
|                                                                                          | 25 (9.0%)               | 35 (16.28)              | 15 (10.58)              | 18 (27.38)              | 2 (28.68)               |

## Intrinsic factor: sex

Consistent with the disease demographics for HCC, the majority of patients were men (82.8%). The overall safety profile of Atezo+Bev was comparable between men and women with the following exceptions: a numerically higher percentage of men experienced Grade 5 AEs (5.1% vs 1.2%) and treatment-related Grade 5 AEs (2.2% vs. 0). Due to the relatively smaller number of female patients compared with the male patients, these differences should be interpreted with caution.

Table 69: Overview of Adverse Events by Sex (safety-evaluable population)

|                                                                     | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|---------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                                     | Female (N=27)           | Female (N=27)           | Male (N=129)            | Male (N=129)            | Female (N=85)           | Female (N=85)           | Male (N=408)            | Male (N=408)            |
| Total number of patients with at least one AE                       |                         | 27 (100%)               |                         | 127 (98.4%)             |                         | 83 (97.6%)              |                         | 397 (97.3%)             |
| Total number of events                                              |                         | 218                     | 1081                    | 1081                    | 796                     | 796                     | 3903                    | 3903                    |
| Total number of patients with at least one                          |                         |                         |                         |                         |                         |                         |                         |                         |
| Treatment-related AE                                                | 27                      | (100%)                  | 120                     | (93.0%)                 | 70                      | (82.4%)                 | 338                     | (82.8%)                 |
| Atezo-related AE                                                    | 0                       |                         | 0                       |                         | 62                      | (72.9%)                 | 306                     | (75.0%)                 |
| Grade3-4AE                                                          | 16                      | (59.3%)                 | 70                      | (54.3%)                 | 46                      | (54.1%)                 | 217                     | (53.2%)                 |
| Treatment-related Grade 3-4 AE                                      | 12                      | (44.4%)                 | 59                      | (45.7%)                 | 29                      | (34.1%)                 | 141                     | (34.6%)                 |
| Atezo-relatedGrade3-4 AE                                            | 0                       |                         | 0                       |                         | 22                      | (25.9%)                 | 95                      | (23.3%)                 |
| Grade 5 AE                                                          | 0                       |                         | 9                       | 7.0%)                   | 1                       | (1.2%)                  | 21                      | ( 5.1%)                 |
| Treatment-related Grade 5 AE                                        | 0                       |                         | 1                       | 0.8%)                   | 0                       |                         | 9                       | (2.2%)                  |
| Atezo-relatedGrade5 AE                                              | 0                       |                         | 0                       |                         | 0                       |                         | 7                       | (1.7%)                  |
| Serious AE                                                          | 7                       | (25.9%)                 | 41                      | (31.8%)                 | 32                      | (37.6%)                 | 154                     | (37.7%)                 |
| Treatment-related serious AE                                        | 3                       | (11.1%)                 | 21                      | (16.3%)                 | 16                      | (18.8%)                 | 72                      | (17.6%)                 |
| Atezo-related serious AE                                            | 0                       |                         | 0                       |                         | 12                      | (14.1%)                 | 53                      | (13.0%)                 |
| AE leading to any Study Treatment withdrawal                        | 5                       | (18.5%)                 | 11                      | (8.5%)                  | 13                      | (15.3%)                 | 62                      | (15.2%)                 |
| AE leading to Atezo withdrawal                                      | 0                       |                         | 0                       |                         | 8                       | (9.4%)                  | 34                      | (8.3%)                  |
| AE leading to any Dose modification or Study Treatment interruption | 15                      | (55.6%)                 | 80                      | (62.0%)                 | 42                      | (49.4%)                 | 180                     | (44.1%)                 |
| AE leading to Atezo interruption                                    | 0                       |                         | 0                       |                         | 29                      | (34.1%)                 |                         | 136 (33.3%)             |

Atezo=Atezolizumab Bev=Bevacizumab.Sorafenib HCC: Yo40245(Arm B).Atezo+Bev HCC: YO40245 (Arm A) + G030140(Arm A+F1).

Investigator text for AEs encoded using MedDRA v22.0. Percentages are based on N in the column headings. Multiple occurrences of the same AE in one individual are counted only once except for \"Total number of events\" rows, multiple occurrences of the same AE in an individual are counted separately. All treatment emergent AEs are included. Clinical cut-off dates: Y040245:29AUG2019, G030140:14JUN2019.

<div style=\"page-break-after: always\"></div>

Table 70: Overview AESI for Atezo by Sex

<!-- image -->

|                                                                                         | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|-----------------------------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|
|                                                                                         | Female (N=85)           | Male (N=408)            | Male (N=408)            |
| Total number of patients with at least one AE of Special Interest                       | 53 (62.4%)              | 267                     | (65.4%)                 |
| Total number of events                                                                  | 104                     |                         | 649                     |
| Total number of patients with at least one                                              |                         |                         |                         |
| Treatment-related AE of Special Interest                                                | 39 (45.9)               | 201                     | (49.3)                  |
| Atezo-related AE of Special Interest                                                    | 38 (44.7%)              | 191                     | (46.8%)                 |
| Gmade.......AE...f...pecial...ntemes..                                                  | 1.8. (21...23)          | .9.7.                   | (23...8%)               |
| Treatment-related Grade 3-4 AE of Special Interest                                      | 11 (12.9)               | 53                      | (13.0)                  |
| Atezo-related Grade 3-4 AE of Special Interest                                          | 11 (12.9)               | 48                      | (11.8)                  |
| Grade 5 AE of SpecialInterest                                                           | 0                       | 6                       | 1.5)                    |
| Treatment-related Grade 5 AE of Special Interest                                        | 0                       | 5                       | 1.21)                   |
| ASaIaauI...RTRRdS...O...R...S...PRIO..PaaRTaI-OZaaM                                     | 0                       | .5.                     | 1:251                   |
|                                                                                         | 10 (11.8:)              | .9.5.                   | (13.7%)                 |
| Treatment-related Serious AE of Special Interest                                        | 5 5.9)                  | 29                      | 7.1)                    |
| Atezo-related Serious AE of Special Interest                                            | 5 5.9%)                 | 25                      | 6.18)                   |
| AE of Special Interest leading to any Study Treatment withdrawal                        | 4 ( 4.7%)               | 25                      | 6.1%)                   |
| AE of Special Interest leading to Atezo withdrawal                                      | 4 (4.7)                 | 18                      | (4.48)                  |
| AE of Special Interest leading to any Dose modification or Study Treatment interruption | 11 (12.9)               | 70                      | (17.2)                  |
| AE of Special Interest leading to Atezo interruption                                    | 6 (10.6)                | 61                      | (15.0%)                 |
| AE of Special Interest Requiring the Use of Systemic Corticosteroids                    | 11 (12.9)               | 49                      | (12-04)                 |
| Special Interest AE Medical Concepts: patients with at least one                        |                         |                         |                         |
| Immune-Mediated Hepatitis (Diagmosis and Lab Abnormalities)                             | 24 (28.29)              | 167                     | (40.9)                  |
| Immune-Mediated Hepatitis (Lab Abnormalities)                                           | 23 (27.18)              | 148                     | (36.38)                 |
| Immune-Mediated Rash                                                                    | 20 (23.5)               | 68                      | (21.8#)                 |
| Immune-Mediated Hepatitis (Diagmosis)                                                   | 6 7.18) 5               | 54                      | (13.2)                  |
| Immune-Mediated Hypothyroidism                                                          | 5.98)                   | 44                      | (10.8)                  |
| Infusion-Related Reactions                                                              | 10 (11.8)               | 33                      | (8.1)                   |
| Immune-Mediated Hyperthyroidism                                                         | 3 3.5)                  | 13                      | (3.2)                   |
| Immune-Mediated Pancreatitis                                                            | 3 3.5:)                 | 8                       | (2.0)                   |
| Immune-Mediated Diabetes Mellitus                                                       | 3 3.5)                  | 7                       | (1.78)                  |
| Immune-Mediated Colitis                                                                 | 2 2.48)                 | 7                       | 1.7)                    |
| Immune-Mediated Pneumonitis                                                             | 1 1.2)                  | 6                       | (1.5)                   |
| Immune-Mediated Nephritis                                                               | 1 1.2*)                 | 2                       | 0.5)                    |
| Immune-Mediated Myositis (Myositis+Rhabdomyolysis)                                      | 0                       | 3                       | 0.7)                    |
| Immune-Mediated Adrenal Insufficiency                                                   | 0                       | 2                       | 0.58)                   |
| Rhabdomyolysis                                                                          | 0                       | 2                       | 0.5)                    |
| Autoimmune Hemolytic Anemia                                                             | 0                       | 2                       | 0.5%)                   |
| Immune-Mediated Meningoencephalitis                                                     | 0                       |                         | 0.2%)                   |
| Immune-Mediated Myositis                                                                | 0                       | 1                       | 0.28)                   |
| Systemic Immune Activation                                                              | 0                       | 1                       | 0.2:)                   |
| Immune-Mediated Ocular Inflammatory Toxicity                                            | 0                       | 1                       | 0.2%)                   |
| Immune-Mediated Myocarditis                                                             | 0                       | 1                       | 0.2%)                   |
| Immune-Mediated Guillain-Barre Syndrome                                                 | 0                       | 1 1                     | 0.2%) 0.2%)             |
| Immune-Mediated Encephalitis Immune-Mediated Vasculitis                                 | 0 0                     | 1                       | 0.2:)                   |

## Intrinsic factor: Race

Overall, the highest frequency in AE grade 3-4 were reported Hypertension, AST increased, Proteinuria blood bilirubin increased, platelet count decreased, ALT increased and Hyponatraemia in all subgroups.

However, the majority of patients in the Atezo+Bev population were Asians (62.1%), with Whites accounting for 31.0%. Given the relatively small sample sizes in 'Black' (n=13) and 'Other' (n=21) subgroups, the safety analyses by race is presented for the Asian and White subgroups only.

While there was a numerical increase in incidence of events in AE categories in White patients when compared to Asian patients, these increases were not driven by any specific SOC or PT.

<div style=\"page-break-after: always\"></div>

Table 71: Overview of Adverse Events in Atezo+Bev and Sorafenib HCC Patients by Race (Safety Evaluable Patients)

|                                                                      | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|----------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                                      | White (N=51)            | Black (N=4)             | White (N=153)           | Black (N=13)            |
| Total number of patients with at least one AE Total number of events | 51 (100%) 437           | 4 (100%) 20             | 152 (99.3%) 1605        | 13 3(100%) 194          |
| Total number of patients with at least one                           |                         |                         |                         |                         |
| Treatment-related AE                                                 | 48 (94.1%)              | 4 (100%)                | 134 (87.6%)             | 11 (84.6%)              |
| Atezo-related AE                                                     | 0                       | 0                       | 120 (78.4%)             | 10 (76.9%)              |
| Grade 3-4 AE                                                         | 29 (56.9%)              | 2 (50.0%)               | 87 (56.9%)              | 9 (69.2%)               |
| Treatment-related Grade 3-4 AE                                       | 21 (41.2%)              | 2 (50.0%)               | 55 (35.9%)              | 4 (30.8%)               |
| Atezo-related Grade 3-4 AE                                           | 0                       | 0                       | 38 (24.8%)              | 3 (23.1%)               |
| Grade5AE                                                             | 5 9.8%)                 | 0                       | 8 5.2%)                 | 1 (7.7%)                |
| Treatment-relatedGrade5 AE                                           | 1 2.0%) 0               | 0                       | 2 1.3%)                 | 0                       |
| Atezo-relatedGrade 5AE                                               |                         | 0                       | 2 1.3%)                 | 0                       |
| Serious AE                                                           | 24 (47.1%)              | 0                       | 63 (41.2%)              | 7 (53.8%)               |
| Treatment-related serious AE                                         | 10 (19.6%)              | 0                       | 29 (19.0%)              | 3 (23.1%)               |
| Atezo-related serious AE                                             | 0                       | 0                       | 21 (13.7%)              | 1 (7.7%)                |
| AE leading to any Study Treatment withdrawal                         | 6 (11.8%)               | 0                       | 31 (20.3%)              | 2 (15.4%)               |
| AE leading to Atezo withdrawal                                       | 0                       | 0                       | 16 (10.5%)              | 2 (15.4%)               |
|                                                                      | 34 (66.7%)              | 2 (50.0%)               | 82 (53.6%)              | 8 (61.5%)               |
| AE leading to Atezo interruption                                     | 0                       | 0                       | 71 (46.4%)              | 5 (38.5%)               |

|                                                                      | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|----------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                                      | Asian (N=88)            | Other (N=13)            | Asian (N=306)           | Other (N=21)            |
| Total number of patients with at least one AE Total number of events | 86(97.7) 726            | 13(100) 116             | 294 (96.1) 2621         | 21(100号) 279            |
| Total number of patients with at least one                           |                         |                         |                         |                         |
| Treatment-related AE                                                 | 82 (93.2)               | 13 （ 100%)              | 247 (80.7)              | 16 (76.25)              |
| Atezo-related AE                                                     | 0                       | 0                       | 222 (72.53)             | 16 (76.25)              |
| Grade3-4AE                                                           | 49 (55.7%)              | 6 (46.23)               | 152 (49.7%)             | 15 (71.48)              |
| Treatment-related Grade 3-4 AE                                       | 40 (45.5)               | 8 (61.5)                | 105 (34.3)              | 6 (28.6%)               |
| Atezo-related Grade 3-4 AE                                           | 0                       | 0                       | 71 (23.2)               | 5 (23.8)                |
| Grade5AE                                                             | 1 1.1$)                 | 3 (23.14)               | 11 3.6)                 | 2 (9.55)                |
| Treatment-related Grade 5 AE                                         | 0 0                     | 0                       | 7 2.3)                  | 0                       |
| Atezo-related Grade5 AE                                              |                         |                         | 5 1.6)                  | 0                       |
| Serious AE                                                           | 16 (18.2)               | 8 (61.55)               | 104 (34.0)              | 12 (57.15)              |
| Treatment-related serious AE                                         | 8 (9.1)                 | 6 (46.2)                | 51 (16.7)               | 5 (23.8%)               |
| Atezo-related serious AE                                             | 0                       | 0                       | 38 (12.4)               | 5 (23.85)               |
| AE leading to any Study Treatment withdrawal                         | 5 5.7)                  | 5 (38.53)               | 37 (12.1) 20            | 5 (23.85)               |
|                                                                      | 0                       | 0                       | 6.5)                    | 4 (19.0%)               |
| AE leading to any Dose modification or Study Treatment interruption  | 51 (58.05)              | 8 (61.53)               | 119 (38.9)              | 13 (61.9%)              |
| AE leading to Atezo interruption                                     | 0                       | 0                       | 78 (25.5%)              | 11 (52.4%)              |

Investigator text for AEs encoded using MedDRA v22.o. Percentages are based on N in the column headings. Multiple occurrences of the same AEin one individual are counted only once except for \"Total number of events\" rows, multiple occurrences of the same AE in an individual are counted separately. All treatment emergent AEs are included. C1inica1 cut-off dates:Y040245:29AUG2019,G030140:14JUN2019.

## Extrinsic factors HCC: Etiology

Approximately half of Atezo + Bev and Sorafenib treated HCC patients had the etiology of hepatitis B virus (HBV) infection (Atezo + Bev: 50.1%, Sorafenib: 45.5%), followed by non-viral etiologies (Atezo + Bev: 27.4%, Sorafenib: 33.3%) and hepatitis C virus (HCV) infection (Atezo + Bev: 22.5%, Sorafenib: 21.2%).

<div style=\"page-break-after: always\"></div>

Table 72: Overview AE by HCC Etiology (safety-evaluable population)

|                                                                      | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|----------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                                      | Hepatitis B (N=71)      | Hepatitis C (N=33)      | Non-viral (N=52)        | Hepatitis B (N=247)     | Hepatitis C (N=111)     | Non-viral (N=135)       |
| Total number of patients with at least one AE Total number of events | 69 (97.2%) 548          | 33(100%) 291            | 52 (100%) 460           | 235 (95.1%) 2103        | 111 (100%) 1277         | 134 (99.3%) 1319        |
| Totalnumber of patientswithatleast one                               |                         |                         |                         |                         |                         |                         |
| Treatment-related AE                                                 | 67 (94.4%)              | 33 (100%)               | 47 (90.4%)              | 189 (76.5%)             | 104 (93.7%)             | 115 (85.2%)             |
| Atezo-relatedl AE                                                    | 0                       | 0                       | 0                       | 166 (67.2%)             | 95 (85.6%)              | 107 (79.3%)             |
| Grade3-4AE                                                           | 34 (47.9%)              | 26 (78.8%)              | 26 (50.0%)              | 116 (47.0%)             | 72 (64.9%)              | 75 (55.6%)              |
| Treatment-related Grade 3-4 AE                                       | 28 (39.4%)              | 20 (60.6%)              | 23 (44.2%)              | 77 (31.2%)              | 52 (46.8%)              | 41 (30.4%)              |
| Atezo-related Grade 3-4 AE                                           | 0                       | 0                       | 0                       | 53 (21.5%)              | 34 (30.6%)              | 30 (22.2%)              |
| Grade 5 AE                                                           | 3 4.2%)                 | 1 (3.0%)                | 5 (9.6%)                | 5 2.0%)                 | 6 5.4%)                 | 11 (8.1%)               |
| Treatment-related Grade5 AE                                          | 1 1.4%)                 | 0                       | 0                       | 2 0.8%)                 | 1.8%)                   | 5 3.7%)                 |
| Atezo-relatedGrade5AE                                                | 0                       | 0                       | 0                       | 2 0.8%)                 | 22 1.8%)                | 3 (.2.2%)               |
| Serious AE                                                           | 10 (14.1%)              | 14 (42.4%)              | 24 (46.2%)              | 81 (32.8%)              | 48 (43.2%)              | 57 (42.2%)              |
| Treatment-related serious AE                                         | 5 (7.0%)                | 5 (15.2%)               | 14 (26.9%)              | 33 (13.4%)              | 26 (23.4%)              | 29 (21.5%)              |
| Atezo-related serious AE                                             | 0                       | 0                       | 0                       | 25 (10.1%)              | 16 (14.4%)              | 24 (17.8%)              |
| AE leading to any Study Treatment withdrawal                         | 3 (4.2%) 0              | 3 (9.1%)                | 10 (19.2%)              | 31 (12.6%)              | 20 (18.0%)              | 24 (17.8%)              |
| AE leading to Atezo withdrawal                                       |                         | 0                       | 0                       | 15 (6.1%)               | 10 (9.0%)               | 17 (12.6%)              |
| AE leading to any Dose modification or Study Treatment interruption  | 37 (52.1%)              | 26 (78.8%)              | 32 (61.5%)              | 86 (34.8%)              | 66 (59.5%)              | 70 (51.9%)              |
| AE leading to Atezo interruption                                     | 0                       | 0                       | 0                       | 59 (23.9%)              | 50 (45.0%)              | 56 (41.5%)              |

+G030140(Amm A+F1) Investigator text for AEs encoded using MedDRA v22.0. Percentages are based on N in the column headings. Multiple occurrences of the same AEin one individual are counted only once except for\"Total number of events\"rows,multiple occurrences of the same AE in an Clinical cut-off dates:Y040245:29AUG2019, G030140:14JUN2019.

Table 73: AE grade 3-4 PT by HCC Etiology (Atezo+Bev population)

|                                      | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|--------------------------------------|-------------------------|-------------------------|-------------------------|
| MedDRA Preferred Term                | Hepatitis B (N=247)     | Hepatitis C (N=111)     | Non-viral (N=135)       |
| HYPERTENSION                         | 27 (10.98)              | 21 (18.9%)              | 20 (14.8%)              |
| ASPARTATE AMINOTRANSFERASE INCREASED | 12 4.98)                | 12 (10.8%)              | 6 4.4%)                 |
| PROTEINURIA                          | 8 3.2)                  | 8 7.28)                 | 4 3.0%)                 |
| BLOOD BILIRUBININCREASED             | 7 2.88)                 | 4 3.6)                  | 5 3.7%)                 |
| PLATELET COUNT DECREASED             | 6 3.6%)                 | 2 1.8%)                 | 5 3.78)                 |
| ALANINE AMINOTRANSFERASEINCREASED    | 9 3.6%)                 | 5 4.5%)                 | 1 0.7%)                 |
| HYPONATRAEMIA                        | 6 2.48)                 | 4 3.6%)                 | 5 3.78)                 |
| ANAEMIA                              | 8 3.2)                  | 2 1.8%)                 | 3 2.28)                 |
| DIARRHOEA                            | 4 1.6%)                 | 2 1.8%)                 | 4 3.0%)                 |
| ASCITES                              | 5 2.0%)                 | 3 2.7%)                 | 1 0.7%)                 |
| DYSPNOEA                             | 1 0.48)                 | 2 1.8%)                 | 6 4.4%)                 |
| FATIGUE                              | 4 1.6%)                 | 3 2.7%)                 | 2 1.5*)                 |
| NEUTROPHILCOUNT DECREASED            | 5 2.0*)                 | 2 1.8%) 3               | 2 1.5%)                 |
| ABDOMINALPAIN                        | 3 1.2*)                 | 2.7%)                   | 2 1.5)                  |
| CHOLANGITIS                          | 5 2.08)                 | 1 0.9%)                 | 2 1.5)                  |
| INFUSION RELATED REACTION            | 4 1.6)                  | 0                       | 4 3.0%)                 |
| OESOPHAGEALVARICESHAEMORRHAGE        | 4 1.6)                  | 1 0.9%)                 | 3 2.28)                 |
| PYREXIA                              | 4 1.6)                  | 1 (6*0                  | 2 1.5*)                 |
|                                      | 1 0.48)                 | 2 1.8%)                 | 3 2.2%)                 |
| GAMMA-GLUTAMYLTRANSFERASEINCREASED   | 5 2.0%)                 | 1 0.9%)                 | 0                       |
| HYPERBILIRUBINAEMIA                  | 2 0.8%)                 | 3 2.7%) 1               | 1 0.7%)                 |
| PNEUMONIA                            | 3 1.2)                  | 0.9%)                   | 2 1.5%)                 |
| THROMBOCYTOPENIA                     | 4 1.6%)                 | 2 1.8%)                 | 0                       |
| DECREASEDAPPETITE                    | 1 0.4%)                 | 3 2.7)                  | 1 0.7%)                 |
| GASTROINTESTINAL HAEMORRHAGE         | 2 0.8%)                 | 1 0.9) 2                | 2 1.5)                  |
| HEPATICENCEPHALOPATHY                | 2 0.8%)                 | 1.8%)                   | 1 0.7%)                 |
| HYPERKALAEMIA                        | 1 0.4%)                 | 3 2.7%)                 | 1 0.78)                 |
| SEPSIS                               | 1 0.4%)                 | 1 (%6*0                 | 3 2.28)                 |
| CONFUSIONAL STATE                    | 1 0.4%)                 | 1 (%6*0                 | 2 1.58)                 |
| HYPERGLYCAEMIA                       | 1 0.4%)                 | 2 1.8%)                 | 1 0.7%)                 |
| HYPOALBUMINAEMIA                     | 1 0.48)                 | 1 0.9%)                 | 2 1.5%)                 |
| HYPOGLYCAEMIA                        | 2 0.8%)                 | 0                       | 2 1.5%)                 |
| LYMPHOCYTE COUNT DECREASED           | 3 1.28)                 | 1 0.9号)                 | 0                       |
| PULMONARY EMBOLISM STOMATITIS        | 1 0.4%) 2 0.88)         | 0 2                     | 3 (2.2%) 0              |
| UPPERGASTROINTESTINALHAEMORRHAGE     | 4 1.6%1                 |                         |                         |
|                                      |                         | 1.8%)                   | 0                       |
|                                      |                         | 0                       |                         |

SAE by HCC etiology

<div style=\"page-break-after: always\"></div>

Table 74: SAE by HCC etiology (Atezo+Bev population)

|                                                 |                 | Atezo+Bev HCC (N=493)                | Atezo+Bev HCC (N=493)        | Atezo+Bev HCC (N=493)                | Atezo+Bev HCC (N=493)                |
|-------------------------------------------------|-----------------|--------------------------------------|------------------------------|--------------------------------------|--------------------------------------|
| MedDRA System Organ Class MedDRA Preferred Term | Grade           | Hepatitis B (N=247)                  | Hepatitis C (N=111)          | Non-viral (N=135)                    | Non-viral (N=135)                    |
| Any adverse events                              | Any Grade       | 81 (32.8) 3 1.28) 12 4.9%) 53 (21.5) | 48 (43.28) 2 1.8*) 4 3.6) 30 | 57 (42.2) 1 0.78) 5 (3.7) 34 (25.2%) | 57 (42.2) 1 0.78) 5 (3.7) 34 (25.2%) |
|                                                 | 1               |                                      |                              |                                      |                                      |
|                                                 | 2m              |                                      | (27.0%)                      |                                      |                                      |
|                                                 |                 | 8 3.28)                              | 6 5.48)                      | 6 (4.4)                              | 6 (4.4)                              |
|                                                 |                 |                                      | 6                            | 11                                   | 11                                   |
|                                                 | 45              |                                      |                              |                                      |                                      |
|                                                 |                 | 5 2.0%)                              | 5.4%)                        | 8.1%)                                | 8.1%)                                |
| GASTROINTESTINALDISORDERS -Overall-             | Any Grade 12 3  | 33 (13.48) 0 6 2.48) 24 9.78) 14     | 17 (15.3#) No                | 11 1.8) 0.78) (12.6) 14 (10.4%)      | 11 1.8) 0.78) (12.6) 14 (10.4%)      |
|                                                 |                 | 0.48) 0                              |                              | 1 0.78)                              | 1 0.78)                              |
|                                                 |                 | 1 2                                  |                              |                                      |                                      |
|                                                 |                 | 0.8%) 1                              |                              |                                      |                                      |
| OESOPHAGEALVARICESHAEMORRHAGE                   | 45 一 Any Grade  | 5 2.0%) 1 0.4%)                      | 0.98) 0.9)                   | 3 2.2+) 4 3.0%)                      | 3 2.2+) 4 3.0%)                      |
|                                                 | 2 3             | 1 4 1.68) 1                          | 0 0.9)                       | 0 3 2.2#)                            | 0 3 2.2#)                            |
|                                                 |                 | 0                                    |                              | 1 0.7%)                              | 1 0.7%)                              |
| GASTROINTESTINAL HAEMORRHAGE                    | 5 一 Any Grade   | 4 1.6*) 0                            | No 1.8*)                     | 3 2.28) 0                            | 3 2.28) 0                            |
|                                                 | 2 3             | 11 1 0.4)                            | 0.9%)                        | 2                                    | 2                                    |
|                                                 | 4               |                                      | (6*0                         | 1.5#)                                | 1.5#)                                |
|                                                 |                 | 1                                    | 0                            | 0                                    | 0                                    |
|                                                 | 5               | 0.4) 2 0.8%)                         |                              | 1 0.7%) 1.58)                        | 1 0.7%) 1.58)                        |
|                                                 | Any Gradle      | 3 1.2)                               | (6*0                         | 1                                    | 1                                    |
| ASCITES                                         |                 | 0 1.2)                               | 0.9%)                        | 0.74) 0.78)                          | 0.74) 0.78)                          |
|                                                 | 3               | 3 1 0.48)                            | 010122101 1.8*)              | 1 2 1.5)                             | 1 2 1.5)                             |
| DIARRHOEA                                       | 一 Any Grade     | 0.4)                                 | 1.8%)                        | (1.5$)                               | (1.5$)                               |
| UPPERGASTROINTESTINALHAEMORRHAGE                | 3 一 Any Grade   | 1 4 1.68)                            | 0.98)                        |                                      |                                      |
|                                                 |                 | 4 0                                  |                              |                                      |                                      |
|                                                 | m5              | 1.68)                                | 0.9%)                        | N000                                 | N000                                 |
| INFECTIONS AND INFESTATIONS Overall             | Any Grade 2     | 12 4.9%) 2 0.8) 2.8%) 0.4%)          | 0.9#) 5.4%) 0.9%)            | 8.1%) 1 0.7#) 10 2                   | 16 (11.98)                           |
|                                                 | 3 4 5           | ONTTTG 1                             |                              | 7.48) 1.5*)                          | 7.48) 1.5*)                          |
| PNEUMONIA                                       | Any Grade       | 2 0.8%) 2                            | 0.9) 1.8#)                   | 3 2.2) 1.5$)                         | 3 2.2) 1.5$)                         |
|                                                 | 2               | 0.8) 1 0.4%) 1 1                     | 0.9%)                        | 0 1 0.7%)                            | 0 1 0.7%)                            |
| SEPSIS                                          | 3 5             | 0.48) 1 1.28)                        | 6'0                          | 1 0.78) m 2.2)                       | 1 0.78) m 2.2)                       |
|                                                 | Any Grade- 2    | 0 0 0.4)                             |                              | 0                                    | 0                                    |
|                                                 |                 | 3 1 0                                |                              |                                      |                                      |
|                                                 | 3               | 0 0 1 0.4) 0 1 0.4%) 0               |                              | 3 2.2) 0                             | 3 2.2) 0                             |
| URINARY TRACT INFECTION                         | 4 5 一 Any Grade | 0 1 0 口                              | (0.9%)                       | 02 1.58) 1 0.7%)                     | 02 1.58) 1 0.7%)                     |
|                                                 | 2m              | 0 1                                  |                              | 1 0.7)                               | 1 0.7)                               |
| BACTERAEMIA                                     |                 | 1 0.48)                              |                              |                                      |                                      |
|                                                 |                 | 0                                    | (0.9#)                       |                                      |                                      |
|                                                 | Any Grade 5     | 1 0                                  |                              | 00                                   | 00                                   |
| HEPATOBILIARY DISORDERS -Overal1l-              |                 |                                      |                              |                                      |                                      |
|                                                 | Any Grade 1     | 0.4) 4.9) 0.4)                       | 7 (                          | 6.3)                                 | 8 (5.9%)                             |
|                                                 | m               | 3.2) 0.8%) 0.4*)                     | 1.88)                        | oomm 0.9%) 2.78) 2.28)               | oomm 0.9%) 2.78) 2.28)               |
|                                                 |                 |                                      | 01321                        | 2.2) 2                               | 2.2) 2                               |
| RESPIRATORY, THORACIC AND MEDIASTINAL           |                 |                                      | 0.9)                         | 1.5*)                                | 1.5*)                                |
| DISORDERS                                       |                 |                                      |                              |                                      |                                      |
|                                                 |                 |                                      |                              | 8.9%)                                | 8.9%)                                |
|                                                 |                 | 口                                    |                              |                                      |                                      |
|                                                 |                 | 2.88)                                |                              |                                      |                                      |
|                                                 | 2m              |                                      |                              |                                      |                                      |
|                                                 |                 | 0                                    |                              | 0.98)                                | 0.98)                                |
|                                                 |                 |                                      |                              | 0.7%) 0.78)                          | 0.7%) 0.78)                          |
|                                                 | 中               |                                      |                              |                                      |                                      |
|                                                 | 5               | 1.2*)                                |                              |                                      |                                      |
|                                                 |                 | qmo                                  |                              |                                      |                                      |
|                                                 |                 |                                      | 1.8*)                        |                                      |                                      |
|                                                 |                 |                                      |                              | 6.78)                                | 6.78)                                |
|                                                 |                 |                                      |                              | 0.9%)                                |                                      |
|                                                 | -Overall        |                                      |                              |                                      |                                      |
|                                                 |                 |                                      |                              | 3.68)                                |                                      |
|                                                 |                 |                                      |                              | 0.7%)                                | 0.7%)                                |
|                                                 | 1.6%)           |                                      |                              |                                      |                                      |
| Any Grade                                       |                 |                                      |                              |                                      |                                      |
|                                                 | 41201           |                                      |                              |                                      |                                      |

<div style=\"page-break-after: always\"></div>

| RESPIRATORY DISTRESS                                                            | Any Grade 5                         | 0 0                                                          | 00                          | 0.7) 0.7#)                      | 0.7) 0.7#)                         | 0.7) 0.7#)                         | 0.7) 0.7#)                         | 0.7) 0.7#)                         | 0.7) 0.7#)                         | 0.7) 0.7#)                         | 0.7) 0.7#)                         | 0.7) 0.7#)                         | 0.7) 0.7#)                         | 0.7) 0.7#)                         |
|---------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------------------------|-----------------------------|---------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| GENERALDISORDERS AND ADMINISTRATION                                             |                                     |                                                              |                             |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
| SITE CONDITIONS Overall                                                         | Any Grade 1                         | B2N9O7NNmH 3.2*) 0.8%)                                       | m201om20 2.7*) 1.88)        | 4.4*) 0.7%)                     | 4.4*) 0.7%)                        | 4.4*) 0.7%)                        | 4.4*) 0.7%)                        | 4.4*) 0.7%)                        | 4.4*) 0.7%)                        | 4.4*) 0.7%)                        | 4.4*) 0.7%)                        | 4.4*) 0.7%)                        | 4.4*) 0.7%)                        | 4.4*) 0.7%)                        |
| PYREXIA                                                                         | 235 Any Grade                       | 1.6%) 2.8%)                                                  | 0.98) 2.7%)                 | 1041 0.8%) 3.0%) 0.7%) 3 2.28)  | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     | 1041 0.8%) 3.0%) 0.7%) 3 2.28)     |
|                                                                                 | 123                                 | 0.8%) 0.8%) 1.2*) 0.4%)                                      | ( 1.88) 1 (6*0 口            | 1 0.78) 0 1.5*)                 | 1 0.78) 0 1.5*)                    | 1 0.78) 0 1.5*)                    | 1 0.78) 0 1.5*)                    | 1 0.78) 0 1.5*)                    | 1 0.78) 0 1.5*)                    | 1 0.78) 0 1.5*)                    | 1 0.78) 0 1.5*)                    | 1 0.78) 0 1.5*)                    | 1 0.78) 0 1.5*)                    | 1 0.78) 0 1.5*)                    |
| FATIGUE                                                                         | 一 Any Grade 3                       | 1 0.4%) 口                                                    | 口 口 口                       | 21 0.78) 1 0.7%) 1 0.7%)        | 21 0.78) 1 0.7%) 1 0.7%)           | 21 0.78) 1 0.7%) 1 0.7%)           | 21 0.78) 1 0.7%) 1 0.7%)           | 21 0.78) 1 0.7%) 1 0.7%)           | 21 0.78) 1 0.7%) 1 0.7%)           | 21 0.78) 1 0.7%) 1 0.7%)           | 21 0.78) 1 0.7%) 1 0.7%)           | 21 0.78) 1 0.7%) 1 0.7%)           | 21 0.78) 1 0.7%) 1 0.7%)           | 21 0.78) 1 0.7%) 1 0.7%)           |
| ASTHENIA                                                                        | Any Grade Any Grade 23 4            | 0 0 2.88)                                                    | 4 3.6%) 3.6%)               | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)   | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      | 1 0.7*) 1 0.7%) 1 0.48) 2.4%)      |
| MULTIPLE ORGANDYSFUNCTIONSYNDROME Overall                                       | 3 - Any Grade 5                     | 口                                                            | 00                          | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*) | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    | 0.78) 6 4.48) 0 3 2.2%) 2 1.5*)    |
| NERVOUS SYSTEMDISORDERS CEREBRALINFARCTION HEPATICENCEPHALOPATHY INVESTIGATIONS | 5 Any Grade 3 4 一 Any Grade 3 12345 | 7１6００１１０２2０１１０ 0.4%) ( 0.48) ( 0.8%) 0.8%) ( 4301 1.6) 1.2*) | 口 口                         |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
| COMPLICATIONS Overall INFUSIONRELATEDREACTION                                   | 234 Any Grade                       | １01101 0.48)                                                 | 口 0 口 口 0 0 00 口 3021 2.7%) | 0.4%) 0.8%) 0.78)               | 0.4%) 0.8%) 0.78)                  | 0.4%) 0.8%) 0.78)                  | 0.4%) 0.8%) 0.78)                  | 0.4%) 0.8%) 0.78)                  | 0.4%) 0.8%) 0.78)                  | 0.4%) 0.8%) 0.78)                  | 0.4%) 0.8%) 0.78)                  | 0.4%) 0.8%) 0.78)                  | 0.4%) 0.8%) 0.78)                  | 0.4%) 0.8%) 0.78)                  |
| PSYCHIATRIC DISORDERS Overall                                                   |                                     |                                                              | 211 5131                    |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 | Grade                               | (                                                            |                             | 624321 5%)                      | 624321 5%)                         | 624321 5%)                         | 624321 5%)                         | 624321 5%)                         | 624321 5%)                         | 624321 5%)                         | 624321 5%)                         | 624321 5%)                         | 624321 5%)                         | 624321 5%)                         |
|                                                                                 | Any                                 |                                                              |                             | 0.7%) 4.43)                     | 0.7%) 4.43)                        | 0.7%) 4.43)                        | 0.7%) 4.43)                        | 0.7%) 4.43)                        | 0.7%) 4.43)                        | 0.7%) 4.43)                        | 0.7%) 4.43)                        | 0.7%) 4.43)                        | 0.7%) 4.43)                        | 0.7%) 4.43)                        |
|                                                                                 | 1231213                             |                                                              | 000000                      |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 | 4 Any Grade 3                       | 0.4%) 0.4%)                                                  |                             | 1 0.7) 101 0.7#)                | 1 0.7) 101 0.7#)                   | 1 0.7) 101 0.7#)                   | 1 0.7) 101 0.7#)                   | 1 0.7) 101 0.7#)                   | 1 0.7) 101 0.7#)                   | 1 0.7) 101 0.7#)                   | 1 0.7) 101 0.7#)                   | 1 0.7) 101 0.7#)                   | 1 0.7) 101 0.7#)                   | 1 0.7) 101 0.7#)                   |
| SUBARACHNOIDHAEMORRHAGE                                                         | 5                                   |                                                              |                             |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 |                                     |                                                              |                             | 0.7%)                           | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              |
|                                                                                 |                                     |                                                              |                             | 4.4%)                           | 4.4%)                              | 4.4%)                              | 4.4%)                              | 4.4%)                              | 4.4%)                              | 4.4%)                              | 4.4%)                              | 4.4%)                              | 4.4%)                              | 4.4%)                              |
| METABOLISMAND NUTRITIONDISORDERS Overall                                        | Any Grade 234                       |                                                              | 1.8%) 0.9%)                 | 6024 1.5*) 3.0%)                | 6024 1.5*) 3.0%)                   | 6024 1.5*) 3.0%)                   | 6024 1.5*) 3.0%)                   | 6024 1.5*) 3.0%)                   | 6024 1.5*) 3.0%)                   | 6024 1.5*) 3.0%)                   | 6024 1.5*) 3.0%)                   | 6024 1.5*) 3.0%)                   | 6024 1.5*) 3.0%)                   | 6024 1.5*) 3.0%)                   |
| Overall VASCULAR DISORDERS                                                      | Any Grade 34                        | 0.48)                                                        | 1.8%) 0.9%) 0.9#)           | 321 5%) 0.7%)                   | 321 5%) 0.7%)                      | 321 5%) 0.7%)                      | 321 5%) 0.7%)                      | 321 5%) 0.7%)                      | 321 5%) 0.7%)                      | 321 5%) 0.7%)                      | 321 5%) 0.7%)                      | 321 5%) 0.7%)                      | 321 5%) 0.7%)                      | 321 5%) 0.7%)                      |
| Overall                                                                         | Any Grade                           | 761 2:8 0.4*) m1N0 1.2*)                                     | 4.5#) 0.9%) ( 0.9%)         | 2110                            | 2110                               | 2110                               | 2110                               | 2110                               | 2110                               | 2110                               | 2110                               | 2110                               | 2110                               | 2110                               |
| Overall                                                                         | Any Grade                           | 4121 1.6%) 0.4%) 0.83)                                       |                             | 2.28) 1.5%)                     | 2.28) 1.5%)                        | 2.28) 1.5%)                        | 2.28) 1.5%)                        | 2.28) 1.5%)                        | 2.28) 1.5%)                        | 2.28) 1.5%)                        | 2.28) 1.5%)                        | 2.28) 1.5%)                        | 2.28) 1.5%)                        | 2.28) 1.5%)                        |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                                            |                                     | 0.4%)                                                        | 1010 0.9*)                  | 3021                            | 3021                               | 3021                               | 3021                               | 3021                               | 3021                               | 3021                               | 3021                               | 3021                               | 3021                               | 3021                               |
|                                                                                 | 234                                 | 0.8)                                                         | ( 1.8%)                     | 0.7%)                           | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              | 0.7%)                              |
| CARDIAC DISORDERS Overall                                                       | Gradle                              |                                                              | NO00ON                      | :8 0.78)                        | :8 0.78)                           | :8 0.78)                           | :8 0.78)                           | :8 0.78)                           | :8 0.78)                           | :8 0.78)                           | :8 0.78)                           | :8 0.78)                           | :8 0.78)                           | :8 0.78)                           |
|                                                                                 |                                     | 0.4*) 0.4#)                                                  |                             | 311010                          | 311010                             | 311010                             | 311010                             | 311010                             | 311010                             | 311010                             | 311010                             | 311010                             | 311010                             | 311010                             |
|                                                                                 |                                     |                                                              | 1.8%)                       |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 |                                     | 0.4%) 0.4*)                                                  |                             |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 |                                     |                                                              |                             | .0%)                            | .0%)                               | .0%)                               | .0%)                               | .0%)                               | .0%)                               | .0%)                               | .0%)                               | .0%)                               | .0%)                               | .0%)                               |
|                                                                                 | Any Grade                           |                                                              | 0.9)                        |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 |                                     |                                                              | 2.7%)                       |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
| DISORDERS                                                                       |                                     |                                                              |                             |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
| MUSCULOSKELETALANDCONNECTIVETISSUE                                              |                                     |                                                              | 1.8号)                       |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 |                                     |                                                              | 0.9%)                       |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 | Any Grade                           |                                                              |                             |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 | Overall                             |                                                              |                             |                                 |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
|                                                                                 |                                     |                                                              |                             | 0.8%)                           | 0.88)                              | 2.2*) 0 0.7%) 0.98) 0.7%)          | 2.2*) 0 0.7%) 0.98) 0.7%)          | 2.2*) 0 0.7%) 0.98) 0.7%)          | 2.2*) 0 0.7%) 0.98) 0.7%)          | 2.2*) 0 0.7%) 0.98) 0.7%)          | 2.2*) 0 0.7%) 0.98) 0.7%)          | 2.2*) 0 0.7%) 0.98) 0.7%)          | 2.2*) 0 0.7%) 0.98) 0.7%)          | 2.2*) 0 0.7%) 0.98) 0.7%)          |
|                                                                                 |                                     |                                                              |                             |                                 |                                    |                                    | 23                                 | 23                                 | 23                                 | 23                                 |                                    |                                    |                                    |                                    |
|                                                                                 |                                     |                                                              |                             |                                 | 4                                  | 4                                  | 4                                  | 4                                  | 4                                  | 4                                  | 4                                  | 4                                  | 4                                  | 4                                  |
|                                                                                 |                                     |                                                              |                             |                                 |                                    | 1010 20 0.7)                       | 1010 20 0.7)                       | 1010 20 0.7)                       | 1010 20 0.7)                       | 1010 20 0.7)                       | 1010 20 0.7)                       | 1010 20 0.7)                       | 1010 20 0.7)                       | 1010 20 0.7)                       |
|                                                                                 |                                     |                                                              |                             |                                 | 3111                               | 3111                               | 3111                               | 3111                               | 3111                               | 3111                               | 3111                               | 3111                               | 3111                               | 3111                               |
|                                                                                 |                                     |                                                              |                             |                                 | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) | １２3４ 21０１0 0.4%) 0.8%) 30120 0.4%) |
|                                                                                 |                                     |                                                              |                             |                                 | 20101 1.5*) 0.7) 0.7)              | 20101 1.5*) 0.7) 0.7)              | 20101 1.5*) 0.7) 0.7)              | 20101 1.5*) 0.7) 0.7)              | 20101 1.5*) 0.7) 0.7)              | 20101 1.5*) 0.7) 0.7)              | 20101 1.5*) 0.7) 0.7)              | 20101 1.5*) 0.7) 0.7)              | 20101 1.5*) 0.7) 0.7)              | 20101 1.5*) 0.7) 0.7)              |
|                                                                                 |                                     |                                                              |                             |                                 | INJURY,POISONING AND PROCEDURAL    | INJURY,POISONING AND PROCEDURAL    | INJURY,POISONING AND PROCEDURAL    | INJURY,POISONING AND PROCEDURAL    | INJURY,POISONING AND PROCEDURAL    | INJURY,POISONING AND PROCEDURAL    | INJURY,POISONING AND PROCEDURAL    | INJURY,POISONING AND PROCEDURAL    | INJURY,POISONING AND PROCEDURAL    | INJURY,POISONING AND PROCEDURAL    |
|                                                                                 |                                     |                                                              |                             |                                 | ２00１1０ 0.4#)                       | ２00１1０ 0.4#)                       | ２00１1０ 0.4#)                       | ２00１1０ 0.4#)                       | ２00１1０ 0.4#)                       | ２00１1０ 0.4#)                       | ２00１1０ 0.4#)                       | ２00１1０ 0.4#)                       | ２00１1０ 0.4#)                       | ２00１1０ 0.4#)                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Extrinsic Factors by Region

## Region

The majority of patients treated with Atezo + Bev and Sorafenib were from Asia-Pacific (Atezo + Bev: n = 279, Sorafenib: n = 86), followed by North America (Atezo + Bev: n = 102, Sorafenib: n = 21), and Europe and Middle East (Atezo + Bev: n = 99, Sorafenib: n = 48).

<div style=\"page-break-after: always\"></div>

Table 75: Overview of AEs in Atezo+Bev and Sorafenib HCC patients by region (safety-evaluable patients)

|                                                                     | Sorafenib HCC (N=156)         | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Atezo+Bev HCC (N=493)         | Atezo+Bev HCC (N=493)   |
|---------------------------------------------------------------------|-------------------------------|-------------------------|-------------------------|-------------------------------|-------------------------|
|                                                                     | Europe and Middle East (N=48) |                         | North America (N=21)    | Europe and Middle East (N=99) | North America (N=102)   |
| Total number of patients with atleast one AE Total number of events | 376                           | 48(100%)                | 21 (100%) 223           | 99 (100%) 836                 | 100 (98.0%) 1360        |
| Total number of patients with at least one                          |                               |                         |                         |                               |                         |
| Treatment-related AE                                                | 45                            | (93.8%)                 | 20 (95.2%)              | 84 (84.8%)                    | 88 (86.3%)              |
| Atezo-related AE                                                    | 0                             |                         | 0                       | 74 (74.7%)                    | 84 (82.4%)              |
| Grade 3-4 AE                                                        | 24                            | (50.0%)                 | 14 (66.7%)              | 53 (53.5%)                    | 61 (59.8%)              |
| Treatment-related Grade 3-4 AE                                      | 22                            | (45.8%)                 | 9 (42.9%)               | 31 (31.3%)                    | 39 (38.2%)              |
| Atezo-related Grade 3-4 AE                                          | 0                             |                         | 0                       | 23 (23.2%)                    | 25 (24.5%)              |
| Grade5AE                                                            | 8                             | (16.7%)                 | 0                       | 6 6.1%)                       | 8 (7.8%)                |
| Treatment-related Grade 5 AE                                        | 1                             | (2.1%)                  | 0                       | 1 1.0%)                       | 2 (2.0%)                |
| Atezo-related Grade 5AE                                             | 0                             |                         | 0                       | 1 (1.0%)                      | 1 (1.0%)                |
| Serious AE                                                          | 23                            | (47.9%)                 | 10 (47.6%)              | 44 (44.4%)                    | 42 (41.2%)              |
| Treatment-related serious AE                                        | 12                            | (25.0%)                 | 4 (19.0%)               | 20 (20.2%)                    | 18 (17.6%)              |
| Atezo-related serious AE                                            | 0                             |                         | 0                       | 15 (15.2%)                    | 11 (10.8%)              |
| AE leading to any Study Treatment withdrawal                        | 9                             | (18.8%)                 | 1 (4.8%)                | 22 (22.2%)                    | 19 (18.6%)              |
| AE leading to Atezo withdrawal                                      | 0                             |                         | 0                       | 13 (13.1%)                    | 13 (12.7%)              |
|                                                                     | 30                            | (62.5%)                 | 15 (71.4%) 0            | 58 (58.6%)                    | 47 (46.1%)              |
| AE leading to Atezo interruption                                    | 0                             |                         |                         | 52 (52.5%)                    | 33 (32.4%)              |

|                                                                      | Sorafenib HCC (N=156)   | Sorafenib HCC (N=156)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   |
|----------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                                      | Asia-Pacific (N=86)     | Australia (N=1)         | Asia-Pacific (N=279)    | Australia (N=13)        |
| Total number of patients with at least one HE Total number of events | 84(97.74) 694           | 1 (100号) 6              | 269(96.49) 2377         | 12 (92.34) 126          |
| Total number of patients with at least one                           |                         |                         |                         |                         |
| Treatment-related AE                                                 | 81 (94.24)              | 1 (100%)                | 227 (81.4%)             | (69.24)                 |
| Atezo-related AE                                                     | 0                       | 0                       | 203 (72.84)             | 7 (53.8%)               |
| Grade 3-4 AE                                                         | 47 [54.75)              | 1 (100号)                | 138 (49.54)             | 11 (84.6%)              |
| Treatment-relatedGrade 3-4 AE                                        | 39 [45.35)              | 1 (100号)                | 97 (34.8%)              | 3 (23.14)               |
| Atezo-related Grade 3-4 AE                                           | 0                       | 0                       | 67 (24.0%)              | 2 (15.44)               |
| Grade 5 AE                                                           | 1 ( 1.2)                | 0                       | 8 2.9%)                 | 0                       |
| Treatment-related Grade 5 AE                                         | 0                       | 0                       | 6 2.24)                 | 0                       |
| Atezo-related Grade 5 AE                                             | 0                       | 0                       | 5 (1.85)                | 0                       |
| Serious AE                                                           | 15 (17.4)               | 0                       | 92 (33.0%)              | 8 (61.55)               |
| Treatment-related serious AE                                         | 8 9.34)                 | 0                       | 48 (17.24)              | 2 (15.4%)               |
| Atezo-related serious AE                                             | 0                       | 0                       | 37 (13.3%)              | 2 (15.44)               |
| AE leading to any Study Treatment withdrawal                         | 5 5.8%)                 | 1 (100号)                | 32 (11.54) 15           | 2 (15.4)                |
| AE leading to Atezo withdrawal                                       | 0                       | 0                       | 5.44)                   | (7.74)                  |
| AE leading                                                           | 50 [58.14)              | 0                       | 111 (39.84)             | 6 (46.24)               |
| AE leading to Atezo interruption                                     | 0                       | 0                       | 74 (26.5%)              | 6 (46.24)               |

14 3o saouatinooo aidrainw *sbutpeay uumtoo aun ur N uo paseg are sabeauaaiad 'o'zz4 taopan butsn papooua sgt iog 4xa4 xoqebtasanul same AE in one individual are counted only once except for \"Total number of events\" rows, multiple occurrences of the same AE in ar C1inica1cut-off dates: Y040245:29AUG2019,G030140:14JUN2019.

The overall distribution of AESIs was comparable across patients in Asia-Pacific, Europe and Middle East, and North America with the following exception: a higher proportion ( ≥ 10% differences) of patients experienced Grade 3-4 atezolizumab AESIs in Europe and Middle East when compared to patients in Asia-Pacific.

<div style=\"page-break-after: always\"></div>

Table 76: SAE Highest NCI CTCAE Grades and by SOC and Preferred Term, by Region [excerpt]

|                                                 |           |           | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)         | Atezo+Bev HCC (N=493)         |
|-------------------------------------------------|-----------|-----------|-------------------------|-------------------------|-------------------------------|-------------------------------|
| MedDRA System Organ Class MedDRA Preferred Term | Grade     |           | Asia-Pacific (N=279)    | Australia (N=13)        | Europe and Middle East (N=99) | North America (N=102)         |
| Any adverse events                              | Any Grade |           | 92 (33.0%) 3 1.1%)      | 8 (61.58) 0             | 44 (44.4%)                    | 42 (41.28)                    |
|                                                 |           |           | 13 （ 4.78)              | 0                       | 1 1.08)                       | 2 (2.0%)                      |
|                                                 | 1234      |           |                         | (53.8%)                 | 5 5.18) (25.38)               | 3 (2.98)                      |
|                                                 |           |           | 62 (22.28)              | 7                       | 25                            | 23 (22.58)                    |
|                                                 |           |           | 6 （ 2.28)               | 7.7%)                   | 7 7.1%)                       | 6 (5.9%)                      |
|                                                 | 5         |           | 8 2.98)                 | 0                       | 9 6.18)                       | 8 (7.8%)                      |
| GASTROINTESTINAL DISORDERS Overall              | Any Grade |           | 32 (11.58) 0 5 1.8%)    | (30.8%) 0 0 4 (30.8%)   | 13 (13.18) 0 3 3.0%)          | 21 (20.6%) 1 (1.0%) 1 (.1.0%) |
|                                                 | 23 4      |           | 23 8.28) 2 0.7%)        | 0                       |                               | 17 (16.7%) 0                  |
|                                                 | 5         |           |                         |                         | 8 8.1%)                       |                               |
|                                                 |           |           | 2 0.7%)                 | 0                       | 0 2 2.0%)                     | 2 2.0%)                       |
| OESOPHAGEALVARICES HAEMORRHAGE                  |           | Any Grade | 5 1.88)                 | 1 7.78)                 | 3 3.0%)                       | 1 1.08)                       |
|                                                 | 2         |           | 0                       | 0                       | 1 1.0%)                       | 0                             |
|                                                 | 3         |           | 5 (1.88)                | 1 7.7%)                 | 1 1.0%)                       | 1 (1.0%)                      |
|                                                 | 5         |           | 0                       | 0                       | 1 1.0%)                       | 0                             |
|                                                 |           |           | 2 0.7%)                 | 0                       | 5.1%)                         | 2 (2.0%)                      |
| GASTROINTESTINAL HAEMORRHAGE                    | 2         | Any Grade |                         | 0                       | 1 1.0%)                       | 0                             |
|                                                 | 3         |           | 0 0                     | 0                       | 3 3.0%)                       | 1 1.0%)                       |
|                                                 | 4         |           | 1 0.48)                 | 0                       | 0                             | 0                             |
|                                                 | 5         |           | 1 0.4%)                 | 0                       | 1.0%)                         | 1 1.0%)                       |

Table 77: Overview of Adverse Events of Special Interest for Atezolizumab, by Region

Table 78: AESI for Atezolizumab by Medical Concept and Preferred Term, by Region (Excerpt)

<!-- image -->

|                                                                      | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)   | Atezo+Bev HCC (N=493)         | Atezo+Bev HCC (N=493)   |
|----------------------------------------------------------------------|-------------------------|-------------------------|-------------------------------|-------------------------|
|                                                                      | Asia-Pacific (N=279)    | Australia (N=13)        | Europe and Middle East (N=99) | North Americt (N=102)   |
| Totalnumber of events                                                | 170( (60.98) 429        | 5 (38.58) 12            | 71 (71.7%) 142                | 74(72.5%) 170           |
| Totalnumber of patients withatleast one                              |                         |                         |                               |                         |
| Treatment-related AE of Special Interest                             | 136 (48.7%)             | 3 (23.18)               | 54 (54.58)                    | 47(46.1%)               |
| Atezo.-related..AE...of..pecial...Interest..                         | 1.3.1. (.4.70%)         | 3 (2.3..1）              | .4.9.. (.4.9..5.%）            | 4....1).                |
| Grade3-4AEofSpecial.Interest.                                        | 53 （0*6T)               | 4. (30.8%）              | 29 (29.3）                     | 2.9. （28.4）             |
| Treatment-related Grade 3-4 AE of Special Interest                   | 31 (11.18)              | 2 (15.48)               | 19 (19.28)                    | 12 (11.88)              |
| Atezo-related Grade 3-4 AE of Special Interest                       | 28 (10.0%)              | 2 (15.4%)               | 17 (17.28)                    | 12 (11.8%)              |
| Grade5 AE of Special Interest                                        | 3 1.1)                  | 0                       | 2 2.08)                       | 1 (1.0%)                |
| Treatment-related Grade 5 AE of Special Interest                     | 3 1.18)                 | 0                       | 1 1.08)                       | 1 1.08)                 |
| Atezo-related Grade 5 AE of Special Interest                         | 3 1.18)                 | 0                       | 1 1.0%)                       | 1 (1.0%)                |
| Serious AE of Special Interest                                       | 28 (10.0%)              | 3 (23.18)               | 19 (19.28)                    | 16 (15.78)              |
| Treatment-related Serious AE of Special Interest                     | 16 5.7%)                | 1 7.7%)                 | 11 (11.1)                     | 6 5.9%)                 |
|                                                                      | 13 4.7%)                | 7.7%)                   | 10\" (10.1)                    | 6 (5.9)                 |
| AE of Special Interest leading to any Study Treatment withdrawal     | 11 3.9%)                | 2 (15.4)                | 11 (11.1)                     | 5 (4.9%)                |
| AE of Special Interest leadingtoAtezowithdrawal                      | 7 2.58)                 | 1 7.78)                 | 6 9.18)                       | 5 （6*）                  |
| interruption                                                         | 34 (12.2%)              | 1 7.78)                 | 29 (29.3%)                    | 17 (16.7%)              |
| AE...of..p..cia... .Interest...leading..o..Atezo...interruption.     | 3.0..(.1...8%).         | .....                   | 2.6. (2.6...3）                | 1.3.....7）              |
| AE of Special Interest Requiring the Use of Systemic Corticosteroids | 25 (9.0%)               | 3 (23.1%)               | 19 (19.2%)                    | 13 (12.7%)              |

Atezo+Bev

|                                                            | HCC (N=493)          | HCC (N=493)      | HCC (N=493)                   | HCC (N=493)           |
|------------------------------------------------------------|----------------------|------------------|-------------------------------|-----------------------|
| Medical Concept MedDRA Preferred Term                      | Asia-Pacific (N=279) | Australia (N=13) | Europe and Middle East (N=99) | North America (N=102) |
| Totalnumber ofpatients with at least one adverse event     | 170 (60.98)          | 5 (38.5%)        | 71(71.78)                     | 74(72.5%)             |
| Immune-Mediated Hepatitis（Diagnosis and Lab Abnormalities) |                      |                  |                               |                       |
| Totalnumber of patients with at least one adverse event    | 66 (35.5%)           | 3 (23.1%)        | 42 (42.48)                    | 47(46.1%)             |
|                                                            | 47 (16.8%)           | 0                | 17 (17.2%)                    | 19 (18.6%)            |
| ALANINEAMINOTRANSFERASEINCREASED                           | 37 (13.38)           | 0                | 10 (10.1%)                    | 14  (13.7%)           |
| BLOOD BILIRUBININCREASED                                   | 33 (11.8%)           | 0                | 11 (11.18)                    | 17(16.7%)             |
| ASCITES                                                    | 14 (5.0%)            | 0                | 10 (10.1%)                    | 10 (9.8%)             |
| GAMMA-GLUTAMYLTRANSFERASEINCREASED                         | 10(3.68)             | 0                | 0                             | 0                     |
| Immune-Mediated Hepatitis (Lab Abnormalities)              |                      |                  |                               |                       |
| Totalnumber of patients withat least one adverse event     | 90 （32.3%)           | 1 (7.78)         | 36(36.4%)                     | 44(43.1%)             |
| ASPARTATEAMINOTRANSFERASEINCREASED                         | 47 (16.8%)           |                  | 17 (17.28)                    | 19 (18.6%)            |
|                                                            | 37 (13.38)           | 0                | 10 (10.18)                    | 14 (13.7%)            |
| BLOOD BILIRUBIN INCREASED                                  | 33 (11.8%)           | 0                | 11 (11.18)                    | 17 (16.7%)            |
| ASCITES                                                    | 14(5.0%)             | 0                | 10 (10.18)                    | 10 (9.8%)             |

<div style=\"page-break-after: always\"></div>

| Immune-Mediated Rash                                     |            |           |            |            |
|----------------------------------------------------------|------------|-----------|------------|------------|
| Totalnumber of patients withat leastone adverseevent     | 60(21.5%)  | 2 (15.48) | 16 (16.2%) | 31 (30.48) |
| RASH                                                     | 43(15.48)  | 0         | 6 (9.18)   | 25(24.5%)  |
| RASH MACULO-PAPULAR                                      | 8(2.9%)    | 1 (7.7%)  | 0          | 5(4.98)    |
| Immune-Mediated Hepatitis (Diagnosis)                    |            |           |            |            |
| Totalnumberof patients withat leastone adverse event     | 26 (9.3%)  | 2 (15.4%) | 18 (18.28) | 14 (13.78) |
| ASCITES                                                  | 14 5.0%)   | 0         | 10 (10.1%) | 10 (9.8%)  |
| HEPATICENCEPHALOPATHY                                    | （ 1.8%)    | 1 7.78)   | 13 (1.0%)  | 3 (2.98)   |
| OESOPHAGEALVARICESHAEMORRHAGE                            | 55 (1.8%)  | 1 7.7%)   | (3.0%)     | 1 (1.0%)   |
| Immune-MediatedHypothyroidism                            |            |           |            |            |
| Total number of patients with at least one adverse event | 32 (11.58) |           | 10(10.1)   | 7 (6.98)   |
| HYPOTHYROIDISM                                           | 26 (9.38)  |           | 10 (10.1%) | S (4.9%)   |
| BLOODTHYROIDSTIMULATING HORMONEINCREASED                 | 6 (2.2%)   | 000       | 1 ( 1.08)  | 2 (2.0%)   |
| Infusion-Related Reactions                               |            |           |            |            |
| Total number of patients with at least one adverse event | 24 (8.68)  | 2 (15.48) | 10 (10.18) | 7 6.98)    |
| INFUSIONRELATEDREACTION                                  | 24 (8.6%)  | 2 (15.48) | 10 (10.18) | 7 6.9%)    |
| Immune-Mediated Hyperthyroidism                          |            |           |            |            |
| Total number of patients with at least one adverse event | 7 (2.58)   | 0         | 8 (8.18)   | 1 (1.0%)   |
| HYPERTHYROIDISM                                          | 7 (2.5%)   | 0         | 8 (8.18)   | 1 (1.0%)   |
| Immune-Mediated Pancreatitis                             |            |           |            |            |
| Total number of patients with at least one adverse event | 4(1.48)    | 1( 7.7%)  | 1 (1.08)   | 5(4.98)    |

## Subgroup Analyses of Safety by Anti-Drug Antibody Status

The impact of atezolizumab ADA status on safety was evaluated. No analysis was done for the impact of bevacizumab ADA status on safety due to the very low bevacizumab ADA positive rate in general.

## Pooled Analysis IMbrave150 and GO31040

Among ADA-evaluable patients, atezolizumab ADA-negative and ADA-positive patients received a median number of 11.0 and 10.0 cycles of atezolizumab, respectively.

An overview of safety by ADA status is shown in Table 1. Numerical differences were observed in treatment related (Atezo-related) AEs specially Grade 3-4 AEs, SAEs AEs and AEs leading to discontinuation of treatment. Several PTs in the All AEs output showed a difference in frequency of more than 5% in the ADA-positive group, but no specific pattern was identified and the majority of the events were commonly reported events in cancer patients. No significant differences were observed in potentially immune related AEs, and no significant difference between groups was seen among SAEs. The incidence of AESIs of any grade by ADA status was comparable (60.8% ADA-negative vs. 61.5% ADA-positive).

<div style=\"page-break-after: always\"></div>

Table 79: Overview of Adverse Events by atezolizumab ADA status

|                                                                  | Atezo+Bev HCC (N=474)   | Atezo+Bev HCC (N=474)   |
|------------------------------------------------------------------|-------------------------|-------------------------|
| ADA EvaluablePatients Protocols:IMbrave150(Y040245),G030140      | ADA- (N=340)            | ADA+ (N=134)            |
| Total numberofpatientswithatleastoneAE                           | 331 (97.4%)             | 131 (97.8%)             |
| Total number of events                                           | 3245                    | 1294                    |
| Total number of patients with at least one:                      |                         |                         |
| Treatment-related AE                                             | 280 (82.4%)             | 114 (85.1%)             |
| Atezo-related AE                                                 | 250 (73.5%)             | 105 (78.4%)             |
| Grade 3-4 AE                                                     | 170 (50.0%)             | 79 (59.0%)              |
| Treatment-relatedGrade3-4AE                                      | 111 (32.6%)             | 50 (37.3%)              |
| Atezo-relatedGrade3-4AE                                          | 73 (21.5%)              | 35 (26.1%)              |
| Grade 5 AE                                                       | 11 (3.2%)               | 9 (6.7%)                |
| Treatment-relatedGrade5AE                                        | 4 (1.2%)                | 4 (3.0%)                |
| Atezo-relatedGrade5AE                                            | 3 (0.9%)                | 3 (2.2%)                |
| Serious AE                                                       | 107 (31.5%)             | 67 (50.0%)              |
| Treatment-relatedseriousAE                                       | 47 (13.8%)              | 36 (26.9%)              |
| Atezo-related serious AE                                         | 37 (10.9%)              | 23 (17.2%)              |
| AE leading to any Study Treatment withdrawal                     | 47 (13.8%)              | 24 (17.9%)              |
| AE leading toAtezo withdrawal                                    | 24 (7.1%)               | 14 (10.4%)              |
| AE leading to anyDose modification orStudy Treatment interuption | 143 (42.1%)             | 73 (54.5%)              |
| AE leading to Atezo interruption                                 | 106 (31.2%)             | 55 (41.0%)              |

ADA=Anti-Drug Antibodies, -=Negative, +=Positive

Atezo=Atezolizumab Bev=Bevacizumab. Atez0+Bev HCC: IMbrave150 (YO40245)

(Atez0+Bev)+GO30140(ArmA+F1).

Investigator text for AEs encoded using MedDRA v22.0.Percentages are based on N in the column headings. Multiple occurrences of the same AE in one individual are counted only once except for\"Total number of events\" rows, multiple occurrences of the same AE in an individual

Clinical cut-off dates: Study IMbrave150 (YO40245) (29 August 2019), G030140 (14 June 2019)

The incidences of AEs are shown in Table 5.5.1.8.13 for terms where a ≥ 5% difference was seen between the two ADA subgroups. There were numerical differences by ADA status with most incidences higher in ADA-positive patients.

<div style=\"page-break-after: always\"></div>

Table 80: Adverse Events by ADA status with 5% difference between ADA subgroups

| ADAEvaluablePatients Protocols: IMbrave150 (YO40245),G030140   | Atezo+Bev HCC (N=474)   | Atezo+Bev HCC (N=474)   |
|----------------------------------------------------------------|-------------------------|-------------------------|
| MedDRAPreferredTerm                                            | ADA- (N=340)            | ADA+ (N= 134)           |
| Proteinuria                                                    | 88 (25.9%)              | 27 (20.1%)              |
| Fatigue                                                        | 71 (20.9%)              | 35 (26.1%)              |
| Decreased Appetite                                             | 76 (22.4%)              | 20 (14.9%)              |
| Pyrexia                                                        | 52 (15.3%)              | 31 (23.1%)              |
| Constipation                                                   | 41 (12.1%)              | 27 (20.1%)              |
| Anaemia                                                        | 26 (7.6%)               | 17 (12.7%)              |
| InfusionRelatedReaction                                        | 23 (6.8%)               | 20 (14.9%)              |

ADA=Anti-Drug Antibodies, -=Negative, +=Positive.

Atez0=Atezolizumab Bev=Bevacizumab.Atez0+Bev HCC: IMbrave150 (YO40245)

(Atez0+Bev)+GO30140(Arm A+F1).

Investigator text for AEs encoded using MedDRA v22.0. All counts represent patients.

Multiple occurrences of the same AE in one individual are counted once. All treatment emergent AEs are included.

Clinical cut-off dates: Study IMbrave150 (YO40245) (29 August 2019), Study G030140 (14 June 2019).

The incidence of Grade 1-2 events was higher in the ADA-negative compared with the ADA-positive subgroup (44.1% vs. 32.1%) whereas Grade 3-4 AEs (50.0% vs. 59.0%) and Grade 5 AEs (3.2% vs. 6.7%) occurred at a higher incidence in the ADA-positive subgroup.

The most common SOCs in which Grade 3-4 AEs were reported with a differential ≥ 5% between ADAnegative and ADA-positive patients included:

- Investigations (15.0% vs. 23.9%), most common AEs were increased AST (5.3% vs. 6.7%), increased ALT (3.2% vs. 3.0%), increased bilirubin (2.9% vs. 3.7%), increased platelets (2.4% vs. 6%) and increased blood alkaline phosphatase (0% vs. 4.9%).
- Hepatobiliary Disorders (4.4% vs. 9.7%), most common AE was cholangitis (1.2% vs. 3.1%).

Other commonly reported Grade 3-4 AEs included proteinuria (ADA-negative: 4.1%; ADA-positive: 3.7%), anemia (ADA-negative: 2.1%; ADA-positive: 3.7%) and IRRs (ADA-negative: 0.9%; ADApositive: 3.0%).

The most common SOCs in which Grade 5 AEs were reported included Gastrointestinal Disorders (ADAnegative subgroup: 2 patients, 0.6%; ADA-positive subgroup: 4 patients, 3.0%) and Infections and Infestations (ADA-negative subgroup: 5 patients, 1.5%; ADA-positive subgroup: 0 patients).

The most frequent Grade 5 AE was pneumonia (PT) among ADA-negative patients (2 patients, 0.6%) and gastrointestinal haemorrhage (PT) among ADA-positive patients (3 patients, 2.2%).

<div style=\"page-break-after: always\"></div>

Table 81: Grade 5 Events by ADA Status

| ADAEvaluablePatients Protocols:IMbrave150(YO40245),G030140   | ADA-Negative N=340   | ADA-Positive N=134   |
|--------------------------------------------------------------|----------------------|----------------------|
| TotalNumberofGrade5AEs                                       | 11 (3%)              | 9 (6.7%)             |
| Gastrointestinal disorders                                   | 2 (0.6%)             | 4 (3.0%)             |
| Gastrointestinal haemorrhage                                 | 0 (0%)               | 3 (2%)               |
| Gastric ulcer perforation                                    | 1 (<1%)              | 0 (0%)               |
| Upper gastrointestinal haemorrhage                           | 0 (0%)               | 1 (0.7%)             |
| Oesophageal variceshaemorhage                                | 1 (<1%)              | (%0) 0               |
| General disorders and administration site Conditions         | 0                    | 1 (0.7%)             |
| Multi organ dysfunction syndrome                             | (%0) 0               | 1 (0.7%)             |
| Respiratory, thoracic and mediastinal disorders              | 1 (0.3%)             | 0 (0%)               |
| Respiratory distress                                         | 1 (0.3%)             | 0 (0%)               |
| Infections and infestations                                  | 5 (1.5%)             | 0                    |
| Pneumonia                                                    | 2 (1%)               | 0 (0%)               |
| Bacteraemia                                                  | 1 (0.3%)             | 0 (0%)               |
| Empyema                                                      | 1 (0.3%)             | 0 (0%)               |
| Peritonitis bacterial                                        | 1 (0.3%)             | 0 (0%)               |
| Nervous system disorders                                     | 0                    | 1 (0.7%)             |
| Subarachnoid haemorrhage                                     | (%0) 0               | 1 (0.7%)             |
| HepatobiliaryDisorders                                       | 2 (0.6%)             | 2 (1.5%)             |
| Abnormal hepatic function                                    | 1 (0.7%)             | 1 (1%)               |
| Hepatic cirrhosis                                            | 1 (0.3%)             | 0 (0%)               |
| Liver injury                                                 | 0 (0%)               | 1 (0.7%)             |
| Cardiacdisorders                                             | 1 (0.3%)             | 1 (0.7%)             |
| Cardiac arrest                                               | 1 (0.3%)             | 1 (0.7%)             |

AE= adverse event; ADA= anti-drug antibody

Data S0urCe: t\\_ae\\_ctc\\_H2A\\_A\\_byada\\_29AUG2019\\_40245P.

The incidence of AEs reported as serious was higher in the ADA-positive subgroup (50.0%) compared with the ADA-negative subgroup (31.5%). The most common serious AEs by preferred term are shown in Table 92. Gastrointestinal hemorrhage was the only SAE with a ≥ 2% difference between ADAnegative and -positive patients (0.9% vs. 4.5%). All other serious AEs were reported at a low incidence.

<div style=\"page-break-after: always\"></div>

Table 82: Common ( ≥ 1% in any Arm) Serious Adverse Events by ADA Status (ADA Evaluable Population)

| ADAEvaluablePatients Protocols: IMbrave150 (Y040245), G030140   | Atezo+Bev HCC (N=474)   | Atezo+Bev HCC (N=474)   |
|-----------------------------------------------------------------|-------------------------|-------------------------|
| MedDRA System Organ Class MedDRAPreferredTerm                   | ADA- (N=340)            | ADA+ (N=134)            |
| - Any adverse events -                                          | 107 (31.5%)             | 67 (50.0%)              |
| Gastrointestinal Haemorrhage                                    | 3 (0.9%)                | 6 (4.5%)                |
| Upper Gastrointestinal Haemorrhage                              | 2 (0.6%)                | 3 (2.2%)                |
| Varices Oesophageal                                             | 0                       | 2 (1.5%)                |
| Ascites                                                         | 4 (1.2%)                | 1 (0.7%)                |
| Oesophageal Varices Haemorrhage                                 | 9 (2.6%)                | 1 (0.7%)                |
| Colitis                                                         | 4 (1.2%)                | 0                       |
| Diarrhoea                                                       | 5 (1.5%)                | 0                       |
| Pneumonia                                                       | 3 (0.9%)                | 3 (2.2%)                |
| Cholangitis                                                     | 4 (1.2%)                | 3 (2.2%)                |
| Autoimmune Hepatitis                                            | 0                       | 2 (1.5%)                |
| Hyperbilirubinaemia                                             | 1 (0.3%)                | 2 (1.5%)                |
| Pyrexia                                                         | 7 (2.1%)                | 4 (3.0%)                |
| Epistaxis                                                       | 0                       | 2 (1.5%)                |
| InfusionRelated Reaction                                        | 1 (0.3%)                | 2 (1.5%)                |

ADA=Anti-Drug Antibodies, -=Negative, +=Positive.

Atez0=Atezolizumab Bev=Bevacizumab. Atez0+Bev HCC: IMbrave150 (YO40245) (Atez0+Bev)+GO30140(Arm A+F1).

Investigator text for AEs encoded using MedDRA v22.0. All counts represent patients.

Multiple occurrences of the same AE in one individual are counted once at the highest grade for this patient. To the SOC Overall row counts, a patient contributes only with the AE occurring with the highest grade within the SOC. Percentages are based on N in the column headings. All treatment emergent AEs are included.

Clinical cut-off dates: Study IMbrave150 (YO40245) (29 August 2019), Study G030140 (14 June 2019).

The incidence of AESIs was generally comparable across the majority of safety categories with the exception of Grade 3-4 AESIs (19.1% ADA-negative vs. 30.6% ADA-positive) (Table 5.5.1.8.16). The difference in Grade 3-4 AESIs was mainly driven by more events of hepatitis laboratory abnormalities in the ADA-positive subgroup.

By medical concept, the most common ( ≥ 10% in either ADA-negative or ADA-positive) AESIs were hepatitis (diagnosis and laboratory abnormalities), rash, hypothyroidism and IRR. The frequency of most AESIs was similar between the ADA subgroups except for hepatitis laboratory abnormalities (32.1% ADA-negative vs. 37.3% ADA-positive) and IRRs (6.5% vs. 14.9%).

- Hepatitis laboratory abnormalities were mainly of Grade 1-2 severity in the ADA-negative group (Grade 1-2: 20.0% vs. Grade 3-4: 11.8%) whereas in the ADA-positive group, Grade 34 events were more common (Grade 3-4: 20.2% vs. Grade 1-2: 16.4%).
- IRRs were mainly Grade 1-2 in both ADA subgroups (ADA-negative: 5.5% vs. ADA-positive: 12.0%) and the overall incidence of Grade 3 IRRs was low (ADA-negative: 0.9% vs. ADApositive: 3.0%). There were no Grade 4 or Grade 5 IRRs. There were no events of hypersensitivity or anaphylaxis in the ADA-positive subgroup;

There was one case of Grade 4 cytokine release syndrome in this subgroup.

<div style=\"page-break-after: always\"></div>

Table 83: Overview of Adverse Events of Special Interest for Atezolizumab by ADA Status

|                                                                                 | Atezo+Bev HCC     | Atezo+Bev HCC   |
|---------------------------------------------------------------------------------|-------------------|-----------------|
| ADAEvaluablePatients Protocols:IMbrave150(Y040245),G030140                      | ADA- (N=340)      | ADA+ (N=134)    |
| Total number of patientswith at least one AEof Special Interest                 | 219 (64.4%)       | 88 (65.7%)      |
| Totalnumberofevents                                                             | 520               | 199             |
| Totalnumberofpatientswithatleastone:                                            |                   |                 |
| Treatment-related AEofSpecial Interest                                          | 162 (47.6%)       | 68 (50.7%)      |
| Atezo-relatedAEofSpecialInterest                                                | 156 (45.9%)       | 63 (47.0%)      |
| Grade3-4AEofSpecialInterest                                                     | 65 (19.1%)        | 41 (30.6%)      |
| Treatment-relatedGrade3-4AEofSpecialInterest                                    | 35 (10.3%)        | 23 (17.2%)      |
| Atezo-relatedGrade3-4AEofSpecialInterest                                        | 31 (9.1%)         | 22 (16.4%)      |
| Grade5AEofSpecial Interest                                                      | 3 (0.9%)          | 2 (1.5%)        |
| Treatment-relatedGrade5AEofSpecialInterest                                      | 2 (0.6%)          | 2 (1.5%)        |
| Atezo-relatedGrade5AEofSpecialInterest                                          | 2 (0.6%)          | 2 (1.5%)        |
| SeriousAEofSpecialInterest                                                      | 40 (11.8%)        | 21 (15.7%)      |
| Treatment-relatedSeriousAEofSpecialInterest                                     | 20 (5.9%)         | 12 (9.0%)       |
| Atezo-relatedSeriousAEofSpecialInterest                                         | 17 (5.0%)         | 11 (8.2%)       |
| AEofSpecialInterestleadingtoanyStudyTreatment withdrawal                        | 20 (5.9%)         | 8 (6.0%)        |
| AE of Special Interest leading toAtezo withdrawal                               | 13 (3.8%)         | 8 (6.0%)        |
| AEofSpecial Interest leading toanyDosemodificationor StudyTreatmentinterruption | 53 (15.6%)        | 26 (19.4%)      |
| AE of Special Interest leading to Atezo interruption                            | 48 (14.1%)        | 21 (15.7%)      |
| AE of Special Interest Requiring the Use of Systemic Corticosteroids            | 35 (10.3%)        | 18 (13.4%)      |
| SpecialInterestAEMedicalConcepts:patientswithatleastone:                        |                   |                 |
| Immune-MediatedHepatitis(DiagnosisandLab Abnormalities)                         | 124 (36.5%)       | 55 (41.0%)      |
| Immune-Mediated Hepatitis(LabAbnormalities)                                     | 109 (32.1%)       | 50 (37.3%)      |
| Immune-MediatedRash                                                             | 81 (23.8%)        | 26 (19.4%)      |
| Immune-Mediated Hepatitis (Diagnosis)                                           | 39 (11.5%)        | 19 (14.2%)      |
| Immune-Mediated Hypothyroidism                                                  | 35 (10.3%)        | 12 (9.0%)       |
| Infusion-RelatedReactions                                                       | 22 (6.5%)         | 20 (14.9%)      |
| Immune-MediatedHyperthyroidism                                                  | 12 (3.5%)         | 4 (3.0%)        |
| Immune-MediatedPancreatitis                                                     | 8 (2.4%)          | 3 (2.2%)        |
| Immune-MediatedDiabetesMellitus                                                 | 7 (2.1%)          | 3 (2.2%)        |
| Immune-MediatedColitis                                                          | 8 (2.4%)          | 1 (0.7%)        |
| Immune-MediatedPneumonitis                                                      | 4 (1.2%)          | 2 (1.5%)        |
| Immune-Mediated Nephritis                                                       | 2 (0.6%)          | 1 (0.7%)        |
| Immune-Mediated Myositis(Myositis+Rhabdomyolysis)                               | 1 (0.3%)          | 2 (1.5%)        |
| Immune-Mediated Adrenal Insufficiency                                           | 2 (0.6%)          | 0               |
| Rhabdomyolysis                                                                  | 0                 | 2 (1.5%)        |
| AutoimmuneHemolyticAnemia                                                       | 1 (0.3%)          | 1 (0.7%)        |
| Immune-MediatedMeningoencephalitis                                              | 1 (0.3%)          | 0               |
| Immune-Mediated Myositis                                                        | 1 (0.3%)          | 0               |
| SystemicImmuneActivation                                                        | 0                 | 1 (0.7%)        |
| Immune-Mediated Ocular InflammatoryToxicity                                     | 1 (0.3%)          | 0               |
| Immune-MediatedGuillain-BarreSyndrome                                           | 0                 | 1 (0.7%)        |
| Immune-Mediated Encephalitis Immune-MediatedVasculitis                          | 1 (0.3%) 1 (0.3%) | 0 0             |

ADA=Anti-DrugAntibodies,-=Negative,+=Positive

Atez0=AtezolizumabBev=Bevacizumab.Atez0+BevHCC:IMbrave150(YO40245) (Atez0+Bev)+GO30140(ArmA+F1). InvestigatortextforAEsencodedusingMedDRAv22.0.PercentagesarebasedonNinthe columnheadings.MultipleoccurrencesofthesameAEinoneindividualarecountedonlyonce exceptfor\"Totalnumberofevents\"rows,multipleoccurrencesofthesameAEinanindividual Clinicalcut-offdates:StudyIMbrave150(YO40245)(29August2019),StudyGO30140 (14 June 2019).

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No drug-drug interaction studies have been submitted with this application.

## Discontinuation due to adverse events

Table 84 : Adverse events reported in ≥1% of patients in any tr eatment arm leading to withdrawal of study treatment (Safety-evaluable population)

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                         | Sorafenib (N=156)   | Atezo+Bev (N=329)   | Atezo+Bev (N=329)    | Atezo+Bev (N=329)     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|-----------------------|
| MedDRA System Organ Class MedDRA Preferred Term                                                                                                                                                                                                                                                                                                                                         | Sorafenib           | Atezo               | Bev                  | Any treatment         |
| Totalnumber of patients with at least oneadverseevent                                                                                                                                                                                                                                                                                                                                   | 16 (10.38)          | 28 (8.58)           | 48 (14.68)           | 51 (15.58)            |
| Overalltotalnumberofevents                                                                                                                                                                                                                                                                                                                                                              | 17                  | 30                  | 49                   | 55                    |
| Gastrointestinal disorders Totalnumber ofpatients with at least one adverseevent Totalnumberof events Oesophageal varices haemorrhage                                                                                                                                                                                                                                                   | 2 (1.3%) 2 0        | 6 (1.8%) 6 0        | 18(5.58) 18 4 (1.2%) | 18 (5.58) 18 4 (1.28) |
| data cutoff date. Investigator text for AEs are encoded using MedDRA version 22.0. Percentages are based on N in the columnheadings.For frequency counts by preferred term,multiple occurrences of the same AE in an individual are counted only once.For frequencycounts of\"Total number of events\" rows, multiple occurrences of the same AE in an individual are counted separately. |                     |                     |                      |                       |

## AEs leading to dose modification/interruption

AEs that led to dose reduction were reported in 37.2% of patients in the Sorafenib arm. Dose reductions for any reason were not permitted in the Atezo+Bev arm. A numerically lower proportion of patients in the Sorafenib arm (41.0%) experienced AEs that led to dose interruption compared to the Atezo + Bev arm (49.5%). The most common AEs (&gt; 2% of patients) leading to dose reduction/interruption of sorafenib in the Sorafenib arm were palmar-plantar erythrodysaesthesia syndrome (17.3%), diarrhea (10.9%), blood bilirubin increased (5.1%), fatigue (4.5%), decreased appetite (4.5%), hypertension (3.8%), platelet count decreased (3.2%), pyrexia (3.2%), vomiting (3.2%), rash (3.2%), aspartate aminotransferase increased

(3.2%), ascites (2.6%), nausea (2.6%), abdominal pain (2.6%), alanine aminotransferase increased (2.6%), and asthenia (2.6%). The most common AEs (&gt; 2% of patients) leading to dose interruption of any treatment in the Atezo+Bev arm were proteinuria (6.7%), hypertension (6.1%), aspartate aminotransferase increased (5.2%), alanine aminotransferase increased (3.3%), hyperthyroidism (2.7%), platelet count decreased (2.4%), and pyrexia (2.4%).

## Post marketing experience

Since the International Birth Date (18 May 2016) through 17 May 2019, an estimated cumulative total of 46,699 patients have received atezolizumab from marketing experience (US n = 29,044; EU n = 8,253; Japan n = 3,796; Rest of the World n = 5,605). No new or unexpected safety findings were identified in the post-marketing setting for atezolizumab used as a monotherapy or in the approved combination therapies.

<div style=\"page-break-after: always\"></div>

## Safety in Patients developing ADA

Table 85: Safety summary profile by atezolizumab ADA status (ADA-evaluable atezolizumab patients in safety-evaluable population) (IMbrave150 study)

<!-- image -->

Table 86: Grade 3 or Grade 4 adverse events by MedDRA preferred term by ADA status with a &gt;2% difference between ADA-negative and ADA-positive patients (ADA-evaluable atezolizumab patients in safety-evaluable population) (IMbrave150 study)

|                           |       | ADA- (N=227)   | ADA+ (N=88)   |
|---------------------------|-------|----------------|---------------|
| MedDRAPreferred Term      | Grade |                |               |
| AST increased             | 3     | 11 (4.8%)      | 8 (9.1%)      |
| Hyponatremia              | 3     | 4 (1.8%)       | 5 (5.7%)      |
| Infusion-related reaction | 3     | 3 (1.3%)       | 4 (4.5%)      |
| Blood ALP increased       | 3     | 0              | 4 (4.5%)      |
| Hyperbilirubinemia        | 3     | 0              | 2 (2.3%)      |
| Varices esophageal        | 3     | 0              | 2 (2.3%)      |
| Proteinuria               | 3     | 9 (4.0%)       | 1 (1.1%)      |
| Fatigue                   | 3     | 7 (3.19%)      | 1 (1.1%)      |

AST=aspartate aminotransferase; ALP=alkaline phosphatase.

Source:t\\_ae\\_ctc\\_IMM\\_teada

No 2% Difference in Grade 4 AEs were identified

<div style=\"page-break-after: always\"></div>

Table 87: Serious adverse events by MedDRA preferred term by ADA status with a &gt;2% (&gt;1 patient) difference between ADA-negative and ADA-positive patients (ADA-evaluable atezolizumab patients in safety-evaluable population) (IMbrave150 study)

|                                | ADA- (N=227)   | ADA+ (N=88)   |
|--------------------------------|----------------|---------------|
| MedDRAPreferred Term           |                |               |
| Gastrointestinalhemorrhage     | 3 (1.3%)       | 5 (5.7%)      |
| Blood bilirubin increased      | 1 (0.4%)       | 3 (3.4%)      |
| Varices esophageal             | D              | 2 (2.3%)      |
| Autoimmune hepatitis           | 0              | 2 (2.3%)      |
| Hyperbilirubinemia             | D              | 2 (2.3%)      |
| Esophageal varices haemorrhage | 7 (3.1%)       | 1 (1.1%)      |

Table 88: Common ( ≥ 1% in any Arm) Serious Adverse Events by ADA Status (ADA Evaluable Population)

| ADAEvaluablePatients Protocols:IMbrave150(Y040245),G030140   | Atezo+Bev HCC (N=474)   | Atezo+Bev HCC (N=474)   |
|--------------------------------------------------------------|-------------------------|-------------------------|
| MedDRA System Organ Class MedDRAPreferredTerm                | ADA- (N=340)            | ADA+ (N= 134)           |
| - Any adverse events -                                       | 107 (31.5%)             | 67 (50.0%)              |
| Gastrointestinal Haemorrhage                                 | 3 (0.9%)                | 6 (4.5%)                |
| Upper Gastrointestinal Haemorrhage                           | 2 (0.6%)                | 3 (2.2%)                |
| Varices Oesophageal                                          | 0                       | 2 (1.5%)                |
| Ascites                                                      | 4 (1.2%)                | 1 (0.7%)                |
| Oesophageal Varices Haemorrhage                              | 9 (2.6%)                | 1 (0.7%)                |
| Colitis                                                      | 4 (1.2%)                | 0                       |
| Diarrhoea                                                    | 5 (1.5%)                | 0                       |
| Pneumonia                                                    | 3 (0.9%)                | 3 (2.2%)                |
| Cholangitis                                                  | 4 (1.2%)                | 3 (2.2%)                |
| Autoimmune Hepatitis                                         | 0                       | 2 (1.5%)                |
| Hyperbilirubinaemia                                          | 1 (0.3%)                | 2 (1.5%)                |
| Pyrexia                                                      | 7 (2.1%)                | 4 (3.0%)                |
| Epistaxis                                                    | 0                       | 2 (1.5%)                |
| InfusionRelated Reaction                                     | 1 (0.3%)                | 2 (1.5%)                |

ADA=Anti-Drug Antibodies, -=Negative, +=Positive

Atez0=AtezolizumabBeV=Bevacizumab.Atez0+BevHCC: IMbrave150 (YO40245) (Atez0+Bev)+GO30140(Arm A+F1).

Investigator text for AEs encoded using MedDRA v22.0. All counts represent patients

Multiple occurrences of the same AE in one individual are counted once at the highest grade for this patient. To the SOC Overall row counts, a patient contributes only with the AE occurring with the highest grade within the SoC. Percentages are based on N in the column headings. All treatment emergent AEs are included.

Clinical cut-off dates: Study IMbrave150 (Y040245) (29 August 2019), Study G030140 (14 June 2019).

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

The analysis of safety is based on the findings in the pivotal study IMbrave150, where a sufficient number of patients have been exposed to atezo+bev for a sufficient period of time. The safety database should allow a thorough assessment of the safety profile of atezo+bev.

Overall, the observed AEs reflect the known safety profile of sorafenib, atezo and bev. These AEs are well-known  by  clinicians,  and  the  majority  of  them  are  manageable  in  the  clinically  setting  with supportive therapy, etc.

The incidence of Grade 3-4 and Grade 5 AEs is similar between the two treatment arms. Looking at Grade 3-4, higher incidences in atezo+bev arm are seen in terms of ALT increase, decreased platelet count, hypertension, proteinuria and IRR. There were more deaths in the sorafenib arm, both due to AEs and disease progression. In the sorafenib arm, 9 (5.8%) patients died due to AEs compared to 15 (4.6%) patients in the atezo+bev arm. Six patients in the atezo+bev arm died due to fatal bleedings, and 3 of them were deemed related to bevacizumab by the investigators. Precautionary measures are reflected in section 4.4 of the SmPC.

A higher incidence of SAEs is observed in the atezo+bev arm, and the main differences are seen in terms of gastrointestinal disorder, including bleedings (14.9% vs. 11.5%) and infections (7.3% vs 1.9%).

A higher incidence of fatal infections is seen in the atezo+bev arm. Although 'infections' is reflected in section 4.8, and 'sepsis' is mentioned in footnote 'e', the MAH was requested to clearly reflect the risk of sepsis in table 2 of section 4.8 of the SmPC.

HCC patients are at higher risk of esophageal/gastric varices due to the underlying disease. Despite attempts to exclude all patients with prior bleeding due to esophageal and/or gastric varices within 6 months prior to study treatment, and perform esophagogastroduodenoscopy (EGD) on all patients in order to treat all size varices, a considerable number of patients experienced gastrointestinal bleedings in the atezo+bev arm.

Dose modifications were not allowed in the atezo+bev arm. Overall, a higher incidence of discontinuation was observed in the atezo+bev arm, 15.6% vs. 10.3%. approximately 1/3 of discontinuations were due to gastrointestinal bleeding. Bevacizumab was discontinued due to AEs much more often than atezo, 14.6% vs 8.5%. This clearly reflects that bevacizumab is less well tolerated than atezo.

A higher number of patients needed a dose interruption in the atezo+bev arm, and the most common AEs  leading  to  dose  interruption  were  proteinuria  (6.7%),  hypertension  (6.1%),  ALT/AST  increase (5.2%), hyperthyroidism (2.7%), thrombocytopenia (2.4%) and pyrexia (2.4%). Again, it is clearly seen that the majority of dose interruptions were due to AEs related to the use of bevacizumab.

Finally, the MAH provided an analysis of safety depending on the ADA status. ADA+ patients overall experience more AEs, Grade 3-4 AEs, Grade 5 AEs, SAEs, and AEs leading to discontinuation of treatment or dose interruption. Looking at Grade 3-4 AEs and SAEs, patients with ADA+ status experienced more gastrointestinal bleedings and liver toxicity.

Data in HCC patients with Child-Pugh B liver disease treated with atezolizumab in combination with bevacizumab are very limited and there are currently no data available in HCC patients with Child-Pugh C liver disease.

Patients treated with bevacizumab have an increased risk of haemorrhage, and cases of severe gastrointestinal haemorrhage, including fatal events, were reported in patients with hepatocellular carcinoma (HCC) treated with atezolizumab in combination with bevacizumab. In patients with HCC, screening for and subsequent treatment of oesophageal varices should be performed as per clinical practice prior to starting treatment with the combination of atezolizumab and bevacizumab.

<div style=\"page-break-after: always\"></div>

Bevacizumab should be permanently discontinued in patients who experience Grade 3 or 4 bleeding with the combination treatment.

Diabetes mellitus can occur during treatment with atezolizumab in combination with bevacizumab. Physicians should monitor blood glucose levels prior to and periodically during treatment with atezolizumab in combination with bevacizumab as clinically indicated (see section 4.4 of the SmPC).

## 2.5.2. Conclusions on clinical safety

The incidence of Grade 3-4 and Grade 5 AEs is similar between the atezo+bev and sorafenib arms. Despite attempts to exclude all patients at risk for gastrointestinal bleeding from the study higher incidences of bleeding, including fatal bleedings, infections, discontinuations and dose interruptions due to AEs were seen in the atezo+bev arm. The use of bevacizumab in patients with HCC is challenging, because many of these patients have a higher risk of bleeding due to their underlying disease and adequate information has been reflected in section 4.4 of the SmPC.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 13.1 is acceptable.

The CHMP endorsed the Risk Management Plan version 13.1 with the following content:

## Safety concerns

Table 78: Summary of the Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related hepatitis Immune-related pneumonitis Immune-related colitis Immune-related pancreatitis Immune-related endocrinopathies (diabetes mellitus, hypothyroidism, hyperthyroidism, adrenal insufficiency and hypophysitis) Immune-related neuropathies (Guillain-Barré syndrome, and myasthenic syndrome / myasthenia gravis) Immune-related meningoencephalitis Infusion-related reactions Immune-related myocarditis Immune-related nephritis |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                   |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | Immune-related myositis                                                                                                                                                                                      |
| Important potential risks    | Anti-drug antibodies Embryo-fetal toxicity                                                                                                                                                                   |
| Missing information          | Concomitant use with other immuno-modulatory drugs Long term use Concomitant or sequential use of atezolizumab with intra-vesical Bacillus Calmette-Guérin vaccine for the treatment of urothelial carcinoma |

## Pharmacovigilance plan

Table 79: On-going and planned additional pharmacovigilance activities

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                                                                                         | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                                    | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                               | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                                                                                                  | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                               | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                               | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing                                                                                                               |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                                    | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                                    | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| GO29322: A Phase IB Study of the Safety and Pharmacology of atezolizumab Administered with Ipilimumab or Interferon-Alpha in Patients with Locally Advanced or Metastatic Solid Tumors Ongoing                             | To evaluate the safety and tolerability of atezolizumab and ipilimumab in combination in patients with advanced or metastatic NSCLC or melanoma. To evaluate the safety and tolerability of atezolizumab and interferon alfa-2b in combination in patients with advanced or metastatic RCC or | Concomitant use with other immunomodulatory drugs                                                                                                                                                                          | Final CSR                                                                                                                                                                                                                  | November 2020                                                                                                                                                                                                              |
| WO29635: A Phase IB/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered with or without Bacille Calmette-Guérin in Patients with High Risk Non Muscle- Invasive Bladder Cancer Ongoing        | To evaluate the safety and tolerability of atezolizumab as a single agent and in combination with BCG. To identify the DLTs and to determine the MTD or tolerability at the MAD of BCG in combination with atezolizumab                                                                       | Concomitant or sequential use of atezolizumab with intra-vesical BCG vaccine for the treatment of urothelial carcinoma                                                                                                     | Final CSR                                                                                                                                                                                                                  | June 2022                                                                                                                                                                                                                  |
| MO39171 (TAIL): Single-Arm Long- Term Safety and Efficacy Study of                                                                                                                                                         | To evaluate the long- term safety of atezolizumab on the bases of the following                                                                                                                                                                                                               | Long-term use                                                                                                                                                                                                              | Final CSR                                                                                                                                                                                                                  | May 2022                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| atezolizumab in previously treated NSCLC Patients Ongoing                                                                                                                                                                                                                                                                                                                  | endpoints: The incidence of all serious adverse events (SAEs) related to atezolizumab treatment and the incidence of immune-related adverse events (irAEs) related to atezolizumab treatment                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                 |                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------|
| MO29983: An Open- Label, Single Arm, Multicenter, Safety Study of atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract Ongoing                                                                                                                                                                                       | To evaluate the safety of atezolizumab based on the following endpoints: Nature, severity, duration, frequency and timing of adverse events (AEs) and changes in vital signs, physical findings, and clinical laboratory results during and following atezolizumab                                                                                                                | Long-term use                                                                                                                                                                                                                                                                                                                                                                                                                                              | Final CSR                                       | Q1 2023                                   |
| WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions Ongoing | administration. The overall objective is to evaluate the effectiveness of the HCP brochure designed to mitigate important immune-related risks in patients receiving atezolizumab in the European Union. Data from HCP surveys and reporting rates for the important identified immune related risks will be collected and analyzed to evaluate effectiveness of the HCP brochure | Immune-related hepatitis Immune-related pneumonitis Immune-related colitis Immune-related pancreatitis Immune-related endocrinopathies (diabetes mellitus, hypothyroidism, hyperthyroidism, adrenal insufficiency, and hypophysitis) Immune-related neuropathies (Guillain- Barré syndrome, and myasthenic syndrome / myasthenia gravis) Immune related meningoencephalitis Infusion-related reactions Immune-related myocarditis Immune-related nephritis | Protocol submission Interim report Final Report | February 2018 December 2020 December 2022 |

<div style=\"page-break-after: always\"></div>

ADAs = anti-drug antibodies; BCG = bacillus Calmette-Guerin; CSR = Clinical Study Report; DLT = dose-limiting toxicity; HCP = healthcare professional; MAD = maximum administered dose; MTD = maximum tolerated dose; NSCLC = non-small cell lung cancer; OS = overall survival; RCC = renal cell carcinoma; TBD = to be determined.

## Risk minimisation measures

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Hepatitis   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and |
| Immune-Related Pneumonitis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials                                | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks:                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Safety concern              | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                             | for HCPs • Patient alert cards                                                                                                                                                                                                                                                                                                                          | Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions.                                                                                                                                                                                                                                                                                                                                                     |
| Immune-Related Colitis      | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions. |
| Immune-Related Pancreatitis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures:                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                 | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                | • Educational materials for HCPs • Patient alert cards                                                                                                                                                                                                                                                                                                  | immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions.                                                                                                                                                                                                                                                                                                                              |
| Immune-Related Endocrinopathies (Diabetes Mellitus, Hypothyroidism, Hyperthryroidism, Adrenal Insufficiency, and Hypophysitis) | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis and infusion-related reactions. |
| Immune-Related Neuropathies (Guillain-Barre Syndrome and Myasthenia Gravis)                                                    | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures:                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Safety concern                     | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                    | • Educational materials for HCPs • Patient alert cards                                                                                                                                                                                                                                                                                                  | immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions.                                                                                                                                                                                                                                                                                                                              |
| Immune-Related Meningoencephalitis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis and infusion-related reactions. |
| Infusion-Related Reactions         | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures:                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | • Educational materials for HCPs • Patient alert cards                                                                                                                                                                                                                                                                                                  | immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions.                                                                                                                                                                                                                                                                                                                                  |
| Immune-Related Myocarditis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition of and intervention in the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions. |
| Immune-related nephritis   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 -Undesirable effects Additional risk minimization measures:                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition of and intervention in the following important                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Safety concern          | Risk minimization measures                                                                                                                                                                                                                                                                                                        | Pharmacovigilance activities                                                                                                                                                      |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                         | • Educational materials for HCPs Patient alert cards                                                                                                                                                                                                                                                                              | immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions. |
| Immune-related myositis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                  |
| Anti-drug Antibodies    | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.8 Undesirable effects No additional risk minimization measures                                                                                                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                  |
| Embryo-fetal toxicity   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.6 Fertility, pregnancy                                                                                                                                                                               | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities:                                       |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                               | Risk minimization measures                                                                                                                                                                                                                                                 | Pharmacovigilance activities                                                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                              | and lactation Section 5.3 Preclinical safety data No additional risk minimization measures                                                                                                                                                                                 | None                                                                                                                                                                     |
| Concomitant use with other immuno-modulatory agents                                                                                          | Routine risk minimization measures: This safety concern considered as missing information is mentioned as one of the exclusion criteria within the Warnings and Precautions and description of studies included in the E.U. SmPC. No Additional risk minimization measures | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study GO29322                |
| Long-term use                                                                                                                                | Routine risk minimization measures: Proposed text in E.U. SmPC: None No Additional risk minimization measures                                                                                                                                                              | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Studies: • MO29983 • MO39171 |
| Concomitant or sequential use of atezolizumab with intra-vesical Bacillus Calmette-Guérin vaccine for the treatment of urothelial carcinoma. | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.4 Special Warnings and Precautions for Use: Includes language that patients who were administered a live attenuated vaccine with 28 days      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study WO29635                |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk                                                                                           | Pharmacovigilance activities   |
|------------------|------------------------------------------------------------------------------------------------|--------------------------------|
|                  | prior to enrolment were excluded from clinical trials No Additional risk minimization measures |                                |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. Particularly, a new warning with regard to the very limited data in HCC patients with Child-Pugh B liver disease and the absence of data in HCC patients with Child-Pugh C liver disease. A new warning has also been included to reflect patients excluded from the clinical trials in HCC.

The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current QRD template, which were reviewed and accepted by the CHMP.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- No significant changes impacting the readability of the package leaflet are made. In particular, key safety messages are not affected by this extension. The new additions follow the same structure and use similar descriptions and terminology as used in the approved package leaflet.
- The posology proposed in this application is the same as for the currently approved indications.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It occurs in patients with  chronic  liver  inflammation  due  to  HBV,  HCV,  excessive  alcohol  intake  or  other  toxins  such  as aflatoxin.  Furthermore,  haemochromatosis,  alpha  1-antitrypsin  deficiency,  metabolic  syndrome  and NASH increase the risk of HCC.

The Applicant seeks approval for:

'Tecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).'

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

Sorafenib remains the global standard of care for treatment of patients with unresectable HCC based on two  multicenter,  randomized,  double -blind,  placebo-controlled  Phase III  trials:  the  SHARP  trial  in Western  regions  and  a  trial  conducted  in  the  Asia-Pacific  region  (Asia-Pacific  Trial).  Both  studies demonstrated a survival benefit of sorafenib vs. placebo. Sorafenib is often poorly tolerated, and dose reductions or drug discontinuations due to AEs are common (Nexavar EPAR).

Recently, treatment with lenvatinib, a multi-targeted receptor tyrosine kinase inhibitor, was shown to be non-inferior to sorafenib in terms of the primary efficacy endpoint of OS (lenvatinib vs. sorafenib: median OS 13.6 months vs. 12.3 months; hazard ratio [HR] = 0.92, 95% confidence interval [CI]: 0.79, 1.06; non-inferiority  margin = 1.08) though a statistically  significant improvement  in  OS  was  not  observed (REFLECT) (Lenvima II/11/G EPAR).

Despite available treatment options, there is a still a high unmet need for effective treatment options in these patients, who have a dismal prognosis.

## 3.1.3. Main clinical studies

The MAH has provided Study IMbrave150, a phase III, open-label, randomized study of atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma.

## 3.2. Favourable effects

The study met its co-primary endpoint by showing statistically significant PFS gain, with a median PFS of 6.83 vs 4.27 months in atezo+bev and sorafenib arms respectively. The HR is 0.59 (0.47, 0.76), p&lt;0.0001.

The OS data from the 1 st  IA show a statistically significant HR of 0.58 (0.42, 0.79) with a p-value of 0.0006.

The key secondary endpoints showed statistically  significant  and  clinically  meaningful  differences  in favour  of  atezo+bev.  ORR  by  IRF  per  RECIST  1.1  showed  27.3%  vs  11.9%,  ORR  by  IRF  per  HCC mRECIST showed 33.2% vs. 13.3%. DOR was also considerably longer in the atezo+bev arm.

## 3.3. Uncertainties and limitations about favourable effects

The OS and DOR data are not mature yet. More mature data will be provided post approval (recommendation).

There seems to be a trend showing a negative impact of ADA on OS and PFS, however data should be interpreted with caution, because of differences in baseline disease characteristics between ADA- and ADA+ patients and immature OS data in the ADA subgroups. The MAH provided analyses of OS and PFS comparing ADA- and ADA+, adjusting for multiple baseline covariates that indicated similar OS results between the ADA+ population and sorafenib, whereas an OS benefit was shown for the ADAsubgroup compared to sorafenib. It is not possible to draw any firm conclusion regarding the clinical relevance of the impact of ADA on efficacy given that ADA is a post-randomization variable.

Although no reliable conclusions can be drawn from the exploratory PD-L1 expression analyses of available samples in only 40% of the study population, efficacy outcomes appear to be associated with PD-L1 expression status, with a larger benefit for the PD-L1 positive subgroup (PD-L1 TC/IC ≥ 1%).

<div style=\"page-break-after: always\"></div>

However, available data suggest a small overall survival benefit for Atezo + Bev compared to Sorafenib also in the PD-L1 negative subgroup without detrimental effects with regard to PFS or response status. Efficacy data by PD-L1 expression status should be provided with updated OS data post approval.

## 3.4. Unfavourable effects

Higher incidences of Grade 3-4 AEs are seen in the atezo+bev arm in terms of ALT increase, decreased platelet count, hypertension, proteinuria and IRR.

Six patients in the atezo+bev arm died due to fatal bleedings. Furthermore, a higher incidence of fatal infections is seen in the atezo+bev arm.

A higher incidence of SAEs is observed in the atezo+bev arm, and the main differences are seen in terms of gastrointestinal disorder, including bleedings (14.9% vs. 11.5%) and infections (7.3% vs 1.9%).

Dose modifications were not allowed in the atezo+bev arm. Overall, a higher incidence of discontinuation was observed in the atezo+bev arm, 15.6% vs. 10.3%. approximately 1/3 of discontinuations were due to gastrointestinal bleeding. Bevacizumab was discontinued due to AEs much more often than atezo, 14.6% vs 8.5%.

A higher number of patients needed a dose interruption in the atezo+bev arm, and the most common AEs  leading  to  dose  interruption  were  proteinuria  (6.7%),  hypertension  (6.1%),  ALT/AST  increase (5.2%), hyperthyroidism (2.7%), thrombocytopenia (2.4%) and pyrexia (2.4%).

## 3.5. Uncertainties and limitations about unfavourable effects

An analysis of safety as function of ADA status seems to show that ADA+ patients overall experience more AEs, Grade 3-4 AEs, Grade 5 AEs, SAEs, and AEs leading to discontinuation of treatment or dose interruption.  Looking  at  Grade  3-4  AEs  and  SAEs,  patients  with  ADA+  status  experienced  more gastrointestinal bleedings and liver toxicity.

## 3.6. Effects Table

Table 89: Effects Table for Tecentriq in combination with bevacizumab for 1L HCC (IMbrave150; data cut-off: 29 August 2019)

| Effect               | Short description                       | Unit                 | Atezo+Bev            | Sorafenib            | Uncertainties / Strength of evidence                                                                                             |
|----------------------|-----------------------------------------|----------------------|----------------------|----------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Favourable Effects   | Favourable Effects                      | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                                                               |
| OS                   |                                         | Months               | NA                   | 13.3                 | OS data immature (IA OS, 32% event rate, median follow-up 8.6 months) Only data for patients with well- preserved liver function |
| OS                   |                                         | HR (95%CI)           |                      | 0.58 (0.42, 0.79)    | OS data immature (IA OS, 32% event rate, median follow-up 8.6 months) Only data for patients with well- preserved liver function |
| PFS                  | IRF-assessed per RECIST v1.1            | Months               | 6.8                  | 4.3                  | OS data immature (IA OS, 32% event rate, median follow-up 8.6 months) Only data for patients with well- preserved liver function |
| PFS                  |                                         | HR (95%CI)           |                      | 0.59 (0.47, 0.76)    | OS data immature (IA OS, 32% event rate, median follow-up 8.6 months) Only data for patients with well- preserved liver function |
| ORR                  | Confirmed, IRF-assessed per RECIST v1.1 | %                    | 27                   | 12                   | OS data immature (IA OS, 32% event rate, median follow-up 8.6 months) Only data for patients with well- preserved liver function |
| ORR                  | Confirmed, IRF-assessed per mRECIST     | %                    | 33                   | 13                   | OS data immature (IA OS, 32% event rate, median follow-up 8.6 months) Only data for patients with well- preserved liver function |
| Unfavourable Effects | Unfavourable Effects                    | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                                             |
|                      | AEs                                     | %                    | 98.2                 | 98.7                 | • Higher percentage of SAEs in                                                                                                   |
|                      | G3/4 AEs                                | %                    | 56.5                 | 55.1                 | • Higher percentage of SAEs in                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect   | Short description                        | Unit   | Atezo+Bev   | Sorafenib   | Uncertainties / Strength of evidence                                                                            |
|----------|------------------------------------------|--------|-------------|-------------|-----------------------------------------------------------------------------------------------------------------|
|          | Related G3/4 AEs                         | %      | 35.6        | 45.5        | Atezo+Bev driven by gastrointestinal bleeding AEs • Higher incidences in hyperthyroidism and diabetes mellitus. |
|          | Serious AEs                              | %      | 38.0        | 30.8        | Atezo+Bev driven by gastrointestinal bleeding AEs • Higher incidences in hyperthyroidism and diabetes mellitus. |
|          | AESIs                                    | %      | 60.5        | 72.0        | Atezo+Bev driven by gastrointestinal bleeding AEs • Higher incidences in hyperthyroidism and diabetes mellitus. |
|          | G5 AEs                                   | %(n)   | 1.8 (6)     | 0.6 (1)     | Atezo+Bev driven by gastrointestinal bleeding AEs • Higher incidences in hyperthyroidism and diabetes mellitus. |
|          | AEs leading to treatment discontinuation | %      | 15.5        | 10.         | Atezo+Bev driven by gastrointestinal bleeding AEs • Higher incidences in hyperthyroidism and diabetes mellitus. |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Patients with HCC have a dismal prognosis with a relatively short median OS, as seen in the control arm. Thus, there is a high unmet need for new effective treatment options that can prolong OS in these patients. Atezolizumab in combination with bevacizumab seems to prolong both PFS and OS. These findings are further supported by an increase in ORR and DOR.

Efficacy results appear to be associated with PD-L1 expression status based on exploratory analysis in only 40% of the study population. Available data suggest a small overall survival benefit for Atezo + Bev compared to Sorafenib also in the PD-L1 negative subgroup. Considering also the safety profiles of both treatment arms and the fact that biopsies are often not part of the routine clinical management, a favourable benefit-risk assessment is accepted in an all-comer population.

Atezolizumab in combination with bevacizumab gives rise to considerably more bleeding episodes, including fatal bleeding, compared to sorafenib. Despite attempts to exclude all patients at risk for gastrointestinal bleeding from the study, a higher incidence of bleeding, including fatal bleeding, infections, discontinuations and dose interruptions due to AEs were seen in the atezo+bev arm. Overall the incidence of Grade 3-4 and Grade 5 AEs is similar between the two treatment arms.

## 3.7.2. Balance of benefits and risks

The demonstrated benefit in the overall study population is considered clinically relevant and there are no major safety concerns apart from a higher risk of gastrointestinal bleeding, which is clearly reflected in the SmPC, where precautionary measures are also reflected.  The benefits of atezolizumab in combination with bevacizumab outweigh the safety concerns in the target population.

## 3.7.3. Additional considerations on the benefit-risk balance

Raising ADA development as a concern is difficult since developing ADAs is a risk and cannot be determined a priori .

## 3.8. Conclusions

The overall B/R of atezolizumab in combination with bevacizumab is positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include, in combination with with bevacizumab, the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, based on the results of the pivotal study YO40245 (IMbrave150) as well as data from Arms A and F of the supportive Phase Ib study GO30140. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the Tecentriq 1200mg concentrate for solution for infusion SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1.

An updated RMP version 13.1 was agreed during the procedure.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Tecentriq EMEA/H/C/004143/II/0039.

## Attachments

1. EN PI (changes highlighted) as adopted by the CHMP on 17 September 2020.

<div style=\"page-break-after: always\"></div>

## Reminders to the MAH

1. In accordance with Article 13(3) of Regulation (EC) No 726/2004 the Agency makes available a European Public Assessment Report (EPAR) on the medicinal product assessed by the Committee for Medicinal Products for Human Use. The EPAR is first published after the granting of the initial marketing authorisation (MA) and is continuously updated during the lifecycle of the medicinal product. In particular, following a major change to the MA, the Agency further publishes the assessment report of the CHMP and the reasons for its opinion in favour of granting the change to the authorisation, after deletion of any information of a commercially confidential nature.

Should you consider that the CHMP assessment report contains commercially confidential information, please provide the EMA Procedure Assistant your proposal for deletion of commercially confidential information (CCI) in 'track changes' and with detailed justification by 06 October 2020. The principles to be applied for the deletion of CCI are published on the EMA website at https://www.ema.europa.eu/en/documents/other/heads-medicinesagencies/european-medicines-agency-guidance-document-identification-commerciallyconfidential-information\\_en.pdf.

2. The MAH is reminded to submit an eCTD closing sequence with the final documents provided by Eudralink during the procedure (including final PI translations, if applicable) within 15 days after the Commission Decision, if there will be one within 2 months from adoption of the CHMP Opinion, or prior to the next regulatory activity, whichever is first. If the Commission Decision will be adopted within 12 months from CHMP Opinion, the closing sequence should be submitted within 30 days after the Opinion. For additional guidance see chapter 4.1 of the Harmonised Technical Guidance for eCTD Submissions in the EU.
3. The MAH is reminded that, at the same time as the submission on the eCTD closing sequence mentioned above, an updated version of Annex I of the RMP template, reflecting the final RMP agreed at the time of the Opinion should be submitted to h-eurmp-evinterface@emea.europa.eu.
4. If the approved RMP is using Rev. 2 of the 'Guidance on the format of the RMP in the EU' and the RMP 'Part VI: Summary of the risk management plan' has been updated in the procedure, the MAH is reminded to provide to the EMA Procedure Assistant by Eudralink a PDF version of the 'Part VI: Summary of the risk management plan' as a standalone document, within 14 calendar days of the receipt of the CHMP Opinion. The PDF should contain only text and tables and be free of metadata, headers and footers.